Document:

EX-4.2

 Exhibit 4.2 

Execution Version 
  

 
  

DEPOSIT AGREEMENT 
 among 

Northern Trust Corporation, 
 as
the Company 
 Wells Fargo Bank, N.A. 

as Depositary, 
 and 

THE HOLDERS FROM TIME TO TIME OF 

THE DEPOSITARY RECEIPTS DESCRIBED HEREIN 

Dated as of August 8, 2016 

Relating to the Series D Non-Cumulative Perpetual Preferred Stock of the Company 

 
  

 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 ARTICLE I
	 	 DEFINED TERMS
	  	 	1	  
	 Section 1.1
	 	 Definitions
	  	 	1	  
			
	 ARTICLE II
	 	 FORM OF RECEIPTS, DEPOSIT OF SERIES D PREFERRED STOCK, EXECUTION AND DELIVERY, TRANSFER,
SURRENDER AND REDEMPTION OF RECEIPTS
	  	 	3	  
	 Section 2.1
	 	 Form and Transfer of Receipts
	  	 	3	  
	 Section 2.2
	 	 Deposit of Series D Preferred Stock; Execution and Delivery of Receipts in Respect
Thereof
	  	 	4	  
	 Section 2.3
	 	 Registration of Transfer of Receipts
	  	 	5	  
	 Section 2.4
	 	 Split-ups and Combinations of Receipts; Surrender of Receipts and Withdrawal of Series D
Preferred Stock
	  	 	5	  
	 Section 2.5
	 	 Limitations on Execution and Delivery, Transfer, Surrender and Exchange of Receipts
	  	 	6	  
	 Section 2.6
	 	 Lost Receipts, etc
	  	 	7	  
	 Section 2.7
	 	 Cancellation and Destruction of Surrendered Receipts
	  	 	7	  
	 Section 2.8
	 	 Redemption of Series D Preferred Stock
	  	 	7	  
	 Section 2.9
	 	 Receipts Issuable in Global Registered Form
	  	 	8	  
			
	 ARTICLE III
	 	 CERTAIN OBLIGATIONS OF HOLDERS OF RECEIPTS AND THE COMPANY
	  	 	10	  
	 Section 3.1
	 	 Filing Proofs, Certificates and Other Information
	  	 	10	  
	 Section 3.2
	 	 Payment of Taxes or Other Governmental Charges
	  	 	10	  
	 Section 3.3
	 	 Warranty as to Series D Preferred Stock
	  	 	10	  
	 Section 3.4
	 	 Warranty as to Receipts
	  	 	10	  
			
	 ARTICLE IV
	 	 THE DEPOSITED SECURITIES; NOTICES
	  	 	11	  
	 Section 4.1
	 	 Cash Distributions
	  	 	11	  
	 Section 4.2
	 	 Distributions Other than Cash, Rights, Preferences or Privileges
	  	 	11	  
	 Section 4.3
	 	 Subscription Rights, Preferences or Privileges
	  	 	12	  
	 Section 4.4
	 	 Fixing Record Date for Holders of Receipts
	  	 	13	  
	 Section 4.5
	 	 Voting Rights
	  	 	13	  
	 Section 4.6
	 	 Changes Affecting Deposited Securities and Reclassifications, Recapitalizations, etc
	  	 	13	  
	 Section 4.7
	 	 Delivery of Reports
	  	 	14	  
	 Section 4.8
	 	 Lists of Receipt Holders
	  	 	14	  
			
	 ARTICLE V
	 	 THE DEPOSITARY, THE DEPOSITARY’S AGENTS, THE REGISTRAR AND THE COMPANY
	  	 	14	  
	 Section 5.1
	 	 Maintenance of Offices, Agencies and Transfer Books by the Depositary; Registrar
	  	 	14	  
	 Section 5.2
	 	 Prevention of or Delay in Performance by the Depositary, the Depositary’s Agents, the
Registrar or the Company
	  	 	15	  

  
 i 

 TABLE OF CONTENTS 

(CONTINUED) 
  

							
	 	 	 	  	Page	 
	 Section 5.3
	 	 Obligations of the Depositary, the Depositary’s Agents, the Registrar and the
Company
	  	 	16	  
	 Section 5.4
	 	 Resignation and Removal of the Depositary; Appointment of Successor Depositary
	  	 	17	  
	 Section 5.5
	 	 Corporate Notices and Reports
	  	 	18	  
	 Section 5.6
	 	 Indemnification by the Company
	  	 	18	  
	 Section 5.7
	 	 Fees, Charges and Expenses
	  	 	18	  
			
	 ARTICLE VI
	 	 AMENDMENT AND TERMINATION
	  	 	19	  
	 Section 6.1
	 	 Amendment
	  	 	19	  
	 Section 6.2
	 	 Termination
	  	 	19	  
			
	 ARTICLE VII
	 	 MISCELLANEOUS
	  	 	19	  
	 Section 7.1
	 	 Counterparts
	  	 	19	  
	 Section 7.2
	 	 Exclusive Benefit of Parties
	  	 	20	  
	 Section 7.3
	 	 Invalidity of Provisions
	  	 	20	  
	 Section 7.4
	 	 Notices
	  	 	20	  
	 Section 7.5
	 	 Depositary’s Agents
	  	 	21	  
	 Section 7.6
	 	 Appointment of Registrar, Dividend Disbursing Agent and Redemption Agent in Respect of the
Receipts and Series D Preferred Stock
	  	 	21	  
	 Section 7.7
	 	 Holders of Receipts Are Parties
	  	 	21	  
	 Section 7.8
	 	 Governing Law
	  	 	21	  
	 Section 7.9
	 	 Inspection of Deposit Agreement
	  	 	21	  
	 Section 7.10
	 	 Headings
	  	 	21	  

  

							
	 EXHIBIT A
	 	 FORM OF RECEIPT
	  	 	A-1	  
			
	 EXHIBIT B
	 	 CERTIFICATE OF DESIGNATION
	  	 	B-1	  

  
 ii 

 DEPOSIT AGREEMENT dated as of August 8, 2016, among (i) Northern Trust Corporation, a
Delaware corporation, (ii) Wells Fargo Bank, N.A., a national banking association formed under the laws of the United States, as Depositary and (iii) the holders from time to time of the Receipts described herein. 

WHEREAS, it is desired to provide, as hereinafter set forth in this Deposit Agreement, for the deposit of shares of Series D Non-Cumulative
Perpetual Preferred Stock of the Company with the Depositary for the purposes set forth in this Deposit Agreement and for the issuance hereunder of Depositary Shares representing a fractional interest in the Series D Preferred Stock deposited and
for the execution and delivery of Receipts evidencing Depositary Shares; 
 WHEREAS, the Receipts are to be substantially in the form of
Exhibit A attached hereto, with appropriate insertions, modifications and omissions, as hereinafter provided in this Deposit Agreement; and 

WHEREAS, the terms and conditions of the Series D Preferred Stock of the Company are set forth in the Certificate of Designation attached
hereto as Exhibit B. 
 NOW, THEREFORE, in consideration of the premises contained herein, the parties hereto agree as follows: 

ARTICLE I 
 DEFINED
TERMS 
 Section 1.1 Definitions. 

The following definitions shall for all purposes, unless otherwise indicated, apply to the respective terms (in the singular and plural forms
of such terms) used in this Deposit Agreement and the Receipts: 
 “Certificate of Designation” shall mean the relevant
Certificate of Designation filed with the Secretary of State of the State of Delaware establishing the Series D Preferred Stock as a series of preferred stock of the Company. 

“Company” shall mean Northern Trust Corporation, a Delaware corporation, and its successors. 

“Deposit Agreement” shall mean this agreement, as the same may be amended, modified or supplemented from time to time in
accordance with the terms hereof. 
 “Depositary” shall mean Wells Fargo Bank, N.A., a national banking association formed
under the laws of the United States, and any successor as Depositary hereunder. 
 “Depositary Share Redemption Price”
shall have the meaning set forth in Section 2.8. 
 “Depositary Shares” shall mean the depositary shares, each
representing a 1/100th fractional interest in a share of the Series D Preferred Stock, and the same proportionate interest 

 
in any and all other property received by the Depositary in respect of such share of Series D Preferred Stock and held under this Deposit Agreement, all as evidenced by the Receipts issued
hereunder. Subject to the terms of this Deposit Agreement, each owner of a Depositary Share is entitled, proportionately, to all the rights, preferences and privileges of the Series D Preferred Stock represented by such Depositary Share (including
the dividend, voting, redemption and liquidation rights contained in the Certificate of Designation). 
 “Depositary’s
Agent” shall mean an agent appointed by the Depositary pursuant to Section 7.5. 
 “Depositary’s
Office” shall mean the principal office of the Depositary at which at any particular time its depositary receipt business in respect of matters governed by this Deposit Agreement shall be administered. 

“DTC” shall mean The Depository Trust Company. 

“Exchange Event” shall mean with respect to any Global Registered Receipt: 

(1) (A) the Global Receipt Depository which is the holder of such Global Registered Receipt or Receipts notifies the Company
that it is no longer willing or able to properly discharge its responsibilities under any Letter of Representations or that it is no longer eligible or in good standing under the Securities Exchange Act, and (B) the Company has not appointed a
qualified successor Global Receipt Depository within ninety (90) calendar days after the Company received such notice, or 

(2) the Company in its sole discretion notifies the Depositary in writing that the Receipts or portion thereof issued or
issuable in the form of one or more Global Registered Receipts shall no longer be represented by such Global Registered Receipt or Receipts. 

“Global Receipt Depository” shall mean, with respect to any Receipt issued hereunder, DTC or such other entity designated as
Global Receipt Depository by the Company in or pursuant to this Deposit Agreement, which entity must be, to the extent required by any applicable law or regulation, a clearing agency registered under the Securities Exchange Act. 

“Global Registered Receipt” shall mean a global registered Receipt, in definitive or book-entry form, registered in the name
of a nominee of DTC. 
 “Letter of Representations” shall mean any applicable agreement among the Company, the Depositary
and a Global Receipt Depository with respect to such Global Receipt Depository’s rights and obligations with respect to any Global Registered Receipts, as the same may be amended, supplemented, restated or otherwise modified from time to time
and any successor agreement thereto. 
 “Preferred Stock Redemption Price” shall have the meaning set forth in
Section 2.8. 

  
 2 

 “Receipt” shall mean a receipt issued hereunder to evidence one or more
Depositary Shares held of record by the record holder of such Depositary Shares, whether in definitive or temporary form, substantially in the form set forth as Exhibit A. 

“record holder” or “holder” as applied to a Receipt shall mean the person in whose name a Receipt is
registered on the books of the Depositary maintained by the Depositary for such purpose. 
 “Redemption Date” shall have
the meaning set forth in Section 2.8. 
 “Registrar” shall mean the Depositary or such other bank or trust
company which shall be appointed by the Company to register ownership and transfers of Receipts as herein provided and if a Registrar shall be so appointed, references herein to “the books” of or maintained by the Depositary shall be
deemed, as applicable, to refer as well to the register maintained by such Registrar for such purpose. 
 “Securities Act”
shall mean the Securities Act of 1933, as amended. 
 “Securities Exchange Act” shall mean the Securities Exchange Act of
1934, as amended. 
 “Series D Preferred Stock” shall mean shares of the Company’s Series D Non-Cumulative Perpetual
Preferred Stock, without par value, with a liquidation preference amount of $100,000 per share, designated and described in the Certificate of Designation. 

ARTICLE II 
 FORM OF
RECEIPTS, DEPOSIT OF SERIES D PREFERRED STOCK, 
 EXECUTION AND DELIVERY, TRANSFER, 

SURRENDER AND REDEMPTION OF RECEIPTS 

Section 2.1 Form and Transfer of Receipts. 

Definitive Receipts shall be substantially in the form set forth in Exhibit A attached to this Deposit Agreement, in each case with
appropriate insertions, modifications and omissions, as hereinafter provided and shall be engraved or otherwise prepared so as to comply with any applicable laws, rules or regulations. 

Receipts shall be executed by the Depositary by the manual signature of a duly authorized officer of the Depositary; provided, that
such signature may be a facsimile if a Registrar for the Receipts (other than the Depositary) shall have been appointed and such Receipts are countersigned by a duly authorized officer of the Registrar. No Receipt shall be entitled to any benefits
under this Deposit Agreement or be valid or obligatory for any purpose unless it shall have been executed manually by a duly authorized officer of the Depositary or, if a Registrar for the Receipts (other than the Depositary) shall have been
appointed, by manual or facsimile signature of a duly authorized officer of the Depositary and countersigned by a duly authorized officer of such Registrar. The Depositary shall record on its books each Receipt so signed and delivered as hereinafter
provided. 

  
 3 

 Receipts shall be in denominations of any number of whole Depositary Shares. All receipts shall
be dated the date of their issuance. 
 Receipts may be endorsed with or have incorporated in the text thereof such legends or recitals or
changes not inconsistent with the provisions of this Deposit Agreement all as may be required by the Depositary and approved by the Company or required to comply with any applicable law or any regulation thereunder or with the rules and regulations
of any securities exchange upon which the Series D Preferred Stock, the Depositary Shares or the Receipts may be listed or to conform with any usage with respect thereto, or to indicate any special limitations or restrictions to which any particular
Receipts are subject. 
 Title to Depositary Shares evidenced by a Receipt which is properly endorsed or accompanied by a properly executed
instrument of transfer shall be transferable by delivery with the same effect as in the case of a negotiable instrument; provided, however, that until transfer of any particular Receipt shall be registered on the books of the
Depositary as provided in Section 2.3, the Depositary may, notwithstanding any notice to the contrary, treat the record holder thereof at such time as the absolute owner thereof for the purpose of determining the person entitled to
distributions of dividends or other distributions or to any notice provided for in this Deposit Agreement and for all other purposes. 

Section 2.2 Deposit of Series D Preferred Stock; Execution and Delivery of Receipts in Respect Thereof. 

Subject to the terms and conditions of this Deposit Agreement, the Company may from time to time deposit shares of the Series D Preferred Stock
under this Deposit Agreement by delivering to the Depositary, including via electronic book-entry, such shares of the Series D Preferred Stock to be deposited, properly endorsed or accompanied by a duly executed instrument of transfer or
endorsement, if applicable and required by the Depositary, in form reasonably satisfactory to the Depositary, together with all such certifications as may be required by the Depositary in accordance with the provisions of this Deposit Agreement and
all other information required to be set forth, and together with a written order of the Company directing the Depositary to execute and deliver to, or upon the written order of, the person or persons stated in such order a Receipt or Receipts
evidencing in the aggregate the number of Depositary Shares representing such deposited Series D Preferred Stock. 
 Deposited Series D
Preferred Stock shall be held by the Depositary at the Depositary’s Office or at such other place or places as the Depositary shall determine. The Depositary shall not lend any Series D Preferred Stock deposited hereunder. 

Upon receipt by the Depositary of Series D Preferred Stock deposited in accordance with the provisions of this Section 2.2,
together with the other documents required as above specified, and upon recordation of the Series D Preferred Stock on the books of the Company (or its duly appointed transfer agent) in the name of the Depositary or its nominee, the Depositary,
subject to the terms and conditions of this Deposit Agreement, shall execute and deliver to or upon the order of the person or persons named in the written order delivered to the Depositary referred to in the first paragraph of this
Section 2.2, a Receipt or Receipts evidencing in the aggregate the number of Depositary Shares representing the Series D Preferred Stock so deposited and 

  
 4 

 
registered in such name or names as may be requested by such person or persons. The Depositary shall execute and deliver such Receipt or Receipts at the Depositary’s Office or such other
offices, if any, as the Depositary may designate. Delivery at other offices shall be at the risk and expense of the person requesting such delivery. 

Section 2.3 Registration of Transfer of Receipts. 

Subject to the terms and conditions of this Deposit Agreement, the Depositary shall register on its books from time to time transfers of
Receipts upon any surrender thereof by the holder in person or by duly authorized attorney, properly endorsed or accompanied by a properly executed instrument of transfer. Thereupon, the Depositary shall execute a new Receipt or Receipts evidencing
the same aggregate number of Depositary Shares as those evidenced by the Receipt or Receipts surrendered and deliver such new Receipt or Receipts to or upon the order of the person entitled thereto. 

The Depositary shall not be required (a) to issue, transfer or exchange any Receipts for a period beginning at the opening of business
fifteen days next preceding any selection of Depositary Shares and Series D Preferred Stock to be redeemed and ending at the close of business on the day of the mailing of notice of redemption, or (b) to transfer or exchange for another Receipt
any Receipt called or being called for redemption in whole or in part except as provided in Section 2.8. 
 Section 2.4
Split-ups and Combinations of Receipts; Surrender of Receipts and Withdrawal of Series D Preferred Stock. 
 Upon surrender of a
Receipt or Receipts at the Depositary’s Office or at such other offices as it may designate for the purpose of effecting a split-up or combination of such Receipt or Receipts, and subject to the terms and conditions of this Deposit Agreement,
the Depositary shall execute a new Receipt or Receipts in the authorized denomination or denominations requested, evidencing the aggregate number of Depositary Shares evidenced by the Receipt or Receipts surrendered, and shall deliver such new
Receipt or Receipts to or upon the order of the holder of the Receipt or Receipts so surrendered. 
 Any holder of a Receipt or Receipts may
withdraw the number of whole shares of Series D Preferred Stock and all money and other property, if any, represented thereby by surrendering such Receipt or Receipts, at the Depositary’s Office or at such other offices as the Depositary may
designate for such withdrawals; provided, that a holder of a Receipt or Receipts may not withdraw such Series D Preferred Stock (or money and other property, if any, represented thereby) which has previously been called for redemption.
Thereafter, without unreasonable delay, the Depositary shall deliver to such holder, or to the person or persons designated by such holder as hereinafter provided, the number of whole shares of Series D Preferred Stock and all money and other
property, if any, represented by the Receipt or Receipts so surrendered for withdrawal, but holders of such whole shares of Series D Preferred Stock will not thereafter be entitled to deposit such Series D Preferred Stock hereunder or to receive a
Receipt evidencing Depositary Shares therefor. If a Receipt delivered by the holder to the Depositary in connection with such withdrawal shall evidence a number of Depositary Shares in excess of the number of Depositary Shares representing the
number of whole shares of Series D Preferred Stock to be so 

  
 5 

 
withdrawn, the Depositary shall at the same time, in addition to such number of whole shares of Series D Preferred Stock and such money and other property, if any, to be so withdrawn, deliver to
such holder, or subject to Section 2.3 upon such holder’s order, a new Receipt evidencing such excess number of Depositary Shares. 

In no event will fractional shares of Series D Preferred Stock (or any cash payment in lieu thereof) be delivered by the Depositary. Delivery
of the Series D Preferred Stock and money and other property, if any, being withdrawn may be made by the delivery of such certificates, documents of title and other instruments as the Depositary may deem appropriate. 

If the Series D Preferred Stock and the money and other property, if any, being withdrawn are to be delivered to a person or persons other
than the record holder of the Receipt or Receipts being surrendered for withdrawal of Series D Preferred Stock, such holder shall execute and deliver to the Depositary a written order so directing the Depositary and the Depositary may require that
the Receipt or Receipts surrendered by such holder for withdrawal of such shares of Series D Preferred Stock be properly endorsed in blank or accompanied by a properly executed instrument of transfer in blank. 

Delivery of the Series D Preferred Stock and the money and other property, if any, represented by Receipts surrendered for withdrawal shall be
made by the Depositary at the Depositary’s Office, except that, at the request, risk and expense of the holder surrendering such Receipt or Receipts and for the account of the holder thereof, such delivery may be made at such other place as may
be designated by such holder. 
 Section 2.5 Limitations on Execution and Delivery, Transfer, Surrender and Exchange of
Receipts. 
 As a condition precedent to the execution and delivery, registration of transfer, split-up, combination, surrender or
exchange of any Receipt, the Depositary, any of the Depositary’s Agents or the Company may require payment to it of a sum sufficient for the payment (or, in the event that the Depositary or the Company shall have made such payment, the
reimbursement to it) of any charges or expenses payable by the holder of a Receipt pursuant to Section 5.7, may require the production of evidence satisfactory to it as to the identity and genuineness of any signature and may also
require compliance with such regulations, if any, as the Depositary or the Company may establish consistent with the provisions of this Deposit Agreement and/or applicable law. 

The deposit of Series D Preferred Stock may be refused, the delivery of Receipts against Series D Preferred Stock may be suspended, the
registration of transfer of Receipts may be refused and the registration of transfer, surrender or exchange of outstanding Receipts may be suspended (i) during any period when the register of stockholders of the Company is closed or
(ii) if any such action is deemed necessary or advisable by the Depositary, any of the Depositary’s Agents or the Company at any time or from time to time because of any requirement of law or of any government or governmental body or
commission or under any provision of this Deposit Agreement. 

  
 6 

 Section 2.6 Lost Receipts, etc. 

In case any Receipt shall be mutilated, destroyed, lost or stolen, the Depositary in its discretion may execute and deliver a Receipt of like
form and tenor in exchange and substitution for such mutilated Receipt, or in lieu of and in substitution for such destroyed, lost or stolen Receipt, upon (i) the filing by the holder thereof with the Depositary of evidence satisfactory to the
Depositary of such destruction or loss or theft of such Receipt, of the authenticity thereof and of such holder’s ownership thereof and (ii) the holder thereof furnishing of the Depositary with reasonable indemnification satisfactory to
the Depositary. 
 Section 2.7 Cancellation and Destruction of Surrendered Receipts. 

All Receipts surrendered to the Depositary or any Depositary’s Agent shall be cancelled by the Depositary. Except as prohibited by
applicable law or regulation, the Depositary is authorized and directed to destroy all Receipts so cancelled. 
 Section 2.8
Redemption of Series D Preferred Stock. 
 Whenever the Company shall be permitted and shall elect to redeem shares of Series D
Preferred Stock in accordance with the provisions of the Certificate of Designation (including on account of a Regulatory Capital Treatment Event, as described therein), it shall (unless otherwise agreed to in writing with the Depositary) give or
cause to be given to the Depositary, not less than 40 days and not more than 70 days prior to the Redemption Date (as defined below), notice of the date of such proposed redemption of Series D Preferred Stock and of the number of such shares held by
the Depositary to be so redeemed and the applicable Depositary Share Redemption Price, which notice shall be accompanied by a certificate from the Company stating that such redemption of Series D Preferred Stock is in accordance with the provisions
of the Certificate of Designation. On the date of such redemption, provided, that the Company shall then have paid or caused to be paid in full to the Depositary the redemption price per share of Series D Preferred Stock to be redeemed, plus
an amount equal to any declared and unpaid dividends thereon to the date fixed for redemption, in accordance with and as required by the provisions of the Certificate of Designation (the “Preferred Stock Redemption Price”), the
Depositary shall redeem the number of Depositary Shares representing such Series D Preferred Stock. The Depositary shall mail notice of the Company’s redemption of Series D Preferred Stock and the proposed simultaneous redemption of the number
of Depositary Shares representing the Series D Preferred Stock to be redeemed by first-class mail, postage prepaid (or another reasonably acceptable transmission method), not less than 30 days and not more than 60 days prior to the date fixed for
redemption of such Series D Preferred Stock and Depositary Shares (the “Redemption Date”), to the record holders of the Receipts evidencing the Depositary Shares to be so redeemed at the addresses of such holders as they appear on
the records of the Depositary, but neither failure to mail any such notice of redemption of Depositary Shares to one or more such holders nor any defect in any notice of redemption of Depositary Shares to one or more such holders shall affect the
sufficiency of the proceedings for redemption as to the other holders. Each such notice shall be prepared by the Company and shall state: (i) the Redemption Date; (ii) the number of Depositary Shares to be redeemed and, if less than all
the Depositary Shares held by any such holder are to be redeemed, the number of such Depositary Shares held by such holder to be so redeemed; (iii) the Depositary Share Redemption Price (as defined

  
 7 

 
below); (iv) the place or places where Receipts evidencing Depositary Shares are to be surrendered for payment of the Depositary Share Redemption Price; and (v) that dividends on the
Series D Preferred Stock underlying the Depositary Shares to be redeemed will cease to accrue on the Redemption Date. In case less than all the outstanding Depositary Shares are to be redeemed, the Depositary Shares to be so redeemed shall be
selected by the Depositary pro rata (as nearly as may be) or in any other manner consistent with the rules and policies of any securities exchange upon which the Series D Preferred Stock or the Depositary Shares may be listed determined by
the Depositary in its sole discretion to be fair and equitable. In any case, the Depositary will redeem Depositary Shares only in increments of 100 Depositary Shares and multiples thereof. 

Notice having been mailed or transmitted by the Depositary as aforesaid, from and after the Redemption Date (unless the Company shall have
failed to provide the funds necessary to redeem the Series D Preferred Stock evidenced by the Depositary Shares called for redemption) (i) all shares of Series D Preferred Stock called for redemption shall cease to be outstanding and any rights
with respect to such shares shall cease and terminate (except for the right to receive the Preferred Stock Redemption Price without interest), (ii) the Depositary Shares being redeemed from such proceeds shall cease to be outstanding and all
rights of the holders of Receipts evidencing such Depositary Shares shall, to the extent of such Depositary Shares, cease and terminate (except the right to receive the Depositary Share Redemption Price without interest), and (iii) upon
surrender in accordance with such redemption notice of the Receipts evidencing any such Depositary Shares called for redemption (properly endorsed or assigned for transfer, if the Depositary or applicable law shall so require), such Depositary
Shares shall be redeemed by the Depositary at a redemption price per Depositary Share (the “Depositary Share Redemption Price”) equal to 1/100th of the Preferred Stock Redemption Price per share of Series D Preferred Stock so
redeemed plus all money and other property, if any, represented by such Depositary Shares. 
 If fewer than all of the Depositary Shares
evidenced by a Receipt are called for redemption, the Depositary will deliver to the holder of such Receipt upon its surrender to the Depositary, together with the redemption payment, a new Receipt evidencing the Depositary Shares evidenced by such
prior Receipt and not called for redemption. 
 The foregoing shall be further subject to the terms and conditions of the Certificate of
Designation. In the event of any conflict between the provisions of the Deposit Agreement and the provisions of the Certificate of Designation, the provisions of the Certificate of Designation will govern and the Company will instruct the
Depositary, as applicable, in writing accordingly of such governing terms; provided, however, that under no circumstances will the Certificate of Designation be deemed to change or modify any of the rights, duties or immunities of the
Depositary contained herein. 
 Section 2.9 Receipts Issuable in Global Registered Form. 

If the Company shall determine in a writing delivered to the Depositary that the Receipts are to be issued in whole or in part in the form of
one or more Global Registered Receipts, then the Depositary shall, in accordance with the other provisions of this Deposit Agreement, execute and deliver one or more Global Registered Receipts evidencing such Receipts, which (i) shall

  
 8 

 
represent, and shall be denominated in an amount equal to the aggregate principal amount of, the Receipts to be represented by such Global Registered Receipt or Receipts, and (ii) shall be
registered in the name of the Global Receipt Depository therefor or its nominee. 
 Notwithstanding any other provision of this Deposit
Agreement to the contrary, unless otherwise provided in the Global Registered Receipt, a Global Registered Receipt may only be transferred in whole and only by the applicable Global Receipt Depository for such Global Registered Receipt to a nominee
of such Global Receipt Depository, or by a nominee of such Global Receipt Depository to such Global Receipt Depository or another nominee of such Global Receipt Depository, or by such Global Receipt Depository or any such nominee to a successor
Global Receipt Depository for such Global Registered Receipt selected or approved by the Company or to a nominee of such successor Global Receipt Depository. Except as provided below, owners solely of beneficial interests in a Global Registered
Receipt shall not be entitled to receive physical delivery of the Receipts represented by such Global Registered Receipt. Neither any such beneficial owner nor any direct or indirect participant of a Global Receipt Depository shall have any rights
under this Deposit Agreement with respect to any Global Registered Receipt held on their behalf by a Global Receipt Depository and such Global Receipt Depository may be treated by the Company, the Depositary and any director, officer, employee or
agent of the Company or the Depositary as the holder of such Global Registered Receipt for all purposes whatsoever. 
 Unless and until
definitive Receipts are delivered to the owners of the beneficial interests in a Global Registered Receipt, (1) the applicable Global Receipt Depository will make book-entry transfers among its participants and receive and transmit all payments
and distributions in respect of the Global Registered Receipts to such participants, in each case, in accordance with its applicable procedures and arrangements, and (2) whenever any notice, payment or other communication to the holders of
Global Registered Receipts is required under this Deposit Agreement, the Company and the Depositary shall give all such notices, payments and communications specified herein to be given to such holders to the applicable Global Receipt Depository.

 If an Exchange Event has occurred with respect to any Global Registered Receipt, then, in any such event, the Depositary, upon receipt of
a written order from the Company for the execution and delivery of individual definitive registered Receipts in exchange for such Global Registered Receipt, shall execute and deliver individual definitive registered Receipts, in authorized
denominations and of like tenor and terms in an aggregate principal amount equal to the principal amount of the Global Registered Receipt surrendered, in exchange for such Global Registered Receipt. 

Definitive registered Receipts issued in exchange for a Global Registered Receipt pursuant to this Section 2.9 shall be registered
in such names and in such authorized denominations as the Global Receipt Depository for such Global Registered Receipt, pursuant to instructions from its participants, shall instruct the Depositary in writing. The Depositary shall deliver such
Receipts to the persons in whose names such Receipts are so registered. 

  
 9 

 Notwithstanding anything to the contrary in this Deposit Agreement, should the Company determine
that the Receipts should be issued as a Global Registered Receipt, the parties hereto shall comply with the terms of each Letter of Representations. 

ARTICLE III 
 CERTAIN
OBLIGATIONS OF 
 HOLDERS OF RECEIPTS AND THE COMPANY 

Section 3.1 Filing Proofs, Certificates and Other Information. 

Any holder of a Receipt may be required from time to time to file such proof of residence, or other matters or other information, to execute
such certificates and to make such representations and warranties as the Depositary or the Company may reasonably deem necessary or proper. The Depositary or the Company may withhold the delivery, or delay the registration of transfer or redemption,
of any Receipt or the withdrawal of the Series D Preferred Stock represented by the Depositary Shares evidenced by any Receipt or the distribution of any dividend or other distribution or the sale of any rights or of the proceeds thereof until such
proof or other information is filed or such certificates are executed or such representations and warranties are made. 
 Section 3.2
Payment of Taxes or Other Governmental Charges. 
 Holders of Receipts shall be obligated to make payments to the Depositary of
certain charges and expenses, as provided in Section 5.7. Registration of transfer of any Receipt or any withdrawal of Series D Preferred Stock and all money or other property, if any, represented by the Depositary Shares evidenced by
such Receipt may be refused until any such payment due is made, and any dividends or other distributions may be withheld or any part of or all the Series D Preferred Stock or other property represented by the Depositary Shares evidenced by such
Receipt and not theretofore sold may be sold for the account of the holder thereof (after attempting by reasonable means to notify such holder prior to such sale), and such dividends or other distributions or the proceeds of any such sale may be
applied to any payment of such charges or expenses, the holder of such Receipt remaining liable for any deficiency. 
 Section 3.3
Warranty as to Series D Preferred Stock. 
 The Company hereby represents and warrants that the Series D Preferred Stock, when issued,
will be duly authorized, validly issued, fully paid and nonassessable. Such representation and warranty shall survive the deposit of the Series D Preferred Stock and the issuance of Receipts. 

Section 3.4 Warranty as to Receipts. 

The Company hereby represents and warrants that the Receipts, when issued, will represent legal and valid interests in the Series D Preferred
Stock. Such representation and warranty shall survive the deposit of the Series D Preferred Stock and the issuance of Receipts. 

  
 10 

 ARTICLE IV 

THE DEPOSITED SECURITIES; NOTICES 

Section 4.1 Cash Distributions. 

Whenever the Depositary shall receive any cash dividend or other cash distribution on Series D Preferred Stock, the Depositary shall, subject
to Sections 3.1 and 3.2, distribute to record holders of Receipts on the record date fixed pursuant to Section 4.4 such amounts of such dividend or distribution as are, as nearly as practicable, in proportion to the
respective numbers of Depositary Shares evidenced by the Receipts held by such holders; provided, however, that in case the Company or the Depositary shall be required to withhold and shall withhold from any cash dividend or other cash
distribution in respect of the Series D Preferred Stock an amount on account of taxes, the amount made available for distribution or distributed in respect of Depositary Shares shall be reduced accordingly. The Depositary shall distribute or make
available for distribution, as the case may be, only such amount, however, as can be distributed without attributing to any holder of Depositary Shares a fraction of one cent. Any such fractional amounts shall be rounded down to the nearest whole
cent and so distributed to registered holders entitled thereto and any balance thus not so distributable shall be held by the Depositary (without liability for interest thereon) and shall be added to and be treated as part of the next sum received
by the Depositary for distribution to record holders of such Receipts. Each holder of a Receipt shall provide the Depositary with its certified tax identification number on a properly completed Form W-8 or W-9, as may be applicable. Each holder of a
Receipt acknowledges that, in the event of non-compliance with the preceding sentence, the Internal Revenue Code of 1986, as amended, may require withholding by the Depositary of a portion of any of the distributions to be made hereunder. 

Section 4.2 Distributions Other than Cash, Rights, Preferences or Privileges. 

Whenever the Depositary shall receive any distribution other than cash, rights, preferences or privileges upon Series D Preferred Stock, the
Depositary shall, at the direction of the Company, subject to Sections 3.1 and 3.2, distribute to record holders of Receipts on the record date fixed pursuant to Section 4.4 such amounts of the securities or property
received by it as are, as nearly as practicable, in proportion to the respective numbers of Depositary Shares evidenced by the Receipts held by such holders, in any manner that the Company may deem equitable and practicable for accomplishing such
distribution. If in the opinion of the Depositary such distribution cannot be made proportionately among such record holders in accordance with the direction of the Company, or if for any other reason (including any requirement that the Company or
the Depositary withhold an amount on account of taxes) the Depositary deems, after consultation with the Company, such distribution not to be feasible, the Depositary may, with the approval of the Company, adopt such method as it deems equitable and
practicable for the purpose of effecting such distribution, including the sale (at public or private sale) of the securities or property thus received, or any part thereof, in a commercially reasonable manner. The net proceeds of any such sale
shall, subject to Sections 3.1 and 3.2, be distributed or made available for distribution, as the case may be, by the Depositary to record holders of Receipts as provided by Section 4.1 in the case of a distribution
received in cash. The Company shall not make any distribution of such securities or property to the Depositary and the Depositary shall 

  
 11 

 
not make any distribution of such securities or property to the holders of Receipts unless the Company shall have provided an opinion of counsel stating that such securities or property have been
registered under the Securities Act or do not need to be registered in connection with such distributions. 
 Section 4.3
Subscription Rights, Preferences or Privileges. 
 If the Company shall at any time offer or cause to be offered to the persons in
whose names Series D Preferred Stock is recorded on the books of the Company any rights, preferences or privileges to subscribe for or to purchase any securities or any rights, preferences or privileges of any other nature, such rights, preferences
or privileges shall in each such instance be made available by the Depositary to the record holders of Receipts in such manner as the Company shall instruct the Depositary in writing, either by the issue to such record holders of warrants
representing such rights, preferences or privileges or by such other method as may be approved by the Company; provided, however, that (i) if at the time of issue or offer of any such rights, preferences or privileges the
Depositary determines that it is not lawful or (after consultation with the Company) not feasible to make such rights, preferences or privileges available to holders of Receipts by the issue of warrants or otherwise, or (ii) if and to the
extent so instructed by holders of Receipts who do not desire to exercise such rights, preferences or privileges, then the Depositary shall, if so directed by the Company, and if applicable laws or the terms of such rights, preferences or privileges
permit such transfer, sell such rights, preferences or privileges at public or private sale, at such place or places and upon such terms as it may deem proper. The net proceeds of any such sale shall, subject to Sections 3.1 and 3.2,
be distributed by the Depositary to the record holders of Receipts entitled thereto as provided by Section 4.1 in the case of a distribution received in cash. 

The Company shall notify the Depositary whether registration under the Securities Act of the securities to which any rights, preferences or
privileges relate is required in order for holders of Receipts to be offered or sold the securities to which such rights, preferences or privileges relate, and the Company agrees with the Depositary that it will file promptly a registration
statement pursuant to the Securities Act with respect to such rights, preferences or privileges and securities and use its reasonable best efforts and take all steps available to it to cause such registration statement to become effective
sufficiently in advance of the expiration of such rights, preferences or privileges to enable such holders to exercise such rights, preferences or privileges. In no event shall the Depositary make available to the holders of Receipts any right,
preference or privilege to subscribe for or to purchase any securities unless and until such registration statement shall have become effective, or the Company shall have provided to the Depositary an opinion of counsel to the effect that the
offering and sale of such securities to such holders are exempt from registration under the provisions of the Securities Act. 
 The Company
shall notify the Depositary whether any other action under the laws of any jurisdiction or any governmental or administrative authorization, consent or permit is required in order for such rights, preferences or privileges to be made available to
holders of Receipts, and the Company agrees with the Depositary that the Company will use its reasonable best efforts to take such action or obtain such authorization, consent or permit sufficiently in advance of the expiration of such rights,
preferences or privileges to enable such holders to exercise such rights, preferences or privileges. 

  
 12 

 Section 4.4 Fixing Record Date for Holders of Receipts. 

Whenever any cash dividend or other cash distribution shall become payable or any distribution other than cash shall be made, or if rights,
preferences or privileges shall at any time be offered, with respect to Series D Preferred Stock, or whenever the Depositary shall receive notice of any meeting at which holders of Series D Preferred Stock are entitled to vote or of which holders of
Series D Preferred Stock are entitled to notice, or whenever the Depositary and the Company shall decide it is appropriate, the Depositary shall in each such instance fix a record date (which shall be the same date as the record date fixed by the
Company with respect to, or otherwise in accordance with the terms of, the Series D Preferred Stock, as identified in a written notice to the Depositary of such record date) for the determination of the holders of Receipts who shall be entitled to
receive such dividend, distribution, rights, preferences or privileges or the net proceeds of the sale thereof, or to give instructions for the exercise of voting rights at any such meeting, or who shall be entitled to notice of such meeting or for
any other appropriate reasons. 
 Section 4.5 Voting Rights. 

Upon receipt of notice of any meeting at which the holders of Series D Preferred Stock are entitled to vote, the Depositary shall, as soon as
reasonably practicable thereafter, mail or cause the Company to mail to the record holders of Receipts a notice prepared by the Company which shall contain (i) such information as is contained in such notice of meeting and (ii) a statement
that the record holders on the applicable record date may, subject to any applicable restrictions, instruct the Depositary as to the exercise of the voting rights pertaining to the amount of Series D Preferred Stock represented by their respective
Depositary Shares (including an express indication that instructions may be given to the Depositary to give a discretionary proxy to a person designated by the Company). Upon the written request of the record holders of Receipts on the relevant
record date, the Depositary shall endeavor insofar as reasonably practicable to vote or cause to be voted, in accordance with the instructions provided by the holder(s) of Receipts set forth in such requests, the maximum number of whole shares of
Series D Preferred Stock represented by the Depositary Shares evidenced by all Receipts as to which any particular voting instructions are received. The Company hereby agrees to take all reasonable action which may be deemed necessary by the
Depositary in order to enable the Depositary to vote such Series D Preferred Stock or cause such Series D Preferred Stock to be voted in accordance with such instructions. In the absence of any specific instructions from a holder of Receipts, the
Depositary will, subject to any applicable restrictions, cast votes pertaining to the number of whole shares of Series D Preferred Stock represented by such Depositary Shares proportionately with instructions actually received. 

Section 4.6 Changes Affecting Deposited Securities and Reclassifications, Recapitalizations, etc. 

Upon any change in par or stated value, split-up, combination or any other reclassification of the Series D Preferred Stock subject to the
provisions of the Certificate of Designation, or upon any recapitalization, reorganization, merger or consolidation affecting the Company or to which it is a party, the Depositary may in its discretion with the approval of, and shall upon the
instructions of, the Company, and (in either case) in such manner as the Depositary may deem equitable, (i) make such adjustments as are certified by the Company in 

  
 13 

 
the fraction of an interest represented by one Depositary Share in one share of Series D Preferred Stock and in the ratio of the Depositary Share Redemption Price to the Preferred Stock
Redemption Price, in each case as may be necessary fully to reflect the effects of such change in par or stated value, split-up, combination or other reclassification of Series D Preferred Stock, or of such recapitalization, reorganization, merger
or consolidation and (ii) treat any securities which shall be received by the Depositary in exchange for or upon conversion of or in respect of the Series D Preferred Stock as new deposited securities so received in exchange for or upon
conversion or in respect of such Series D Preferred Stock. In any such case the Depositary may in its discretion, with the approval of the Company, execute and deliver additional Receipts or may call for the surrender of all outstanding Receipts to
be exchanged for new Receipts specifically describing such new deposited securities. Anything to the contrary herein notwithstanding, holders of Receipts shall have the right from and after the effective date of any such change in par or stated
value, split-up, combination or other reclassification of the Series D Preferred Stock or any such recapitalization, reorganization, merger or consolidation to surrender such Receipts to the Depositary with instructions to convert, exchange or
surrender the Series D Preferred Stock represented thereby only into or for, as the case may be, the kind and amount of shares of Series D Preferred Stock and other securities and property and cash into which the Series D Preferred Stock represented
by such Receipts might have been converted or for which such Series D Preferred Stock might have been exchanged or surrendered immediately prior to the effective date of such transaction. 

Section 4.7 Delivery of Reports. 

The Depositary shall furnish to holders of Receipts any reports and communications received from the Company which are received by the
Depositary and which the Company is required to furnish to the holders of the Series D Preferred Stock. In addition, the Depositary shall make available for inspection by holders of Receipts during business hours at the Depositary’s Office, and
at such other places as it may from time to time deem advisable, any reports and communications the Company delivers to the Depositary as the holder of the Series D Preferred Stock. 

Section 4.8 Lists of Receipt Holders. 

Promptly upon request from time to time by the Company, the Depositary shall furnish to it a list, as of the most recent practicable date, of
the names, addresses and holdings of Depositary Shares of all record holders of Receipts. 
 ARTICLE V 

THE DEPOSITARY, THE DEPOSITARY’S 

AGENTS, THE REGISTRAR AND THE COMPANY 

Section 5.1 Maintenance of Offices, Agencies and Transfer Books by the Depositary; Registrar. 

Upon execution of this Deposit Agreement, the Depositary shall maintain at the Depositary’s Office, facilities for the execution and
delivery, registration and registration of 

  
 14 

 
transfer, surrender and exchange of Receipts, and at the offices of the Depositary’s Agents, if any, facilities for the delivery, registration of transfer, surrender and exchange of
Receipts, all in accordance with the provisions of this Deposit Agreement. 
 The Depositary shall keep books at the Depositary’s
Office for the registration and registration of transfer, surrender and exchange of Receipts, which books at all reasonable times shall be open for inspection by the record holders of Receipts; provided, that any such holder requesting to
exercise such right shall certify to the Depositary that such inspection shall be for a proper purpose reasonably related to such person’s interest as an owner of Depositary Shares evidenced by the Receipts. 

The Depositary may close such books, at any time or from time to time, when deemed expedient by it in connection with the performance of its
duties hereunder. 
 The Depositary may, with the approval of the Company, appoint a Registrar for registration of the Receipts or the
Depositary Shares evidenced thereby. If the Receipts or the Depositary Shares evidenced thereby or the Series D Preferred Stock represented by such Depositary Shares shall be listed on one or more national stock exchanges, the Depositary will
appoint a Registrar (acceptable to the Company) for registration of such Receipts or Depositary Shares in accordance with any requirements of such exchange. Such Registrar (which may be the Depositary if so permitted by the requirements of any such
exchange) may be removed and a substitute Registrar appointed by the Depositary upon the request or with the approval of the Company. If the Receipts, such Depositary Shares or such Series D Preferred Stock are listed on one or more other stock
exchanges, the Depositary will, at the request of the Company, arrange such facilities for the delivery, registration, registration of transfer, surrender and exchange of such Receipts, such Depositary Shares or such Series D Preferred Stock as may
be required by law or applicable stock exchange regulation. 
 Section 5.2 Prevention of or Delay in Performance by the Depositary,
the Depositary’s Agents, the Registrar or the Company. 
 Neither the Depositary nor any Depositary’s Agent nor any Registrar
nor the Company shall incur any liability to any holder of any Receipt if by reason of any provision of any present or future law, or regulation thereunder, of the United States of America or of any other governmental authority or, in the case of
the Depositary, the Depositary’s Agent or the Registrar, by reason of any provision, present or future, of the Company’s Restated Certificate of Incorporation, as amended (including the Certificate of Designation), or if by reason of any
act of God or war or other circumstance beyond the control of the relevant party, the Depositary, the Depositary’s Agent, the Registrar or the Company shall be prevented or forbidden from, or subjected to any penalty on account of, doing or
performing any act or thing which the terms of this Deposit Agreement provide shall be done or performed; nor shall the Depositary, any Depositary’s Agent, any Registrar or the Company incur liability to any holder of a Receipt (i) by
reason of any nonperformance or delay, caused as aforesaid, in the performance of any act or thing which the terms of this Deposit Agreement shall provide shall or may be done or performed, or (ii) by reason of any exercise of, or failure to
exercise, any discretion provided for in this Deposit Agreement except as otherwise explicitly set forth in this Deposit Agreement. 

  
 15 

 Section 5.3 Obligations of the Depositary, the Depositary’s Agents, the Registrar
and the Company. 
 The Depositary will indemnify the Company against any liability which may arise out of acts performed or omitted by
the Depositary due to its gross negligence or willful misconduct. Notwithstanding anything in this Deposit Agreement to the contrary, neither the Depositary nor the Depositary’s Agent nor any Registrar nor the Company shall be liable in any
event for special, punitive, incidental, indirect or consequential losses or damages of any kind whatsoever (including but not limited to lost profits). 

Neither the Depositary nor any Depositary’s Agent nor any Registrar nor the Company shall be under any obligation to appear in, prosecute
or defend any action, suit or other proceeding in respect of the Series D Preferred Stock, the Depositary Shares or the Receipts which in its opinion may involve it in expense or liability unless indemnity satisfactory to it against all expense and
liability be furnished as often as may be required. 
 Neither the Depositary nor any Depositary’s Agent nor any Registrar nor the
Company shall be liable for any action or any failure to act by it in reliance upon the advice of legal counsel or accountants, or information from any person presenting Series D Preferred Stock for deposit, any holder of a Receipt or any other
person believed by it in good faith to be competent to give such information. The Depositary, any Depositary’s Agent, any Registrar and the Company may each rely and shall each be protected in acting upon or omitting to act upon any written
notice, request, direction or other document believed by it to be genuine and to have been signed or presented by the proper party or parties. 

The Depositary shall not be responsible for any failure to carry out any instruction to vote any of the shares of Series D Preferred Stock or
for the manner or effect of any such vote made, as long as any such action or non-action is not the result of gross negligence or willful misconduct by the Depositary. The Depositary undertakes, and any Registrar shall be required to undertake, to
perform such duties and only such duties as are specifically set forth in this Deposit Agreement, and no implied covenants or obligations shall be read into this Deposit Agreement against the Depositary or any Registrar. 

The Depositary, the Depositary’s Agents, and any Registrar may own and deal in any class of securities of the Company and its affiliates
and in Receipts. The Depositary may also act as transfer agent or registrar of any of the securities of the Company and its affiliates. 

The Depositary shall not be under any liability for interest on any monies at any time received by it pursuant to any of the provisions of
this Deposit Agreement or of the Receipts, the Depositary Shares or the Series D Preferred Stock nor shall it be obligated to segregate such monies from other monies held by it, except as required by law. The Depositary shall not be responsible for
advancing funds on behalf of the Company and shall have no duty or obligation to make any payments if it has not timely received sufficient funds to make timely payments. 

In the event the Depositary believes any ambiguity or uncertainty exists hereunder or in any notice, instruction, direction, request or other
communication, paper or document received by the Depositary hereunder, or in the administration of any of the provisions of this Deposit 

  
 16 

 
Agreement, the Depositary shall deem it necessary or desirable that a matter be proved or established prior to taking, omitting or suffering to take any action hereunder, the Depositary may, in
its sole discretion upon written notice to the Company, refrain from taking any action and shall be fully protected and shall not be liable in any way to the Company, any holders of Receipts or any other person or entity for refraining from taking
such action, unless the Depositary receives written instructions or a certificate signed by the Company which eliminates such ambiguity or uncertainty to the reasonable satisfaction of the Depositary or which proves or establishes the applicable
matter to the satisfaction of the Depositary. The Depositary shall not be liable to the Company or any holder of Receipts for any action taken by it in accordance with the written instruction of the Company or the holders of Receipts. 

Section 5.4 Resignation and Removal of the Depositary; Appointment of Successor Depositary. 

The Depositary may at any time resign as Depositary hereunder by delivering notice of its election to do so to the Company, such resignation to
take effect upon the appointment of a successor Depositary and its acceptance of such appointment as hereinafter provided. 
 The Depositary
may at any time be removed by the Company by notice of such removal delivered to the Depositary, such removal to take effect upon the appointment of a successor Depositary hereunder and its acceptance of such appointment as hereinafter provided.

 In case at any time the Depositary acting hereunder shall resign or be removed, the Company shall, within 60 days after the delivery of
the notice of resignation or removal, as the case may be, appoint a successor Depositary, which shall be a bank or trust company having its principal office in the United States of America and having a combined capital and surplus of at least
$50,000,000. If no successor Depositary shall have been so appointed and accepted appointment within 60 days after delivery of such notice, the resigning or removed Depositary may petition any court of competent jurisdiction for the appointment of a
successor Depositary. Every successor Depositary shall execute and deliver to its predecessor and to the Company an instrument in writing accepting its appointment hereunder, and thereupon such successor Depositary, without any further act or deed,
shall become fully vested with all the rights, powers, duties and obligations of its predecessor and for all purposes shall be the Depositary under this Deposit Agreement, and such predecessor, upon payment of all sums due it and on the written
request of the Company, shall promptly execute and deliver an instrument transferring to such successor all rights and powers of such predecessor hereunder, shall duly assign, transfer and deliver all right, title and interest in the Series D
Preferred Stock and any moneys or property held hereunder to such successor, and shall deliver to such successor a list of the record holders of all outstanding Receipts and such records, books and other information in its possession relating
thereto. Any successor Depositary shall promptly mail notice of its appointment to the record holders of Receipts. 
 Any entity into or
with which the Depositary may be merged, consolidated or converted shall be the successor of such Depositary without the execution or filing of any document or any further act, and notice thereof shall not be required hereunder. Such successor
Depositary may authenticate the Receipts in the name of the predecessor Depositary or in the name of the successor Depositary. 

  
 17 

 Section 5.5 Corporate Notices and Reports. 

The Company agrees that it will deliver to the Depositary, and the Depositary will, promptly after receipt thereof, transmit to the record
holders of Receipts, in each case at the addresses recorded in the Depositary’s books, copies of all notices and reports (including without limitation financial statements) required by law, by the rules of any national securities exchange upon
which the Series D Preferred Stock, the Depositary Shares or the Receipts are listed or by the Company’s Restated Certificate of Incorporation, as amended (including the Certificate of Designation), to be furnished to the record holders of
Receipts. Such transmission will be at the Company’s expense and the Company will provide the Depositary with such number of copies of such documents as the Depositary may reasonably request. In addition, the Depositary will transmit to the
record holders of Receipts at the Company’s expense such other documents as may be requested by the Company. Unless otherwise required by law, the requirements set forth in this Section 5.5 may be satisfied by publicly filing or
furnishing such information with or to the U.S. Securities and Exchange Commission. 
 Section 5.6 Indemnification by the
Company. 
 Notwithstanding Section 5.3 to the contrary, the Company shall indemnify the Depositary, any Depositary’s
Agent and any Registrar (including each of their officers, directors, agents and employees) against any and all losses, liabilities, costs, damages or expenses (“Losses”) which may arise out of acts performed, suffered or omitted to be
taken in connection with this Deposit Agreement and the Receipts by the Depositary, any Registrar or any of their respective agents (including any Depositary’s Agent) and any transactions or documents contemplated hereby, except for any Losses
that are finally adjudicated to have been directly caused by the gross negligence or willful misconduct on the respective parts of any such person or persons. The obligations of the Company set forth in this Section 5.6 shall survive any
succession of any Depositary, Registrar or Depositary’s Agent. 
 Section 5.7 Fees, Charges and Expenses. 

The Company agrees promptly to pay the Depositary the compensation to be agreed upon with the Company for all services rendered by the
Depositary hereunder and to reimburse the Depositary for its reasonable out-of-pocket expenses (including reasonable counsel fees and expenses) incurred by the Depositary without gross negligence or willful misconduct on its part (or on the part of
any Depositary’s Agent) in connection with the services rendered by it (or such Depositary’s Agent) hereunder. The Company shall pay all charges of the Depositary in connection with the initial deposit of the Series D Preferred Stock and
the initial issuance of the Depositary Shares, all withdrawals of shares of the Series D Preferred Stock by owners of Depositary Shares, and any redemption or exchange of the Series D Preferred Stock at the option of the Company. The Company shall
pay all transfer and other taxes and governmental charges arising solely from the existence of the depositary arrangements. All other transfer and other taxes and governmental charges shall be at the expense of holders of Depositary Shares evidenced
by Receipts. If, at the request of a holder of Receipts, the Depositary incurs charges or expenses for which the Company is not otherwise liable hereunder, such holder will be liable for such charges and expenses; provided, however,
that the Depositary may, at its sole option, require a holder of a Receipt to prepay the Depositary any charge or expense the Depositary has 

  
 18 

 
been asked to incur at the request of such holder of Receipts. The Depositary shall present its statement for charges and expenses to the Company at such intervals as the Company and the
Depositary may agree. 
 ARTICLE VI 

AMENDMENT AND TERMINATION 

Section 6.1 Amendment. 

The form of the Receipts and any provisions of this Deposit Agreement may at any time and from time to time be amended by agreement between the
Company and the Depositary in any respect which they may deem necessary or desirable; provided, however, that no such amendment which shall materially and adversely alter the rights of the holders of Receipts shall be effective unless
such amendment shall have been approved by the holders of at least a majority (or, in the case of such amendments relating to or affecting rights to receive dividends or distributions or voting or redemption rights, holders of at least two-thirds)
of the Depositary Shares then outstanding. Every holder of an outstanding Receipt at the time any such amendment becomes effective shall be deemed, by continuing to hold such Receipt, to consent and agree to such amendment and to be bound by the
Deposit Agreement as amended thereby. In no event shall any amendment impair the right, subject to the provisions of Sections 2.4 and 2.5 and Article III, of any owner of Depositary Shares to surrender any Receipt evidencing
such Depositary Shares to the Depositary with instructions to deliver to the holder the Series D Preferred Stock and all money and other property, if any, represented thereby, except in order to comply with mandatory provisions of applicable law or
the rules and regulations of any governmental body, agency or commission, or applicable stock exchange. 
 Section 6.2
Termination. 
 This Deposit Agreement may be terminated by the Company or the Depositary only if (i) all outstanding Depositary
Shares have been redeemed pursuant to Section 2.8 or (ii) there shall have been made a final distribution in respect of the Series D Preferred Stock in connection with any liquidation, dissolution or winding up of the Company and
such distribution shall have been distributed to the holders of Depositary Shares pursuant to Section 4.1 or 4.2, as applicable. 

Upon the termination of this Deposit Agreement, the Company shall be discharged from all obligations under this Deposit Agreement except for
its obligations to the Depositary, any Depositary’s Agent and any Registrar under Sections 5.6 and 5.7. 
 ARTICLE VII

 MISCELLANEOUS 

Section 7.1 Counterparts. 

This Deposit Agreement may be executed in any number of counterparts, and by each of the parties hereto on separate counterparts, each of which
counterparts, when so executed and delivered, shall be deemed an original, but all such counterparts taken together shall constitute 

  
 19 

 
one and the same instrument. Delivery of an executed counterpart of a signature page to this Deposit Agreement by facsimile or electronic mail shall be effective as delivery of a manually
executed counterpart of this Deposit Agreement. 
 Section 7.2 Exclusive Benefit of Parties. 

This Deposit Agreement is for the exclusive benefit of the parties hereto, and their respective successors hereunder, and shall not be deemed
to give any legal or equitable right, remedy or claim to any other person whatsoever. 
 Section 7.3 Invalidity of Provisions.

 In case any one or more of the provisions contained in this Deposit Agreement or in the Receipts should be or become invalid, illegal or
unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein or therein shall in no way be affected, prejudiced or disturbed thereby. 

Section 7.4 Notices. 

Any and all notices to be given to the Company hereunder or under the Receipts shall be in writing and shall be deemed to have been duly given
if personally delivered or sent by mail, or by email confirmed by letter, addressed to the Company at 
 Northern Trust Corporation 

Attention: Stephanie S. Greisch, Corporate Secretary 

50 South LaSalle Street 
 Chicago,
Illinois 60603 
 Email: sg321@ntrs.com 

or at any other addresses of which the Company shall have notified the Depositary in writing. 

Any and all notices to be given to the Depositary hereunder or under the Receipts shall be in writing and shall be deemed to have been duly
given if personally delivered or sent by mail, or by facsimile transmission or email confirmed by letter, addressed to the Depositary at the Depositary’s Office at 

Wells Fargo Bank, N.A. 
 1110
Centre Pointe Curve, Suite 101 
 Mendota Heights, MN 55120 

Facsimile No.: (651) 450-4078 

Email: wfssaccountmanagement@wellsfargo.com 

or at any other address of which the Depositary shall have notified the Company in writing. 

Any and all notices to be given to any record holder of a Receipt hereunder or under the Receipts shall be in writing and shall be deemed to
have been duly given if personally delivered or sent by mail or facsimile transmission confirmed by letter, addressed to such record holder at the address of such record holder as it appears on the books of the Depositary, or if such holder shall
have timely filed with the Depositary a written request that notices intended for such holder be mailed to some other address, at the address designated in such request. 

  
 20 

 Delivery of a notice sent by mail or by facsimile transmission or email shall be deemed to be
effected at the time when a duly addressed letter containing the same (or a confirmation thereof in the case of a facsimile transmission or email) is deposited, postage prepaid, in a post office letter box. The Depositary or the Company may,
however, act upon any facsimile transmission or email received by it from the other or from any holder of a Receipt, notwithstanding that such facsimile transmission or email shall not subsequently be confirmed by letter or as aforesaid. 

Section 7.5 Depositary’s Agents. 

The Depositary may from time to time appoint Depositary’s Agents to act in any respect for the Depositary for the purposes of this Deposit
Agreement and may at any time appoint additional Depositary’s Agents and vary or terminate the appointment of such Depositary’s Agents. The Depositary will promptly notify the Company of any such action. 

Section 7.6 Appointment of Registrar, Dividend Disbursing Agent and Redemption Agent in Respect of the Receipts and Series D Preferred
Stock. 
 The Company hereby appoints the Depositary as Registrar, dividend disbursing agent and redemption agent in respect of the
Receipts and the Series D Preferred Stock and the Depositary hereby accepts such appointments. 
 Section 7.7 Holders of Receipts
Are Parties. 
 The holders of Receipts from time to time shall be parties to this Deposit Agreement and shall be bound by all of the
terms and conditions hereof and of the Receipts by acceptance of delivery thereof. 
 Section 7.8 Governing Law. 

This Deposit Agreement and the Receipts and all rights hereunder and thereunder and provisions hereof and thereof shall be governed by, and
construed in accordance with, the laws of the State of New York. 

  
 21 

 Section 7.9 Inspection of Deposit Agreement. 

Copies of this Deposit Agreement shall be filed with the Depositary and, to the extent determined by the Depositary, with the Depositary’s
Agents, and shall be open to inspection during business hours at the Depositary’s Office and the respective offices of such Depositary’s Agents, if any, by any holder of a Receipt. 

Section 7.10 Headings. 

The headings of articles and sections in this Deposit Agreement and in the form of the Receipt set forth in Exhibit A hereto have been
inserted for convenience only and are not to be regarded as a part of this Deposit Agreement or the Receipts or to have any bearing upon the meaning or interpretation of any provision contained herein or in the Receipts. 

[Signature Page Follows] 

  
 22 

 IN WITNESS WHEREOF, the Company and the Depositary have duly executed this Deposit Agreement as
of the day and year first above set forth, and all holders of Receipts shall become parties hereto by and upon acceptance by them of delivery of Receipts issued in accordance with the terms hereof. 

 

			
	NORTHERN TRUST CORPORATION
		
	By:	 	 /s/ David L. Tentinger

	Name:	 	David L. Tentinger
	Title:	 	Executive Vice President and Treasurer
	
	WELLS FARGO BANK, N.A.
		
	By:	 	 /s/ Anne St. Martin

	Name:	 	Anne St. Martin
	Title:	 	VP - Client Services

 EXHIBIT A 

[FORM OF FACE OF RECEIPT] 
 Unless this receipt
is presented by an authorized representative of The Depository Trust Company, a New York corporation (“DTC”), to Northern Trust Corporation or its agent for registration of transfer, exchange, or payment, and any certificate issued
is registered in the name of CEDE & Co. or in such other name as is requested by an authorized representative of DTC (and any payment is made to CEDE & Co. or to such other entity as is requested by an authorized representative of
DTC), ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL inasmuch as the registered owner hereof, CEDE & Co., has an interest herein. 

DEPOSITARY SHARES 
 DEPOSITARY
RECEIPT FOR DEPOSITARY SHARES, EACH 
 REPRESENTING ONE-HUNDREDTH OF ONE SHARE OF 

SERIES D NON-CUMULATIVE PERPETUAL PREFERRED STOCK, 

OF 
 NORTHERN TRUST CORPORATION 

INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE 

CUSIP 665859 AQ7 
 SEE REVERSE FOR
CERTAIN DEFINITIONS 
 Wells Fargo Bank, N.A., as Depositary (the “Depositary”), hereby certifies that CEDE & Co.
is the registered owner of Five Hundred Thousand (500,000) DEPOSITARY SHARES (“Depositary Shares”), each Depositary Share representing one-hundredth of one share of Series D Non-Cumulative Perpetual Preferred Stock, liquidation
preference $100,000 per share, without par value (the “Series D Preferred Stock”), of Northern Trust Corporation, a Delaware corporation (the “Corporation”), on deposit with the Depositary, subject to the terms and
entitled to the benefits of the Deposit Agreement dated as of August 8, 2016 (the “Deposit Agreement”), among the Corporation, the Depositary and the Holders from time to time of the Depositary Receipts. By accepting this
Depositary Receipt, the holder hereof becomes a party to and agrees to be bound by all the terms and conditions of the Deposit Agreement. This Depositary Receipt shall not be valid or obligatory for any purpose or entitled to any benefits under the
Deposit Agreement unless it shall have been executed by the Depositary by the manual signature of a duly authorized officer or, if executed in facsimile by the Depositary, countersigned by a Registrar in respect of the Depositary Receipts by the
manual signature of a duly authorized officer thereof. 
 Dated:
                     
  

			
	Wells Fargo Bank, N.A.
	Depositary
		
	By:	 	  

	Authorized Officer

  
 A-1 

 [FORM OF REVERSE OF RECEIPT] 

NORTHERN TRUST CORPORATION 

NORTHERN TRUST CORPORATION WILL FURNISH WITHOUT CHARGE TO EACH RECEIPTHOLDER WHO SO REQUESTS A COPY OF THE DEPOSIT AGREEMENT AND A COPY OF THE
CERTIFICATE OF DESIGNATION OF THE SERIES D NON-CUMULATIVE PERPETUAL PREFERRED STOCK OF NORTHERN TRUST CORPORATION. ANY SUCH REQUEST IS TO BE ADDRESSED TO THE DEPOSITARY NAMED ON THE FACE OF THIS RECEIPT. 

The Corporation will furnish without charge to each receiptholder who so requests the powers, designations, preferences and relative,
participating, optional or other special rights of each class of stock or series thereof of the Corporation, and the qualifications, limitations or restrictions of such preferences and/or rights. Such request may be made to the Corporation or to the
Registrar. 
 EXPLANATION OF ABBREVIATIONS 

The following abbreviations when used in the form of ownership on the face of this certificate shall be construed as though they were written
out in full according to applicable laws or regulations. Abbreviations in addition to those appearing below may be used. 
  

							
	 Abbreviation
	  	 Equivalent Phrase
	  	 Abbreviation
	  	 Equivalent Phrase

	JT TEN	  	As joint tenants, with right of survivorship and not as tenants in common	  	TEN BY ENT	  	As tenants by the entireties
	TEN IN COM	  	As tenants in common	  	UNIF GIFT MIN ACT	  	Uniform Gifts to Minors Act

  

											
	 Abbreviation
	  	 Equivalent Word
	  	Abbreviation	  	 Equivalent

Word
	  	Abbreviation	  	 Equivalent

Word

	ADM	  	Administrator(s), Administratrix	  	EX	  	Executor(s), Executrix	  	PAR	  	Paragraph
	AGMT	  	Agreement	  	FBO	  	For the benefit of	  	PL	  	Public Law
	ART	  	Article	  	FDN	  	Foundation	  	TR	  	(As) trustee(s), for, of
	CH	  	Chapter	  	GDN	  	Guardian(s)	  	U	  	Under
	CUST	  	Custodian for	  	GDNSHP	  	Guardianship	  	UA	  	Under agreement
	DEC	  	Declaration	  	MIN	  	Minor(s)	  	UW	  	Under will of, Of will of, Under last will & testament
	EST	  	Estate, of Estate of	  		  		  		  	

 For value received,
                     hereby sell(s), assign(s) and transfer(s) unto 

INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE 

PRINT OR TYPEWRITE NAME AND ADDRESS INCLUDING POSTAL ZIP CODE OF ASSIGNEE Depositary Shares represented by the within Receipt, and do(es)
hereby irrevocably constitute and appoint                     
                     Attorney to transfer the said Depositary Shares on the books of the within named Depositary with full power of substitution in
the premises. 

  
 A-2 

 Dated:
                     
 NOTICE: The signature to the
assignment must correspond with the name as written upon the face of this Receipt in every particular, without alteration or enlargement or any change whatsoever. 

SIGNATURE GUARANTEED 
 NOTICE: If applicable, the signature(s)
should be guaranteed by an eligible guarantor institution (banks, stockbrokers, savings and loan associations, and credit unions with membership in an approved signature guarantee medallion program), pursuant to Rule 17Ad-15 under the Securities
Exchange Act of 1934. 

  
 A-3 

 EXHIBIT B 

CERTIFICATE OF DESIGNATION 

OF 
 SERIES D
NON-CUMULATIVE PERPETUAL PREFERRED STOCK 
 OF 

NORTHERN TRUST CORPORATION 

Section 1. Designation. The designation of the series of preferred stock shall be Series D Non-Cumulative Perpetual Preferred
Stock (hereinafter referred to as the “Series D Preferred Stock”). Each share of Series D Preferred Stock shall be identical in all respects to every other share of Series D Preferred Stock. Series D Preferred Stock
will rank equally with Parity Stock, if any, and will rank senior to Junior Stock with respect to the payment of dividends and the distribution of assets in the event of any voluntary or involuntary liquidation, dissolution or winding up of the
Corporation. 
 Section 2. Number of Shares. The number of authorized shares of Series D Preferred Stock shall be 5,000.
Such number may from time to time be increased (but not in excess of the total number of authorized shares of preferred stock) or decreased (but not below the number of shares of Series D Preferred Stock then outstanding) by further resolution duly
adopted by the Board of Directors of the Corporation or any duly authorized committee of the Board of Directors of the Corporation and by the filing of a certificate pursuant to the provisions of the General Corporation Law of the State of Delaware
stating that such increase or reduction, as the case may be, has been so authorized. The Corporation shall have the authority to issue fractional shares of Series D Preferred Stock. 

Section 3. Definitions. As used herein with respect to Series D Preferred Stock: 

“Appropriate Federal Banking Agency” means the “appropriate Federal banking agency” with respect to the Corporation
as defined in Section 3(q) of the Federal Deposit Insurance Act (12 U.S.C. Section 1813(q)), or any successor provision. 

“Board of Directors” means the Board of Directors of the Corporation. 

“Business Day” means each Monday, Tuesday, Wednesday, Thursday or Friday on which banking institutions are not authorized or
obligated by law, regulation or executive order to close in New York, New York. 
 “Calculation Agent” means, at any time,
the person or entity appointed by the Corporation and serving as such agent at such time. 
 “Corporation” means Northern
Trust Corporation. 
 “Depositary Company” shall have the meaning set forth in Section 6(d) hereof. 

“Dividend Payment Date” means (i) the 1st day of April and October of each year, commencing on April 1, 2017, to
and including October 1, 2026, and (ii) the 1st day of January, April, July and October of each year, commencing on January 1, 2027; provided, however, that (x) if any such date on or before October 1, 2026 is not a Business
Day, then such date shall nevertheless be a Dividend Payment Date but dividends on the Series D Preferred Stock, when, as and if declared, shall be paid on the next succeeding Business Day (without any adjustment to the amount of the dividend paid
per share of Series 

  
 B-1 

 
D Preferred Stock), and (y) if any such date after October 1, 2026 is not a Business Day, then the next succeeding Business Day shall be the applicable Dividend Payment Date and
dividends, when, as and if declared, shall be paid on such next succeeding Business Day. Each Dividend Payment Date “relates” to the Dividend Period most recently ending before such Dividend Payment Date, and vice versa (with the words
“related” and “relating” having correlative meanings). 
 “Dividend Period” shall have the meaning set
forth in Section 4(a) hereof. 
 “DTC” means The Depository Trust Company, together with its successors and assigns.

 “Fixed Rate Period” means each Dividend Period relating to a Dividend Payment Date on or before October 1, 2026.

 “Floating Rate Period” means each Dividend Period relating to a Dividend Payment Date after October 1, 2026. 

“Junior Stock” means the Corporation’s common stock, Series A Junior Participating Preferred Stock (if and when issued
and outstanding) and any other class or series of stock of the Corporation hereafter authorized over which the Series D Preferred Stock has preference or priority in the payment of dividends or in the distribution of assets on any liquidation,
dissolution or winding up of the Corporation. 
 “London Banking Day” means any day on which commercial banks are open for
general business (including dealings in deposits in U.S. dollars) in London, England. 
 “Parity Stock” means the Series C
Preferred Stock and any other class or series of stock of the Corporation hereafter authorized that ranks equally with the Series C Preferred Stock and the Series D Preferred Stock in the payment of dividends (whether such dividends are cumulative
or non-cumulative) and in the distribution of assets on any liquidation, dissolution or winding up of the Corporation. 

“Redemption Price” shall have the meaning set forth in Section 6(a) hereof. 

“Regulatory Capital Treatment Event” means the good faith determination by the Corporation that, as a result of (i) any
amendment to, or change (including any announced prospective change) in, the laws or regulations of the United States or any political subdivision of or in the United States that is enacted or becomes effective after the initial issuance of any
share of Series D Preferred Stock, (ii) any proposed change in those laws or regulations that is announced after the initial issuance of any share of Series D Preferred Stock, or (iii) any official administrative decision or judicial
decision or administrative action or other official pronouncement interpreting or applying those laws or regulations that is announced after the initial issuance of any share of Series D Preferred Stock, there is more than an insubstantial risk that
the Corporation will not be entitled to treat the full liquidation preference of the shares of Series D Preferred Stock then outstanding as “additional tier 1 capital” (or its equivalent) for purposes of the capital adequacy rules of the
Board of Governors of the Federal Reserve System in 12 CFR Part 217 (or, as and if applicable, the capital adequacy rules and regulations of any successor Appropriate Federal Banking Agency), as then in effect and applicable, for as long as any
share of Series D Preferred Stock is outstanding. 
 “Reuters Screen LIBOR01” means the display on the Reuters Eikon (or
any successor service) on the “LIBOR01” page (or any other page as may replace such page on such service for the purpose of displaying the London interbank rates of major banks for U.S. dollar deposits). 

“Series C Preferred Stock” means the Corporation’s Series C Non-Cumulative Perpetual Preferred Stock, without par value.

 “Series D Preferred Stock” shall have the meaning set forth in Section 1 hereof. 

  
 B-2 

 “Three-month LIBOR” means, with respect to any Floating Rate Period, the offered
rate expressed as a percentage per annum for deposits in U.S. dollars for a three-month period commencing on the first day of such Floating Rate Period, as that rate appears on Reuters Screen LIBOR01 as of 11:00 A.M., London time, on the second
London Banking Day immediately preceding the first day of such Floating Rate Period. If Three-month LIBOR does not appear on Reuters Screen LIBOR01, Three-month LIBOR shall be determined on the basis of the rates at which deposits in U.S. dollars
for a three-month period, commencing on the first day of such Floating Rate Period, and in a principal amount of not less than $1,000,000 are offered to prime banks in the London interbank market by four major banks in that market selected by the
Corporation and identified to the Calculation Agent, at approximately 11:00 A.M., London time, on the second London Banking Day immediately preceding the first day of such Floating Rate Period. The Calculation Agent shall request the principal
London office of each of these banks to provide a quotation of its rate. If at least two such quotations are provided, Three-month LIBOR for such Floating Rate Period shall be the arithmetic mean of such quotations (rounded upward if necessary to
the nearest 0.00001%). If fewer than two such quotations are provided as described in the third sentence hereof, Three-month LIBOR with respect to such Floating Rate Period shall be the arithmetic mean (rounded upward if necessary to the nearest
0.00001%) of the rates quoted by three major banks in New York City selected by the Corporation and identified to the Calculation Agent, at approximately 11:00 A.M., New York City time, on the first day of such Floating Rate Period for loans in U.S.
dollars to leading European banks for a three-month period, commencing on the first day of such Floating Rate Period, and in a principal amount of not less than $1,000,000. If fewer than three banks selected by the Corporation and identified to the
Calculation Agent to provide quotations are quoting as described in the preceding sentence, Three-month LIBOR with respect to such Floating Rate Period shall be the Three-month LIBOR in effect for the prior Floating Rate Period or, in the case of
the first Floating Rate Period, the most recent Three-month LIBOR that could have been determined had the Floating Rate Period been applicable prior to the first Floating Rate Period. 

Section 4. Dividends. 

(a) Rate. Holders of Series D Preferred Stock shall be entitled to receive, if, when and as declared by the Board of Directors of the
Corporation or any duly authorized committee of the Board of Directors of the Corporation, but only out of assets legally available therefor, non-cumulative cash dividends on the liquidation preference of $100,000 per share of Series D Preferred
Stock, and no more, payable in arrears on each Dividend Payment Date. The period from, and including, the date of issuance of the Series D Preferred Stock or any Dividend Payment Date to, but excluding, the next Dividend Payment Date is a
“Dividend Period.” Dividends on each share of Series D Preferred Stock will accrue on the liquidation preference of $100,000 per share at a rate per annum equal to (i) 4.60% on each Dividend Payment Date relating to a
Fixed Rate Period (and for such Fixed Rate Period) and (ii) Three-month LIBOR plus 3.202% on each Dividend Payment Date relating to a Floating Rate Period (and for such Floating Rate Period). The record date for payment of dividends on the
Series D Preferred Stock shall be the 15th day of the calendar month immediately preceding the month during which the Dividend Payment Date falls. Notwithstanding any other provision hereof,
dividends on the Series D Preferred Stock shall not be declared, paid or set aside for payment to the extent such act would cause the Corporation to fail to comply with laws and regulations applicable thereto, including applicable capital
regulations. 
 The amount of dividends payable in respect of each Fixed Rate Period shall be calculated by the Calculation Agent on
the basis of a 360-day year consisting of twelve 30-day months. The amount of dividends payable on the Series D Preferred Stock in respect of each Floating Rate Period shall be calculated by the Calculation Agent by multiplying the per annum
dividend rate in effect for that Floating Rate Period by a fraction, the numerator of which will be the actual number of days in that Floating Rate Period and the denominator of which will be 360, and multiplying the rate obtained by $100,000 to
determine the dividend per share of Series D Preferred Stock. 
 The Calculation Agent’s determination of any dividend rate, and its
calculation of the amount of dividends for any Dividend Period, will be maintained on file at the Corporation’s principal offices and will be available to any holder of Series D Preferred Stock upon request and will be final and binding in

  
 B-3 

 
the absence of manifest error. The Corporation may terminate the appointment of the Calculation Agent and may appoint a successor agent at any time and from time to
time, provided that the Corporation shall use its best efforts to ensure that there is, at all relevant times when the Series D Preferred Stock is outstanding, a person or entity appointed and serving as such agent.
The Calculation Agent may be a person or entity affiliated with the Corporation. 
 (b) Non-Cumulative Dividends. Dividends on
shares of Series D Preferred Stock shall be noncumulative. To the extent that any dividends payable on the shares of Series D Preferred Stock on any Dividend Payment Date are not declared and paid, in full or otherwise, on such Dividend Payment
Date, then such unpaid dividends shall not cumulate and shall cease to accrue and be payable and the Corporation shall have no obligation to pay, and the holders of Series D Preferred Stock shall have no right to receive, dividends accrued for such
Dividend Period after the Dividend Payment Date for such Dividend Period or interest with respect to such dividends, whether or not dividends are declared for any subsequent Dividend Period with respect to Series D Preferred Stock, Parity Stock,
Junior Stock or any other class or series of authorized stock of the Corporation. 
 (c) Priority of Dividends. So long as any
share of Series D Preferred Stock remains outstanding, unless the full dividends for the most recently completed Dividend Period on all outstanding shares of Series D Preferred Stock have been declared and paid or declared and a sum sufficient for
the payment thereof has been set aside: 
 (i) no dividend shall be declared or paid or set aside for payment and no distribution shall be
declared or made or set aside for payment on any Junior Stock (other than a dividend payable solely in Junior Stock or any dividend in connection with the implementation of a stockholders’ rights plan, or the redemption or repurchase of any
rights under any such plan); 
 (ii) no shares of Junior Stock shall be repurchased, redeemed or otherwise acquired for consideration by the
Corporation, directly or indirectly (other than (A) as a result of a reclassification of Junior Stock for or into other Junior Stock; (B) the exchange or conversion of one share of Junior Stock for or into another share of Junior Stock;
(C) through the use of the proceeds of a substantially contemporaneous sale of other shares of Junior Stock; (D) purchases, redemptions or other acquisitions of shares of the Junior Stock in connection with any employment contract, benefit
plan or other similar arrangement with or for the benefit of employees, officers, directors or consultants; (E) purchases of shares of Junior Stock pursuant to a contractually binding requirement to buy Junior Stock existing prior to the
preceding Dividend Period, including under a contractually binding stock repurchase plan; (F) the purchase of fractional interests in shares of Junior Stock pursuant to the conversion or exchange provisions of such stock or the security being
converted or exchanged; (G) purchases or other acquisitions by any of the Corporation’s broker-dealer subsidiaries solely for the purpose of market making, stabilization or customer facilitation transactions in Junior Stock in the ordinary
course of business; (H) purchases by any of the Corporation’s broker-dealer subsidiaries of the Corporation’s capital stock for resale pursuant to an offering by the Corporation of such capital stock underwritten by such broker-dealer
subsidiary; or (I) the acquisition by the Corporation or any of its subsidiaries of record ownership in Junior Stock for the beneficial ownership of any other persons (other than for the beneficial ownership by the Corporation or any of its
subsidiaries), including as trustees or custodians) nor shall any monies be paid to or made available for a sinking fund for the redemption of any such securities by the Corporation; and 

(iii) no shares of Parity Stock shall be repurchased, redeemed or otherwise acquired for consideration by the Corporation (other than
(A) pursuant to pro rata offers to purchase all, or a pro rata portion, of the Series D Preferred Stock and such 

  
 B-4 

 
Parity Stock; (B) as a result of a reclassification of Parity Stock for or into other Parity Stock or Junior Stock; (C) the exchange or conversion of Parity Stock for or into other
Parity Stock or Junior Stock; (D) through the use of the proceeds of a substantially contemporaneous sale of other shares of Parity Stock or Junior Stock; (E) purchases of shares of Parity Stock pursuant to a contractually binding
requirement to buy Parity Stock existing prior to the preceding Dividend Period, including under a contractually binding stock repurchase plan; (F) the purchase of fractional interests in shares of Parity Stock pursuant to the conversion or
exchange provisions of such stock or the security being converted or exchanged; (G) purchases or other acquisitions by any of the Corporation’s broker-dealer subsidiaries solely for the purpose of market making, stabilization or customer
facilitation transactions in Parity Stock in the ordinary course of business; (H) purchases by any of the Corporation’s broker-dealer subsidiaries of the Corporation’s capital stock for resale pursuant to an offering by the
Corporation of such capital stock underwritten by such broker-dealer subsidiary; or (I) the acquisition by the Corporation or any of its subsidiaries of record ownership in Parity Stock for the beneficial ownership of any other persons (other
than for the beneficial ownership by the Corporation or any of its subsidiaries), including as trustees or custodians). 
 When dividends are not paid in
full upon the shares of Series D Preferred Stock and any Parity Stock, all dividends declared upon shares of Series D Preferred Stock and any Parity Stock will be declared on a proportional basis so that the amount of dividends declared per share
will bear to each other the same ratio that accrued dividends per share on Series D Preferred Stock, and accrued dividends, including any accumulations, on any Parity Stock, bear to each other. To the extent a dividend period with respect to any
Parity Stock coincides with more than one Dividend Period with respect to the Series D Preferred Stock, for purposes of the immediately preceding sentence, the Board of Directors shall treat such dividend period(s) with respect to any Parity Stock
and Dividend Period(s) with respect to the Series D Preferred Stock in a manner that it deems to be fair and equitable in order to achieve proportional payments of dividends on such Parity Stock and the Series D Preferred Stock. To the extent a
Dividend Period with respect to the Series D Preferred Stock coincides with more than one dividend period with respect to any Parity Stock, for purposes of the first sentence of this paragraph, the Board of Directors shall treat such Dividend
Period(s) with respect to the Series D Preferred Stock and dividend period(s) with respect to any Parity Stock in a manner that it deems to be fair and equitable in order to achieve proportional payments of dividends on the Series D Preferred Stock
and such Parity Stock. The term “dividend period” as used in this paragraph means such dividend periods as are provided for in the terms of any Parity Stock. 

No interest will be payable in respect of any dividend payment on shares of Series D Preferred Stock that may be in arrears. If the Board of Directors of the
Corporation determines not to pay any dividend or a full dividend on a Dividend Payment Date, the Corporation will provide, or cause to be provided, written notice to the holders of the Series D Preferred Stock prior to such date. Subject to the
foregoing, and not otherwise, such dividends (payable in cash, stock or otherwise), as may be determined by the Board of Directors of the Corporation or any duly authorized committee of the Board of Directors of the Corporation, may be declared and
paid on any Junior Stock or Parity Stock from time to time out of any assets legally available for such payment, and the holders of Series D Preferred Stock shall not be entitled to participate in any such dividends. 

Section 5. Liquidation Rights. 

(a) Liquidation. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, holders of
Series D Preferred Stock shall be entitled, out of assets legally available therefor, before any distribution or payment out of the assets of the Corporation may be made to or set aside for the holders of any Junior Stock and subject to the rights
of the holders of any class or series of securities ranking senior to Series D Preferred Stock upon liquidation and the rights of the Corporation’s depositors and other creditors, to receive in full a liquidating distribution in the amount of

  
 B-5 

 
the liquidation preference of $100,000 per share, plus any declared and unpaid dividends, without accumulation of any undeclared dividends, to the date of liquidation. The holders of Series D
Preferred Stock shall not be entitled to any further payments in the event of any such voluntary or involuntary liquidation, dissolution or winding up of the Corporation other than what is expressly provided for in this Section 5. 

(b) Partial Payment. If the assets of the Corporation are not sufficient to pay the liquidation preference plus any declared and
unpaid dividends in full to all holders of Series D Preferred Stock and all holders of any Parity Stock, the amounts paid to the holders of Series D Preferred Stock and to the holders of all Parity Stock shall be pro rata in accordance with
the respective aggregate liquidation preferences plus any declared and unpaid dividends, including any accumulations, of Series D Preferred Stock and all such Parity Stock. 

(c) Residual Distributions. If the liquidation preference plus any declared and unpaid dividends has been paid in full to all
holders of Series D Preferred Stock and all holders of any Parity Stock, the holders of Junior Stock shall be entitled to receive all remaining assets of the Corporation according to their respective rights and preferences. 

(d) Merger, Consolidation and Sale of Assets Not Liquidation. For purposes of this Section 5, the sale, lease, conveyance,
exchange or transfer (for cash, securities or other property) of all or substantially all of the property and assets of the Corporation shall not be deemed a voluntary or involuntary liquidation, dissolution or winding up of the Corporation, nor
shall the merger, consolidation or any other business combination transaction of the Corporation into or with any other corporation or person or the merger, consolidation or any other business combination transaction of any other corporation or
person into or with the Corporation (in each case, for cash, securities or other property) be deemed to be a voluntary or involuntary liquidation, dissolution or winding up of the Corporation. 

Section 6. Redemption. 

(a) Optional Redemption. The Corporation, at the option of its Board of Directors or any duly authorized committee of the Board
of Directors of the Corporation, may redeem in whole or in part the shares of Series D Preferred Stock at the time outstanding, on any Dividend Payment Date on or after October 1, 2026, upon notice given as provided in Section 6(b) below.
The redemption price for shares of Series D Preferred Stock shall be $100,000 per share plus dividends that have been declared but not paid, without accumulation of any undeclared dividends (the “Redemption Price”). Notwithstanding
the foregoing, within 90 days following the occurrence of a Regulatory Capital Treatment Event, the Corporation, at its option, subject to the approval of the Appropriate Federal Banking Agency, may provide notice of its intent to redeem as provided
in Section 6(b) below, and subsequently redeem, all (but not less than all) of the shares of Series D Preferred Stock at the time outstanding, at the Redemption Price applicable on such date of redemption. 

(b) Notice of Redemption. Notice of every redemption of shares of Series D Preferred Stock shall be mailed by first class mail, postage
prepaid, addressed to the holders of record of such shares to be redeemed at their respective last addresses appearing on the stock register of the Corporation. Such mailing shall be at least 30 days and not more than 60 days before the date fixed
for redemption. Notwithstanding the foregoing, if the Series D Preferred Stock is held in book-entry form through DTC, the Corporation may give such notice in any manner permitted by DTC. Any notice mailed as provided in this Section 6(b) shall
be conclusively presumed to have been duly given, whether or not the holder receives such notice, but failure duly to give such notice by mail, or any defect in such notice or in the mailing thereof, to any holder of shares of Series D Preferred
Stock designated for redemption shall not affect the validity of the proceedings for the redemption of any other shares of Series D Preferred Stock. Each notice shall state (i) the redemption date; (ii) the number of shares of the Series D
Preferred Stock to be redeemed and, if less than all the shares held by such holder are to be redeemed, the number of such shares to be redeemed from such holder; (iii) the Redemption Price; (iv) the place or places where the certificates
evidencing shares of Series D Preferred Stock are to be surrendered for payment of the Redemption Price; and (v) that dividends on the shares to be redeemed will cease to accrue on the redemption date. 

  
 B-6 

 (c) Partial Redemption. In case of any redemption of only part of the shares of Series D
Preferred Stock at the time outstanding, the shares of Series D Preferred Stock to be redeemed shall be selected either pro rata from the holders of record of Series D Preferred Stock in proportion to the number of Series D
Preferred Stock held by such holders or by lot or in such other manner as the Board of Directors of the Corporation or any duly authorized committee of the Board of Directors of the Corporation may determine to be fair and equitable. Subject to the
provisions of this Section 6, the Board of Directors of the Corporation or any duly authorized committee of the Board of Directors shall have full power and authority to prescribe the terms and conditions upon which shares of Series D Preferred
Stock shall be redeemed from time to time. 
 (d) Effectiveness of Redemption. If notice of redemption has been duly given and
if on or before the redemption date specified in the notice all funds necessary for the redemption have been set aside by the Corporation, separate and apart from its other assets, in trust for the pro rata benefit of the
holders of the shares called for redemption, so as to be and continue to be available therefor, or deposited by the Corporation with a bank or trust company selected by the Board of Directors of the Corporation or any duly authorized committee of
the Board of Directors (the “Depositary Company”) in trust for the pro rata benefit of the holders of the shares called for redemption, then, notwithstanding that any certificate for any share so
called for redemption has not been surrendered for cancellation, on and after the redemption date all shares so called for redemption shall cease to be outstanding, all dividends with respect to such shares shall cease to accrue after such
redemption date, and all rights with respect to such shares shall forthwith on such redemption date cease and terminate, except only the right of the holders thereof to receive the amount payable on such redemption from the Corporation or such bank
or trust company at any time after the redemption date from the funds so set apart or deposited, without interest. The Corporation shall be entitled to receive, from time to time, from the Depositary Company any interest accrued on such funds, and
the holders of any shares called for redemption shall have no claim to any such interest. Any funds so deposited and unclaimed at the end of three years from the redemption date shall, to the extent permitted by law, be released or repaid to the
Corporation, and in the event of such repayment to the Corporation, the holders of record of the shares so called for redemption shall be deemed to be unsecured creditors of the Corporation for an amount equivalent to the amount deposited as stated
above for the redemption of such shares and so repaid to the Corporation, but shall in no event be entitled to any interest. 

Section 7. Voting Rights. The holders of Series D Preferred Stock will have no voting rights, except as expressly provided by law
and except that: 
 (a) Supermajority Voting Rights—Amendments. Unless the vote or consent of the holders of a greater
number of shares shall then be required by law, the affirmative vote or consent of the holders of at least 66 2/3% of all of the shares of the Series D Preferred Stock at the time outstanding, voting separately as a single class, shall be required
to authorize any amendment of the Restated Certificate of Incorporation or of any certificate amendatory thereof or supplemental thereto (including any certificate of designation or any similar document relating to any series of preferred stock) or
the Corporation’s By-laws which will materially and adversely affect the powers, preferences, privileges or rights of the Series D Preferred Stock, taken as a whole; provided, however, that any increase in the amount of the authorized or issued
Series D Preferred Stock or authorized preferred stock of the Corporation or the creation and issuance, or an increase in the authorized or issued amount, of other series of preferred stock ranking equally with and/or junior to the Series D
Preferred Stock with respect to the payment of dividends (whether such dividends are cumulative or non-cumulative) and/or the distribution of assets upon liquidation, dissolution or winding up of the Corporation will not be deemed to adversely
affect the powers, preferences, privileges or rights of the Series D Preferred Stock. 
 (b) Supermajority Voting
Rights—Priority. Unless the vote or consent of the holders of a greater number of shares shall then be required by law, the affirmative vote or consent of the holders of at least 66 2/3% of all of the shares of the Series D Preferred Stock
at the time 

  
 B-7 

 
outstanding, voting separately as a single class, shall be required to issue, authorize or increase the authorized amount of, or to issue or authorize any obligation or security convertible into
or evidencing the right to purchase, any class or series of stock ranking senior to the Series D Preferred Stock and all other Parity Stock with respect to payment of dividends or the distribution of assets upon liquidation, dissolution or winding
up of the Corporation. 
 The foregoing voting provisions will not apply if, at or prior to the time when the act with respect to which such
vote would otherwise be required shall be effected, all outstanding shares of Series D Preferred Stock shall have been redeemed or called for redemption upon proper notice and sufficient funds shall have been set aside by the Corporation for the
benefit of the holders of the Series D Preferred Stock to effect such redemption. 
 Section 8. Conversion. The holders of
Series D Preferred Stock shall not have any rights to convert such Series D Preferred Stock into shares of any other class or series of capital stock of the Corporation or other securities. 

Section 9. Rank. Notwithstanding anything set forth in the Restated Certificate of Incorporation or this Certificate of
Designation to the contrary, the Board of Directors of the Corporation or any authorized committee of the Board of Directors of the Corporation, without the vote of the holders of the Series D Preferred Stock, may authorize the issuance of
additional shares of Junior Stock, Parity Stock or, subject to the voting rights granted in Section 7(b), any class of securities ranking senior to the Series D Preferred Stock as to dividends and the distribution of assets upon any voluntary
or involuntary liquidation, dissolution or winding up of the Corporation. 
 Section 10. Repurchase. Subject to the limitations
imposed herein, the Corporation may purchase and sell Series D Preferred Stock from time to time to such extent, in such manner, and upon such terms as the Board of Directors of the Corporation or any duly authorized committee of the Board of
Directors of the Corporation may determine; provided, however, that the Corporation shall not use any of its funds for any such purchase when there are reasonable grounds to believe that the Corporation is,
or by such purchase would be, rendered insolvent. 
 Section 11. Unissued or Reacquired Shares. Shares of Series D
Preferred Stock not issued or which have been issued and redeemed or otherwise purchased or acquired by the Corporation shall be restored to the status of authorized but unissued shares of preferred stock without designation as to series.

 Section 12. No Sinking Fund. Shares of Series D Preferred Stock are not subject to the operation of a sinking fund. 

* * * * 

  
 B-8EX-10.1

			
	 Confidential Materials omitted and filed separately with
the
 Securities and Exchange Commission. Double asterisks denote omissions.
	  	EXECUTION VERSION

  

			
		  	
Exhibit 10.1
  

  
 MASTER RESEARCH AND COLLABORATION
AGREEMENT 
 by and among 

AGIOS PHARMACEUTICALS, INC. 
 and

 CELGENE CORPORATION 
 and

 CELGENE RIVOT LTD. 
 Dated as
of May 17, 2016 
  

 TABLE OF CONTENTS 
  

							
		    		  	 	Page	  
		
	 ARTICLE I DEFINITIONS
	  	 	1	  
			
	 1.1
	    	 Terms
	  	 	1	  
			
	 1.2
	    	 Additional Definitions
	  	 	15	  
		
	 ARTICLE II COLLABORATION; PRE-OPTION EXERCISE DEVELOPMENT
	  	 	17	  
			
	 2.1
	    	 Scope and Collaboration Overview
	  	 	17	  
			
	 2.2
	    	 Designation of Research Programs
	  	 	20	  
			
	 2.3
	    	 Nomination of Development Candidates; Designation of Designated Development Programs
	  	 	21	  
			
	 2.4
	    	 Disposition of Programs After the End of the Research Term
	  	 	22	  
			
	 2.5
	    	 Completion of Pre-Exercise Phase I Development
	  	 	23	  
			
	 2.6
	    	 Regulatory Affairs
	  	 	23	  
			
	 2.7
	    	 Reports; Results; Testing by the Parties
	  	 	24	  
			
	 2.8
	    	 No Representation
	  	 	24	  
			
	 2.9
	    	 Subcontracting
	  	 	24	  
			
	 2.10
	    	 Academic Collaborators
	  	 	24	  
			
	 2.11
	    	 Material Transfer
	  	 	25	  
			
	 2.12
	    	 Reversion of Rights
	  	 	26	  
		
	 ARTICLE III OPTION EXERCISE; DEVELOPMENT & COMMERCIALIZATION AGREEMENTS
	  	 	26	  
			
	 3.1
	    	 Option Grant and Exercise
	  	 	26	  
			
	 3.2
	    	 Government Approvals
	  	 	28	  
		
	 ARTICLE IV GOVERNANCE
	  	 	31	  
			
	 4.1
	    	 General
	  	 	31	  
			
	 4.2
	    	 Joint Steering Committee
	  	 	32	  
			
	 4.3
	    	 Joint Research Committee
	  	 	33	  
			
	 4.4
	    	 Joint Development Committee
	  	 	34	  
			
	 4.5
	    	 Joint Commercialization Committee
	  	 	36	  
			
	 4.6
	    	 Joint Patent Committee
	  	 	37	  
			
	 4.7
	    	 Alliance Managers
	  	 	37	  
			
	 4.8
	    	 General Committee Membership and Procedures
	  	 	37	  
			
	 4.9
	    	 Responsibilities under Specific Agreements
	  	 	38	  
			
	 4.10
	    	 Decision-Making
	  	 	39	  

  
 - i - 

							
			
	 4.11
	    	 Scope of Governance
	  	 	40	  
			
	 4.12
	    	 Agios Right to Discontinue Participation
	  	 	40	  
		
	 ARTICLE V LICENSES; EXCLUSIVITY
	  	 	41	  
			
	 5.1
	    	 Licenses
	  	 	41	  
			
	 5.2
	    	 Exclusivity
	  	 	42	  
		
	 ARTICLE VI FINANCIAL TERMS
	  	 	45	  
			
	 6.1
	    	 Upfront Payment
	  	 	45	  
			
	 6.2
	    	 Designation Fees
	  	 	45	  
			
	 6.3
	    	 Research Term Extension Fee
	  	 	45	  
			
	 6.4
	    	 Development Costs and Manufacturing Costs
	  	 	45	  
			
	 6.5
	    	 Financial Records
	  	 	45	  
			
	 6.6
	    	 Tax Matters
	  	 	45	  
			
	 6.7
	    	 Payments; Currency Exchange
	  	 	46	  
			
	 6.8
	    	 Late Payments
	  	 	46	  
		
	 ARTICLE VII INTELLECTUAL PROPERTY
	  	 	47	  
			
	 7.1
	    	 Ownership of Inventions
	  	 	47	  
			
	 7.2
	    	 Prosecution of Patents
	  	 	47	  
			
	 7.3
	    	 Defense of Claims Brought by Third Parties
	  	 	47	  
			
	 7.4
	    	 Enforcement and Defense of Patents
	  	 	47	  
			
	 7.5
	    	 Third Party Licenses
	  	 	48	  
		
	 ARTICLE VIII CONFIDENTIALITY
	  	 	48	  
			
	 8.1
	    	 Confidential Information
	  	 	48	  
			
	 8.2
	    	 Permitted Disclosure
	  	 	49	  
			
	 8.3
	    	 Publicity; Terms of this Agreement; Non-Use of Names
	  	 	49	  
			
	 8.4
	    	 Publications
	  	 	52	  
			
	 8.5
	    	 Term
	  	 	53	  
			
	 8.6
	    	 Return of Confidential Information
	  	 	53	  
		
	 ARTICLE IX REPRESENTATIONS AND WARRANTIES
	  	 	54	  
			
	 9.1
	    	 Mutual Representations
	  	 	54	  
			
	 9.2
	    	 Additional Agios Representations
	  	 	54	  
			
	 9.3
	    	 Covenants
	  	 	56	  
			
	 9.4
	    	 Disclaimer
	  	 	57	  
		
	 ARTICLE X INDEMNIFICATION; INSURANCE
	  	 	58	  
			
	 10.1
	    	 By Celgene
	  	 	58	  

  
 - ii - 

							
			
	 10.2
	    	 By Agios
	  	 	58	  
			
	 10.3
	    	 Indemnification Following Exercise of an Option
	  	 	59	  
			
	 10.4
	    	 Joint Defendants
	  	 	59	  
			
	 10.5
	    	 Limitation of Liability
	  	 	60	  
			
	 10.6
	    	 Insurance
	  	 	60	  
		
	 ARTICLE XI TERM AND TERMINATION
	  	 	60	  
			
	 11.1
	    	 Term; Expiration
	  	 	60	  
			
	 11.2
	    	 Termination for Convenience
	  	 	60	  
			
	 11.3
	    	 Termination for Breach
	  	 	61	  
			
	 11.4
	    	 Termination for Insolvency
	  	 	62	  
			
	 11.5
	    	 Effects of Termination
	  	 	62	  
			
	 11.6
	    	 Surviving Provisions
	  	 	63	  
		
	 ARTICLE XII MISCELLANEOUS
	  	 	64	  
			
	 12.1
	    	 Dispute Resolution
	  	 	64	  
			
	 12.2
	    	 Submission to Court for Resolution
	  	 	64	  
			
	 12.3
	    	 Governing Law
	  	 	64	  
			
	 12.4
	    	 Assignment
	  	 	64	  
			
	 12.5
	    	 Force Majeure
	  	 	66	  
			
	 12.6
	    	 Notices
	  	 	66	  
			
	 12.7
	    	 Waiver
	  	 	67	  
			
	 12.8
	    	 Severability
	  	 	67	  
			
	 12.9
	    	 Entire Agreement
	  	 	67	  
			
	 12.10
	    	 Modification
	  	 	67	  
			
	 12.11
	    	 Independent Contractors; No Intended Third Party Beneficiaries
	  	 	68	  
			
	 12.12
	    	 Interpretation; Construction
	  	 	68	  
			
	 12.13
	    	 Performance by Affiliates
	  	 	68	  
			
	 12.14
	    	 Counterparts
	  	 	68	  
			
	 12.15
	    	 Equitable Relief
	  	 	69	  
			
	 12.16
	    	 Further Assurances
	  	 	69	  

  
 - iii - 

 LIST OF APPENDICES 
  

			
	 Appendix A
	  	 Form of Co-Development and Co-Commercialization Agreement

		
	 Appendix B
	  	 Form of License Agreement

		
	 Appendix C
	  	 Certain Financial Definitions

 LIST OF SCHEDULES 
  

			
	 Schedule 1.1.29
	  	 Data Package Information

		
	 Schedule 1.1.35
	  	 Development Candidate Criteria

		
	 Schedule 1.1.82
	  	 Publication Guidelines

		
	 Schedule 1.1.83
	  	 Qualified Early Exercise I&I Program Criteria

		
	 Schedule 9.2.9
	  	 Agios Patents

  
 - iv - 

 MASTER RESEARCH AND COLLABORATION AGREEMENT 

This Master Research and Collaboration Agreement (this “Agreement”) is entered into as of May 17, 2016 (the
“Effective Date”) by and among Agios Pharmaceuticals, Inc., a Delaware corporation (“Agios”), on the one hand, and Celgene Corporation, a Delaware corporation (“Celgene Corp.”), with respect to all
rights and obligations under this Agreement in the United States, and Celgene RIVOT Ltd., a Bermuda entity (“Celgene RIVOT”), with respect to all rights and obligations under this Agreement outside of the United States (Celgene
RIVOT and Celgene Corp. together, “Celgene”), on the other hand. Celgene and Agios are each referred to herein by name or as a “Party”, or, collectively, as the “Parties.” 

RECITALS 

WHEREAS, Agios is a clinical-stage company engaged in the research and development of novel therapies relating to
cellular metabolism, including for the treatment of cancer through targeting cancer metabolism or the immune system; 

WHEREAS, Celgene is engaged in the research, development and commercialization of therapeutic products to treat various
diseases and conditions, including for the treatment of cancer and diseases and conditions of the immune system; 

WHEREAS, the Parties intend to collaborate on the research and development of immunotherapies against certain metabolic
targets that exert their antitumor efficacy primarily via the immune system; 
 WHEREAS, Agios may conduct certain
research and development activities to identify therapeutics directed to certain metabolic targets, and Celgene will obtain exclusive options to enter into a co-development and co-commercialization agreement or a license agreement with Agios
with respect to such therapeutics, as further described herein; 
 WHEREAS, upon each exercise of each such option,
the Parties shall enter into a separate co-development and co-commercialization agreement or license agreement, on the terms and subject to the conditions set forth herein; 

NOW, THEREFORE, in consideration of the foregoing and the mutual agreements set forth below, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 
 ARTICLE I 

DEFINITIONS 

1.1    Terms. 

1.1.1    “2010 Agreement” means the Discovery and Development Collaboration and License
Agreement between Agios and Celgene dated April 14, 2010, as amended. 

 1.1.2    “Active” or
“Activity” means, with respect to a given chemical entity in relation to a given Program Target, that such chemical entity has a level of potency against the applicable Program Target, in the same direction of modulation, expressed
as [**], as applicable, for a Development Candidate for such Program, as measured in a cellular, or, if not available, biochemical, assay for such Program Target, as designated by the JRC. The JRC may establish more specific baseline criteria
for activity in modulating a particular Program Target based on the foregoing criteria. For example, if the [**]. 

1.1.3    “Affiliate” means, as to any Person, any other Person that, directly or
indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, as the case may be, for so long as such control exists. As used in this Section 1.1.3, “control”
means: (a) to possess, directly or indirectly, the power to direct the management and policies of a Person, whether through ownership of voting securities or by contract relating to voting rights or corporate governance; or (b) direct or
indirect beneficial ownership of at least fifty percent (50%) (or such lesser percentage that is the maximum allowed to be owned by a foreign Person in a particular jurisdiction) of the voting share capital in a Person. For purposes of this
Agreement and any Development & Commercialization Agreement, neither Celgene nor Agios shall be deemed an Affiliate of the other Party. 

1.1.4    “Agios Intellectual Property” means Agios Know-How and Agios Patents,
collectively. 
 1.1.5    “Agios Know-How” means any Know-How that is (a) Controlled
by Agios as of the Effective Date or during the Term, and (b) necessary or useful for the Development, Manufacture and/or Commercialization of any Program Compound(s) or Program Product(s). 

1.1.6    “Agios Lead Shared Program” means a Shared 50/50 Program, other than a Celgene
Lead Shared Program, for which Agios will be the “Lead U.S. Party” (as defined in Appendix A), subject to the terms and conditions of the applicable Co-Development and Co-Commercialization Agreement. 

1.1.7    “Agios Patents” means any and all Patents that (a) are Controlled by Agios as
of the Effective Date or during the Term, and (b) Cover the Development, Manufacture and/or Commercialization of any Program Compound(s) or Program Product(s) (including the composition of matter, manufacture or any use thereof). 

1.1.8    “Antitrust Law” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976
and the rules and regulations promulgated thereunder (the “HSR Act”), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Laws related to merger control or designed
to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade, in the following jurisdictions: the United States, all states and territories thereof, Australia, Brazil, Canada, the countries
that are officially recognized as member states of the European Union from time to time (the “EU”), Republic of Korea, Japan, Mexico, Taiwan, and any other jurisdiction that Celgene, in its good faith judgment, determines requires
a pre-merger notification filing prior to consummation of the transactions contemplated by the Development & Commercialization Agreements in accordance with Section 3.2 of this Agreement. 

  
 - 2 - 

 1.1.9    “beneficial owner,”
“beneficially owns,” “beneficial ownership” and terms of similar import used in this Agreement shall, with respect to a Person, have the meaning set forth in Rule 13d-3 under the Securities Exchange Act of 1934, as
amended (i) assuming the full conversion into, and exercise and exchange for, shares of common stock, other voting stock or any securities exercisable for common stock or other voting stock beneficially owned by such Person and (ii) determined
without regard for the number of days in which such Person has the right to acquire such beneficial ownership. 

1.1.10    “Business Day” means a day other than a Saturday or Sunday or federal holiday
in Cambridge, Massachusetts or Summit, New Jersey. 
 1.1.11    “Calendar Quarter”
means a calendar quarter ending on the last day of March, June, September or December; provided, however, that (a) the first Calendar Quarter shall begin on the Effective Date and end on the last day of June, 2016, and (b) the
final Calendar Quarter shall end on the last day of the Term. 
 1.1.12    “Calendar
Year” means a period of time commencing on January 1 and ending on the following December 31; provided, however, that (a) the first Calendar Year shall begin on the Effective Date and end on December 31, 2016, and
(b) the final Calendar Year shall end on the last day of the Term. 
 1.1.13    “Celgene
Collaboration Intellectual Property” means any Patents or Know-How, or Celgene’s and/or its Affiliates’ interest therein, that is developed or generated by or on behalf of Celgene and/or its Affiliate(s) through the use of Agios
Know-How, Joint Collaboration Know-How or materials disclosed or transferred by Agios to Celgene in the conduct of the Collaboration during the Option Term and is necessary or useful for the Development, Manufacture and/or Commercialization of any
Program Compound(s) or Program Product(s). 
 1.1.14    “Celgene Intellectual
Property” means Celgene Know-How and Celgene Patents, collectively. 

1.1.15    “Celgene Know-How” means any Know-How that is (a) Controlled by Celgene as of
the Effective Date or during the Term; (b) necessary or useful for the Development, Manufacture and/or Commercialization of any Program Compound(s) or Program Product(s); and (c) contributed by Celgene, in Celgene’s sole discretion, to the
Collaboration, as evidenced by written notice from Celgene to Agios; but excluding Celgene Collaboration Intellectual Property. 

1.1.16    “Celgene Lead Shared Program” means the Shared 65/35 Program or any Shared
50/50 Program for which Celgene will be the “Lead U.S. Party” (as defined in Appendix A), subject to the terms and conditions of the applicable Co-Development and Co-Commercialization Agreement. 

1.1.17    “Celgene Patents” means any Patents that (a) are Controlled by Celgene as of
the Effective Date or during the Term; (b) Cover the Development, Manufacture and/or Commercialization of any Program Compound(s) or Program Product(s) (including the 

  
 - 3 - 

 
composition of matter, manufacture or any use thereof); and (c) are contributed by Celgene, in Celgene’s sole discretion, to the Collaboration, as evidenced by written notice from Celgene to
Agios; but excluding Celgene Collaboration Intellectual Property. 

1.1.18    “Change of Control” of a Party means any of the following, in a single
transaction or a series of related transactions: (a) the sale or disposition of all or substantially all of the assets of such Party to a Third Party, (b) the direct or indirect acquisition by a Third Party (other than an employee benefit plan
(or related trust) sponsored or maintained by such Party or any of its Affiliates) of beneficial ownership of more than [**] percent ([**]%) of the then-outstanding common shares or voting power of such Party or any direct or indirect entity which
holds, directly or indirectly, beneficial ownership of more than [**] percent ([**]%) of the then-outstanding common shares or voting power of such Party (a “Parent Entity”), or (c) the merger or consolidation of such Party or any
Parent Entity with or into a Third Party, unless, following such merger or consolidation, the stockholders of such Party or Parent Entity immediately prior to such merger or consolidation beneficially own directly or indirectly more than [**]
percent ([**]%) of the then-outstanding common shares or voting power of the entity resulting from such merger or consolidation. 

1.1.19    “Chemistry, Manufacturing and Controls” or “CMC” means the
part of pharmaceutical development that is directed to the Development and Manufacture of products, the specifications therefor, and other parameters which indicate that the finished drug or biologic product and the manufacturing process are
consistent and controlled, in each case, as specified by the FDA or other applicable Regulatory Authorities in the chemistry, manufacturing and controls section of an IND or other regulatory filing in the United States, or the equivalent section of
regulatory filings made outside of the United States. 
 1.1.20    “Claims” means any
and all suits, claims, actions, proceedings or demands brought by a Third Party. 

1.1.21    “Commercialization” or “Commercialize” means any activities
directed to using, marketing, promoting, distributing, importing, offering to sell and/or selling a product, after or in expectation of receipt of Regulatory Approval for such product (but excluding Development). 

1.1.22    “Commercially Reasonable Efforts” means, with respect to the performing Party
under this Agreement or any Development & Commercialization Agreement, [**]. 

1.1.23    “Companion Diagnostic” means a biomarker or diagnostic test that is developed
by a Party or jointly by the Parties in the course of the Collaboration as a companion diagnostic for use with a Program Compound or Program Product in accordance with the Regulatory Approval(s) therefor to generate a result for the purposes of
diagnosing a disease or condition, or to facilitate the application of the Program Compound or Program Product in the cure, mitigation, treatment, or prevention of disease, including a biomarker or diagnostic test used to diagnose the likelihood
that a specific patient will contract a disease or condition or to predict which patients are suitable candidates for a specific form of therapy using the Program Compound or Program Product. 

  
 - 4 - 

 1.1.24    “Confidential Information” means
(a) all confidential or proprietary information relating to any Program Target(s), Program Compound(s) or Program Product(s), including information in the Data Packages, and (b) all other confidential or proprietary documents, technology, Know-How
or other information (whether or not patentable) actually disclosed by one Party to the other pursuant to this Agreement, the 2010 Agreement (solely with respect to information relating to the [**]) or the Prior Confidentiality Agreement, including
information regarding a Party’s technology, products, business information or objectives and reports under Section 2.7, and all proprietary biological materials of a Party. 

1.1.25    “Continuation Program” means a Research Program under which Agios may continue
to carry out Development activities directed to the identification and nomination of a Development Candidate as of the end of the Research Term and that Celgene designates as a Continuation Program in accordance with Section 2.4.2. 

1.1.26     “Control” or “Controlled” means, with respect to any (a)
Know-How or other information or materials, (b) any compounds, or (c) intellectual property right, the possession (whether by license (other than a license granted under this Agreement) or ownership) by a Party of the ability to grant to the other
Party access and/or a license, as provided herein, without violating the terms of any agreement with any Third Party existing as of the Effective Date or thereafter during the Term. Notwithstanding the foregoing, for the purpose of defining
whether intellectual property, Patents, Know-How or Confidential Information is Controlled by a Party, if such intellectual property, Patents, Know-How or Confidential Information is first acquired, licensed or otherwise made available to such Party
after the Effective Date, or the effective date of the applicable Development & Commercialization Agreement, as applicable, and if the use, practice or exploitation thereof by or on behalf of the other Party, its Affiliates or sublicensees would
require the first Party to pay any amounts to the Third Party from which the first Party acquired, licensed or otherwise obtained such intellectual property, Patents, Know-How or Confidential Information (“Additional Amounts”), such
intellectual property, Patents, Know-How or Confidential Information shall be deemed to be Controlled by the first Party only if the other Party agrees to pay (if necessary) and does in fact pay all Additional Amounts with respect to such other
Party’s use of or license to such intellectual property, Patents, Know-How or Confidential Information to the extent specified in this Agreement or the applicable Development & Commercialization Agreement. 

1.1.27     “Cover,” “Covering” or “Covered” means
that, with respect to a product or technology, but for a license granted to a Person under the Patents under which such license is granted, the Development, Manufacture, Commercialization or other use of such product or practice of such technology
by such Person would infringe a claim of any such Patents or, with respect to a claim included in any patent application, would infringe such claim if such patent application were to issue as a patent. 

1.1.28    “Damages” means all claims, threatened claims, damages, losses, suits,
proceedings, liabilities, costs (including reasonable legal expenses, costs of litigation and reasonable attorney’s fees), or judgments, whether for money or equitable relief, of any kind and is not limited to matters asserted by Third Parties
against a Party, but includes claims, threatened claims, damages, losses, suits, proceedings, liabilities, costs (including reasonable legal expenses, costs of litigation and reasonable attorney’s fees) or judgments incurred or sustained

  
 - 5 - 

 
by a Party in the absence of Third Party claims; provided that no Party shall be liable to hold harmless or indemnify the Agios Indemnified Parties or Celgene Indemnified Parties,
as applicable, for any claims, threatened claims, damages, losses, suits, proceedings, liabilities, costs or judgments for punitive or exemplary damages, except to the extent the Party seeking indemnification is actually liable to a Third Party for
such punitive or exemplary damages in connection with a claim by such Third Party. 

1.1.29    “Data Package” means, on a Program-by-Program basis, a data package prepared
in accordance with the terms and conditions of this Agreement (including Section 1.1.62) by Agios with respect to Development activities conducted under a Program and provided by Agios to Celgene upon the occurrence of the following events: 

[**] 
 The
foregoing Data Packages shall contain the applicable information outlined in Schedule 1.1.29 for such Data Package, in a form reasonable under the circumstances. 

1.1.30    “Defense” means any actions brought to defend a Patent against a challenge to
such Patent, including without limitation interferences, oppositions, reexaminations, inter partes reviews or post-grant reviews, excluding any actions included within Prosecution. “Defend” will have the correlative
meaning. 
 1.1.31    “Designated Development Program” means a Research Program that
has been designated by Celgene as a Designated Development Program in accordance with Section 2.3.2(b). 

1.1.32    “Develop” or “Development” means discovery, research,
preclinical, non-clinical and clinical development activities, including activities relating to screening, assays, test method development and stability testing, toxicology, pharmacology, formulation, quality assurance/quality control development,
clinical trials (including Phase IV clinical trials), technology transfer, statistical analysis, process development and scale-up, pharmacokinetic studies, data collection and management, report writing and other pre-Regulatory Approval activities.

 1.1.33    “Development & Commercialization Agreement” means an agreement in the
form attached hereto as Appendix A (“Co-Development and Co-Commercialization Agreement”) or in the form attached hereto as Appendix B (“License Agreement”), as applicable. 

1.1.34    “Development Candidate” means, on a Program-by-Program basis, a Program
Compound in such Program that is (a) Developed by or on behalf of Agios or any of its Affiliates prior to or after the Effective Date until expiration of the Option Term and (b) nominated by either Agios or Celgene in accordance with Section 2.3.1
and has been determined or deemed, as applicable, to meet the Development Candidate Criteria pursuant to Section 2.3.2(a). 

1.1.35    “Development Candidate Criteria” means the criteria set forth in Schedule
1.1.35. 

  
 - 6 - 

 1.1.36    “Dollars” or “$”
means the legal tender of the United States. 
 1.1.37    “Executive Officers” means
Celgene’s Chief Executive Officer (or the officer or employee of Celgene then serving in a substantially equivalent capacity) or his designee and Agios’ Chief Executive Officer (or the officer or employee of Agios then serving in a
substantially equivalent capacity) or his designee; provided that any such designee must have decision-making authority on behalf of the applicable Party. 

1.1.38    “FDA” means the United States Food and Drug Administration, or any successor
agency thereof. 
 1.1.39    “FDCA” means the United States Federal Food, Drug, and
Cosmetic Act, and the regulations promulgated thereunder, each as amended from time to time. 

1.1.40    “FTE” means the equivalent of the work of one (1) full-time employee of a
Party or its Affiliates for one (1) year (consisting of [**] hours per year) in directly conducting Development, Manufacturing and/or Commercialization activities hereunder. Any Party’s employee who devotes fewer than [**] hours per year
on the applicable activities shall be treated as an FTE on a pro-rata basis, calculated by dividing the actual number of hours worked by such employee on such activities by [**]. Any employee who devotes more than [**] hours per year on the
applicable activities shall be treated as one (1) FTE. For the avoidance of doubt, FTE shall not include the work of general corporate or administrative personnel, except for the portion of such personnel’s work time actually spent on
conducting scientific, technical or commercial activities directly related to the Development, Manufacture or Commercialization of Program Products. 

1.1.41    “FTE Rate” means, during the Term: (a) with respect to Development activities,
$[**] per FTE and (b) with respect to Commercialization activities, $[**] per FTE. On January 1, 2017 and on January 1st of each subsequent Calendar Year, the foregoing rate shall be
increased for the Calendar Year then commencing by the percentage increase, if any, in the Consumer Price Index (“CPI”) as of December 31 of the then most recently completed Calendar Year with respect to the level of the CPI on
December 31, 2015. As used in this definition, Consumer Price Index or CPI means the Consumer Price Index – Urban Wage Earners and Clerical Workers, US City Average, All Items, 1982-84 = 100, published by the United States Department of
Labor, Bureau of Labor Statistics (or its successor equivalent index).
 1.1.42    “Good
Clinical Practices” or “GCP” means the ethical and scientific quality standards for designing, conducting, recording, and reporting trials that involve the participation of human subjects as are required by applicable
Regulatory Authorities or Law in the relevant jurisdiction. In the United States, GCP shall be based on Good Clinical Practices established through FDA guidances (including Guideline for Good Clinical Practice – ICH Harmonized Tripartite
Guideline (ICH E6)), and, outside the United States, GCP shall be based on Guideline for Good Clinical Practice – ICH Harmonized Tripartite Guideline (ICH E6).

  
 - 7 - 

 1.1.43    “Good Laboratory Practices” or
“GLP” means the then-current good laboratory practice standards promulgated or endorsed by the FDA, as defined in U.S. 21 C.F.R. Part 58 (or such other comparable regulatory standards in jurisdictions outside the United States,
as they may be updated from time to time). 
 1.1.44    “Good Manufacturing Practices”
or “GMP” means all applicable standards relating to manufacturing practices for fine chemicals, intermediates, bulk products and/or finished pharmaceutical products, including (a) all applicable requirements detailed in the
FDA’s current Good Manufacturing Practices regulations, U.S. 21 C.F.R. Parts 210 and 211 and “The Rules Governing Medicinal Products in the European Community, Volume IV, Good Manufacturing Practice for Medicinal Products”, as each
may be amended from time to time, and (b) all applicable Laws promulgated by any Governmental Authority having jurisdiction over the Manufacture of any Post-Exercise Product. 

1.1.45    “Governmental Authority” means any: (a) nation, principality, state,
commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental authority of any nature (including any
governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or entity and any court or other tribunal); (d) multinational
organization or body; or (e) individual, entity or body exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature. 

1.1.46    “I&I Field” means the treatment, prevention or palliation of Indications
in which there is an immune system dysregulation, including, without limitation, an inappropriate or excessive immune response against normal tissue present in the body such that the immune system recognizes such normal tissue cells as non-self.

 1.1.47    “I&I Program” means any Post-Exercise Program (assuming exercise of
an Option) that would not be an IO Program.  
 1.1.48    “IND” means any
Investigational New Drug application, filed with the FDA pursuant to Part 312 of Title 21 of the U.S. Code of Federal Regulations, including any supplements or amendments thereto. References herein to IND shall include, to the extent
applicable, any comparable filing(s) outside the United States (such as a Clinical Trial Application (“CTA”) in the countries that are officially recognized as member states of the EU). 

1.1.49    “Indication” means any human disease, condition or syndrome, or sign or
symptom of, or associated with, a human disease, condition or syndrome. 

1.1.50    “Inventions” means all inventions, whether or not patentable, that are
designed, discovered, generated, invented or conceived by or on behalf of either Party or its respective Affiliates or both Parties or their respective Affiliates, whether solely or jointly with any Third Party, in the course of activities performed
under this Agreement or any Development & Commercialization Agreement, as applicable. 

  
 - 8 - 

 1.1.51    “IO Field” means the treatment,
prevention or palliation of oncology and/or hematologic malignancy Indications through the use of immunotherapies, the efficacy of which is demonstrated to be mediated primarily through the immune system. 

1.1.52    “IO Program” means any Post-Exercise Program (assuming exercise of an Option)
for which, based upon then-current good scientific practice and understanding (taking into account published studies and industry-generated, Agios-generated or Celgene-generated data), at the time of exercise of such Option, the initial contemplated
Indication would be in the IO Field. 
 1.1.53    “Joint Collaboration IP” means,
collectively: 
 (a)    “Joint Collaboration Know-How,” which means all Know-How,
including physical embodiments of Program Compound(s), Program Product(s) and Companion Diagnostics, that is discovered, generated or invented by or on behalf of both Parties or their respective Affiliates, whether solely or jointly with any Third
Party, pursuant to the conduct of activities under the Collaboration at any time during the Term; and 

(b)    “Joint Collaboration Patents,” which means Patents that Cover any Joint
Collaboration Know-How. 
 1.1.54     “Know-How” means any tangible or intangible
trade secrets, know-how, expertise, discoveries, inventions, information, data or materials, including ideas, concepts, formulas, methods, procedures, designs, technologies, compositions, plans, applications, technical data, assays, manufacturing
information or data, samples, chemical and biological materials and all derivatives, modifications and improvements thereof. 

1.1.55    “Law” means any law, statute, rule, regulation, ordinance or other
pronouncement having the effect of law, of any federal, national, multinational, state, provincial, county, city or other political subdivision, as from time to time enacted, repealed or amended, including Good Clinical Practices and adverse event
reporting requirements, guidance from the International Conference on Harmonization or other generally accepted conventions, the FDCA and similar laws and regulations in countries outside the United States, and all other rules, regulations and
requirements of the FDA and other applicable Regulatory Authorities. 
 1.1.56    “Licensed
Product” means a Program Product that is the subject of a Licensed Program. 

1.1.57    “Licensed Program” means a Post-Exercise Program as to which the Parties have
entered into a License Agreement. 
 1.1.58    “Manufacture” or
“Manufacturing” means, as applicable, all activities associated with the production, manufacture, processing, filling, packaging, labeling, shipping and storage of a drug substance or drug product, and/or any components thereof,
including process and formulation development, process validation, stability testing, manufacturing scale-up, preclinical, clinical and commercial manufacture and analytical methods development and validation, product characterization, quality
assurance and quality control development, testing and release. 

  
 - 9 - 

 1.1.59    “[**]” means [**]. 

1.1.60    “[**]” means [**]. 

1.1.61    “Metabolic Target” means any one or more isoforms or mutated forms of a
metabolic enzyme (or any combination thereof) that interconverts specific metabolites, or a transporter (including isoforms or mutated forms) that transports specific metabolites into or out of a cell or a subcellular compartment. For the
avoidance of doubt, Metabolic Target will exclude, for example, [**]. The Parties understand and agree that, subject to the terms and conditions of Section 2.1.1(d), any one or more isoforms or mutated forms of a metabolic enzyme (or any
combination thereof) that interconverts specific metabolites, or a transporter (including isoforms or mutated forms) that transports specific metabolites into or out of a cell or a subcellular compartment shall be deemed to be one “Metabolic
Target” under this Agreement. Subject to the terms and conditions of Section 2.1.1(d), isoforms may be considered by the JSC to be separated into distinct Metabolic Targets if (a) [**] and (b) [**].

1.1.62    “Option Data Package Verification Date” means, with respect to an Option Data
Package, the date that is [**] days after the date of receipt by Celgene of such Option Data Package; provided that, if Celgene requests additional reasonable information and clarifications during such [**] day period, then such [**]
day period will be automatically extended (as necessary) until the later of (a) [**] days following receipt by Celgene (or any designee) of such additional reasonable information and clarifications are supplied by Agios and (b) the original [**] day
period. 
 1.1.63    “Option Exercise Notice” means, on a Program-by-Program basis,
the written notice provided to Agios by Celgene pursuant to Section 3.1.2(a), such notice constituting Celgene’s exercise of its Option with respect to a Qualified Early Exercise I&I Program, Designated Development Program or a Continuation
Program to convert it into a Post-Exercise Program. 
 1.1.64    “Option Term” means
the period commencing on the Effective Date and ending on the later of (a) the expiration of the Research Term or (b) the expiration of the last-to-expire Option Exercise Window for any Continuation Program or any Designated Development Program;
provided, however, that the Option Term shall not extend after January 1, 2030. 

1.1.65    “Patent” means (a) patents and patent applications anywhere in the world, (b)
all divisionals, continuations, continuations in-part thereof or any other patent application claiming priority, or entitled to claim priority, directly or indirectly to (i) any such patents or patent applications or (ii) any patent or patent
application from which such patents or patent applications claim, or is entitled to claim, direct or indirect priority, and (c) all patents issuing on any of the foregoing anywhere in the world, together with all registrations, reissues,
re-examinations, patents of addition, renewals, patent term extensions, supplemental protection certificates, or extensions of any of the foregoing anywhere in the world. 

1.1.66    “Person” means any corporation, limited or general partnership, limited
liability company, joint venture, trust, unincorporated association, governmental body, authority, bureau or agency, any other entity or body, or an individual. 

  
 - 10 - 

 1.1.67    “Phase I Study” means a human
clinical trial of a product, the principal purpose of which is a preliminary determination of safety, tolerability and pharmacokinetics in study subjects where potential pharmacological activity may be determined or similar clinical study prescribed
by the Regulatory Authorities, from time to time, pursuant to applicable Law or otherwise, including for example the trials referred to in 21 C.F.R. §312.21(a), as amended (or the non-United States equivalent thereof). 

1.1.68    “Phase II Study” means a human clinical trial intended to explore a variety of
doses, dose response, and duration of effect, and to generate evidence of clinical safety and effectiveness for a particular Indication or Indications in a target patient population, or a similar clinical study prescribed by the relevant Regulatory
Authorities, from time to time, pursuant to applicable Law or otherwise, including for example the trials referred to in 21 C.F.R. §312.21(b), as amended (or the non-United States equivalent thereof). 

1.1.69    “Phase III Study” means a human clinical trial of a product in any country
that would satisfy the requirements of 21 C.F.R. §312.21(c), as amended (or the non-United States equivalent thereof) and is intended to (a) establish that the product is safe and efficacious for its intended use, (b) define contraindications,
warnings, precautions and adverse reactions that are associated with the product in the dosage range to be prescribed, and (c) support Regulatory Approval for such product. 

1.1.70     “Pivotal Clinical Trial” means a human clinical trial of a product on a
sufficient number of subjects that, prior to commencement of the trial, satisfies both of the following ((a) and (b)): 
  

	 	(a)	 such trial is designed to establish that such product has an acceptable safety and efficacy profile for its
intended use, and to determine warnings, precautions, and adverse reactions that are associated with such product in the dosage range to be prescribed, which trial is intended to support Regulatory Approval of such product, or a similar clinical
study prescribed by the U.S. or EMA; and 

  

	 	(b)	 such trial is a registration trial designed to be sufficient to support the filing of an application for a
Regulatory Approval for such product in the U.S. or another country or some or all of an extra-national territory, as evidenced by (i) an agreement with or statement from the FDA or the EMA on a Special Protocol Assessment or equivalent, or (ii)
other guidance or minutes issued by the FDA or EMA, for such registration trial. 

1.1.71    “Post-Exercise Product” means a Shared Product or a Licensed Product, as
applicable. 
 1.1.72    “Post-Exercise Program” means a Qualified Early Exercise
I&I Program, Designated Development Program or Continuation Program, in each case as to which Celgene has exercised its Option.

  
 - 11 - 

 1.1.73    “Pre-Exercise Phase I
Development” means: 
  

	 	(a)	 for any Indication in the IO Field, the conduct of a first Phase I Study of a first Development Candidate of a
Designated Development Program or a Continuation Program through a single-agent, dose-escalation Phase I Study, [**] data to warrant advancing the Program Compound, if appropriate, to combination and/or Phase II Studies [**] and preclinical
Development necessary to enable the conduct of such Phase I Study; and 

  

	 	(b)	 for any Indication in the I&I Field, “Pre-Exercise Phase I Development” means the conduct
of (I) first single ascending dose and multiple ascending dose Phase I Studies of a first Development Candidate of a Designated Development Program or a Continuation Program in [**] data to warrant advancing the Program Compound, if appropriate, to
combination and/or further Phase II Studies. Notwithstanding the foregoing or anything to the contrary herein or in any applicable License Agreement, as to any Qualified Early Exercise I&I Program as to which Celgene exercises its Option as set
forth in Section 3.1.1(b), Pre-Exercise Phase I Development shall be deemed to have been completed, and Agios shall have no responsibility therefor (including for any applicable Ongoing Clinical Trial (as defined in Appendix B) hereunder or
under the applicable License Agreement following such early Option exercise by Celgene. 

1.1.74    “Pre-Exercise Program” means a Research Program, Designated Development
Program, or Continuation Program. 
 1.1.75    “Prior Confidentiality Agreement” means
the Mutual Confidentiality Agreement between Agios and Celgene, dated as of December 16, 2015. 

1.1.76    “Program” means a Pre-Exercise Program or a Post-Exercise Program.

1.1.77    “Program Compound” means a chemical entity (including any salt,
fluorinated derivative, free acid, free base, clathrate, solvate, hydrate, hemihydrates, anhydride, ester, chelate, conformer, congener, crystal form, crystal habit, polymorph, amorphous solid, isomer, stereoisomer, enantiomer, racemate, prodrug,
isotopic or radiolabeled equivalent, metabolite, conjugate, complex or mixture of such chemical entity, each a “Related Compound”) Developed or Controlled by Agios or any Affiliates identified as [**], as of the date of its
inclusion in a Program or thereafter found to have such activity (whether or not during the Research Term or, in the case of any Related Compound, during or after the Research Term) against a Program Target, in the applicable direction of
modulation, in the course of conducting a Program. For the avoidance of doubt, Compounds (as defined in Appendix A or Appendix B) shall be limited to (a) the Program Compounds that the Parties reasonably agree at the time of
Option exercise are Active against the applicable Program Target and are listed on Exhibit A to the applicable Development & Commercialization Agreement, which, for the avoidance of doubt, shall include the applicable Development
Candidate and (b) such other Compounds (as defined in Appendix A or Appendix B) that are Active against the applicable Program Target. 

  
 - 12 - 

 1.1.78    “Program Product” means a product
that contains as an active ingredient a Program Compound. 
 1.1.79    “Program
Target” means a Metabolic Target that, together with Program Compounds that are either activators or inhibitors of such Metabolic Target, is the focus of a Program. For clarity, each Program will only include activators or inhibitors,
but not both, of a Metabolic Target, but if a Metabolic Target is the focus of both an activator Program and an inhibitor Program, such Metabolic Target shall be deemed a Program Target of each such Program. 

1.1.80    “Prosecution” or “Prosecute” means the filing, preparation,
prosecution and maintenance of Patents, including any and all pre-grant proceedings before any patent authority, such as interferences. 

1.1.81    “Publication” means any publication in a scientific journal, any scientific
abstract to be presented to any audience, any presentation at any scientific conference, including slides and texts of oral or other public presentations, any other scientific presentation and any other oral, written or electronic scientific
disclosure directed to any audience that pertains to any Program Target(s), Program Compound(s) or Program Product(s), or the use of any of the foregoing, or the data or result from any work under any Program. 

1.1.82    “Publication Guidelines” means the criteria for Publication set forth on
Schedule 1.1.82. 
 1.1.83    “Qualified Early Exercise I&I Program” means
a Research Program that, at the time of Celgene’s exercise of its Option therefor pursuant to Section 3.1.1(b), (a) has achieved the criteria set forth in Schedule 1.1.83, (b) does not include any Program Compounds that have been nominated or
designated as Development Candidates in accordance with Section 2.3.1 or 2.3.2, (c) includes Program Compounds that have been identified as having potential application in the I&I Field and (d) does not include Program Compounds that are being
Developed in the conduct of the Collaboration for potential application in the IO Field. Notwithstanding the foregoing, once Celgene has exercised its Option as to [**] Qualified Early Exercise I&I Programs in accordance with Section
3.1.1(b), no other Research Programs shall be Qualified Early Exercise I&I Programs, and Celgene shall have no further right to exercise Options therefor under Section 3.1.1(b). 

1.1.84     “Regulatory Approval” means all approvals of the applicable Regulatory
Authority necessary for the commercial marketing and sale of a product for a particular indication in a country (including separate Regulatory Authority pricing or reimbursement approvals whether or not legally required in order to sell the product
in such country, it being understood that, as of the Effective Date, no such Regulatory Authority pricing or reimbursement approval requirement is applicable in the United States). 

  
 - 13 - 

 1.1.85    “Regulatory Authority” means a
federal, national, multinational, state, provincial or local regulatory agency, department, bureau or other governmental entity with authority over the testing, manufacture, use, storage, import, promotion, marketing or sale (including pricing
and reimbursement approval) of a product in a country or territory. 
 1.1.86    “Research
Program” means a program comprising Development activities by and on behalf of Agios and its Affiliates directed to a Program Target and Program Compounds that are either activators of the Program Target or inhibitors of the Program Target
(i.e., if both activators and inhibitors of a Program Target will be pursued, each will be deemed as a separate Research Program) in the IO Field or I&I Field; it being understood and agreed that (a) the JRC shall, from time to time,
designate each such program as a Research Program in accordance with Section 2.2.1 (but any failure of the JRC to so designate shall not affect in any way the designation of any such program as a “Research Program” or prevent Celgene from
exercising an Option under this Agreement); (b) each Research Program may be conducted pursuant to a research plan (which Agios may prepare and may be amended from time to time by the JRC pursuant to ARTICLE IV) governing the activities of the
Collaboration to be conducted by Agios and its Affiliates (and, with Celgene’s prior written consent, Celgene and its Affiliates) during the Option Term (each such research plan, the “Research Plan”), and (c) any failure to
include any Development activities directed to a Program Target and Program Compounds in a Research Plan shall not, in any way, exclude such activities from constituting a Research Program or prevent Celgene from exercising an Option under this
Agreement. The [**]Program and the [**] Program shall be deemed to be Research Programs as of the Effective Date. 

1.1.87    “Research Term” means the period commencing on the Effective Date and, unless
earlier terminated in accordance with this Agreement, if Celgene does not exercise its option to extend the Research Term pursuant to Section 2.1.2, ending on the fourth (4th) anniversary of the
Effective Date, or, if Celgene exercise its option(s) to extend the Research Term pursuant to Section 2.1.2, ending on the fifth (5th), sixth
(6th), seventh (7th) or eighth (8th) anniversary of the Effective Date, as applicable.

 1.1.88    “Shared 50/50 Program” means a Post-Exercise Program as to which the
Parties are required hereunder, or have, entered into a Co-Development and Co-Commercialization Agreement pursuant to which Profit or Loss (as defined in Appendix A) is allocated fifty percent (50%) to Celgene and fifty percent (50%) to
Agios. 
 1.1.89    “Shared 65/35 Program” means the Post-Exercise Program as to which
the Parties are required hereunder, or have, entered into a Co-Development and Co-Commercialization Agreement pursuant to which Profit or Loss (as defined in Appendix A) is allocated sixty-five percent (65%) to Celgene and thirty-five percent
(35%) to Agios. 
 1.1.90    “Shared Product” means a Program Product that is the
subject of a Shared Program (including any such Program Product after an Agios Opt-Out Date (as defined in Appendix A) with respect to such Program Product pursuant to a Co-Development and Co-Commercialization Agreement). 

1.1.91    “Shared Program” means the Shared 65/35 Program or a Shared 50/50 Program.

  
 - 14 - 

 1.1.92    “[**]” means [**]. 

1.1.93    “[**] Program” means the Agios program conducted before the Effective Date and
during the Term and comprising Development activities directed to inhibition of the Program Target [**]. 

1.1.94    “Third Party” means any Person other than Agios or Celgene or each
Party’s respective Affiliates. 
 1.1.95    “United States” or
“U.S.” means the United States of America and all of its territories and possessions, including Puerto Rico. 

1.2    Additional Definitions. Each of the following terms has the meaning described in the
corresponding section of this Agreement indicated below: 
  

							
		 	 DEFINITION:
	  	 SECTION:
	  	
		 	[**]	  	5.2.3(c)	  	
	
                       
 
	 	Accounting Standards	  	Appendix C	  	
		 	Acquirer Program	  	5.2.3(e)(iv)	  	
		 	Additional Amounts	  	1.1.26	  	
		 	Agios	  	Preamble	  	
		 	Agios Indemnified Parties	  	10.1.1	  	
                       
                     

		 	Agios Program Assets	  	9.3.2	  	
		 	Agreement	  	Preamble	  	
		 	Alliance Manager	  	4.7	  	
		 	Alternating Mechanism	  	3.1.2(c)	  	
		 	Antitrust Clearance Date	  	3.2.2	  	
		 	Bankruptcy Code	  	5.1.7	  	
		 	Celgene	  	Preamble	  	
		 	Celgene Corp.	  	Preamble	  	
		 	Celgene Indemnified Parties	  	10.2.1	  	
		 	Celgene RIVOT	  	Preamble	  	
		 	Closed Target	  	2.1.1(f)	  	
		 	Closed Target Notice	  	2.1.1(f)	  	
		 	Co-Co Agreement	  	9.3.1(e)(ii)	  	
		 	Co-Development and Co-Commercialization Agreement	  	1.1.33	  	
		 	Collaboration	  	2.1	  	
		 	Committee	  	4.1.1	  	
		 	Competitive Program	  	5.2.3(d)	  	
		 	Competitive Program Party	  	5.2.3(d)	  	
		 	Control	  	1.1.3	  	
		 	Cooperating Party	  	8.3.2(c)	  	
		 	CPI	  	1.1.41	  	
		 	CTA	  	1.1.48	  	
		 	Cure Period	  	11.3.1	  	

  
 - 15 - 

							
		 	 DEFINITION:
	  	 SECTION:
	  	
		 	Deemed DC Program	  	2.4.3	  	
		 	Defend	  	1.1.30	  	
	
                       
 
	 	Designation Fee	  	6.2	  	
		 	Development Candidate Nomination Data Package	  	1.1.29(a)	  	
		 	Development Costs	  	Appendix C	  	
                       
                     

		 	Disclosing Party	  	8.1	  	
		 	Dispute	  	12.1	  	
		 	DOJ	  	3.2.2	  	
		 	Early Option Exercise Window	  	3.1.1(b)	  	
		 	Effective Date	  	Preamble	  	
		 	Electronic Delivery	  	12.14	  	
		 	End-of-Research Term Program Data Package	  	1.1.29(b)	  	
		 	EU	  	1.1.8	  	
		 	force majeure event	  	12.5	  	
		 	FTC	  	3.2.2	  	
		 	[**]	  	5.2.3(e)(ii)	  	
		 	HSR Act	  	1.1.8	  	
		 	HSR/Antitrust Filing	  	3.2.2	  	
		 	Implementation Date	  	3.2.2	  	
		 	[**]	  	6.6.1	  	
		 	JCC	  	4.1.1	  	
		 	JDC	  	4.1.1	  	
		 	JPC	  	4.1.1	  	
		 	JRC	  	4.1.1	  	
		 	JSC	  	4.1.1	  	
		 	License Agreement	  	1.1.33	  	
		 	Limited Information	  	2.1.1(f)	  	
		 	Manufacturing Costs	  	Appendix C	  	
		 	Material Breach	  	11.3.1	  	
		 	Material Receiving Party	  	2.11.1	  	
		 	Materials	  	2.11.1	  	
		 	Option	  	3.1.1(a)	  	
		 	Option Data Package	  	1.1.29(c)	  	
		 	Option Exercise Window	  	3.1.1(a)	  	
		 	Out-of-Pocket Costs	  	Appendix C	  	
		 	Parent Entity	  	1.1.18	  	
		 	Party or Parties	  	Preamble	  	
		 	Payee Party	  	6.6.1	  	
		 	Paying Party	  	6.6.1	  	
		 	Productivity Requirement	  	2.1.2(b)	  	
		 	Proposed Targets	  	2.1.1(c)	  	

  
 - 16 - 

							
		 	 DEFINITION:
	  	 SECTION:
	  	
		 	 Purpose
	  	 2.11.1
	  	
	
                       
 
	 	 Qualified Scientist
	  	 2.1.1(d)
	  	
		 	 Receiving Party
	  	 8.1
	  	
		 	 Redacted Version
	  	 8.3.2(a)
	  	
		 	 Regulatory Expenses
	  	 Appendix C
	  	
                       
                     

		 	 Related Compound
	  	 1.1.77
	  	
		 	 Requesting Party
	  	 8.3.2(c)
	  	
		 	 Research Plan
	  	 1.1.86(b)
	  	
		 	 ROW Co-Co Agreement
	  	 9.3.1(e)(i)
	  	
		 	 Research Term Extension Fee
	  	 6.3
	  	
		 	 Scientific Panel
	  	 2.1.1(d)
	  	
		 	 SEC
	  	 8.3.2(a)
	  	
		 	 Subcommittee
	  	 4.1.2
	  	
		 	 Term
	  	 11.1
	  	
		 	 Third Party License
	  	 7.5.2
	  	
		 	 Third Party Program
	  	 2.2.2
	  	
		 	 Transferring Party
	  	 2.11.1
	  	
		 	 U.S. Co-Co Agreement
	  	 9.3.1(e)(i)
	  	

 ARTICLE II 

COLLABORATION; PRE-OPTION EXERCISE DEVELOPMENT 

2.1    Scope and Collaboration Overview. Pursuant to this Agreement and as further provided in this
ARTICLE II, during the Research Term, Agios: (a) may conduct discovery activities to identify programs for designation as Research Programs and shall provide regular updates to Celgene at JRC meetings in accordance with ARTICLE IV with respect to
its activities pursuant to each Research Program, together with all material data and information in Agios’ possession relating to Program Targets, (b) shall be responsible for the research strategy and the conduct of activities under each
Research Program, (c) may nominate Program Compounds from Research Programs as Development Candidates pursuant to the terms and conditions of this Agreement, and (d) as to Development Candidates in Designated Development Programs and
Continuation Programs, may conduct Pre-Exercise Phase I Development. The activities conducted pursuant to this ARTICLE II, the activities performed by a Party or the Parties relating to the [**] Program and the [**] Program under the 2010
Agreement before the Effective Date, as well as activities conducted pursuant to Development & Commercialization Agreements following Celgene’s exercise of its Option rights, together, shall be the “Collaboration”. 

  
 - 17 - 

 2.1.1    Agios Responsibility for Research and Pre-Option
Exercise Development.
 (a)    Commencing on the Effective Date, during the Research Term prior to
the exercise by Celgene of an Option on a Program-by-Program basis, Agios may, in its discretion, conduct Development activities with respect to each Program with the goal of identifying Development Candidates and Developing and progressing such
Development Candidates in Designated Development Programs and Continuation Programs through Pre-Exercise Phase I Development. During the Research Term, Agios shall have sole discretion regarding which Programs it selects to progress, and the
Development activities performed thereunder, and following Celgene’s designation of a Designated Development Program pursuant to Section 2.3.2(b), Agios (x) may conduct Pre-Exercise Phase I Development and (y) shall offer Celgene the
opportunity to obtain rights to the applicable Designated Development Program through the exercise of Celgene’s Option in accordance with ARTICLE III. Following Celgene’s designation of a Continuation Program in accordance with
Section 2.4.2, Agios (i) may conduct Development activities with the goal of identifying and nominating a Program Compound from such Continuation Program as a Development Candidate and, pursuant to Section 2.4.3, conduct Pre-Exercise Phase I
Development, and (ii) shall offer Celgene the opportunity to obtain the rights to the applicable Continuation Program through the exercise of Celgene’s Option in accordance with ARTICLE III. Agios may decide to cease activities under any
Program it conducts prior to the exercise of the Option by Celgene at any time (and, for clarity, no such cessation of activity shall in any way affect Celgene’s rights to exercise such Option under this Agreement). 

(b)    During the Research Term, Agios shall discuss with Celgene, on a regular basis at JRC meetings,
Metabolic Targets as potential Program Targets identified by Agios in the course of its ongoing research activities in the IO Field and I&I Field as well as discuss with Celgene material developments in or new data or information in Agios’
possession and Control relating to previously identified Metabolic Targets; provided that Agios shall not have any obligation to discuss with Celgene any developments, data or information relating to Programs that have reverted to
Agios pursuant to Section 2.12. 
 (c)    Beginning with the first meeting of the JRC and at every
other JRC meeting thereafter during the Research Term (meaning [**]): (i) Agios shall prepare and the Parties shall review a list of any Metabolic Targets for which activities would be the subject of a Research Program in the next [**],
including any Metabolic Target suggested by Celgene which Agios may consider in its sole discretion (collectively, the “Proposed Targets”) and any available reports, data and other information related thereto; and (ii) for each
Proposed Target, the Parties shall discuss whether to include such Proposed Target in a Research Plan as a Program Target. 

(d)    If during the Research Term either (but not both) of the Parties believes that [**], then the
Parties agree to submit such matter to a panel of three Qualified Scientists (each and every such panel of three Qualified Scientists, a “Scientific Panel”) appointed as provided in this Section 2.1.1(d) to determine whether or not
[**], all in accordance with the procedures as provided in this Section 2.1.1(d); it being understood and agreed that, in connection with any review and determination by the Scientific Panel, the Scientific Panel will render a decision that is
consistent with the definition of Metabolic Target as to whether or not any [**] under this Agreement. Within [**] following any such request for a Scientific Panel, 

  
 - 18 - 

 
each of Agios and Celgene shall nominate a Qualified Scientist to participate on the applicable Scientific Panel and, if the Parties are unable to agree upon a third Qualified Scientist for such
Scientific Panel within [**] following any such request for a Scientific Panel, then the initial two Qualified Scientists shall select such third Qualified Scientist. Each Scientific Panel shall act as follows: (i) each Qualified Scientist
(and the Scientific Panel as a whole) shall act as an expert and not as an arbitrator; (ii) each decision of the Scientific Panel shall be by majority vote of the three Qualified Scientists; and (iii) the decision of the Scientific Panel is, in the
absence of fraud or manifest error, final and binding on the Parties. The costs of the Scientific Panel shall be shared equally by Agios and Celgene. For purposes of this Agreement, a “Qualified Scientist” shall mean any
scientist (A) with at least ten (10) years of applicable pharmaceutical industry experience in the IO Field or I&I Field, (B) who has not worked for or been engaged by either Party in the three (3) year period immediately prior to the formation
of the applicable Scientific Panel, and (C) who does not own equity in either Party. If such Scientific Panel determines that any [**] (based upon the terms and conditions of this Agreement and then-current good scientific practice and
understanding, data generated, and the proposed discovery and development research plan with respect to such Program), then each such different Metabolic Target shall be deemed part of different Research Programs. Conversely, if such Scientific
Panel determines that [**] (based upon the terms and conditions of this Agreement and then-current good scientific practice and understanding, data generated, and the proposed discovery and development research plan with respect to such Program),
then only one Metabolic Target shall be deemed to exist as part of one Research Program. 
 (e)    The
Parties understand and agree that in no event shall a Party be entitled to request that a Scientific Panel review any matter for which a Scientific Panel has previously rendered a decision in accordance with Section 2.1.1(d). 

(f)    Notwithstanding anything to the contrary contained herein, Celgene shall be entitled to designate,
in a written notice (“Closed Target Notice”) to Agios, any Metabolic Target or Proposed Target, or Program Target as a Metabolic Target for which Celgene wishes to receive specified or no additional information and/or to have a
Third Party designee receive and review such information (any such designated Target, a “Closed Target”); it being understood and agreed that Celgene shall be entitled to modify (i) the designation of any Closed Target such that the
corresponding Metabolic Target is no longer a Closed Target, and (ii) the information restrictions and recipients then-imposed with respect to such Closed Target. In each initial Closed Target Notice and in any subsequent modifications to such
Closed Target Notice, Celgene shall include (x) the identity of the corresponding Closed Target, (y) a detailed written description of the limited information, if any, that Celgene wishes to receive for such Closed Target (such limited information
the “Limited Information”), and (z) the identity and address of Celgene’s designee (if any) that Celgene wishes to receive the Limited Information. 

2.1.2    Extension of Research Term.

(a)    Initial Extension Right. Celgene may, at its election, extend the Research Term for up
to two (2) one (1) year extension periods (each to run consecutively after the end of the then-current Research Term) by giving notice to Agios of each such election at least [**] prior to the expiration of the then-current Research Term and paying
the Research Term Extension Fee as set forth in Section 6.3.

  
 - 19 - 

 (b)    Productivity Extension Right. If (i)
Celgene has elected to extend the Research Term for both of the foregoing one (1) year extension periods as provided in Section 2.1.2(a), and (ii) [**] prior to the sixth (6th) anniversary of the
Effective Date, Celgene has not designated at least [**] Program Compounds for [**] different Research Programs (other than Program Compounds that are inhibitors of [**] or [**]) as Development Candidates pursuant to Section 2.3.2(b), which have
been (in the case of each such [**] Program Compounds) dosed in a patient as part of a Phase I Study (the “Productivity Requirement”), then Celgene may, at its election, extend the Research Term for an additional one (1) year period
(to run after the end of the then-current Research Term) by providing notice to Agios of such election at least [**] prior to the sixth (6th) anniversary of the Effective Date and paying the
Research Term Extension Fee as set forth in Section 6.3. If, prior to the seventh (7th) anniversary of the Effective Date, the Productivity Requirement has still not been satisfied, then
Celgene may, at its election, extend the Research Term for one (1) additional year, by providing notice to Agios of such election at least [**] prior to the seventh (7th) anniversary of the
Effective Date and paying the Research Term Extension Fee as set forth in Section 6.3. 

2.2    Designation of Research Programs. 

2.2.1    Designation of Research Programs. From time to time during the Research Term,
each Party may identify potential Research Programs and recommend them to the JRC for designation as Research Programs. The JRC shall review such recommendations and determine whether or not to designate each proposed Research Program in
accordance with Section 4.3.2(a). If Celgene’s JRC representatives oppose the designation of a Research Program, but such designation occurs in accordance with the escalation and final decision-making provisions of ARTICLE IV, then Celgene
may, by giving notice of such election to Agios within [**] after the designation of such Research Program, elect to drop such Research Program from the Collaboration, in which case all rights thereto shall revert to Agios in accordance with Section
2.12 and such Research Program shall otherwise be treated as never having been included in the Collaboration. Except as provided in the immediately preceding sentence, no failure by Agios to identify or the JRC to approve any Development
activities by and on behalf of Agios and its Affiliates directed to a Program Target and Program Compounds that are either activators or inhibitors of such Program Target in the IO Field or I&I Field as contemplated by this Section 2.2.1 shall
prevent such Development activities from being deemed a “Research Program” (and, accordingly, Celgene shall have an Option for any such Research Program under this Agreement). 

2.2.2    Third Party Programs. During the Research Term, if Agios identifies a Third Party
research and development program, or Third Party intellectual property assets that could be used as the basis for a research and development program, in each case in the IO Field or in the I&I Field (each such program or assets, a “Third
Party Program”), which Third Party Program Agios desires to license or acquire for designation as a Program hereunder, Agios may license or acquire such Third Party Program, in which case such Third Party Program shall be designated as a
Program hereunder and, except as specifically set forth in any Development & Commercialization Agreement, all licensing costs and expenses relating to such Third Party Program shall be paid for by Agios. 

  
 - 20 - 

 2.3    Nomination of Development Candidates; Designation
of Designated Development Programs. 
 2.3.1    Nomination of Development Candidates; Delivery
of Development Candidate Nomination Data Package. Based upon the Development Candidate Criteria and the results of Development activities with respect to a Research Program, Agios may nominate a Program Compound directed to the Program
Target that is the subject of such Research Program as a Development Candidate, by providing written notification thereof to Celgene and the JRC. In addition, following [**], Celgene may propose to nominate a Program Compound directed to any
Program Target as a Development Candidate, by providing written notification thereof to Agios and the JRC. Within [**] following any such proposed nomination, Agios shall use its reasonable efforts (without any requirement to perform any
additional pre-clinical testing activity but solely based upon work then completed to date) to deliver to Celgene a Development Candidate Nomination Data Package; provided that, for any Program nominated by Celgene, Agios shall include
only as much data or information as is available at the time of Celgene’s request for such Development Candidate Nomination Data Package. 

2.3.2    Designation of Designated Development Programs; Payment of Designation Fee.

(a)    Following nomination of a Program Compound as a Development Candidate and delivery of a
Development Candidate Nomination Data Package by Agios pursuant to Section 2.3.1, the JRC shall determine, in accordance with Section 4.3.2(c), whether such Program Compound meets the Development Candidate Criteria as follows: (i) any such
determination by the JRC must be unanimous; or (ii) in the event that the JRC does not unanimously agree that such Program Compound meets the Development Candidate Criteria, then (A) the Parties shall refer such dispute to a Scientific Panel
appointed as provided in this Section 2.3.2(a) for determination of whether or not such Program Compound meets the Development Candidate Criteria; it being understood and agreed that, in connection with any review and determination by the Scientific
Panel, the Scientific Panel will render a decision that is consistent with the Development Candidate Criteria; (B) within [**] following any such request for a Scientific Panel, each of Agios and Celgene shall nominate a Qualified Scientist to
participate on the applicable Scientific Panel and, if the Parties are unable to agree upon a third Qualified Scientist for such Scientific Panel within [**] following any such request for a Scientific Panel, then the initial two Qualified
Scientists shall select such third Qualified Scientist. Each Scientific Panel shall act as follows: (I) each Qualified Scientist (and the Scientific Panel as a whole) shall act as an expert and not as an arbitrator; (II) each decision of the
Scientific Panel shall be by majority vote of the three Qualified Scientists; (III) the decision of the Scientific Panel is, in the absence of fraud or manifest error, final and binding on the Parties; (IV) the costs of the Scientific Panel shall be
shared equally by Agios and Celgene; and (V) the Parties agree that only if such Scientific Panel determines that the Program Compound meets the Development Candidate Criteria, will such Program Compound shall be deemed a Development Candidate.
Conversely, if such Scientific Panel determines that any such Program Compound does not meet the Development Candidate Criteria, then such Program Compound shall remain eligible for nomination as a Development Candidate during the Research Term.
Following the proposed nomination of a Program Compound as a Development Candidate by 

  
 - 21 - 

 
Celgene pursuant to Section 2.3.1 and subject to Celgene’s written confirmation to Agios within [**] following receipt of the Development Candidate Nomination Data Package pursuant to
Section 2.3.1 (or a Scientific Panel’s determination) that such Program Compound is a Development Candidate, such Program Compound shall be deemed to satisfy the Development Candidate Criteria (whether or not the Development Candidate Criteria
have actually been satisfied). Agios shall use reasonable efforts to respond to requests from the JRC and Celgene for additional reasonable information and clarifications regarding content of the Development Candidate Nomination Data Package.

 (b)    Celgene shall be entitled, in its sole discretion, to designate any applicable Research
Program as a Designated Development Program either: (i) in the case of a Program Compound nominated by Agios as a Development Candidate pursuant to Section 2.3.1, within [**] following delivery by Agios of a Development Candidate Nomination
Data Package and determination by the JRC that the applicable Program Compound meets the Development Candidate Criteria, or (ii) in the case of a Program Compound nominated by Celgene as a Development Candidate pursuant to Section 2.3.1 following
[**], at any time following such [**] until [**] following the receipt by Celgene of the applicable Development Candidate Nomination Data Package, either of which designations Celgene shall make by giving notice thereof to Agios prior to the end of
the applicable [**] period and paying the Designation Fee as set forth in Section 6.2. During such [**] period, Agios shall use reasonable efforts to respond to requests from Celgene for additional reasonable information and clarifications
regarding content of the Development Candidate Nomination Data Package. If Celgene makes such designation, Agios may thereafter conduct Pre-Exercise Phase I Development as to such Designated Development Program. 

2.3.3    Disposition of Programs Not Designated as Designated Development Programs. If a
Program Compound has been determined or deemed, as applicable, to meet the Development Candidate Criteria pursuant to Section 2.3.2(a), and Celgene does not designate the applicable Research Program as a Designated Development Program in accordance
with Section 2.3.2(b) and therefore does not pay the Designation Fee, then such Research Program shall be dropped from the Collaboration and all rights thereto shall revert to Agios in accordance with Section 2.12.

2.4    Disposition of Programs After the End of the Research Term. 

2.4.1    Designated Development Programs After the End of the Research Term. Agios’
conduct of Pre-Exercise Phase I Development as to Designated Development Programs that were designated prior to the end of the Research Term may continue following the expiration of the Research Term, and the Parties’ respective rights and
obligations as to such Designated Development Programs shall continue in accordance with this Agreement following such Research Term expiration without any change on account of such expiration. 

2.4.2    Programs that are Not Designated Development Programs as of the End of the Research
Term. Upon expiration of the Research Term, Agios shall provide Celgene with an End-of-Research Term Program Data Package as to each Research Program (including, if applicable, the [**] Program or the [**] Program), excluding any Qualified
Early Exercise I&I Program as to which the Parties have entered into a License Agreement, from which no 

  
 - 22 - 

 
Development Candidate has been nominated and designated. Celgene shall have a period of [**] following Celgene’s receipt of each End-of-Research Term Program Data Package from Agios
pursuant to this Section 2.4.2 to elect, in its sole discretion, to designate up to three (3) such ongoing Research Programs as a Continuation Program (including, for the avoidance of doubt, the Deemed DC Program), which elections Celgene shall make
by giving notice thereof to Agios prior to the end of such [**] period and paying the Designation Fees for each such Continuation Program as set forth in Section 6.2. During such [**] period, Agios shall use reasonable efforts to respond to
requests from Celgene for additional reasonable information and clarifications regarding content in any End-of-Research Term Program Data Package, provided that, unless otherwise agreed by Agios, such [**] period shall not be extended
to facilitate such responses. If Celgene makes any such election, Agios may elect in its sole discretion to conduct Development activities with the goal of identifying and nominating a Program Compound in such Continuation Program as a
Development Candidate and thereafter may conduct Pre-Exercise Phase I Development as to such Continuation Program. The Parties’ respective rights and obligations as to such Continuation Programs shall otherwise be the same as for
Designated Development Programs (that were designated as Designated Development Programs prior to the end of the Research Term) and shall continue in accordance with this Agreement following the Research Term expiration. 

2.4.3    Treatment of Continuation Programs. If Celgene designates one or more Continuation
Programs (including, if applicable, the [**] Program or the [**] Program) in accordance with Section 2.4.2, the Continuation Program that, in Celgene’s reasonable determination, has progressed the furthest shall constitute the “Deemed
DC Program.” Each Continuation Program (including the Deemed DC Program) shall be conducted without adjustment to the terms contemplated by Section 2.4.2 (i.e., any Pre-Exercise Phase I Development activities for such
Continuation Program that may be conducted by Agios shall be at Agios’ sole discretion and expense). 

2.4.4    Disposition of Programs Not Designated as Continuation Programs. Any Research
Program that Celgene does not designate as a Continuation Program in accordance with Section 2.4.2 shall be dropped from the Collaboration and all rights thereto shall revert to Agios in accordance with Section 2.12.

2.5    Completion of Pre-Exercise Phase I Development. Upon Agios’ completion of Pre-Exercise
Phase I Development as to any Designated Development Program or Continuation Program, or earlier upon Celgene’s written request, Agios shall provide Celgene with an Option Data Package for such Program (in any case within [**] following such
completion of Pre-Exercise Phase I Development as to any Designated Development Program or Continuation Program or Celgene’s request, as applicable). During the period between Celgene’s receipt of such Option Data Package and the
applicable Option Data Package Verification Date, Agios shall use reasonable efforts to respond to requests from Celgene for additional reasonable information and clarifications regarding content of the Option Data Package. 

2.6    Regulatory Affairs. Agios shall be responsible for and shall control all regulatory matters
relating to each Pre-Exercise Program. For all regulatory matters concerning any Pre-Exercise Program, until such time that Celgene either exercises its Option and enters into a Development & Commercialization Agreement or such Pre-Exercise
Program reverts to Agios in accordance with Section 2.12, Agios shall consult with Celgene with respect to filing strategy and document preparation, and shall reasonably consider all timely comments made by Celgene with respect thereto. 

  
 - 23 - 

 2.7    Reports; Results; Testing by the Parties. Each
Party shall maintain complete, current and accurate records of all Development activities conducted by it under the Collaboration, and all data and other information resulting from such activities. Such records shall fully and properly reflect
all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory and patent purposes. Each Party shall document all non-clinical studies and clinical trials for Programs in
formal written study records according to applicable Laws, including national and international guidelines such as ICH, GCP, GLP and GMP. Each Party shall have the right to review and copy such records maintained by the other Party at
reasonable times, as reasonably requested by a Party. At each meeting of the JRC or the JDC held pursuant to Section 4.8.2, each Party shall provide the other Party a written progress report summary (which may consist solely of slides) on the
status of its activities under each Program during the Research Term, including summaries of data associated with such Party’s activities, it being understood that Celgene may reasonably request additional information regarding any such written
progress report summary. 
 2.8    No Representation. Neither Party makes any representation,
warranty or guarantee that the Collaboration will be successful, or that any other particular results will be achieved with respect to the Collaboration, any Program, any Program Target, any Program Compound, any Development Candidate or any Program
Product hereunder. 
 2.9    Subcontracting. Subject to the terms of this Agreement or any
Development & Commercialization Agreement, as applicable, each Party shall have the right to engage Affiliates or Third Party subcontractors to perform certain of its obligations under this Agreement or any Development & Commercialization
Agreement, as applicable. Any such Affiliate or subcontractor shall meet the qualifications typically required by such Party for the performance of work similar in scope and complexity to the subcontracted activity and perform such work
consistent with the terms of this Agreement or any Development & Commercialization Agreement, as applicable; provided, however, that any Party engaging an Affiliate or subcontractor hereunder shall remain fully responsible
and obligated for such activities. Unless otherwise agreed by the Parties, each Party will obligate each Third Party subcontractor to agree in writing to assign to such Party ownership of, or grant to such Party an exclusive, royalty-free,
worldwide, perpetual and irrevocable license (with the right to grant sublicenses) to, any inventions arising under its agreement with such Third Party to the extent related to Development, Manufacture or Commercialization with respect to Program
Compounds, as applicable; and such Party shall structure such assignment or exclusive license so as to enable such Party to sublicense such Third Party inventions to the other Party pursuant to the applicable provisions of this Agreement and of any
applicable Development & Commercialization Agreement (including permitting such other Party to grant further sublicenses). 

2.10    Academic Collaborators. If either Party collaborates with an academic institution and/or
one or more individuals at an academic institution to perform research on Program Targets or Program Compounds, such Party shall be required to obligate such academic collaborator to agree in writing to grant the same rights specified in Section 2.9
with respect to 

  
 - 24 - 

 
ownership or licenses to inventions; it being understood and agreed that, [**], which sublicensing rights must permit sublicensing to the other Party pursuant to the applicable provisions of this
Agreement and of any applicable Development & Commercialization Agreement (including permitting such other Party to grant further sublicenses). 

2.11    Material Transfer. 

2.11.1    Transfer. On a Program-by-Program basis, during the Option Term, either Party (the
“Transferring Party”) shall transfer, if such Party agrees in writing to make such transfer (such agreement not to be unreasonably withheld) upon reasonable request by the other Party (the “Material Receiving
Party”), certain tangible materials (the “Materials”) for use by the Material Receiving Party in furtherance of its rights and the conduct of its obligations under this Agreement, as mutually agreed by the Parties and set
forth in an appropriate material transfer agreement (the “Purpose”). The Parties agree that the exchanged Materials shall be used in compliance with applicable Law and the terms and conditions of this Agreement, and shall not
be reverse engineered or chemically analyzed, except as required for verification purposes (if needed). 

2.11.2    License; Ownership. At the time the Transferring Party provides Materials to the
Material Receiving Party as provided herein and to the extent not separately licensed under this Agreement, the Transferring Party hereby grants to the Material Receiving Party a non-exclusive license under the Patents and Know-How Controlled by the
Transferring Party to use such Materials solely for the Purpose, and such license, upon termination of this Agreement (subject to ARTICLE XI), completion of the Purpose, or discontinuation of the use of such Materials (whichever occurs first), shall
automatically terminate. Except as otherwise provided under this Agreement, all such Materials delivered by the Transferring Party to the Material Receiving Party shall remain the sole property of the Transferring Party, shall only be used by
the Material Receiving Party in furtherance of the Purpose, and shall be returned to the Transferring Party or destroyed, in the Transferring Party’s sole discretion, upon the termination of this Agreement (subject to ARTICLE XI), the
expiration of the Option Exercise Window with respect to any Program to which such Materials solely relate (unless the Option is exercised for the Program for which such transfer occurred), or upon the discontinuation of the use of such Materials
(whichever occurs first). The Material Receiving Party shall not permit the Materials to be used by or delivered to or for the benefit of any Third Party without the prior written consent of the Transferring Party unless such Third Party is a
Third Party subcontractor as set forth in Section 2.9. 
 2.11.3    No Warranties;
Liability. THE MATERIALS SUPPLIED BY THE TRANSFERRING PARTY UNDER THIS SECTION 2.11 ARE SUPPLIED “AS IS” AND, EXCEPT AS OTHERWISE SET FORTH IN THIS AGREEMENT, THE TRANSFERRING PARTY MAKES NO REPRESENTATIONS AND EXTENDS NO
WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE MATERIALS OR USE THEREOF DO NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS OF A
THIRD PARTY. The Material Receiving Party assumes all liability for Damages that may arise from its use, storage or disposal of the Materials. Except as otherwise set forth in this Agreement, the Transferring Party shall

  
 - 25 - 

 
not be liable to the Material Receiving Party for any loss, claim or demand made by the Material Receiving Party, or made against the Material Receiving Party by any Third Party, due to or
arising from the use of the Materials, except to the extent such loss, claim or demand is caused by the gross negligence or willful misconduct of the Transferring Party. 

2.12    Reversion of Rights.

2.12.1    Programs. If Section 2.2.1, Section 2.3.3, Section 2.4.4, Section 3.1.3 or Section
11.5.1(a) specifies that rights to a Program are to be dropped from the Collaboration or if Celgene does not exercise its Option with respect to any Programs within the applicable Option Exercise Window for such Program, then (a) all rights granted
by Agios to Celgene with respect to such Program, if any, shall revert to Agios, and (b) subject to ARTICLE VIII, Celgene shall return to Agios, or destroy, at Agios’ option, all Confidential Information and/or Materials provided by Agios to
Celgene in relation to such Program; provided, however, that any Confidential Information and/or Materials that also relate to a non-terminated Program may be retained by Celgene. 

2.12.2    Reversion License. Effective upon any of the events set forth in Section 2.12.1
with respect to a Program, Celgene hereby grants to Agios [**] with the right to grant sublicenses as set forth in Section 5.1.4, under Celgene’s rights in Celgene Collaboration Intellectual Property and Joint Collaboration IP, to Develop,
Manufacture and/or Commercialize Program Compounds or Program Products under such Program; provided that, for this purpose, “Celgene Collaboration Intellectual Property” means Celgene Collaboration Intellectual Property only
to the extent that it is actually used in such Program prior to the applicable reversion set forth in this Section 2.12; provided further that the foregoing license under this Section 2.12.2 shall be [**] with respect to the
applicable Program to the extent of claims within the Patents included in the Celgene Collaboration Intellectual Property and Joint Collaboration IP that Cover a composition of matter of any such Program Compound or Program Product. Agios shall
not owe royalties or milestones with respect to any license in this Section 2.12.2, but Agios shall be solely responsible for any payments owed by Celgene to any Third Party licensors of Celgene Collaboration Intellectual Property or Joint
Collaboration IP, and shall be responsible for complying with the terms of any license agreements with such third Party licensors, in either case, directly related to Agios’ exercise of such licenses 

2.12.3    Optioned Programs. For the avoidance of doubt, none of the reversion events
described in this Section 2.12 shall affect Celgene’s rights with respect to any other Program for which Celgene retains Option rights or has delivered an Option Exercise Notice pursuant to Section 3.1.2(a). 

ARTICLE III 
 OPTION EXERCISE;
DEVELOPMENT & COMMERCIALIZATION AGREEMENTS 
 3.1    Option Grant and Exercise. 

3.1.1    Option Grant by Agios.

  
 - 26 - 

 (a)    Subject to the terms and conditions of this Agreement
on a Designated Development Program-by-Designated Development Program and Continuation Program-by-Continuation Program basis, Agios hereby grants to Celgene, with respect to each Designated Development Program and Continuation Program, an exclusive
option (each, an “Option”), exercisable at any time during the period commencing on the date that a Development Candidate for such Designated Development Program is designated pursuant to the terms and conditions of this Agreement
or the date on which a Continuation Program is designated pursuant to the terms and conditions of this Agreement, as applicable, and ending [**] following the applicable Option Data Package Verification Date (each such period for each Designated
Development Program and Continuation Program, as applicable, the “Option Exercise Window”) to enter into a Development & Commercialization Agreement with respect to such Designated Development Program or Continuation Program,
pursuant to this Section 3.1.
 (b)    In addition, subject to the terms and conditions of this
Agreement on an Qualified Early Exercise I&I Program-by-Qualified Early Exercise I&I Program basis, Celgene may exercise an Option with respect to up to [**] Qualified Early Exercise I&I Programs at any time during the Research Term that
such Qualified Early Exercise I&I Program remains a Qualified Early Exercise I&I Program (the “Early Option Exercise Window”), to enter into a License Agreement with respect to such Qualified Early Exercise I&I
Program.
 3.1.2    Option Exercise. 

(a)    Celgene shall have the right, but not the obligation, to exercise the Option for a given
Designated Development Program or Continuation Program by delivering an Option Exercise Notice to Agios within the applicable Option Exercise Window. Celgene shall have the right, but not the obligation, to exercise the Option for a given
Qualified Early Exercise I&I Program by delivering an Option Exercise Notice to Agios within the Early Option Exercise Window. Upon such exercise, the applicable Qualified Early Exercise I&I Program, Designated Development Program or
Continuation Program shall become a “Post-Exercise Program”. Within [**] following each Option Exercise Notice delivery, Celgene (or an Affiliate designated by Celgene) and Agios and each Affiliate of Agios that holds Agios
Intellectual Property relating to the applicable Qualified Early Exercise I&I Program, Designated Development Program or Continuation Program will enter into (i) a Co-Development and Co-Commercialization Agreement with respect to any such
Post-Exercise Program that is an IO Program, [**] Program or [**] Program, or (ii) a License Agreement with respect to any such Post-Exercise Program that is an I&I Program; and in either case will update the exhibits and schedules thereto, as
applicable, including to identify the Program Compound(s) and Program Target that are the subject of such Development & Commercialization Agreement. Following the applicable Implementation Date for Development & Commercialization
Agreement, Celgene shall pay the applicable fees set forth in such Development & Commercialization Agreement in accordance therewith.

(b)    At any time during the Option Exercise Window, with respect to any Designated Development Program
or Continuation Program that is an IO Program, other than the [**] Program and/or [**] Program, Celgene shall have the right to designate one of such IO Programs as the Shared 65/35 Program. Celgene shall indicate in the applicable Option

  
 - 27 - 

 
Exercise Notice whether it is designating any such IO Program as the Shared 65/35 Program. For clarity: (i) if Celgene exercises its Option with respect to the [**] Program or the [**]
Program, such Program shall be a Shared 50/50 Program subject to the provisions set forth in Section 3.1.2(c) below, and (ii) for so long as Celgene has not previously designated an IO Program (other than the [**] Program and/or [**] Program) as the
Shared 65/35 Program, it shall always be entitled to designate an IO Program as the Shared 65/35 Program at the time of the exercise of the Option for such IO Program (and such designated Shared 65/35 Program shall not be considered as a
“Shared 50/50 Program” for any purpose under Section 3.1.2(c) below, including with regard to the Alternating Mechanism). 

(c)    Subject to Celgene’s right to select the Shared 65/35 Program pursuant to Section 3.1.2(b),
at any time during the Option Exercise Window, with respect to any Designated Development Program or Continuation Program that is an IO Program (including for purposes of this Section 3.1.2(c) the [**] Program and [**] Program), Agios shall have the
option of designating the first Shared 50/50 Program as an Agios Lead Shared Program on or prior to the execution of the applicable Co-Commercialization and Co-Development Agreement. If Agios does not elect to designate the first Shared 50/50
Program as an Agios Lead Shared Program, then such Shared 50/50 Program shall be a Celgene Lead Shared Program and the second Shared 50/50 Program shall be an Agios Lead Shared Program. Thereafter, the designation of any further Shared 50/50
Programs shall alternate between the Parties, i.e., if the prior designated Shared 50/50 Program was an Agios Lead Shared Program, the next designated Shared 50/50 Program would be a Celgene Lead Shared Program, and vice versa, with
respect to each subsequently designated Shared 50/50 Program (the “Alternating Mechanism”). By way of example, if the first Shared 50/50 Program is designated an Agios Lead Shared Program, and the second IO Program for which
Celgene exercises its Option is designated the Shared 65/35 Program pursuant to Section 3.1.2(b), then the third IO Program for which Celgene exercises an Option as a Shared 50/50 Program shall be automatically designated a Celgene Lead Shared
Program. 
 3.1.3    Expiration of Option Exercise Windows. If Celgene does not
exercise an Option during the applicable Option Exercise Window, then the corresponding Designated Development Program or Continuation Program shall be dropped from the Collaboration in accordance with Section 2.12 and shall no longer be subject to
Celgene’s rights under this Agreement, including ARTICLE V and all rights thereto shall revert to Agios in accordance with Section 2.12. 

3.2    Government Approvals. 

3.2.1    Efforts. Each of Agios and Celgene will use its commercially reasonable good faith
efforts to eliminate any concern on the part of any Governmental Authority regarding the legality of any proposed Development & Commercialization Agreement including, if required by Governmental Authorities, promptly taking all steps to remove
any and all impediments to consummation of the transactions contemplated by the Development & Commercialization Agreements, including obtaining government antitrust clearance, cooperating in good faith with any Governmental Authority
investigation, promptly producing any documents and information and providing witness testimony if requested by a Governmental Authority. Notwithstanding anything to the contrary in this Agreement and the Development
& Commercialization Agreements, this Section 3.2 and the term “commercially reasonable good faith efforts” do not require that either Party (a) [**], (b) [**], or (c) [**]. 

  
 - 28 - 

 3.2.2    HSR/Antitrust Filings. Each of Agios
and Celgene will, within [**] after the execution of the relevant Development & Commercialization Agreement (or such later time as may be agreed to in writing by the Parties) file with the U.S. Federal Trade Commission (“FTC”)
and the Antitrust Division of the U.S. Department of Justice (“DOJ”) any HSR/Antitrust Filing required of it under the HSR Act and, as soon as practicable, file with the appropriate Governmental Authority any other HSR/Antitrust
Filing required of it under any other Antitrust Law as determined in the reasonable opinion of either Party with respect to the transactions contemplated by the relevant Development & Commercialization Agreement. The Parties shall cooperate
with one another to the extent necessary in the preparation of any such HSR/Antitrust Filing. Each Party shall be responsible for its own costs, expenses and filing fees associated with any HSR/Antitrust Filing; provided, however,
that the Parties shall [**]. In the event that the Parties make an HSR/Antitrust Filing under this Section 3.2, the relevant Development & Commercialization Agreement shall terminate (a) at the election of either Party, immediately
upon notice to the other Party, in the event that the FTC, DOJ or other Governmental Authority obtains a preliminary injunction or final order under Antitrust Law enjoining the transactions contemplated by such Development & Commercialization
Agreement, or (b) at the election of either Party, immediately upon notice to the other Party, in the event that the Antitrust Clearance Date shall not have occurred on or prior to [**] after the effective date of the last HSR/Antitrust Filing
submitted to a Governmental Authority in relation to the relevant Development & Commercialization Agreement. Notwithstanding anything to the contrary contained herein, except for the terms and conditions of this Section 3.2, none of the
terms and conditions contained in the relevant Development & Commercialization Agreement shall be effective until the “Implementation Date,” which is agreed and understood to mean the later of (i) the execution date of the
relevant Development & Commercialization Agreement, (ii) if a determination is made pursuant to this Section 3.2 that an HSR/Antitrust Filing is not required to be made under any Antitrust Law for the relevant Development & Commercialization
Agreement, the date of such determination, or (iii) if a determination is made pursuant to this Section 3.2 that an HSR/Antitrust Filing is required to be made under any Antitrust Law for the relevant Development & Commercialization Agreement,
the Antitrust Clearance Date. As used herein: (x) “Antitrust Clearance Date” means the earliest date on which the Parties have actual knowledge that all applicable waiting periods under the HSR Act and any comparable
waiting periods as required under any other Antitrust Law, in each case with respect to the transactions contemplated by the relevant Development & Commercialization Agreement have expired or have been terminated; and (y)
“HSR/Antitrust Filing” means (i) a filing by Agios and Celgene with the FTC and the DOJ of a Notification and Report Form for Certain Mergers and Acquisitions (as that term is defined in the HSR Act), together with all required
documentary attachments thereto or (ii) any comparable filing by Agios or Celgene required under any other Antitrust Law, in each case ((i) and (ii)) with respect to the transactions contemplated by the Development & Commercialization
Agreements. 
 3.2.3    Information Exchange. Each of Agios and Celgene will, in connection
with any HSR/Antitrust Filing, (a) reasonably cooperate with each other in connection with any communication, filing or submission and in connection with any investigation or other inquiry, 

  
 - 29 - 

 
including any proceeding initiated by a private party; (b) keep the other Party and/or its counsel informed of any communication received by such Party from, or given by such Party to, the FTC,
the DOJ or any other U.S. or other Governmental Authority and of any communication received or given in connection with any proceeding by a private party, in each case regarding the transactions contemplated by any Development &
Commercialization Agreement; (c) consult with each other in advance of any meeting or conference with the FTC, the DOJ or any other Governmental Authority or, in connection with any proceeding by a private party, with any other Person, and to the
extent permitted by the FTC, the DOJ or such other Governmental Authority or other Person, give the Parties and/or their counsel the opportunity to attend and participate in such meetings and conferences; and (d) to the extent practicable, permit
the other Party and/or its counsel to review in advance any submission, filing or communication (and documents submitted therewith) intended to be given by it to the FTC, the DOJ or any other Governmental Authority; provided that
materials may be redacted to remove references concerning the [**]. Agios and Celgene, as each deems advisable and necessary, may reasonably designate any competitively sensitive material to be provided to the other under this Section 3.2.3 as
“Antitrust Counsel Only Material.” Such materials and the information contained therein shall be given only to the outside antitrust counsel of the recipient and will not be disclosed by such outside counsel to employees, officers or
directors of the recipient unless express permission is obtained in advance from the source of the materials (Agios or Celgene, as the case may be) or its legal counsel. 

3.2.4    Assistance Unrelated to Antitrust Law. Subject to this Section 3.2, Agios and
Celgene shall cooperate and use respectively all reasonable efforts to make all other registrations, filings and applications, to give all notices and to obtain as soon as practicable all governmental or other consents, transfers, approvals, orders,
qualifications, authorizations, permits and waivers, if any, and to do all other thing necessary or desirable for the consummation of the transactions as contemplated hereby. 

3.2.5    No Further Obligations. If any Development & Commercialization Agreement is
terminated pursuant to this Section 3.2, then, notwithstanding any provision in this Agreement to the contrary, neither Party shall have any further obligation to the other Party with respect to the subject matter of the relevant Development &
Commercialization Agreement; provided that, prior to termination of a Development & Commercialization Agreement pursuant to this Section 3.2, Celgene shall instead be permitted to [**], if required to comply with any Antitrust Law;
provided further that, the right to [**] set forth in the prior proviso shall not apply if a breach by Celgene of its obligations under Section 5.2 is a material cause of the failure to obtain clearance under Antitrust Laws and,
in such event, rights to such Program shall revert to Agios in accordance with the terms of the applicable Development & Commercialization Agreement. 

  
 - 30 - 

 ARTICLE IV 

GOVERNANCE 

4.1    General.

4.1.1    Governance Committees. The Parties shall establish (a) a Joint Steering Committee
(“JSC”) to oversee and coordinate the overall conduct of all Programs hereunder; (b) a Joint Research Committee (“JRC”) to oversee and coordinate discovery, research and pre-clinical Development activities with
respect to each Research Program until nomination of a Development Candidate for such Research Program; (c) a Joint Development Committee (“JDC”) for each Program as to which a Development Candidate has been nominated and designated
and for which Celgene retains an Option; (d) a Joint Commercialization Committee (“JCC”) to oversee Commercialization activities under a Development & Commercialization Agreement; and (e) a Joint Patent Committee
(“JPC”) to oversee Patent Prosecution and enforcement (the JSC, the JRC, the JDC, the JCC and the JPC shall each be referred to as a “Committee”). Each Committee shall have decision-making authority with
respect to the matters within its purview to the extent expressly and as more specifically provided herein; it being understood and agreed that with respect to any Program that is subject to an executed License Agreement, no Committee shall have any
review or decision-making authority. For the avoidance of doubt, from and after the Effective Date, no “Committee” or other working group established under the 2010 Agreement shall have the authority to address any matters involving this
Collaboration.
 4.1.2    From time to time, each Committee may establish subcommittees to oversee
particular projects or activities, as it deems necessary or advisable (each, a “Subcommittee”). Each Subcommittee shall consist of such number of members as the applicable Committee determines is appropriate from time to
time. Such members shall be individuals with expertise and responsibilities in the relevant areas such as [**], as applicable to the stage of the project or activity. Such Subcommittees shall operate under the same principles as are set
forth in this ARTICLE IV for the Committee forming such Subcommittee. 
 4.1.3    Execution of
Co-Development and Co-Commercialization Agreement. On a Program-by-Program basis, upon execution of the applicable Co-Development and Co-Commercialization Agreement for such Program, such Program and matters related thereto shall continue
to be within the purview of the applicable Committee, in accordance with and pursuant to the terms of the applicable Co-Development and Co-Commercialization Agreement. 

4.1.4    Certain Interactions with and Effects on the 2010 Agreement. Upon and after the
Effective Date, notwithstanding anything to the contrary in the 2010 Agreement (with each quoted term below having the meaning given in the 2010 Agreement): 

(a)    All activities regarding Development, Manufacturing and Commercialization of Program Compounds and
Program Products for the [**] Program or the [**] Program under the 2010 Agreement and all future such activities shall be conducted solely under this Agreement. 

(b)    None of the Parties’ activities performed in accordance with this Agreement (including those
activities specifically permitted upon and after termination) shall be deemed a violation of, nor shall they be subject to, the 2010 Agreement. 

(c)    No Program Compound or Program Product for the [**] Program or the [**] Program is or can be (i)
included as an “Agreement Compound” or in any of the classes of compounds comprising “Agreement Compounds”, (ii) part of the “Compound List,” (iii) included in any of the “Picks”, or (iv) part of an
“Agios Reverted Program,” or “Celgene Reverted Program”, each of (i) – (iv) under the 2010 Agreement. 

  
 - 31 - 

 (d)    No payments, including any “IND Amount” or
“Phase I Amount”, any milestones or any royalties, will be due under the 2010 Agreement with respect to any Program Compounds and Program Products under this Agreement (including the [**] Program or the [**] Program). 

(e)    No decision of any “Committee” or working group under the 2010 Agreement shall have any
binding effect on any Committee or working group under this Agreement, and no decision of any Committee or working group under this Agreement shall have any binding effect on any “Committee” or working group under the 2010 Agreement
notwithstanding that the members of any such committees may contain some or all of the same individual representatives for each Party. 

(f)    All “Confidential Information” disclosed under the 2010 Agreement that solely relates to
the [**] Program or the [**] Program shall be deemed to be Confidential Information disclosed under this Agreement and not the 2010 Agreement. All “Confidential Information” disclosed under the 2010 Agreement that relates to, but does
not solely relate to, the [**] Program or the [**] Program shall be deemed “Confidential Information” disclosed under the 2010 Agreement and also Confidential Information disclosed under this Agreement; provided, however,
that any disclosure of such information that is permitted under the 2010 Agreement shall not be deemed a breach of this Agreement and any disclosure of such information that is permitted under this Agreement shall not be deemed a breach of
the 2010 Agreement. 
 4.2    Joint Steering Committee. 

4.2.1    Establishment. Within [**] following the Effective Date, Agios and Celgene shall
establish the JSC. The JSC shall have oversight over each Program, subject to Sections 4.10 and 4.11. 

4.2.2    Duties. The JSC shall: 

(a)    manage the strategic direction of the Collaboration; 

(b)    oversee implementation of the Collaboration in accordance with this Agreement; 

(c)    review and monitor progress of the Collaboration and serve as a forum for exchanging information
and facilitating discussions regarding the conduct of the Collaboration; 
 (d)    oversee and
coordinate the conduct of all Programs and related matters within the responsibilities of the Committees hereunder; 

(e)    discuss and determine appropriate measures to take in view of Third Party rights; 

  
 - 32 - 

 (f)    provide strategic guidance, and coordinate efforts
between the Parties, with respect to any Publications and, by mutual agreement, approve requests for Publication, from either Party, according to the Publication Guidelines and Section 8.4 hereof; 

(g)    serve as a forum for dispute resolution in accordance with Section 4.10 with respect to matters
that are not resolved at the JRC, JDC, JCC or JPC; and 
 (h)    perform such other duties as are
specifically assigned to the JSC under this Agreement or any Development & Commercialization Agreement. 

4.3    Joint Research Committee. 

4.3.1    Establishment. Within [**] following the Effective Date, Agios and Celgene shall
establish the JRC. The JRC shall have oversight over each Research Program until a Development Candidate has been nominated and designated for such Program, subject to Sections 4.10 and 4.11. 

4.3.2    Duties. The JRC shall: 

(a)    approve the designation of Research Programs in accordance with Section 2.2.1; 

(b)    oversee, review and provide strategic guidance to the Parties with respect to the conduct of each
Research Program, including the prioritization of Research Programs; 
 (c)    review the basis [**]
that a Program Compound has met the criteria for a Development Candidate and determine whether such Program Compound has met such criteria; 

(d)    [**]; 

(e)    in conjunction with the JDC, discuss additional Indications for Development of Program Compounds
or Development Candidates of Designated Development Programs or Continuation Programs; 

(f)    oversee the initial development of any biomarkers; 

(g)    oversee and coordinate the Parties’ activities with respect to the IND-enabling activities
and Manufacture of pre-clinical and clinical supply of Program Compounds and Program Products (to the extent the JDC has not yet been formed); 

(h)    provide a forum for the Parties (i) to discuss the objectives of each Research Program; and (ii)
to exchange and review scientific information and data relating to the activities being conducted under each Research Program; 

  
 - 33 - 

 (i)    provide a forum for the Parties to identify and
discuss which Research Programs satisfy the criteria for Qualified Early Exercise I&I Programs and are eligible for early Option exercise by Celgene pursuant to Section 3.1.1(b); 

(j)    discuss and attempt to resolve any disputes in the JRC; and 

(k)    perform such other duties as are specifically assigned to the JRC under this Agreement. 

4.3.3    Dissolution. The JRC shall be dissolved and its activities and authority terminated
upon the end of the Option Term. 
 4.4    Joint Development Committee. 

4.4.1    Establishment. Within [**] following Celgene’s first designation of a
Designated Development Program pursuant to Section 2.3.2(b) or of a Continuation Program pursuant to Section 2.4.2, Agios and Celgene shall establish the JDC. The JDC shall have oversight over Development activities with respect to each
Designated Development Program or Continuation Program and as to which Celgene retains an Option hereunder or that has become a Shared Program. 

4.4.2    Duties Prior to Option Exercise by Celgene. The JDC shall: 

(a)    Review and approve the applicable Development plans for each Designated Development Program and
Continuation Program and any proposed updates or amendments to such Development plans, and propose revisions to each of such Development plans as needed; 

(b)    review and approve the content of any IND for a Program Product and oversee, review and coordinate
the studies required for the preparation of the CMC section of an IND for filing with Regulatory Authorities for the Program Products, including studies relating to analytical methods and purity analysis; 

(c)    provide a forum for the Parties to share information with respect to the Development of Program
Compounds and Program Products, including reviewing and commenting on updates on such Development; 

(d)    provide a forum for the Parties to discuss whether to conduct additional Development activities
for a Related Compound (other than the designated Development Candidate for a Designated Development Program or a Program Compound for a Continuation Program) for a Designated Development Program or Continuation Program; 

(e)    [**]; 

(f)    [**]; 

(g)    oversee, review and coordinate process research and development activities (including
Manufacturing and formulation development activities); 

  
 - 34 - 

 (h)    oversee and coordinate the Parties’ activities
with respect to the Manufacture of pre-clinical and clinical supply of Program Compounds and Program Products, including discussion, review and implementation of any Supply Plan(s) (as defined in Exhibit A); 

(i)    discuss and attempt to resolve any disputes in the JDC; and 

(j)    perform such other duties as are specifically assigned to the JDC under this Agreement or a
Development & Commercialization Agreement. 
 4.4.3    Duties Post Option
Exercise by Celgene. The JDC shall, solely with respect to any Shared Program under an executed Co-Development and Co-Commercialization Agreement: 

(a)    review and recommend to the JSC approval of the initial Development Plan (as provided in the
Co-Development and Co-Commercialization Agreement) and any proposed updates or amendments to the Development Plan (and applicable Development Budget) (each as defined in Appendix A) as needed; 

(b)    oversee, review, coordinate and provide strategic guidance to the Parties on the Development of
the Compounds and Licensed Products (each as defined in Appendix A), including assigning activities to be performed by each Party, subject to the provisions of the Co-Development and Co-Commercialization Agreement; 

(c)    review and coordinate such committees’ activities with respect to the Development of the
Compounds and Licensed Products with the Parties activities under the Co-Development and Co-Commercialization Agreement; 

(d)    subject to and within the parameters of each Development Plan (i) oversee the implementation of
the Development Plan (including evaluation of clinical trial protocols and review of the conduct of clinical trials conducted pursuant to the Development Plan); and (ii) oversee and approve the overall strategy and positioning of all material
submissions and filings with the applicable Regulatory Authorities; 
 (e)    oversee the Development
of any Companion Diagnostics, including the Development of any biomarkers; 
 (f)    oversee, review
and coordinate (in conjunction with the JCC) formulation and Manufacturing development studies, together with associated regulatory activities; 

(g)    oversee, review and coordinate the Parties’ activities with respect to Manufacturing of
Compounds and Licensed Product for Development purposes, including, in conjunction with the JCC, pre-clinical and clinical supply; 

(h)    develop and approve a publication plan for any Publications made prior to the First Commercial
Sale (as defined in the Co-Development and Co-Commercialization Agreement) of a Shared Product; 

  
 - 35 - 

 (i)    discuss and attempt to resolve any disputes in the
JDC; and 
 (j)    perform such other duties as are specifically assigned to the JDC under the
Co-Development & Co-Commercialization Agreement. 
 4.5    Joint Commercialization Committee.

 No later than the earlier of (a) the date upon which the Parties commence the first Phase III Study, or (b) the date upon
which the Parties commence the first Pivotal Clinical Trial, or within [**] after request by either Party if requested by either Party earlier, the Parties shall establish the JCC. The Parties intend that the JCC shall have the responsibility
for overseeing the Commercialization of Shared Products under the Collaboration pursuant to the terms of each Co-Development and Co-Commercialization Agreement. 

4.5.1    Meetings. The first scheduled meeting of the JCC shall be held no later than [**]
after establishment of the JCC unless otherwise agreed by the Parties. After the first scheduled meeting of the JCC until the JCC is disbanded, the JCC shall meet in person or telephonically at least [**], as further provided in Section
4.8. The JCC shall disband upon the expiration or termination of all Co-Development and Co-Commercialization Agreements. Each Party will bear all expenses it incurs in regard to participating in all meetings of the JCC, including all travel and
living expenses. 
 4.5.2    Duties. The JCC shall: 

(a)    approve the initial Commercialization Plan (as defined in Appendix A) for each Shared
Product and, each year thereafter, shall review and approve the Commercialization Plan for the then-current Calendar Year and the next succeeding Calendar Year; 

(b)    oversee implementation of the Commercialization Plan; 

(c)    review and coordinate the Commercialization activities of Celgene and Agios with respect to Shared
Products, including pre-launch and post-launch activities in the United States; 
 (d)    review and
comment on approaches and plans proposed by the applicable Lead Party in the relevant portion of the Territory (each as defined in Appendix A) [**]; 

(e)    discuss any branding and/or co-branding matters; 

(f)    establish target numbers regarding reach and frequency of sales performance; 

(g)    discuss, review and implement any Supply Plan(s) (as defined in Appendix A); 

(h)    discuss and attempt to resolve any disputes in the JCC; and 

(i)    such other responsibilities as may be set forth in a Co-Development and Co-Commercialization
Agreement or mutually agreed by the Parties from time to time. For 

  
 - 36 - 

 
purposes of clarity, the JCC shall not have any authority beyond the specific matters set forth in this Section 4.5. In any case where a matter within the JCC’s authority arises, the
JCC shall convene a meeting and consider such matter as soon as reasonably practicable, but in no event later than [**] after the matter is first brought to the JCC’s attention (or, if earlier, at the next regularly scheduled JCC meeting). 

4.6    Joint Patent Committee. 

4.6.1    Establishment. The initial members of the JPC for each Party will be determined by
each Party, respectively, within [**] after the Effective Date. The Parties intend that the JPC shall have the responsibility for sharing information and coordinating Patent Prosecution matters involving Agios Patents, Celgene Patents, Patents
included in the Celgene Collaboration Intellectual Property and Joint Collaboration Patents. 

4.6.2    Duties. The JPC shall: 

(a)    discuss the current status of all Agios Patents, Celgene Patents, Patents included in the Celgene
Collaboration Intellectual Property and Joint Collaboration Patents; 
 (b)    discuss filing and
claiming strategies involving Agios Patents, Celgene Patents, Patents included in the Celgene Collaboration Intellectual Property and Joint Collaboration Patents both existing as of the Effective Date as well as any new applications filed after the
Effective Date; 
 (c)    coordinate the timing and conduct of transfer of the Parties’
responsibilities under a Co-Development and Co-Commercialization Agreement with respect to Prosecution; 

(d)    coordinate the Parties’ respective activities in preparation for potential litigation
involving the assertion of the Agios Patents, Celgene Patents, Patents included in the Celgene Collaboration Intellectual Property and Joint Collaboration Patents; 

(e)    discuss and attempt to resolve any disputes in the JPC; and 

(f)    perform such other duties as are specifically assigned to the JPC under this Agreement or any
Co-Development and Co-Commercialization Agreement. 
 4.7    Alliance Managers. Each Party shall
appoint one designated representative to serve as an alliance manager (“Alliance Manager”) with responsibility for being the primary point of contact between the Parties with respect to the Collaboration. The Alliance Managers
shall attend JSC, JRC, JDC, JCC and JPC meetings, as necessary, as non-voting observers. Nothing herein shall prohibit a Party from appointing its Alliance Manager as a member of one or more Committees. 

4.8    General Committee Membership and Procedures. 

  
 - 37 - 

 4.8.1    Committee Membership. Each Committee
shall each be composed of three (3) representatives from each of Celgene and Agios (provided that the JPC shall be composed of two (2) representatives from each of Celgene and Agios), each of which representatives shall be of the seniority and
experience appropriate for service on the applicable Committee in light of the functions, responsibilities and authority of such Committee and the status of Development of the Program Products being pursued hereunder from time to time. Each
Party may replace any of its representatives on any Committee at any time with prior written notice to the other Party; provided that such replacement meets this standard. Each Committee shall appoint a chairperson from among its
members, with the chairperson for the JRC and JDC being a representative from [**], and the chairperson for the JSC being a representative from [**]. The JSC shall appoint the chairpersons for the JCC and the JPC. Within [**] following
each Committee meeting, the chairperson of each Committee shall circulate to all Committee members a draft of the minutes of such meeting. The Committee shall then approve, by mutual agreement, such minutes within [**] following circulation.

 4.8.2    Committee Meetings. 

(a)    The JSC and JRC shall hold an initial joint meeting within [**] after the Effective Date or as
otherwise agreed by the Parties. The JDC shall meet at the time the JDC is formed in accordance with Section 4.4.1. Thereafter, each Committee shall meet at least [**], unless the respective Committee members otherwise agree. All
Committee meetings shall be conducted in person or, for [**] of such meetings each year, by teleconference, unless otherwise determined by the applicable Committee. 

(b)    Unless otherwise agreed by the Parties, all in-person meetings for each Committee shall be held on
an alternating basis between Agios’ facilities in Cambridge, Massachusetts (or such future location as Agios’ facilities may move to) and Celgene’s facilities in Summit, New Jersey, Seattle, Washington, San Francisco, California or
San Diego, California, as determined by Celgene (or such future location as Celgene’s facilities may move to). A reasonable number of other representatives of a Party may attend any Committee meeting as non-voting observers;
provided that such additional representatives are under obligations of confidentiality and non-use applicable to the Confidential Information of the other Party that are at least as stringent as those set forth in ARTICLE VIII; and
provided further that the Parties, reasonably in advance of the applicable Committee meeting, approve the list of non-voting observers to attend such meeting. Each Party shall be responsible for all of its own personnel and
travel costs and expenses relating to participation in Committee meetings. 
 4.9    Responsibilities
under Specific Agreements. Following the execution of a Development & Commercialization Agreement for a given Program: 

4.9.1    License Agreement. After the Parties have entered into a License Agreement to govern
the further Development and Commercialization of Licensed Product under a specified Program, no Committee shall have any review or decision-making authority. 

4.9.2    Co-Development and Co-Commercialization Agreement. After the Parties have entered
into a Co-Development and Co-Commercialization Agreement to govern the further Development and Commercialization of Shared Products for a specified Program, the 

  
 - 38 - 

 
Committees other than the JRC shall continue to have review and oversight of the Development, Manufacture and Commercialization of Shared Products as set forth in this Agreement and the
applicable Co-Development and Co-Commercialization Agreement.
 4.10    Decision-Making. 

4.10.1    Committee; Referral to JSC and to Executive Officers. All decisions of a Committee
shall be made by unanimous vote, with each Party’s Representatives collectively having one (1) vote, and shall be set forth in minutes approved by both Parties. Upon [**] prior written notice, either Party may convene a special meeting of
a Committee for the purpose of resolving any failure to reach agreement on a matter within the scope of the authority and responsibility of such Committee. No Committee shall have the authority to resolve any dispute involving the breach or
alleged breach of this Agreement and shall not have any power to amend, modify or waive the terms of this Agreement (including any amendment of the Development Candidate Criteria), any Development & Commercialization Agreement or any Supply
Agreement (or any other agreement between the Parties), or to alter, increase, expand or waive compliance by a Party with a Party’s obligations under this Agreement or any Development & Commercialization Agreement. If the JRC, JDC, JCC
or JPC is unable to reach agreement on any matter so referred to it for resolution by one or both Parties within [**] after the matter is so referred to it, such matter shall be referred to the JSC for resolution. If the JSC is unable to reach
agreement on any matter within [**] after the matter is referred to it or first considered by it, such matter shall be referred to the Executive Officers for resolution. 

4.10.2    Decision-Making Authority. If the matter is not resolved by the Executive Officers
after discussions between such Executive Officers within [**] after referral to the Executive Officers, then, on a Program-by-Program basis, subject to Section 4.11 and except as otherwise provided herein (a) [**] Executive Officer shall have the
right to decide the unresolved matter as to [**] and (b) the right to decide the unresolved matter as to [**]. 

4.10.3    Notwithstanding the foregoing, neither Party shall have the right to finally resolve a dispute
pursuant to Section 4.10.2: 
 (i)    in a manner that excuses such Party from any of its obligations
specifically enumerated under this Agreement; 
 (ii)    in a manner that negates any consent rights or
other rights specifically allocated to the other Party under this Agreement; 
 (iii)    to resolve any
dispute involving the breach or alleged breach of this Agreement; 
 (iv)    to resolve a matter if the
provisions of this Agreement specify that unanimous or mutual agreement of the Parties or a Committee, or consent of the other Party, is required for such matter; 

(v)    in a manner that would require the other Party to perform any act that is inconsistent with any
Law; 

  
 - 39 - 

 (vi)    to determine whether or not a milestone event has
been achieved under a Development & Commercialization Agreement or whether or not a Qualified Early Exercise I&I Program has satisfied the criteria set forth on Schedule 1.1.83; or 

(vii)    otherwise expand a Party’s rights or reduce a Party’s obligations under this Agreement
or any Development & Commercialization Agreement. 
 4.11    Scope of Governance.
Notwithstanding the creation of each of the Committees, each Party shall retain the rights, powers and discretion granted to it under this Agreement (including, in the case of Celgene, Celgene’s rights to designate Designated Development
Programs pursuant to Section 2.3.2(b), to designate Continuation Programs pursuant to Section 2.4.2, and to elect whether to exercise Options pursuant to Section 3.1), and no Committee shall be delegated or vested with rights, powers or discretion
unless such delegation or vesting is expressly provided herein, or the Parties expressly so agree in writing. It is understood and agreed that issues to be formally decided by a particular Committee are only those specific issues that are
expressly provided in this Agreement to be decided by such Committee, as applicable. 
 4.12    Agios
Right to Discontinue Participation. Notwithstanding anything in this ARTICLE IV to the contrary, Agios shall have the right to discontinue its participation in, and to not appoint members to, any Committee or any subcommittee or project team
upon [**] prior written notice to Celgene; provided that, within such [**] period, Agios shall have [**] in place of its representative [**], subject to Celgene’s prior written consent, such consent not to be unreasonably
withheld, and [**]. If, at any time, following issuance of such a notice, Agios wishes to resume participation in any committee or Subcommittee, Agios shall notify Celgene in writing and, thereafter, Agios’ representatives to such
committee or Subcommittee shall be entitled to attend any subsequent meeting of such committee or Subcommittee and to participate in the activities of, and decision-making by, such committee or Subcommittee as provided in this ARTICLE IV as if such
notice had not been issued by Agios pursuant to this Section 4.12. If Agios discontinues participation in, or does not appoint members [**] to, any Committee or any subcommittee or project team, (a) it shall not be a breach of this Agreement; (b) no
consideration shall be required to be returned; (c) unless and until such members are appointed, Celgene may unilaterally discharge the roles of such Committee, subcommittee or project team, as applicable, for which members were not appointed,
including making in Celgene’s sole discretion all decisions of such Committee, subcommittee, or project team, including decisions requiring mutual agreement; provided that Celgene shall not unilaterally discharge the roles of such
Committee, subcommittee or project team, as applicable, as permitted under this ARTICLE IV unless Agios has not appointed any members within [**] after Celgene has completed its appointment of its members; and (d) Agios shall abide by all decisions
made by Celgene on behalf of the applicable Committee, subcommittee, or project team and shall continue to perform its obligations hereunder. If Agios thereafter appoints members to a Committee, subcommittee or project team, Celgene shall no
longer have the unilateral right to discharge the role of such Committee, subcommittee or project team, as applicable and the applicable Committee shall be re-formed. 

  
 - 40 - 

 ARTICLE V 

LICENSES; EXCLUSIVITY 

5.1    Licenses.

5.1.1    License to Agios. On a Program-by-Program basis, commencing on the Effective Date
and extending until expiration of the applicable Option Exercise Window, subject to the terms and on the conditions set forth in this Agreement, Celgene hereby grants and shall cause (within [**] after the Effective Date) its Affiliates to grant to
Agios a non-exclusive, worldwide, royalty-free right and license, with the right to grant sublicenses (subject to Section 5.1.4), under the Celgene Intellectual Property and Celgene Collaboration Intellectual Property, solely to permit Agios to
perform its obligations under the Research Plan for each Program that is subject to an Option exercisable by Celgene under Section 3.1 to Develop and/or Manufacture, for purposes of such Program, Program Compounds and/or Program Products during the
Option Term. 
 5.1.2    License to Celgene. On a Program-by-Program basis, commencing on
the Effective Date until the expiration of the applicable Option Exercise Window, subject to the terms and on the conditions set forth in this Agreement, Agios hereby grants to Celgene a non-exclusive, worldwide, royalty-free right and license, with
the right to grant sublicenses (subject to Section 5.1.4), under the Agios Intellectual Property, solely to permit Celgene to perform its obligations under the Research Plan for each Program that is subject to an Option exercisable by Celgene under
Section 3.1 to Develop and/or Manufacture, for purposes of such Program, Program Compounds and/or Program Products during the Option Term. 

5.1.3    Additional Licenses. Each Development & Commercialization Agreement will specify
additional licenses for the Development, Manufacture and/or Commercialization of Compounds (as defined in Appendix A or Appendix B) and Post-Exercise Products for the Post-Exercise Programs that are subject to such agreement. 

5.1.4    Sublicenses. Agios shall have the right to grant sublicenses under the rights
granted to it under Section 5.1.1 to its Affiliates and Third Party contractors, and Celgene shall have the right to grant sublicenses under the rights granted to it under Section 5.1.2 to its Affiliates and Third Party contractors. Each such
sublicense granted by either Party shall be subject to and consistent with the terms and conditions of this Agreement, and each Party shall provide the other Party with an unredacted copy of such sublicense. 

5.1.5    Rights Retained by the Parties. For purposes of clarity, each Party retains all
rights under Know-How and Patents Controlled by such Party not expressly granted to the other Party pursuant to this Agreement. 

5.1.6    No Implied Licenses. Except as explicitly set forth in this Agreement, neither Party
shall be deemed by estoppel, implication or otherwise to have granted the other Party any license or other right to any intellectual property of such Party. 

5.1.7    Section 365(n) of the Bankruptcy Code. All licenses granted under this Agreement are
deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of 

  
 - 41 - 

 
rights to “intellectual property” as defined in Section 101 of such Code. Each Party, as licensee, may fully exercise all of its rights and elections under the Bankruptcy
Code. The Parties further agree that, if a Party elects to retain its rights as a licensee under any Bankruptcy Code, such Party shall be entitled to complete access to any technology licensed to it hereunder and all embodiments of such
technology. Such embodiments of the technology shall be delivered to the licensee Party not later than: (a) the commencement of bankruptcy proceedings against the licensor, upon written request, unless the licensor elects to perform its
obligations under the Agreement, or (b) if not delivered under clause (a), upon the rejection of this Agreement by or on behalf of the licensor, upon written request. Any agreements supplemental hereto will be deemed to be “agreements
supplementary to” this Agreement for purposes of Section 365(n) of the Bankruptcy Code. As used herein, “Bankruptcy Code” means the U.S. Bankruptcy Code and any foreign equivalent thereto in any country having jurisdiction
over a Party or its assets. 
 5.2    Exclusivity.

5.2.1    Agios. During the Option Term, except as expressly permitted in this Agreement or
any Development & Commercialization Agreement, or mutually agreed in writing by the Parties, neither Agios nor its Affiliates shall, directly or indirectly, Develop, Manufacture or Commercialize any [**] (a) in the IO Field that [**], (b) in the
I&I Field that [**], (c) that exerts its efficacy primarily through [**] of the Program Target [**] or (d) that exerts its efficacy primarily through [**] of the Program Target [**], in each case ((a), (b), (c) and (d)) [**], except for the
following: 
 (a)    [**] Developed, Manufactured or Commercialized under Programs in accordance with
this Agreement or any Development & Commercialization Agreement; and 
 (b)    [**] that exert
their efficacy primarily through the [**] of Program Targets that are the subject of Programs the rights to which have reverted to Agios in accordance with Section 2.12 or 11.5.1(a). 

5.2.2    Celgene. During the period commencing on the date that Celgene [**] with respect to
a [**] and continuing until [**], except as expressly permitted in this Agreement, or mutually agreed in writing by the Parties, neither Celgene nor its Affiliates shall, directly or indirectly, Develop, Manufacture or Commercialize [**] that (a) if
such Program is anticipated to be in the IO Field [**], (b) if such Program is anticipated to be in the I&I Field [**], (c) if such Program is the [**] Program, exerts its efficacy primarily through [**] of the Program Target [**] or (d) if such
Program is the [**] Program, exerts its efficacy primarily through [**] of the Program Target [**], in each case ((a), (b), (c) and (d)) [**], except for [**] Developed, Manufactured or Commercialized under Programs in accordance with this Agreement
or any Development & Commercialization Agreement. 
 5.2.3    Certain Exceptions to
Exclusivity. 
 (a)    Incidental Discoveries. A Party shall be deemed not to be,
directly or indirectly (whether such activities are conducted internally or with or through a Third Party), Developing, Manufacturing or Commercializing in violation of the provisions of this Section 5.2 as a result of conducting a research program
or discovery effort (or Developing, Manufacturing 

  
 - 42 - 

 
or Commercializing a therapeutic modality resulting from such research program or discovery effort) that has as its specified and primary goal, as evidenced by laboratory notebooks or other
relevant documents contemporaneously kept, taken as a whole, to discover or Develop compounds that are not within the prohibitions set forth in this Section 5.2.

(b)    Celgene Exception. It is agreed and understood by the Parties that any Celgene research,
discovery and commercialization activities [**], whether such activities are undertaken by Celgene alone or in conjunction with one or more partners, licensors, licensees, and/or collaborators, are expressly excluded from the provisions of this
Section 5.2. In particular and without limitation, Celgene research, discovery, and commercialization activities related to (i) [**]; (ii) [**]; (iii) [**]; (iv) [**]; (v) [**]; or (vi) [**], are expressly excluded from the provisions of this
Section 5.2. 
 (c)    Academic Collaborations. Notwithstanding the provisions of Section
5.2.1 or 5.2.2, as applicable, each Party shall be permitted to perform any of the activities that would otherwise be prohibited under Section 5.2.1 or 5.2.2, as applicable, and in relation to the applicable Program Target, if such activities
are (i) the subject of an existing agreement between such Party and an academic institution or academic collaborator entered into prior to the Effective Date, provided that such Party shall not be permitted to amend any such agreement unless such
amendment contains provisions consistent with the terms and conditions of such agreement in effect as of the Effective Date with respect to (A) [**], or (ii) the subject of a new agreement entered into between such Party and an academic institution
or academic collaborator that contains terms and conditions with respect to the [**] consistent with the terms and conditions of [**]; provided that, if any [**] of an amendment described in (a) or an agreement described in (b) would
not be [**] the agreements between such Party and an academic institution or academic collaborator entered into prior to the Effective Date, such Party [**]. 

(d)    Competitive Programs. Section 5.2.1 or 5.2.2, as applicable, shall not apply if,
during the [**], any Party or its Affiliates (other than in [**] with respect to such Party) merges or consolidates with, or otherwise acquires, a Third Party that is then engaged in activities that would otherwise constitute a breach of this
Section 5.2 by any Party or its Affiliates (a “Competitive Program”); it being understood and agreed that, unless the Parties agree otherwise in writing, such Party that is engaged in a Competitive Program (the “Competitive
Program Party”) shall, within [**] after the date of such merger, consolidation or acquisition, notify the other Party that it intends to either: (i) terminate, or cause its relevant Affiliate to terminate, the Competitive
Program or (ii) divest, or cause its relevant Affiliate to divest, whether by license or otherwise, the Competitive Program. If the Competitive Program Party notifies the other Party within such [**] period that it intends to [**], such Competitive
Program, the Competitive Program Party or its relevant Affiliate, shall (i) terminate such Competitive Program as quickly as possible, and in any event within [**] (unless applicable Law requires a longer termination period) after the Competitive
Program Party delivers such notice to the other Party; and (ii) confirm to the other Party when such termination has been completed, and the Competitive Program Party’s continuation of the Competitive Program during such [**] (or, as required
by applicable Law, longer) period shall not constitute a breach of the Competitive Program Party’s exclusivity obligations under Section 5.2.1 or 5.2.2, as applicable. If the Competitive Program Party notifies the other Party within such
[**] period that it intends 

  
 - 43 - 

 
to divest such Competitive Program, the Competitive Program Party or its relevant Affiliate shall use all reasonable efforts to effect such divestiture as quickly as possible, and in any event
within [**] after the Competitive Program Party delivers such notice to the other Party, and shall confirm to the other Party when such divestiture has been completed. If the Competitive Program Party or its relevant Affiliate fails to complete
such divestiture within such [**] period, but has used reasonable efforts to effect such divestiture within such [**] period, then, unless otherwise required by applicable Law, such [**] period shall be extended for such additional reasonable period
thereafter as is necessary to enable such Competitive Program to be in fact divested, not to exceed an additional [**]; provided that such additional [**] period shall be extended for such period as is necessary to obtain any
governmental or regulatory approvals required to complete such divestiture if the Competitive Program Party or its relevant Affiliate is using good faith efforts to obtain such approvals. The Competitive Program Party’s continuation of the
Competitive Program during such divestiture period shall not constitute a breach of the Competitive Program Party’s exclusivity obligations under 5.2.1 or 5.2.2, as applicable. 

(e)    Certain Permitted Activities.

(i)    The [**] shall not constitute a breach of Section 5.2.1 or 5.2.2, as applicable. Each Party
shall report to the JSC on a [**] basis [**] and that would otherwise breach Section 5.2.1 or 5.2.2, as applicable. For clarity, [**] without violation of 5.2.1 or 5.2.2, as applicable, [**] shall not constitute [**] in violation of such
Party’s exclusivity obligations under this Section 5.2 as long as [**]. 
 (ii)    The [**] shall
not constitute a breach of Section 5.2.2; provided that [**] shall be subject to Section 5.2.2 and shall not be permitted under this Section 5.2.3(e)(ii). [**]. 

(iii)    The restrictions set forth in Section 5.2.1 or 5.2.2, as applicable, shall not be deemed to
prevent either Party or its respective Affiliates from (A) fulfilling its obligations under this Agreement, and (B) engaging any subcontractors in accordance with Section 2.9 of this Agreement. 

(iv)    If [**] occurs with respect to either Party with a Third Party and the Third Party already is
conducting or is planning to conduct activities that would cause a Party or an Affiliate to violate Section 5.2.1 or 5.2.2, as applicable, (an “Acquirer Program”), then such Third Party [**]; provided that (i) [**] in
any Acquirer Program, (ii) [**] in any Acquirer Program, (iii) [**] in any such Acquirer Program, and (iv) [**] to such Acquirer Program, including by [**] the activities under this Agreement, and the activities covered under such Acquirer Program
(except that this requirement shall not apply to [**] activities under such Acquirer Program). 

(v)    Clinical Combinations. Notwithstanding anything to the contrary in this Agreement, for
purposes of this Section 5.2, either Party shall, at all times, have the right to conduct clinical Development of Program Products, alone or with Third Parties, in which the [**] for purposes of enabling such Party and such Third Party to include
the relevant use of Program Products [**], provided that [**] may grant to any such Third Party the right to sell, offer for sale and otherwise commercially exploit such Program Products. 

  
 - 44 - 

 ARTICLE VI 

FINANCIAL TERMS 

6.1    Upfront Payment. In consideration for the rights granted to Celgene under this Agreement,
Celgene will make the following one-time, non-refundable, non-creditable upfront payments within [**] after the Effective Date: 

(a)    Celgene Corp. shall pay to Agios [**] U.S. Dollars ($[**]); and 

(b)     Celgene RIVOT shall pay to Agios [**] U.S. Dollars ($[**]). 

6.2    Designation Fees. On a Program-by-Program basis, Celgene will make a non-refundable payment
to Agios of Eight Million Dollars ($8,000,000) (the “Designation Fee”) within [**] after Celgene’s designation of each such Program for further Development pursuant to Section 2.3.2(b) or 2.4.2, as applicable. 

6.3    Research Term Extension Fee. Celgene may elect, in its sole discretion, to extend the
Research Term pursuant to Section 2.1.2 by making a non-refundable payment to Agios of Forty Million Dollars ($40,000,000) for each one (1) year extension (the “Research Term Extension Fee”) within [**] after receipt of Agios’
invoice therefor. 
 6.4    Development Costs and Manufacturing Costs. As between the Parties,
except as expressly set forth herein or otherwise agreed by the Parties, Agios shall be solely responsible, on a Program-by-Program basis, for any and all costs and expenses it incurs in connection with the conduct of Development and Manufacturing
activities for such Program that occur before Celgene exercises the Option for such Program, after which the costs of further Development, Manufacturing and Commercialization activities, for the applicable Post-Exercise Products shall be borne by
the Parties in accordance with the applicable Development & Commercialization Agreement.

6.5    Financial Records. Agios shall keep, and shall require its Affiliates to keep, complete and
accurate books and records containing all data reasonably required for the calculation and verification of amounts payable by Celgene under this ARTICLE VI in accordance with the applicable Accounting Standards. Agios shall keep, and shall
require its Affiliates to keep, such books and records for at least [**] following the end of the Calendar Year to which they pertain. Such books of accounts shall be kept at the principal place of business of the financial personnel with
responsibility for preparing and maintaining such records.
 6.6    Tax Matters. 

6.6.1    Withholding Taxes.

(a)    Each Party shall be entitled to deduct and withhold from any amounts payable under this Agreement
such taxes as are required to be deducted or withheld therefrom under any provision of applicable Law. The Party that is required to make such withholding (the “Paying Party”) will: (i) deduct those taxes from such payment,
(ii) timely 

  
 - 45 - 

 
remit the taxes to the proper taxing authority, and (iii) send evidence of the obligation together with proof of tax payment to the recipient Party (the “Payee Party”) on a
timely basis following that tax payment; provided, however, that, before making any such deduction or withholding, the Paying Party shall give the Payee Party notice of the intention to make such deduction or withholding (and
such notice, which shall set forth in reasonable detail the authority, basis and method of calculation for the proposed deduction or withholding, shall be given at least a reasonable period of time before such deduction or withholding is
required, in order for such Payee Party to obtain reduction of or relief from such deduction or withholding). Each Party agrees to cooperate with the other Parties in claiming refunds or exemptions from such deductions or withholdings under any
relevant agreement or treaty or other applicable Law which is in effect to ensure that any amounts required to be withheld pursuant to this 6.6.1(a) are reduced in amount to the fullest extent permitted by applicable Law. In addition, the
Parties shall co-operate in accordance with applicable Laws to minimize [**] in connection with this Agreement, as applicable. 

(b)    Tax Documentation. Each Party has provided a properly completed and duly executed IRS
Form W-9 or applicable Form W-8 to the other Parties. Each Party and any other recipient of payments under this Agreement shall provide to the other Party, at the time or times reasonably requested by such other Parties or as required by applicable
Law, such other properly completed and duly executed documentation as will permit payments made under this Agreement to be made without, or at a reduced rate of, withholding for taxes, and the applicable payment shall be made without (or at a
reduced rate of) withholding to the extent permitted by such documentation, as reasonably determined by the Paying Party. 

6.6.2    Tax Cooperation. Upon request, each Party shall use Commercially Reasonable Efforts
to cooperate with the other Party to mitigate, reduce or eliminate adverse tax consequences to such other Party from changes in applicable Law, the use of present or future Affiliates of either Party to engage in transactions described in or
contemplated by this Agreement, or from other activities or transactions described in or contemplated by this Agreement. 

6.7    Payments; Currency Exchange. Payments of all amounts payable under this ARTICLE VI shall be
made directly by Celgene to the bank account designated in writing by Agios. Unless otherwise expressly stated in this Agreement, all amounts specified in, and all payments made under, this Agreement shall be in United States
Dollars. Conversion of sales recorded in local currencies to Dollars shall be performed in a manner consistent with Celgene’s normal practices used to prepare its audited financial statements for internal and external reporting
purposes. For clarity, Celgene sets currency transaction rates for the month on the last business day of the prior calendar month. Agios has the right to verify that the exchange rates used by Celgene for a given month are within the
trading range of the last business day of the prior calendar month. 
 6.8    Late Payments.
Celgene shall pay interest to Agios on the aggregate amount of any payments that are not paid on or before the date such payments are due under this Agreement at a rate per annum equal to the lesser of the [**], or the highest rate permitted by
applicable Law, calculated on the number of days such payments are paid after the date such payments are due; provided that, with respect to any disputed payments, no interest payment 

  
 - 46 - 

 
shall be due until such dispute is resolved and the interest which shall be payable thereon shall be based on the finally-resolved amount of such payment, calculated from the original date on
which the disputed payment was due through the date on which payment is actually made. 
 ARTICLE VII 

INTELLECTUAL PROPERTY 

7.1    Ownership of Inventions. Inventorship of Inventions shall be determined by application of
U.S. patent law pertaining to inventorship, and ownership shall follow inventorship. 

7.2    Prosecution of Patents.

7.2.1    As between the Parties, the Party that [**] a Patent relating to a Program, unless otherwise
explicitly provided under a Development & Commercialization Agreement, shall have the sole right (but not the obligation) to Prosecute such Patent, at such Party’s expense, and [**], unless otherwise explicitly provided under a Development
& Commercialization Agreement, shall have the sole right (but not the obligation) to Prosecute all Joint Collaboration Patents, at [**] sole expense.

7.2.2    Until the earlier of (a) Celgene’s exercise of its Option and entry into a Development
& Commercialization Agreement for a given Designated Development Program or Continuation Program, or (b) the expiration of the Option Exercise Window for such Qualified Early Exercise I&I Program, Designated Development Program or
Continuation Program, [**] shall, with respect to any Agios Patent or Joint Collaboration Patent related to such Research Program, Designated Development Program or Continuation Program, (x) keep [**] informed, via the JPC, as to material
developments with respect to the Prosecution of such Agios Patent or Joint Collaboration Patent, including by providing copies of all substantive office actions or any other substantive documents in connection with such Agios Patents or Joint
Collaboration Patents that [**] receives from any patent office, and (y) provide [**] with a reasonable opportunity to comment substantively on the Prosecution of such Agios Patents or Joint Collaboration Patents, prior to taking material actions
(including the filing of initial applications), and will in good faith consider any comments made by and actions recommended by [**], provided, however, that [**] does so promptly and consistently with any applicable filing
deadlines.
 7.3    Defense of Claims Brought by Third Parties. If a Party becomes aware of any
actual or potential claim that the Development, Manufacture or Commercialization of any Program Compound or Program Product infringes or misappropriates the intellectual property rights of any Third Party, such Party shall [**]. Certain
additional rights and obligations of the Parties with respect to any such claim will be set forth in the Development & Commercialization Agreement for such Program (in each case, if applicable). 

7.4    Enforcement and Defense of Patents. As between the Parties, the Party that [**] a Patent
relating to a Program, and [**] with respect to any Joint Collaboration Patents, unless otherwise explicitly provided under a Development & Commercialization Agreement, shall have the sole right, but not the obligation, to institute, prosecute,
and control any action or proceeding with respect to any infringement or Defense of such Patent, by counsel of its own choice, in such Party’s own name and under such Party’s direction, control and expense.

  
 - 47 - 

 7.5    Third Party Licenses.

7.5.1    Notice. On a Program-by-Program basis, if, at any time during the Term, [**]
reasonably determines [**] for the Development, Manufacture or Commercialization of any Program Compound or Program Product that is the subject of Development or Manufacturing efforts under this Agreement (and that is the subject of an Option), then
[**] will [**]. 
 7.5.2    Pre-Option. Prior to the exercise of the Option, on a
Program-by-Program basis, [**] shall have the right, but not the obligation, at its sole discretion, to determine whether [**] wishes to obtain one or more licenses, on commercially reasonable terms, from one or more Third Parties for the
Development, Manufacture or Commercialization of any Program Compound or Program Product that is the subject of Development or Manufacturing efforts under this Agreement (a “Third Party License”) or take other appropriate measures
in view of such Third Party rights. In each case, [**] shall have the right [**] with respect to such Third Party rights. 

7.5.3    Post-Option. On a Program-by-Program basis, following the exercise of the Option for
such Program, the rights and obligations of the Parties with respect to obtaining licenses from Third Parties or taking other appropriate measures in view of such Third Party rights shall be as set forth in the Development & Commercialization
Agreement for such Post-Exercise Program.
 7.5.4    Costs. Subject to Section 2.2.2,
unless otherwise allocated in a Development & Commercialization Agreement or agreed by the Parties in writing, the costs associated with negotiating and obtaining rights under any Third Party License obtained under this Section 7.5 shall be
borne by [**], and the costs associated with exercising rights under any Third Party License obtained under this Section 7.5 shall be borne by [**]. 

ARTICLE VIII 
 CONFIDENTIALITY

 8.1    Confidential Information. Each Party agrees that a Party (the “Receiving
Party”) receiving Confidential Information of any other Party (the “Disclosing Party”) shall (x) maintain in confidence such Confidential Information using not less than the efforts such Receiving Party uses to maintain in
confidence its own proprietary information of similar kind and value, but in no event less than a reasonable degree of effort, (y) not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing
Party, except for disclosures expressly permitted below, and (z) not use such Confidential Information for any purpose except those permitted by this Agreement (it being understood that this clause (z) shall not create or imply any rights or
licenses not expressly granted under this Agreement). No Confidential Information of the Disclosing Party shall be used by the Receiving Party except in performing its obligations or exercising rights explicitly granted under this Agreement or
a Development & Commercialization Agreement, except to the extent that the Confidential Information: 

  
 - 48 - 

 (a)    was known by the Receiving Party or its Affiliates
prior to its date of disclosure to the Receiving Party, as established by written evidence; or 

(b)    is lawfully disclosed to the Receiving Party or its Affiliates by sources other than the
Disclosing Party rightfully in possession of the Confidential Information; or 
 (c)    becomes
published or generally known to the public through no fault or omission on the part of the Receiving Party or its Affiliates; or 

(d)    is independently developed by or for the Receiving Party or its Affiliates without reference to or
reliance upon such Confidential Information, as established by written records. 
 8.2    Permitted
Disclosure. The Receiving Party may provide the Disclosing Party’s Confidential Information: 

(a)    to the Receiving Party’s respective employees, consultants and advisors, and to the
employees, consultants and advisors of such Party’s Affiliates, who have a need to know such information and materials for performing obligations or exercising rights expressly granted under this Agreement or any Development &
Commercialization Agreement and have an obligation to treat such information and materials as confidential; 

(b)    to patent offices in order to seek or obtain Patents or to Regulatory Authorities in order to seek
or obtain approval to conduct clinical trials or to gain Regulatory Approval with respect to any Program Compound(s) or Program Product(s), as contemplated by this Agreement or any Development & Commercialization Agreement; provided
that such disclosure may be made only following reasonable notice to the Disclosing Party and to the extent reasonably necessary to seek or obtain such Patents or approvals; or 

(c)    if such disclosure is required by judicial order or applicable Law or to defend or prosecute
litigation or arbitration; provided that, prior to such disclosure, to the extent permitted by Law, the Receiving Party promptly notifies the Disclosing Party of such requirement, cooperates with the Disclosing Party to take whatever
action it may deem appropriate to protect the confidentiality of the information and furnishes only that portion of the Disclosing Party’s Confidential Information that the Receiving Party is legally required to furnish. 

8.3    Publicity; Terms of this Agreement; Non-Use of Names. 

8.3.1    Except as required by judicial order or applicable Law (in which case, Section 8.3.2 must
be complied with) or as explicitly permitted by this ARTICLE VIII, neither Party shall make any public announcement concerning this Agreement without the prior written consent of the other Party, which consent shall not be unreasonably withheld or
delayed. The Party preparing any such public announcement shall provide the other Party with a draft thereof at least [**] prior to the date on which such Party would like to make the public announcement (or, in extraordinary circumstances,
such shorter period as required to comply with applicable 

  
 - 49 - 

 
Law). Notwithstanding the foregoing, the Parties shall issue a press release, in a form mutually agreed to by the Parties, within [**] after the Effective Date. Neither Party shall use
the name, trademark, trade name or logo of the other Party or its employees in any publicity or news release relating to this Agreement or its subject matter, without the prior express written permission of the other Party. For purposes of
clarity, either Party may issue a press release or public announcement or make such other disclosure relating to this Agreement if the content of such press release, public announcement or disclosure (a) (i) does not consist of financial information
and has previously been made public other than through a breach of this Agreement by the issuing Party or its Affiliates, (ii) is contained in such Party’s financial statements prepared in accordance with Accounting Standards, or (iii) is
contained in the Redacted Version of this Agreement, and (b) is material to the event or purpose for which the new press release or public announcement is made. 

8.3.2    Notwithstanding the terms of this ARTICLE VIII: 

(a)    Either Party shall be permitted to disclose the existence and terms of this Agreement to the
extent required, in the reasonable opinion of such Party’s legal counsel, to comply with applicable Laws, including the rules and regulations promulgated by the Securities and Exchange Commission or any other Governmental
Authority. Notwithstanding the foregoing, before disclosing this Agreement or any of the terms hereof pursuant to this Section 8.3.2, the Parties will coordinate in advance with each other in connection with the redaction of certain provisions
of this Agreement with respect to any filings with the U.S. Securities and Exchange Commission (“SEC”), London Stock Exchange, the UK Listing Authority, NYSE, the NASDAQ Stock Market or any other stock exchange on which securities
issued by a Party or a Party’s Affiliate are traded (the “Redacted Version”), and each Party will use commercially reasonable efforts to seek confidential treatment for such terms as may be reasonably requested by the other
Party; provided that the Parties will use commercially reasonable efforts to file redacted versions with any governing bodies which are consistent with the Redacted Version. 

(b)    Notwithstanding Section 8.1, the Receiving Party may disclose Confidential Information belonging
to the Disclosing Party, and Confidential Information deemed to belong to both the Disclosing Party and the Receiving Party, to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances: 

(i)    subject to Section 8.3.2(a), complying with applicable Laws (including the rules and regulations
of the SEC or any national securities exchange) and with judicial process, if in the reasonable opinion of the Receiving Party’s counsel, such disclosure is necessary for such compliance; 

(ii)    disclosure, solely on a “need to know basis,” to (A) Affiliates, subcontractors,
advisors (including attorneys and accountants), (B) subject to Section 8.3.2(b)(iii), investment bankers, and (C) in each case of (A) and (B), their and each of the Parties’ respective directors, employees, contractors and agents;
provided that, in all cases of (A), (B) and (C), prior to any such disclosure, each disclosee must be bound by written obligations of confidentiality, non-disclosure and non-use no less restrictive than the obligations set forth in
this ARTICLE VIII (provided, however, that, in the case of prospective investment 

  
 - 50 - 

 
bankers, the term of confidentiality may be [**] from the date of disclosure and in the case of legal advisors, no written agreement shall be required), which for the avoidance of doubt, will not
permit use of such Confidential Information for any purpose except those permitted by this Agreement; provided, however, that, in each of the above situations, the Receiving Party shall remain responsible for any failure by any
Person who receives Confidential Information pursuant to this Section 8.2.3(b)(ii) to treat such Confidential Information as required under this ARTICLE VIII; and 

(iii)    in the case of any disclosure of this Agreement, or any executed Development &
Commercialization Agreement, to any actual or potential acquirer, assignee, licensee, licensor, investment banker, institutional investor, lender or other financial partners, such disclosure shall solely be [**]; it being understood and agreed that,
in connection with a proposed Change of Control with respect to such Party, only [**] this Agreement or such Development & Commercialization Agreement, as applicable, to such Third Party; provided that a Party may also disclose an
unredacted version of this Agreement to Third Party attorneys, professional accountants and auditors who are engaged by licensors and lenders and who are under obligations of confidentiality not to disclose the unredacted terms of this Agreement to
such licensors or lenders for the purpose of confirming such Party’s compliance with the terms of its applicable license and loan agreements with such licensors and lenders.

(c)    [**]. Such disclosures may include achievement of milestones, significant events in the
development and regulatory process, commercialization activities and the like. In addition to the initial press release described in Section 8.3.1, a Party (the “Requesting Party”) may elect to make any such public disclosure
of such achievement of milestones, significant events in the Development and regulatory process and Commercialization activities, and in such event it shall first notify the other Party (the “Cooperating Party”) of such planned
press release or public announcement and provide a draft for review at least [**] in advance of issuing such press release or making such public announcement (or, with respect to press releases and public announcements that are required by
applicable Law, or by regulation or rule of any public stock exchange (including NASDAQ), with as much advance notice as possible under the circumstances if it is not possible to provide notice at least [**] in advance); provided,
however, that a Party may issue such press release or public announcement without such prior review by the other Party if (i) the contents of such press release or public announcement have previously been made public other than through
a breach of this Agreement by the issuing Party and (ii) such press release or public announcement does not materially differ from the previously issued press release or other publicly available information. The Cooperating Party may notify the
Requesting Party of any reasonable objections or suggestions that the Cooperating Party may have regarding the proposed press release or public announcement, and the Requesting Party shall reasonably consider any such objections or suggestions that
are provided in a timely manner. The principles to be observed in such disclosures shall include accuracy, compliance with applicable Law and regulatory guidance documents, reasonable sensitivity to potential negative reactions of the FDA (and
its foreign counterparts) and the need to keep investors informed regarding the Requesting Party’s business. 

  
 - 51 - 

 8.4    Publications. The Parties agree that decisions
regarding the timing and content of Publications shall be subject to the oversight and approval of the JSC and neither Party nor its 

Affiliates shall have the right to make Publications pertaining to any Program Compound(s), Program Product(s) or Program Target(s) except as
provided herein. If a Party or its Affiliates desire to make a Publication, such Party must comply with the following procedure: 

8.4.1    The publishing Party shall provide the JSC and the non-publishing Party with an advance copy of
the proposed Publication, and the JSC shall then have [**] prior to submission for any Publication ([**] in the case of an abstract or oral presentation) in which to determine whether the Publication meets the Publication Guidelines and may be
published and under what conditions, including (a) delaying sufficiently long to permit the timely preparation and filing of a patent application or (b) specifying changes the JSC reasonably believes are necessary to preserve any Patents or Know-How
belonging (whether through ownership or license, including under this Agreement) in whole or in part to the non-publishing Party. 

8.4.2    In addition, if the non-publishing Party informs the publishing Party that such Publication, in
the non-publishing Party’s reasonable judgment, discloses any Confidential Information of the non-publishing Party or could be expected to have a material adverse effect on any Know-How which is Confidential Information of the non-publishing
Party, such Confidential Information or Know-How shall be deleted from the Publication. 

8.4.3    Each Party shall have the right to present its Publications approved pursuant to this Section
8.4.3 at scientific conferences, including at any conferences in any country in the world, subject to any conditions imposed by the JSC in its approval. 

8.4.4    Notwithstanding the foregoing, the Parties acknowledge that, to the extent that any Publication
relates to Agios Intellectual Property that Agios has licensed from a Third Party, its licensor(s) may have retained the right to publish certain information, and nothing in this Section 8.4.4 is intended to restrict the exercise of such rights;
provided that, to the extent that Agios has the right to review and comment on any such publications, Agios shall, to the extent permissible under its agreements with such Third Parties, exercise such rights after consultation with
Celgene. 
 8.4.5    Notwithstanding the foregoing, the Parties acknowledge that, to the extent that
any Publication relates to Celgene Intellectual Property that Celgene has licensed from a Third Party, its licensor(s) may have retained the right to publish certain information, and nothing in this Section 8.4.5 is intended to restrict the exercise
of such rights; provided that, to the extent that Celgene has the right to review and comment on any such publications, Celgene shall, to the extent permissible under its agreements with such Third Parties, exercise such rights after
consultation with Agios. 
 8.4.6    For purposes of convenience, the JSC may delegate its
responsibilities under this Section 8.4.6 to one or more representatives of Agios and Celgene. 

  
 - 52 - 

 8.5    Term. All obligations under Sections 8.1, 8.2,
8.3 and 8.6 shall survive termination or expiration of this Agreement and shall expire [**] following termination or expiration of this Agreement. 

8.6    Return of Confidential Information. 

8.6.1    Upon the expiration or termination of this Agreement, the Receiving Party shall return to the
Disclosing Party all Confidential Information received by the Receiving Party from the Disclosing Party (and all copies and reproductions thereof). In addition, the Receiving Party shall destroy: 

(a)    any notes, reports or other documents prepared by the Receiving Party which contain Confidential
Information of the Disclosing Party; and 
 (b)    any Confidential Information of the Disclosing Party
(and all copies and reproductions thereof) which is in electronic form or cannot otherwise be returned to the Disclosing Party. 

8.6.2    Alternatively, upon written request of the Disclosing Party, the Receiving Party shall destroy
all Confidential Information received by the Receiving Party from the Disclosing Party (and all copies and reproductions thereof) and any notes, reports or other documents prepared by the Receiving Party which contain Confidential Information of the
Disclosing Party. Any requested destruction of Confidential Information shall be certified in writing to the Disclosing Party by an authorized officer of the Receiving Party supervising such destruction. 

8.6.3    Nothing in this Section 8.6 shall require the alteration, modification, deletion or destruction
of archival tapes or other electronic back-up media made in the ordinary course of business; provided that the Receiving Party shall continue to be bound by its obligations of confidentiality and other obligations under this ARTICLE
VIII with respect to any Confidential Information contained in such archival tapes or other electronic back-up media. 

8.6.4    Notwithstanding the foregoing, 

(a)    the Receiving Party’s legal counsel may retain one copy of the Disclosing Party’s
Confidential Information solely for the purpose of determining the Receiving Party’s continuing obligations under this ARTICLE VIII; and 

(b)    the Receiving Party may retain the Disclosing Party’s Confidential Information and its own
notes, reports and other documents; 
 (i)    to the extent reasonably required (A) to exercise the
rights and licenses of the Receiving Party expressly surviving expiration or termination of this Agreement; or (B) to perform the obligations of the Receiving Party expressly surviving expiration or termination of this Agreement; or 

(ii)    to the extent it is impracticable to do so without incurring disproportionate cost. 

  
 - 53 - 

 Notwithstanding the return or destruction of the Disclosing Party’s Confidential
Information, the Receiving Party shall continue to be bound by its obligations of confidentiality and other obligations under this ARTICLE VIII. 

ARTICLE IX 
 REPRESENTATIONS AND
WARRANTIES 
 9.1    Mutual Representations. Agios and Celgene each represents, warrants and
covenants to the other Party, as of the Effective Date, that: 
 9.1.1    Authority. It is
duly organized, validly existing and in good standing under the Laws of the jurisdiction of its formation and has full corporate power and authority to enter into this Agreement or any applicable Development & Commercialization Agreement, and to
carry out the provisions hereof or thereof, as applicable. 
 9.1.2    Consents. All
necessary consents, approvals and authorizations of all government authorities and other Persons required to be obtained by it as of the Effective Date in connection with the execution, delivery and performance of this Agreement or any applicable
Development & Commercialization Agreement, and the performance of its obligations hereunder or thereunder, as applicable, have been obtained. 

9.1.3    No Conflict. Notwithstanding anything to the contrary in this Agreement, the
execution and delivery of this Agreement, the performance of such Party’s obligations in the conduct of the Collaboration and the licenses and sublicenses to be granted pursuant to this Agreement (a) do not and will not conflict with or violate
any requirement of applicable Laws existing as of the Effective Date and (b) do not and will not conflict with, violate, breach or constitute a default under any agreement or any provision thereof, or any contract, oral or written, to which it is a
party or by which it or any of its Affiliates is bound, existing as of the Effective Date. 

9.1.4    Enforceability. This Agreement has been duly executed and delivered on behalf of each
Party and is a legal and valid obligation binding upon it and is enforceable in accordance with its terms. 

9.1.5    Employee Obligations. To its knowledge, none of its or its Affiliates’ employees who
have been, are or will be involved in the Collaboration are, as a result of the nature of such Collaboration to be conducted by the Parties, in violation of any covenant in any contract with a Third Party relating to non-disclosure of proprietary
information, noncompetition or non-solicitation. 
 9.2    Additional Agios Representations.
Agios represents, warrants and covenants to Celgene, as of the Effective Date, as follows: 

  
 - 54 - 

 9.2.1    Agios possesses sufficient rights, authorizations
and consents necessary to grant all rights and licenses it purports to grant to Celgene with respect to the Agios Intellectual Property under this Agreement. 

9.2.2    Agios has not used, and during the Term will not knowingly use, any Know-How in a Program
conducted by Agios that is encumbered by any contractual right of or obligation to a Third Party that conflicts or interferes with any of the rights or licenses granted or to be granted to Celgene hereunder or under any Development &
Commercialization Agreement. 
 9.2.3    Agios has not granted, and during the Term Agios will not
grant, any right or license, to any Third Party relating to any of the intellectual property rights it Controls, that conflicts with or limits the scope of the rights or licenses granted or to be granted to Celgene hereunder or under any Development
& Commercialization Agreement. 
 9.2.4    There are no claims, litigations, suits, actions,
disputes, arbitrations, or legal, administrative or other proceedings or governmental investigations pending or, to Agios’ knowledge, threatened against Agios, nor is Agios a party to any judgment or settlement, which would be reasonably
expected to adversely affect or restrict the ability of Agios to consummate the transactions contemplated under this Agreement and to perform its obligations under this Agreement, or which would affect the Agios Intellectual Property, or Agios’
Control thereof, or any Program Target or Program Compound. 
 9.2.5    To Agios’ knowledge, the
practice of the Agios Intellectual Property as contemplated under this Agreement does not (a) infringe any claims of any Patents of any Third Party or (b) misappropriate any Know-How of any Third Party. 

9.2.6    None of (a) the Agios Patents owned by Agios or both Controlled by and Prosecuted by Agios and
(b) to Agios’ knowledge, the Agios Patents Controlled but not Prosecuted by Agios are subject to any pending re-examination, opposition, interference or litigation proceedings. 

9.2.7    There is no agreement with any Third Party to which Agios or any of its Affiliates is a party
pursuant to which Agios Controls any Agios Patent that is necessary or, to Agios’ reasonable belief as of the Effective Date, reasonably useful to Develop, Manufacture or Commercialize any Program Compounds. 

9.2.8    Neither Agios nor any of its Affiliates has granted any liens or security interests on the Agios
Intellectual Property and the Agios Intellectual Property is free and clear of any mortgage, pledge, claim, security interest, covenant, easement, encumbrance, lien or charge of any kind, except in each case with respect to licenses, covenants not
to sue, immunities from suit, standstills, releases and options which would not, in the aggregate, fundamentally frustrate the purposes of the Collaboration. 

9.2.9    Schedule 9.2.9 contains a complete and accurate list of all Patents owned by Agios and/or
its Affiliates as of the Effective Date that are included in the Patents licensed hereunder, indicating any co-owner(s), if applicable. Except as set forth on Schedule 9.2.9, Agios and its Affiliates do not own any Patent that is
necessary or, to Agios’ reasonable belief as of the Effective Date, reasonably useful to research, Develop, Manufacture or Commercialize any Program Compounds. 

  
 - 55 - 

 9.2.10    Agios and its Affiliates are not subject to any
payment obligations to Third Parties as a result of the execution or performance of this Agreement. 

9.3    Covenants. 

9.3.1    Mutual Covenants. Each Party hereby covenants to the other Party that: 

(a)    all employees of such Party or its Affiliates or Third Party subcontractors working under this
Agreement, or any Development & Commercialization Agreement, as applicable, will be under appropriate confidentiality provisions at least as protective as those contained in this Agreement, or any Development & Commercialization Agreement,
as applicable, and, to the extent permitted under applicable Law, the obligation to assign all right, title and interest in and to their inventions and discoveries, whether or not patentable, to such Party as the sole owner thereof; 

(b)    to its knowledge, such Party will not (i) employ or use, nor hire or use any contractor or
consultant that employs or uses, any individual or entity, including a clinical investigator, institution or institutional review board, debarred or disqualified by the FDA (or subject to a similar sanction by any Regulatory Authority outside the
United States) or (ii) employ any individual who or entity that is the subject of an FDA debarment investigation or proceeding (or similar proceeding by any Regulatory Authority outside the United States), in each of subclauses (i) and (ii) in the
conduct of its activities under this Agreement and any Development & Commercialization Agreement, as applicable; 

(c)    neither such Party nor any of its Affiliates shall, during the Term, grant any right or license to
any Third Party relating to any of the intellectual property rights it owns or Controls which would conflict with any of the rights or licenses granted to the other Party hereunder or under any Development & Commercialization Agreement; and 

(d)    such Party and its Affiliates shall perform its activities pursuant to this Agreement and any
Development & Commercialization Agreement, as applicable, in compliance (and shall ensure compliance by any of its subcontractors) in all material respects with all applicable Laws, including GCP, GLP and GMP as applicable and with respect to
the research, Development, Manufacturing and Commercialization activities hereunder. 
 (e)     

(i)    The Parties shall, within [**] after the Effective Date, [**]; and 

(ii)    The Parties agree and acknowledge that (A) Appendices A-1 and A-2 shall supersede
Appendix A for all purposes of this Agreement, and (B) as applicable, references to Appendix A or the “Co-Development and Co-Commercialization Agreement” in the other provisions of this Agreement shall be

  
 - 56 - 

 
deemed replaced with references to the [**] (each, a “Co-Co Agreement”) shall be [**]. For the avoidance of doubt, the revision contemplated in this Section 9.3.1(e) shall
include any necessary or incidental changes to Exhibits thereof. Neither Party shall take any position or cause their Affiliates to take any position inconsistent with this Section 9.3.1(e) for tax purposes (including with respect to filing
U.S. federal income tax returns and in the course of any audit, review or litigation), unless otherwise required by applicable Law. 

(iii)    The Parties agree and acknowledge that, notwithstanding any other provision in this Agreement or
the Co-Co Agreements, (A) [**], and (B) [**]; and 
 (iv)    The Parties agree and acknowledge that (A)
the terms of this Agreement with respect to the Term and (B) the terms of the form of License Agreement attached hereto as Appendix B [**]. Neither Party shall [**], unless otherwise required by applicable Law. 

9.3.2    Agios Covenants During Option Term. Except to the extent expressly permitted under
ARTICLE V, on a Program-by-Program basis, during the Option Term, neither Agios nor its Affiliates will, other than to an Affiliate of Agios who agrees in writing to be bound by the terms and conditions of this Agreement (a) assign, transfer,
convey, encumber (including any liens or charges, but excluding any licenses, which are the subject of subsection (b), below) or dispose of, or enter into any agreement with any Third Party to assign, transfer, convey, encumber (including any liens
or charges, but excluding any licenses, which are the subject of subsection (b), below) or dispose of, any assets specifically related to such Program, including with respect to the applicable Program Compound(s), Program Product(s) and
then-identified Companion Diagnostic(s), or pre-clinical study or Clinical Trial results or other data specifically related to such Program, or any intellectual property specifically related to any of the foregoing (with respect to each Program, the
“Agios Program Assets”), except to the extent such assignment, transfer, conveyance, encumbrance or disposition would not fundamentally frustrate the purpose of this Agreement or any applicable Development & Commercialization
Agreement with respect to such Program, (b) license or grant to any Third Party, or agree to license or grant to any Third Party, any rights to any Agios Program Assets if such license or grant would fundamentally frustrate the purpose of this
Agreement or any applicable Development & Commercialization Agreement with respect to such Program, or (c) disclose any Confidential Information relating to the Agios Program Assets to any Third Party if such disclosure would fundamentally
frustrate the purpose of this Agreement with respect to such Program. Agios and/or its Affiliates shall have the right to assign, transfer, convey or dispose of any assets specifically related to such Program to any Affiliate of Agios, to the
extent permitted by Section 12.4. 
 9.4    Disclaimer. Except as otherwise expressly set forth
in this Agreement or any executed Development & Commercialization Agreement, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY THAT ANY PATENTS ARE VALID OR ENFORCEABLE,
AND EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A 

  
 - 57 - 

 
PARTICULAR PURPOSE AND NONINFRINGEMENT. Without limiting the generality of the foregoing, each Party disclaims any warranties with regards to: (a) the success of any study or test,
including any Program, commenced under this Agreement; (b) the safety or usefulness for any purpose of the technology or materials, including any Program Compound, Program Product or Companion Diagnostic, it provides or discovers under this
Agreement; or (c) the validity, enforceability, or non-infringement of any intellectual property rights or technology it provides or licenses to the other Party under this Agreement. 

ARTICLE X 
 INDEMNIFICATION;
INSURANCE 
 10.1    By Celgene. 

10.1.1    Celgene agrees, at Celgene’s cost and expense, to defend, indemnify and hold harmless
Agios and its Affiliates and their respective directors, officers, employees and agents (the “Agios Indemnified Parties”) from and against any Damages arising out of any Claim relating to: 

(a)    any breach by Celgene of any of its representations, warranties or obligations pursuant to this
Agreement; or 
 (b)    the gross negligence or willful misconduct of Celgene. 

10.1.2    In the event of any such Claim against the Agios Indemnified Parties by any Third Party, Agios
shall promptly, and in any event within [**], notify Celgene in writing of the Claim. Celgene shall have the right, exercisable by notice to Agios within [**] after receipt of notice from Agios of the Claim, to assume direction and control of
the defense, litigation, settlement, appeal or other disposition of the Claim (provided that such Claim is solely for monetary damages and Celgene agrees to pay all Damages relating to such matter, as evidenced in a written confirmation delivered by
Celgene to Agios) with counsel selected by Celgene and reasonably acceptable to Agios; provided that the failure to provide timely notice of a Claim shall not limit an Agios Indemnified Party’s right for indemnification hereunder
except to the extent such failure results in actual prejudice to Celgene. The Agios Indemnified Parties shall cooperate with Celgene and may, at their option and expense, be separately represented in any such action or proceeding. Celgene
shall not be liable for any litigation costs or expenses incurred by the Agios Indemnified Parties without Celgene’s prior written authorization. In addition, Celgene shall not be responsible for the indemnification or defense of any Agios
Indemnified Party to the extent arising from any negligent or intentional acts by any Agios Indemnified Party or the breach by Agios of any representation, obligation or warranty under this Agreement, or any Claims compromised or settled without its
prior written consent. Each Party shall use reasonable efforts to mitigate Damages indemnified under this Section 10.1. 

10.2    By Agios. 

10.2.1    Agios agrees, at Agios’ cost and expense, to defend, indemnify and hold harmless Celgene
and its Affiliates and their respective directors, officers, employees and agents (the “Celgene Indemnified Parties”) from and against any Damages arising out of any Claim relating to: 

  
 - 58 - 

 (a)    any breach by Agios of any of its representations,
warranties or obligations pursuant to this Agreement; 
 (b)    the gross negligence or willful
misconduct of Agios; or 
 (c)    the Development, Manufacture, Commercialization, use, sale or other
disposition by Agios, its Affiliates, licensees (other than Celgene) or sublicensees of any Program Compound(s) or Program Product(s) that have reverted to Agios pursuant to this Agreement. 

10.2.2    In the event of any such Claim against the Celgene Indemnified Parties by any Third Party,
Celgene shall promptly, and in any event within [**], notify Agios in writing of the Claim. Agios shall have the right, exercisable by notice to Celgene within [**] after receipt of notice from Celgene of the Claim, to assume direction and
control of the defense, litigation, settlement, appeal or other disposition of the Claim (provided that such Claim is solely for monetary damages and Agios agrees to pay all Damages relating to such matter, as evidenced in a written confirmation
delivered by Agios to Celgene) with counsel selected by Agios and reasonably acceptable to Celgene; provided that the failure to provide timely notice of a Claim shall not limit a Celgene Indemnified Party’s right for
indemnification hereunder except to the extent such failure results in actual prejudice to Agios. The Celgene Indemnified Parties shall cooperate with Agios and may, at their option and expense, be separately represented in any such action or
proceeding. Agios shall not be liable for any litigation costs or expenses incurred by the Celgene Indemnified Parties without Agios’ prior written authorization. In addition, Agios shall not be responsible for the indemnification or
defense of any Celgene Indemnified Party to the extent arising from any negligent or intentional acts by any Celgene Indemnified Party or the breach by Celgene of any representation, obligation or warranty under this Agreement, or any Claims
compromised or settled without its prior written consent. Each Party shall use reasonable efforts to mitigate Damages indemnified under this Section 10.2. 

10.3    Indemnification Following Exercise of an Option. The Development & Commercialization
Agreements provide separately for each Party’s indemnification obligations with respect to each Program Compound and Program Product that is the subject of such agreement. 

10.4    Joint Defendants. If any suit is brought against either Party relating in any way to any
Program Compound(s) or Program Product(s), and it is not clear from the allegations in the complaint or the known facts surrounding the allegations in the complaint as to whether a Claim exists for which there is a right of indemnification pursuant
to Section 10.1 or 10.2 above, then Agios shall be responsible for controlling the defense of such suit in the first instance. During such period that Agios is controlling such defense, with regard to the costs of such defense, including
attorneys’ fees, Celgene and Agios each shall be responsible for fifty percent (50%) of all such costs. No settlement, consent judgment or other voluntary final disposition of any such suit may be entered into without the prior written
consent of Celgene, which consent shall not be unreasonably withheld or delayed. If, at any time in the course of such suit, it becomes apparent 

  
 - 59 - 

 
from discovery or otherwise that a Claim exists for which indemnification may be obtained in accordance with Section 10.1 or 10.2, then the indemnification provisions of either Section 10.1 or
10.2, whichever is applicable, shall become applicable and govern further proceedings in the suit, and the Party determined to be responsible shall reimburse the other Party for all prior costs incurred by such other Party for which indemnification
should have been obtained in accordance with Section 10.1 or 10.2. 
 10.5    Limitation of
Liability. EXCEPT WITH RESPECT TO A BREACH OF ARTICLE V OR ARTICLE VIII, OR A PARTY’S LIABILITY PURSUANT TO ARTICLE III, SECTION 10.1 OR 10.2, NEITHER PARTY NOR ITS RESPECTIVE AFFILIATES SHALL BE LIABLE FOR SPECIAL, INCIDENTAL,
CONSEQUENTIAL, EXEMPLARY, PUNITIVE, MULTIPLE OR OTHER INDIRECT OR REMOTE DAMAGES, OR FOR LOSS OF PROFITS, LOSS OF DATA OR LOSS OF USE DAMAGES ARISING IN ANY WAY OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, WHETHER BASED UPON
WARRANTY, CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR LOSS. 

10.6    Insurance. Agios, beginning on [**], and Celgene, beginning upon [**], and, both Parties,
thereafter during the Term, shall maintain commercial general liability insurance (including product liability insurance) from a recognized, creditworthy insurance company, with coverage limits of at least $[**] per claim and annual
aggregate. Celgene may elect to self-insure all or parts of the limits described above. Within [**] following written request from the other Party, each Party shall furnish to the other Party a certificate of insurance evidencing such
coverage. If such coverage is modified or cancelled, the insured Party shall notify the other Party and promptly provide such other Party with a new certificate of insurance evidencing that such insured Party’s coverage meets the
requirements of this Section 10.6. 
 ARTICLE XI 

TERM AND TERMINATION 

11.1    Term; Expiration. Unless earlier terminated in accordance with this ARTICLE XI, the term of
this Agreement (the “Term”) shall commence as of the Effective Date and remain in force until the later of (a) the expiration of the last-to-expire of the following (i) all Option Terms, and (ii) the Research Term; and (b) if one or
more Options is exercised, the termination or expiration of the last to expire Development & Commercialization Agreement executed with respect to any Program hereunder. 

11.2    Termination for Convenience. Celgene may terminate this Agreement in its entirety (provided
that there are no Programs that are subject to any surviving Development & Commercialization Agreements) or with respect to one or more Programs (provided that such Program(s) are not subject to any surviving Development & Commercialization
Agreements) upon [**] prior written notice to Agios hereunder at any time; provided that Celgene shall not have the right to terminate this Agreement until [**] following the Effective Date (it being understood and agreed that Celgene
shall be entitled to terminate upon [**] written notice at any time it reasonably determines that such termination is necessary to comply with any Antitrust Law). For the avoidance of doubt, any such termination of any particular Program(s)
pursuant to this Section 11.2 shall not terminate any other Program(s).

  
 - 60 - 

 11.3    Termination for Breach. 

11.3.1    Material Breach. Subject to the other terms of this Agreement, this Agreement and
the rights granted herein may be terminated by either Party (a) on a Program-by-Program basis prior to Celgene’s exercise of its Option for such Program, for the material breach of this Agreement in a manner that fundamentally frustrates the
transactions contemplated by this Agreement taken as a whole (each, a “Material Breach”) by the other Party of this Agreement with respect to such Program, or (b) on a Program-by-Program basis after Celgene’s exercise of its
Option for such Program, if a Development & Commercialization Agreement for such Program is terminated for Material Breach by a Party; provided in each of (a) or (b) that the breaching Party has not cured such breach within [**] after the date
of written notice to the breaching Party of such breach (or [**] in the case of a breach as a result of non-payment of any amounts due under this Agreement or a Development & Commercialization Agreement, as applicable) (the “Cure
Period”), which notice shall describe such breach in reasonable detail and shall state the non-breaching Party’s intention to terminate this Agreement with respect to a given Program, pursuant to this Section 11.3.1 with respect to
such Program. For clarity, but subject to Section 11.3.2, the Cure Period for any allegation made in good faith as to a Material Breach under this Agreement with respect to a given Program for events described in subsections (a) or (b) of this
Section 11.3.1 will run from the date that written notice was first provided to the breaching Party by the non-breaching Party. Any such termination of this Agreement with respect to a given Program under this Section 11.3.1 shall become
effective at the end of the Cure Period, unless the breaching Party has cured any such breach or default prior to the expiration of such Cure Period, or, if such breach is not susceptible to cure within the Cure Period, then, the non-breaching
Party’s right of termination shall be suspended only if and for so long as the breaching Party has provided to the non-breaching Party a written plan that is reasonably calculated to effect a cure and such plan is acceptable to the
non-breaching Party, and the breaching Party commits to and carries out such plan as provided to the non-breaching Party within [**] after the date that written notice was first provided to the breaching Party by the non-breaching Party. For
the avoidance of doubt, termination of any particular Program(s) pursuant to this Section 11.3.1 shall not terminate (i) this Agreement with respect to any other Program(s) or (ii) any Development & Commercialization Agreement for any other
Program. The Parties understand and agree that the totality of this Agreement with respect to a given Program, and the [**]. 

11.3.2    Disagreement as to Material Breach. If the Parties reasonably and in good faith
disagree as to whether there has been a Material Breach pursuant to either subsections (a) or (b) of Section 11.3.1, then subject to Section 12.1: (a) the Party that disputes that there has been a Material Breach may contest the allegation by
referring such matter, within [**] for resolution to the Executive Officers, who shall meet promptly to discuss the matter, and determine, within [**] following referral of such matter, whether or not a Material Breach has occurred pursuant to
subsections (a) or (b) of Section 11.3.1, as applicable; (b) the relevant Cure Period with respect thereto will be tolled from the date the breaching Party notifies the non-breaching Party of such dispute and through the resolution of such dispute
in accordance with the applicable provisions 

  
 - 61 - 

 
of this Agreement (provided that if such dispute relates to payment, the Cure Period will only be tolled with respect to payment of disputed amounts, and not with respect to undisputed amounts),
(c) it is understood and agreed that during the pendency of such dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder) and (d) if it
is finally and conclusively determined that the breaching Party committed such Material Breach, then the breaching Party shall have the right to cure such Material Breach after such determination within the Cure Period. 

11.3.3    If the Executive Officers are unable to resolve a dispute within such [**] period after it is
referred to them, the matter will be resolved as provided in Section 12.1. 
 11.4    Termination for
Insolvency. To the extent permitted by Law, this Agreement may be terminated by either Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of
the assets for the benefit of creditors by the other Party; provided, however, that, in the event of any involuntary bankruptcy or receivership proceeding, such right to terminate shall only become effective if the Party
consents to the involuntary bankruptcy or receivership or such proceeding is not dismissed within [**] after the filing thereof. 

11.5    Effects of Termination. 

11.5.1    Termination by Agios Pursuant to Section 11.3 or 11.4, or by Celgene pursuant to Section
11.2. In the event of termination of this Agreement in part with respect to any one or more Programs, or in its entirety, as applicable, (i) by Agios pursuant to any of Sections 11.3 or 11.4, or (ii) by Celgene pursuant to Section 11.2,
notwithstanding anything contained in this Agreement to the contrary, upon the effective date of such termination: 

(a)    subject to Sections 11.5.1(c), 11.5.1(d) and 11.6, all rights (including all Options granted to
Celgene hereunder) and licenses granted herein to Celgene by Agios with respect to any such terminated Program shall terminate, Celgene shall cease any and all Development, Manufacture and Commercialization activities under this Agreement (if any)
with respect to each terminated Program [**], each such terminated Program shall be dropped from the Collaboration, any and all rights in such terminated Program [**] granted by Agios to Celgene shall revert to Agios, and the provisions of Section
2.12 shall apply with respect to such terminated Program; 
 (b)    Agios shall have no further
obligations to Celgene under this Agreement with respect to any terminated Program, subject to Section 11.6; 

(c)    all Development & Commercialization Agreements previously entered into by the Parties for
Programs for which Celgene exercised its Option that have not been terminated shall continue in full force, in accordance with the terms and conditions of such Development & Commercialization Agreements; 

(d)    each Party shall return or destroy all Confidential Information of the other Party with respect to
any terminated Programs [**] being Developed, Manufactured or Commercialized under this Agreement, as required by ARTICLE VIII; and

  
 - 62 - 

 (e)    Section 11.6 shall apply. 

11.5.2    Termination by Celgene Pursuant to Section 11.3 or 11.4. In the event of
termination of this Agreement with respect to any one or more Programs conducted hereunder or in its entirety by Celgene pursuant to Sections 11.3 or 11.4, notwithstanding anything contained in this Agreement to the contrary, upon the effective date
of such termination: 
 (a)    subject to Sections 11.5.2(c), 11.5.2(e) and 11.6, all rights and
licenses granted herein to Agios by Celgene with respect to any such terminated Programs [**] shall terminate; 

(b)    subject to Section 11.5.2(d) and 11.6, Agios shall have no further obligations to Celgene under
this Agreement with respect to any terminated Program; 
 (c)    all Development &
Commercialization Agreements previously entered into by the Parties for Post-Option Programs that have not been terminated shall continue in full force, in accordance with the terms and conditions of such Development & Commercialization
Agreements, as applicable; 
 (d)    with respect to any terminated Program that is a Research Program,
Continuation Program or a Designated Development Program and for which Pre-Exercise Phase I Development has not been completed as of the effective date of termination, Agios shall provide Celgene with as complete an Option Data Package for such
Program as is reasonable under the circumstances, and Celgene shall have the right to exercise, within [**] after the Option Data Package Verification Date, an Option with respect to such Program to enter into a Development & Commercialization
Agreement for such Program (subject to payment by Celgene of the Option exercise fees set forth in the applicable Development & Commercialization Agreement), [**]; 

(e)    each Party shall return or destroy all Confidential Information of the other Party with respect to
any terminated Programs [**] being Developed, Manufactured or Commercialized under this Agreement, as required by ARTICLE VIII; and 

(f)    Section 11.6 shall apply. 

11.6    Surviving Provisions. 

11.6.1    Accrued Liabilities. Except as otherwise specifically provided herein, termination
of this Agreement shall not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination, nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law
or in equity with respect to any breach of this Agreement nor prejudice either Party’s right to obtain performance of any obligation. In addition, termination of this Agreement shall not terminate provisions which provide by their
respective terms for obligations or undertakings following the expiration of the term of this Agreement. 

  
 - 63 - 

 11.6.2    Survival. The rights and obligations
of the Parties set forth in the following Sections and Articles shall survive the expiration or termination of this Agreement, in addition to those other terms and conditions that are expressly stated to survive termination or expiration of this
Agreement (or by their context are intended to survive): Sections 2.12, 3.1.3, 7.1, 8.5, 8.6, 10.1, 10.2, 10.4, 10.5, 11.5, 11.6, 12.2 and 12.3. 

11.6.3    Equitable Relief. Termination of this Agreement shall be in addition to, and shall
not prejudice, the Parties’ remedies at law or in equity, including the Parties’ ability to receive Damages and/or equitable relief with respect to any breach of this Agreement, regardless of whether or not such breach was the reason for
the termination. 
 11.6.4    Relationship to Other Agreements. Termination of this
Agreement with respect to a Program shall not affect in any way the terms or provisions of any then-existing executed Development & Commercialization Agreement for any other Program. 

ARTICLE XII 
 MISCELLANEOUS

 12.1    Dispute Resolution. Except for any disagreements that are within the authority of
the JSC as provided in ARTICLE IV (which disagreements shall be resolved in accordance with Sections 4.10.1 and 4.10.2), the Parties agree that any disputes arising with respect to the interpretation, enforcement, termination or invalidity of this
Agreement (each, a “Dispute”) shall first be presented to the Parties’ respective Executive Officers for resolution. If the Parties are unable to resolve a given dispute pursuant to this Section 12.1 after discussions
between the Executive Officers within [**] after referring such dispute to the Executive Officers, either Party may, at its sole discretion, seek resolution of such matter in accordance with Section 12.2.

12.2    Submission to Court for Resolution. Subject to Section 12.1, the Parties hereby irrevocably
and unconditionally consent to the exclusive jurisdiction of the courts located in the Southern District of New York for any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement, and agree not to
commence any action, suit or proceeding (other than appeals therefrom) related thereto except in such courts. The Parties further hereby irrevocably and unconditionally waive any objection to the laying of venue of any action, suit or
proceeding (other than appeals therefrom) arising out of or relating to this Agreement in the courts of New York, and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit
or proceeding brought in any such court has been brought in an inconvenient forum. Each Party further agrees that service of any process, summons, notice or document by registered mail to its address set forth in Section 12.6 shall be effective
service of process for any action, suit or proceeding brought against it under this Agreement in any such court. 

12.3    Governing Law. This Agreement and all questions regarding its validity or interpretation,
or the performance or breach of this Agreement, shall be governed by and construed and enforced in accordance with the laws of the State of New York, without reference to conflicts of laws principles.

12.4    Assignment.

  
 - 64 - 

 12.4.1    Generally. This Agreement may not be
assigned by any Party, nor may any Party delegate its obligations or otherwise transfer licenses or other rights created by this Agreement, except as expressly permitted hereunder without the prior written consent of the other Party, which consent
will not be unreasonably withheld, delayed or conditioned. 

12.4.2    Celgene. Notwithstanding the limitations in Section 12.4.1, each of Celgene Corp.
and Celgene RIVOT may assign all of its rights and obligations under this Agreement to (a) one or more Affiliates solely as provided in this Section 12.4.2 or (b) its successor in interest in connection with the merger, consolidation, or sale of all
or substantially all of its assets or that portion of its business pertaining to the subject matter of this Agreement. 

12.4.3    Agios. Notwithstanding the limitations in Section 12.4.1, Agios may assign this
Agreement, or all of its rights or obligations hereunder, to (a) one or more Affiliates solely as provided in this Section 12.4.3 or (b) its successor in connection with the merger, consolidation, or sale of all or substantially all of its assets or
that portion of its business pertaining to the subject matter of this Agreement; provided, however, that, except in the case where [**], (a) Agios provides Celgene with at least [**] advance written notice of any such
assignment(s), (ii) prior to such assignment(s), Agios agrees in a written agreement delivered to Celgene (and upon which Celgene may rely) to remain fully liable for the performance of its obligations under this Agreement by its assignee(s), and
(iii) prior to such assignment(s), the assignee(s) agree in a written agreement delivered to Celgene (and upon which Celgene may rely) to assume performance of all such assigned obligations, (iv) in the case of any assignment(s) by Agios, all Agios
Intellectual Property and Joint Collaboration IP which Agios Controls, and all Program Assets for each Program will be transferred to such assignee(s) effective as of such assignment(s), and (v) all of the matters referred to in clauses (i), (ii),
(iii) and (iv), as applicable, will be set forth in documentation [**] prior to any such assignment(s) ([**]) and in all cases will provide [**]. Subject to the terms of this Section 12.4.3, if Agios wishes to assign any [**], it will be
permitted to do so conditioned on [**], pursuant to which such [**].
 12.4.4    Change of
Control. Notwithstanding anything to the contrary in this Agreement, with respect to any intellectual property rights controlled by the acquiring party or its Affiliates (if other than one of the Parties to this Agreement or any Affiliate
of a Party immediately before such Change of Control) involved in any Change of Control of either Party, such intellectual property rights [**], or to the extent such technology is developed outside the scope of activities conducted with respect to
the Collaboration, any Program, any Program Compounds or Program Products, or any related Companion Diagnostics. The Agios Intellectual Property and the Celgene Intellectual Property shall [**]. 

12.4.5    All Other Assignments Null and Void. The terms of this Agreement will be binding
upon and will inure to the benefit of the successors, heirs, administrators and permitted assigns of the Parties. In the event of any assignment by a Party of its rights and obligations under this Agreement, such Party shall remain primarily
liable to the other Party for the performance thereof. Any purported assignment in violation of this Section 12.4 will be null and void ab initio. 

  
 - 65 - 

 12.5    Force Majeure. If the performance of any part
of this Agreement by a Party is prevented, restricted, interfered with or delayed by an occurrence beyond the control of such Party (and which did not occur as a result of such Party’s financial condition, negligence or fault), including
fire, earthquake, flood, embargo, power shortage or failure, acts of war or terrorism, insurrection, riot, lockout or other labor disturbance, governmental acts or orders or restrictions, acts of God (for the purposes of this Agreement, a
“force majeure event”), such Party shall, upon giving written notice to the other Party, be excused from such performance to the extent of such prevention, restriction, interference or delay; provided
that the affected Party shall use its Commercially Reasonable Efforts to avoid or remove such causes of non-performance and shall continue performance with the utmost dispatch whenever such causes are removed. 

12.6    Notices. Unless otherwise agreed by the Parties or specified in this Agreement, all notices
required or permitted to be given under this Agreement shall be in writing and shall be sufficient if: (a) personally delivered; (b) sent by registered or certified mail (return receipt requested and postage prepaid); (c) sent by express
courier service providing evidence of receipt and postage prepaid where applicable; or (d) sent by facsimile transmission (receipt verified and a copy promptly sent by another permissible method of providing notice described in clauses (a), (b) or
(c) above), to address for a Party set forth below, or such other address for a Party as may be specified in writing by like notice: 
  

			
	To Agios:	  	To Celgene Corp. or Celgene RIVOT:
	  
 Agios Pharmaceuticals, Inc.

88 Sidney Street
 Cambridge, MA 02139

Attention: Chief Executive Officer

Telephone: 617-649-8600
 Facsimile: [**]
	  	  
 Celgene Corporation

86 Morris Avenue
 Summit, NJ 07901

Attention: Senior Vice President Business Development

Telephone: (908) 673-9000
 Facsimile: [**]

 

	With a copy to:	  	With a copy to:
	  
 Agios Pharmaceuticals, Inc.

88 Sidney Street
 Cambridge, MA 02139

Attention: Legal Department
 Telephone: (617)
649-8600
 Facsimile: [**]
  

and
  

WilmerHale
 60 State Street

Boston, MA 02109
 Attention: Steven D. Singer

Telephone: (617) 526-6410
 Facsimile: (617) 526-5000
	  	  
 Celgene Corporation

86 Morris Avenue
 Summit, NJ 07901

Attention: Legal Department
 Telephone: (908)
673-9000
 Facsimile: [**]
  

and
  

Celgene RIVOT Ltd.
 Aon House

30 Woodbourne Avenue
 Pembroke HM 08

Bermuda
 Phone: 441-296-4803

 
 and
  

Dechert LLP
 1900 K St. NW

Washington, DC 20006
 Attention: David E. Schulman

Telephone: (202) 261-3440
 Facsimile: [**]

  
 - 66 - 

 Any such notices shall be effective upon receipt by the Party to whom it is addressed. 

12.7    Waiver. Except as otherwise expressly provided in this Agreement, any term of this
Agreement may be waived only by a written instrument executed by a duly authorized representative of the Party waiving compliance. The delay or failure of either Party at any time to require performance of any provision of this Agreement shall
in no manner affect such Party’s rights at a later time to thereafter enforce such provision. No waiver by either Party of any condition or term in any one or more instances shall be construed as a further or continuing waiver of such
condition or term or of another condition or term. 
 12.8    Severability. If any provision of
this Agreement should be held invalid, illegal or unenforceable in any jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and all
other provisions of this Agreement shall remain in full force and effect in such jurisdiction and shall be liberally construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. If the Parties cannot agree
upon a substitute provision, the invalid, illegal or unenforceable provision of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid, illegal or unenforceable provision is of such essential importance to this
Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid, illegal or unenforceable provision.

12.9    Entire Agreement. This Agreement (including the Schedules and Appendices attached hereto,
including the form of each Development & Commercialization Agreement) constitutes the entire agreement between the Parties relating to its subject matter, and supersedes all prior and contemporaneous agreements, representations or
understandings, either written or oral, between the Parties with respect to such subject matter, including the 2010 Agreement (including Section 3.7 thereof) solely with respect to the [**] Program and the [**] Program. There are no covenants,
promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties relating to the subject matter hereof other than as set forth herein and therein. 

12.10    Modification. No modification, amendment or addition to this Agreement, or any provision
hereof, shall be effective unless reduced to writing and signed by a duly authorized representative of each Party. No provision of this Agreement shall be varied, contradicted or explained by any oral agreement, course of dealing or performance
or any other matter not set forth in an agreement in writing and signed by a duly authorized representative of each Party. 

  
 - 67 - 

 12.11    Independent Contractors; No Intended Third Party
Beneficiaries. Nothing contained in this Agreement is intended or shall be deemed or construed to create any relationship of employer and employee, agent and principal, partnership or joint venture between the Parties. Each Party is an
independent contractor. Neither Party shall assume, either directly or indirectly, any liability of or for the other Party. Neither Party shall have any express or implied right or authority to assume or create any obligations on behalf
of, or in the name of, the other Party, nor to bind the other Party to any contract, agreement or undertaking with any Third Party. There are no express or implied third party beneficiaries hereunder, except for the indemnitees identified in
Sections 10.1 and 10.2.
 12.12    Interpretation; Construction. The captions to the several
Articles and Sections of this Agreement are included only for convenience of reference and shall not in any way affect the construction of, or be taken into consideration in interpreting, this Agreement. In this Agreement, unless the context
requires otherwise, (a) the word “including” shall be deemed to be followed by the phrase “without limitation” or like expression, whether or not followed by the same; (b) references to the singular shall include the plural and
vice versa; (c) references to masculine, feminine and neuter pronouns and expressions shall be interchangeable; (d) the words “herein” or “hereunder” relate to this Agreement; (e) “or” is disjunctive but not necessarily
exclusive; (f) the word “will” shall be construed to have the same meaning and effect as the word “shall”; and (g) all references to “dollars” or “$” herein shall mean U.S. Dollars. Each Party represents
that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no
presumption will apply against the Party which drafted such terms and provisions. 

12.13    Performance by Affiliates. 

12.13.1    A Party may perform any obligation this Agreement imposes on such Party through any of such
Party’s Affiliates. To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party agrees to cause its Affiliates to perform such obligations. 

12.13.2    The Parties hereby acknowledge and agree that (a) Celgene Corp. is the party to this Agreement
with respect to all rights and obligations (including payment obligations) under this Agreement in the United States; and (b) Celgene RIVOT is the party to this Agreement with respect to all rights and obligations (including payment obligations and
the right to enter into any Development & Commercialization Agreement) under this Agreement outside of the United States. 

12.14    Counterparts. This Agreement may be executed in two (2) counterparts, each of which shall
be deemed an original, and both of which together shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of a fax machine or by .pdf, .tif, .gif, .jpeg or similar attachment to electronic mail (any
such delivery, an “Electronic Delivery”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof
delivered in person. No Party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a claim
or defense with respect to the formation of a contract, and each Party forever waives any such claim or defense, except to the extent that such claim or defense relates to lack of authenticity. 

  
 - 68 - 

 12.15    Equitable Relief. Notwithstanding anything to
the contrary herein, the Parties shall be entitled to seek equitable relief, including injunction and specific performance, as a remedy for any breach of this Agreement. Such remedies shall not be deemed to be the exclusive remedies for a
breach of this Agreement but shall be in addition to all other remedies available at law or equity. 

12.16    Further Assurances. Each Party shall execute, acknowledge and deliver such further
instruments, and do all such other acts, as may be necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this Agreement. 

[Signature Page Follows] 

  
 - 69 - 

 IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have
caused this Master Research and Collaboration Agreement to be executed by their respective duly authorized officers as of the Effective Date. 
  

			
	 CELGENE CORPORATION

		
	 By:
	 	   /s/ Mark
Alles                                  

		 	 Name: Mark Alles

		 	 Title: Chief Executive Officer

 [Signature Page to Master Research and Collaboration Agreement] 

  
 - 70 - 

 IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have
caused this Master Research and Collaboration Agreement to be executed by their respective duly authorized officers as of the Effective Date. 
  

			
	Solely with respect to the rights and obligations under this Master Research and Collaboration Agreement outside of the United States (subject to Section 12.13):
	
	 CELGENE RIVOT LTD.

		
	 By:
	 	   /s/ Kevin
Mello                            

		 	 Name: Kevin Mello

		 	 Title: Director

 [Signature Page to Master Research and Collaboration Agreement] 

  
 - 71 - 

 IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have
caused this Master Research and Collaboration Agreement to be executed by their respective duly authorized officers as of the Effective Date. 
  

			
	 AGIOS PHARMACEUTICALS, INC.

		
	 By:
	 	   /s/ David P.
Schenkein                    

		 	 Name: David P. Schenkein

		 	 Title: President and Chief Executive Officer

 [Signature Page to Master Research and Collaboration Agreement] 

  
 - 72 - 

 APPENDIX A 

FORM OF CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT 

  
 A-1 

 FINAL VERSION 

APPENDIX A 
 FORM OF
CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT 
 CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT 

by and among 
 AGIOS
PHARMACEUTICALS, INC. 
 and 

[AGIOS EX-US] 
 and 

CELGENE CORPORATION 
 and 

CELGENE RIVOT LTD. 

 TABLE OF CONTENTS 
  

							
	 ARTICLE I
	  	DEFINITIONS	  	 	1	  
			
	 ARTICLE II
	  	GOVERNANCE; COLLABORATION	  	 	12	  
			
	 ARTICLE III
	  	DEVELOPMENT	  	 	17	  
			
	 ARTICLE IV
	  	MANUFACTURE AND SUPPLY	  	 	24	  
			
	 ARTICLE V
	  	REGULATORY MATTERS	  	 	27	  
			
	 ARTICLE VI
	  	COMMERCIALIZATION	  	 	29	  
			
	 ARTICLE VII
	  	DILIGENCE	  	 	34	  
			
	 ARTICLE VIII
	  	GRANT OF RIGHTS; EXCLUSIVITY	  	 	34	  
			
	 ARTICLE IX
	  	FINANCIAL PROVISIONS	  	 	44	  
			
	 ARTICLE X
	  	INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS	  	 	53	  
			
	 ARTICLE XI
	  	CONFIDENTIALITY	  	 	62	  
			
	 ARTICLE XII
	  	REPRESENTATIONS AND WARRANTIES	  	 	67	  
			
	 ARTICLE XIII
	  	INDEMNIFICATION; PRODUCT LIABILITIES	  	 	71	  
			
	 ARTICLE XIV
	  	TERM AND TERMINATION	  	 	74	  
			
	 ARTICLE XV
	  	MISCELLANEOUS	  	 	84	  

  
 i 

			
	 Exhibits

		
	 Exhibit A
	  	Target, Compound(s), Shared Program Type and Upfront Option Payment
		
	 Exhibit B
	  	Agios Patents, Celgene Patents and Celgene Collaboration Patents (as of the Execution Date)
		
	 Exhibit C
	  	Existing Third Party Agreements
		
	 Exhibit D
	  	Certain Financial Definitions
		
	 Exhibit E
	  	Countries for Filing Agios Patents and Co-Co Collaboration Patents
		
	 Exhibit F
	  	Press Release
		
	 Exhibit G
	  	Certain U.S. Federal Income Tax Matters

 Schedules 

Schedule 6.3             Minimum Agios and Celgene Sales Representative
Qualifications 
 Disclosure Schedules 

[tailor as applicable] 

Schedule 12.2(d) 
 Schedule
12.2(e) 
 Schedule 12.2(f) 

Schedule 12.2(h) 
 Schedule
12.2(i)            Patents 
 Schedule
12.2(j)            Existing Third Party Agreements 

  
 ii 

 CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT 

This Co-Development and Co-Commercialization Agreement (this “Agreement”) is entered into as of [●]
(the “Execution Date”), by and between Agios Pharmaceuticals, Inc., a Delaware corporation (“Agios Pharmaceuticals”) and Celgene Corporation, a Delaware corporation (“Celgene Corp.”), with respect
to all rights and obligations under this Agreement in the United States, and [AGIOS Ex-US (“Agios Ex-US”)] and Celgene RIVOT Ltd., a Bermuda company (“Celgene RIVOT”), with respect to all rights and obligations
under this Agreement outside of the United States (Agios Pharmaceuticals and [Agios Ex-US], together, “Agios,” and Celgene RIVOT and Celgene Corp. together, “Celgene”). Celgene and Agios are each referred to herein
by name or as a “Party”, or, collectively, as the “Parties”. 
 INTRODUCTION 

 

	1.	 Agios and Celgene are parties to the Master Research and Collaboration Agreement, dated as of May 17, 2016
(the “Master Agreement”). 

  

	2.	 Pursuant to the Master Agreement, Agios has discovered and has been developing the compound(s) identified on
Exhibit A, each of which the Parties believe to be a potent [inhibitor/activator] [select the applicable one before signing] of the metabolic target identified on Exhibit A. 

 

	3.	 The Parties have agreed that the further Development and Commercialization of the Compound(s) should be
conducted collaboratively by the Parties pursuant to the terms of this Agreement and that all further such activities related to such Compound(s) should cease under the Master Agreement, except as contemplated herein. 

NOW, THEREFORE, in consideration of the respective representations, warranties, covenants and agreements contained herein, and
for other valuable consideration, the receipt and adequacy of which are hereby acknowledged, Agios and Celgene hereby agree as follows: 

Article I 
 Definitions

 When used in this Agreement, each of the following terms shall have the meanings set forth in this Article I. Terms
used but not defined herein shall have the meaning set forth in the Master Agreement. 
 Section
1.1    “Agios Co-Co Collaboration Intellectual Property,” “Agios Co-Co Collaboration Know-How” and “Agios Co-Co Collaboration Patents” means, respectively, the Co-Co
Collaboration Intellectual Property Controlled by Agios, the Co-Co Collaboration Know-How Controlled by Agios, and the Co-Co Collaboration Patents Controlled by Agios.

Section 1.2    “Agios Intellectual Property” means Agios Know-How and Agios Patents,
collectively.

 Section 1.3    “Agios Know-How” means any
Know-How that is (a) Controlled by Agios as of the Execution Date or during the Term, and (b) necessary or useful for the Development, Manufacture or Commercialization of the Compounds or Licensed Products, but excluding Co-Co Collaboration
Know-How. 
 Section 1.4    “Agios Patents” means any Patents that (a) are Controlled
by Agios as of the Execution Date or during the Term, and (b) Cover, or are useful for, the Development, Manufacture or Commercialization of the Compounds or Licensed Products (including the composition of matter, manufacture or any use thereof);
but excluding Co-Co Collaboration Patents. Agios Patents as of the Execution Date are as set forth on Exhibit B to this Agreement.

Section 1.5    “Agios Profit or Loss Allocation” means (a) fifty percent (50%) if this
Agreement is for a Shared 50/50 Program as indicated in Exhibit A or (b) thirty-five percent (35%) if this Agreement is for a Shared 65/35 Program as indicated in Exhibit A. 

Section 1.6    “Calendar Quarter” means a calendar quarter ending on the last day of
March, June, September or December; provided, however, that the first Calendar Quarter shall begin on the Effective Date and end on the last day of the calendar quarter during which the Effective Date occurs. 

Section 1.7    “Calendar Year” means a period of time commencing on January 1 and
ending on the following December 31; provided, however, that the first Calendar Year shall begin on the Effective Date and end on December 31 of the calendar year during which the Effective Date occurs. 

Section 1.8    “Celgene Collaboration Intellectual Property” means Celgene Collaboration
Know-How and Celgene Collaboration Patents, collectively. 
 Section 1.9    “Celgene
Collaboration Know-How” means, collectively, (a) Know-How within Celgene Collaboration Intellectual Property (as defined in the Master Agreement) and (b) Co-Co Collaboration Know-How Controlled by Celgene that is necessary or useful for the
Development, Manufacture and/or Commercialization of any Compounds or Licensed Products. 
 Section
1.10     “Celgene Collaboration Patents” means, collectively, (a) Patents within Celgene Collaboration Intellectual Property (as defined in the Master Agreement) and (b) Co-Co Collaboration Patents Controlled by
Celgene that are necessary or useful for the Development, Manufacture and/or Commercialization of any Compounds or Licensed Products. Celgene Collaboration Patents as of the Execution Date are as set forth on Exhibit B to this Agreement. 

Section 1.11     “Celgene Intellectual Property” means Celgene Know-How and Celgene
Patents, collectively.
 Section 1.12    “Celgene Know-How” means any Know-How that is
(a) Controlled by Celgene as of the Effective Date or during the Term; (b) necessary or useful for the Development, Manufacture or Commercialization of the Compounds or Licensed Products; and (c) contributed by Celgene, in Celgene’s sole
discretion, for use in the Collaboration, as evidenced by written notice from Celgene to Agios; but excluding Celgene Collaboration Know-How. 

  
 - 2 - 

 Section 1.13    “Celgene Patents” means any
Patents that (a) are Controlled by Celgene as of the Effective Date or during the Term; (b) Cover the Compounds or Licensed Products; and (c) are contributed by Celgene, in Celgene’s sole discretion, for use in the Collaboration, as evidenced
by written notice from Celgene to Agios; but excluding Celgene Collaboration Patents. Celgene Patents as of the Execution Date are as set forth on Exhibit B to this Agreement.

Section 1.14    “Celgene Profit or Loss Allocation” means (a) fifty percent (50%) if this
Agreement is for a Shared 50/50 Program as indicated in Exhibit A or (b) sixty-five percent (65%) if this Agreement is for a Shared 65/35 Program as indicated in Exhibit A. 

Section 1.15    “Clinical Trial” means a Phase I Study, a Phase II Study, a Phase III
Study, a Pivotal Clinical Trial, a Phase IV Study or a combination of any of the foregoing studies. 
 Section
1.16    “Code” means the United States Internal Revenue Code of 1986, as amended. 

Section 1.17    “Co-Co Collaboration Intellectual Property” means Co-Co Collaboration
Know-How and Co-Co Collaboration Patents, collectively. 
 Section 1.18    “Co-Co Collaboration
Know-How” means any Know-How or interest therein that is developed or generated on or after the Execution Date, either (a) solely by or on behalf of Celgene and/or its Affiliates, (b) solely by or on behalf of Agios and/or its Affiliates or
(c) jointly by or on behalf of Persons described in the foregoing clauses (a) and (b), in the conduct of the Collaboration activities pursuant to this Agreement, including Joint Inventions. 

Section 1.19    “Co-Co Collaboration Patents” means any Patents or interest therein that
are, on or after the Execution Date, Controlled solely by Celgene or Agios or Controlled jointly by any of such Persons and that Cover Co-Co Collaboration Know-How, including Joint Patents. 

Section 1.20    “Collaboration” means the activities performed or to be performed by a
Party or Parties, as the case may be, relating to the Development, Manufacturing and Commercialization of the Licensed Products under this Agreement or the Master Agreement. 

Section 1.21    “Companion Diagnostic” means a biomarker or diagnostic test that is
developed by a Party or jointly by the Parties in the course of the Collaboration as a companion diagnostic for use with a Licensed Product in accordance with the Regulatory Approval(s) therefor to generate a result for the purposes of diagnosing a
disease or condition, or to facilitate the application of the Licensed Product in the cure, mitigation, treatment, or prevention of disease, including a biomarker or diagnostic test used to diagnose the likelihood that a specific patient will
contract a certain disease or condition or to predict which patients are suitable candidates for a specific form of therapy using a Compound or Licensed Product. 

Section 1.22    “Compound” means (a) any compound that is listed on Exhibit A and
(b) to the extent Active (as defined in the Master Agreement) against the Target, any salt, fluorinated derivative, free acid, free base, clathrate, solvate, hydrate, hemihydrates, anhydride, ester, chelate, conformer, congener, crystal form,
crystal habit, polymorph, amorphous solid, isomer, stereoisomer, enantiomer, racemate, prodrug, isotopic or radiolabeled equivalent, metabolite, conjugate, complex or mixture, of such chemical entity of any such compound identified in the foregoing
clause (a) or in this clause (b). 

  
 - 3 - 

 Section 1.23    “Confidential Information”
means (a) all confidential or proprietary information relating to the Collaboration, and (b) all other confidential or proprietary documents, technology, Know-How or other information (whether or not patentable) actually disclosed by one Party to
the other pursuant to this Agreement or the Master Agreement[, or, solely with respect to information relating to the [[**] Program/[**] Program], previously disclosed prior to the Execution Date,] [bracketed clause to be included if
relevant] relating to the Licensed Products and all proprietary biological materials of a Party. 
 Section
1.24    “Data” means any and all research data, results, pharmacology data, medicinal chemistry data, preclinical data, market research, clinical data (including investigator reports (both preliminary and final),
statistical analysis, expert opinions and reports, safety and other electronic databases), in any and all forms, including files, reports, raw data, source data (including patient medical records and original patient report forms, but excluding
patient-specific data to the extent required by applicable Laws) and the like, in each case directed to, or used in, the Development, Manufacture or Commercialization of the Licensed Products. 

Section 1.25    “Development Plan” means a development plan and the related Development
Budget approved by the JSC, as amended from time to time pursuant to Section 3.1(a). 
 Section
1.26    “Effective Date” means the date on or after the Execution Date that is the Implementation Date (as defined in the Master Agreement) with respect to this Agreement. 

Section 1.27    “Executive Officers” means Celgene’s Chief Executive Officer (or the
officer or employee of Celgene then serving in a substantially equivalent capacity) or his designee and Agios’ Chief Executive Officer (or the officer or employee of Agios then serving in a substantially equivalent capacity) or his designee;
provided that any such designee must have decision-making authority on behalf of the applicable Party. 

Section 1.28    “Existing Third Party Agreement” means any agreement listed on
Exhibit C to this Agreement. 
 Section 1.29    “Field” means
the treatment, control, mitigation, prevention or cure or diagnosis of any Indications. 
 Section
1.30    “First Commercial Sale” means the first commercial sale of a Licensed Product by a Party, its Affiliates, distributors or agents in a country in an arms’ length transaction to a Third Party following
receipt of applicable Regulatory Approval of such product in such country. Sales for test marketing or clinical trial purposes shall not constitute a First Commercial Sale. 

Section 1.31    “[**]” means [**]. 

  
 - 4 - 

 Section 1.32    “Generic Competition” means,
with respect to a Licensed Product in a given country in a given Calendar Year, that, during such Calendar Year one or more Generic Products shall be commercially available in such country. 

Section 1.33    “Generic Product” means, as to a Licensed Product, any product (including
a “generic product” approved by way of an Abbreviated New Drug Application by the FDA (or equivalent regulatory mechanism for another Regulatory Authority), “biogeneric,” “follow-on biologic,” “follow-on biological
product,” “follow-on protein product,” “similar biological medicinal product,” or “biosimilar product”) that, in each case, (a) is sold by a Third Party that is not a sublicensee of the royalty-paying Party or any
of its Affiliates and that has not otherwise been authorized by the royalty-paying Party or any of its Affiliates under a Regulatory Approval granted by a Regulatory Authority to such Third Party that is based upon or relies upon the Regulatory
Approval granted by such Regulatory Authority for such Licensed Product; and (b) in the United States, is “therapeutically equivalent,” “comparable,” “biosimilar,” or “interchangeable,” as evaluated by the
FDA, applying the definition of “therapeutically equivalent” set forth in the preface to the then-current edition of the FDA publication “Approved Drug Products With Therapeutic Equivalence Evaluations” or any other definitions
set forth in the US Code, FDA regulations, or other source of US Law and, outside the United States, meets such equivalent determination by the applicable Regulatory Authorities (including a determination that the product is “comparable,”
“interchangeable,” “bioequivalent,” or “biosimilar” with respect to the Licensed Product), in each case, as is necessary to permit a pharmacist or other individual authorized to dispense pharmaceuticals under Law to
substitute one product for another product in the absence of specific instruction from a physician or other authorized prescriber under Law. 

Section 1.34    “[**]” means [**]. 

Section 1.35    “Joint Collaboration IP” means, collectively: 

“Joint Collaboration Know-How” which means all Know-How, including physical embodiments of Compound(s),
Licensed Product(s) and Companion Diagnostic(s), that is discovered, generated or invented by or on behalf of both Parties or their respective Affiliates, whether solely or jointly with any Third Party, pursuant to the conduct of activities under
the Collaboration at any time during the Term, including Joint Inventions; and 
 “Joint Collaboration
Patents” which means Patents that Cover any Joint Collaboration Know-How, including Joint Patents. 
 Section
1.36    “Lead Party” means, with respect to the US Territory, the Lead US Party, and, with respect to the ROW Territory, Celgene. Notwithstanding the foregoing, Celgene shall be the Lead Party for the entire
Territory from and after the Agios Opt-Out Date, if any. 
 Section 1.37    “Lead US
Party” means (a) Celgene, if this Agreement is for a Shared 65/35 Program, as indicated on Exhibit A, or (b) the Party designated as the Lead US Party in Exhibit A if this Agreement is for a Shared 50/50 Program, as indicated
on Exhibit A. 

  
 - 5 - 

 Section 1.38    “Licensed Product Data”
means all relevant data included in the Know-How Controlled by either Party or its Affiliates in relation to Licensed Products and/or Companion Diagnostics for use in the Field either: (a) as of the Effective Date; or (b) generated from activities
conducted by or on behalf of a Party under the Development Plan or that otherwise specifically relates to Licensed Products and/or Companion Diagnostics and in each case is necessary or useful for applications for Regulatory Approval, or Regulatory
Approvals, for Licensed Products in the Field and in the Territory. 
 Section 1.39    
“Licensed Products” means (a) a Compound, and (b) any product that contains a Compound as an active ingredient. 

Section 1.40    “Licensee Partner” means any Third Party to whom a Party or any of its
Affiliates or any other Licensee Partner grants a sublicense or license with respect to the Development, Manufacture or Commercialization of Licensed Products in the Field under the rights to Agios Intellectual Property, Celgene Intellectual
Property, Celgene Collaboration Intellectual Property, Agios Co-Co Collaboration Intellectual Property or Joint Collaboration IP, as the case may be, granted to such Party or Affiliate hereunder, in each case excluding (a) Third Party Contractors
and (b) wholesale distributors or any other Third Party that purchases Licensed Product in an arm’s-length transaction, where such Third Party does not have a sublicense to Develop, Manufacture or Commercialize the Licensed Product except for a
limited sublicense to the extent required to enable such Third Party to perform final packaging for such Licensed Product for local distribution. 

Section 1.41    “Major [**]” means [**]. 

Section 1.42    “Major Market” means [**]. 

Section 1.43    “Manufacturing Technology” means copies of all Celgene Know-How, Agios
Know-How, Celgene Collaboration Know-How, Agios Co-Co Collaboration Know-How or Joint Collaboration Know-How, as applicable, which are necessary or useful for Manufacturing preclinical, clinical or commercial supply, as applicable, of the Licensed
Products, including specifications, assays, batch records, quality control data, and transportation and storage requirements. 

Section 1.44    “NDA” means an application submitted to a Regulatory Authority for the
marketing approval of a Licensed Product, including (a) a New Drug Application, Product License Application or Biologics License Application (as such capitalized terms are used in C.F.R Title 21) filed with FDA or any successor applications or
procedures, (b) a foreign equivalent of a US New Drug Application, Product License Application or Biologics License Application or any successor applications or procedures, including a Marketing Authorization Application in the European Union, and
(c) all supplements and amendments that may be filed with respect to the foregoing. 
 Section
1.45    “Non-Supplying Party” means with respect to Agios Clinical-Scale Manufacturing Responsibilities, Agios Commercial-Scale Manufacturing Responsibilities, Celgene Clinical-Scale Manufacturing
Responsibilities and Celgene Commercial-Scale Manufacturing Responsibilities, the Party other than the Responsible Supply Party. 

  
 - 6 - 

 Section 1.46     “Phase IV Study” means a
human clinical trial of a product which is (a) conducted to satisfy a requirement of a Regulatory Authority in order to maintain a Regulatory Approval or (b) conducted voluntarily after Regulatory Approval of the product has been obtained from an
appropriate Regulatory Authority for enhancing marketing or scientific knowledge of an approved Indication. 
 Section
1.47    “Profit or Loss Allocation” means the Agios Profit or Loss Allocation or the Celgene Profit or Loss Allocation, as applicable. 

Section 1.48    “Regulatory Documentation” means, with respect to the Collaboration, all
INDs, NDAs and other regulatory applications submitted to any Regulatory Authority, Regulatory Approvals, pre-clinical and clinical data and information, regulatory materials, drug dossiers, master files (including Drug Master Files, as defined in
21 C.F.R. 314.420 and any non-United States equivalents), and any other data, reports, records, regulatory correspondence and other materials relating to Development or Regulatory Approval of the Licensed Products, or required to Manufacture,
distribute or sell the Licensed Products, including any information that relates to pharmacology, toxicology, chemistry, Manufacturing and controls data, batch records, safety and efficacy, and any safety database. 

Section 1.49    “Regulatory Exclusivity” means, with respect to a Licensed Product in a
country, that the Licensed Product has been granted marketing exclusivity afforded approved drug products, or approved biological products if applicable, pursuant to (a) Sections 505(c), 505(j), and 505A of the FDCA, and the regulations promulgated
thereunder, as amended from time to time, or similar laws enacted to apply to biological products, and the regulations promulgated thereunder, as amended from time to time, or their equivalent in a country other than the United States, (b) the
orphan drug exclusivity afforded approved drugs designated for rare diseases or conditions under Sections 526 and 527 of the FDCA, and the regulations promulgated thereunder, as amended from time to time, or its equivalent in a country other than
the United States, or (c) any future Law. 
 Section 1.50    “Reimbursable Back-up
Expenses” means, if, prior to the Execution Date, [**] conduct of specified Development activities with respect to Compound(s) in addition to the initially designated Development Candidate (as defined in the Master Agreement) that are
[**]. The amount of the Reimbursable Back-up Expenses, if any, is set forth on Annex I to Exhibit A. 
 Section
1.51    “Reimbursable Manufacturing Expenses” means, if, prior to the Execution Date, [**]. The amount of the Reimbursable Manufacturing Expenses, if any, is set forth on Annex I to Exhibit A. 

Section 1.52    “Responsible Supply Party” means Agios, with respect to Agios
Clinical-Scale Manufacturing Responsibilities and Agios Commercial-Scale Manufacturing Responsibilities, and Celgene, with respect to Celgene Clinical-Scale Manufacturing Responsibilities and Celgene Commercial-Scale Manufacturing Responsibilities.

 Section 1.53    “Right of Reference or Use” means a “Right of Reference or
Use” as that term is defined in 21 C.F.R. §314.3(b), and any non-United States equivalents. 
 Section
1.54    “ROW Territory” means all countries in the world other than the US Territory. 

  
 - 7 - 

 Section 1.55    “Supply Failure” means (a) a
failure by the Responsible Supply Party to comply with its obligations to supply relating to, with respect to Agios, Agios Clinical-Scale Manufacturing Responsibilities or Agios Commercial-Scale Manufacturing Responsibilities, and with respect
to Celgene, Celgene Clinical-Scale Manufacturing Responsibilities or Celgene Commercial-Scale Manufacturing Responsibilities under the Supply Agreement, including failure to [**], to be defined under the Supply Agreement in terms of [**], on the
Non-Supplying Party or its Affiliates or Licensee Partners, and such failure is not cured in all material respects within a commercially reasonable period of time, or (b) insolvency of the Responsible Supply Party; provided that a
Supply Failure excludes any event (or anticipated event) to the extent attributable to the [**]. 
 Section
1.56    “Target” means the metabolic target set forth on Exhibit A. 
 Section
1.57     “Territory” means the US Territory and the ROW Territory. 
 Section
1.58    “Third Party Agreement” means (a) each Existing Third Party Agreement and (b) any other Third Party agreement that either Party may enter into, during the Term in accordance with the terms of this
Agreement, to acquire or license Third Party Patents or Know-How that are necessary or useful for the Development, Manufacture or Commercialization of the Compounds or Licensed Products. 

Section 1.59    “Third Party Rights” means, with respect to a Party, any rights of, and
any limitations, restrictions or obligations imposed by, Third Parties pursuant to any Third Party Agreements. 
 Section
1.60    “US Territory” means the United States of America, including its territories, possessions and Puerto Rico. 

Section 1.61    “Valid Claim” means (a) a claim of any issued, unexpired patent that has
not been revoked or held unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction from which no appeal can be taken, or with respect to which an appeal is not taken within the time allowed for appeal, and
that has not been disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (b) a patent application or subject matter of a claim thereof filed by a Person in good faith that has not been cancelled, withdrawn
or abandoned, nor been pending for more than [**] from the earliest filing date to which such patent application or claim is entitled. 

Section 1.62    Additional Definitions. Each of the following definitions is set forth in the
section of this Agreement indicated below: 
  

			
	 DEFINITION
	  	 SECTION

		
	 35 U.S.C. § 102(c) Patent
	  	 Section 10.7

	 [**]
	  	 Section 8.6(b)(iii)

	 Accounting Standards
	  	 Exhibit D

	 Acquirer Program
	  	 Section 8.6(b)(v)(D)

	 Additional Revenue
	  	 Exhibit D

  
 - 8 - 

			
	DEFINITION	  	 SECTION

		
	Additional Study	  	 Section 3.3

	Additional Study Approval	  	 Section 3.3(c)

	Advertising and Market Research Expenses	  	 Exhibit D

	Affiliate	  	 Master Agreement

	Agios	  	 Preamble

	Agios Clinical-Scale Manufacturing Responsibilities	  	 Section 4.1(a)

	Agios Commercial-Scale Manufacturing Responsibilities	  	 Section 4.1(a)

	Agios Indemnified Parties	  	 Section 13.1(a)

	Agios Opt-Out Notice	  	 Section 2.3(a)

	Agios Opt-Out Date	  	 Section 2.3(b)

	Agios Pharmaceuticals	  	 Preamble

	Agios Program Assets	  	 Section 12.4

	Agreement	  	 Preamble

	Annual Net Sales	  	 Exhibit D

	Antitrust Law	  	 Master Agreement

	Audit Team	  	 Section 9.8(a)

	Audit Rights Holder	  	 Section 9.8(e)

	Auditee	  	 Section 9.8(e)

	Bankruptcy Code	  	 Section 8.8

	Business Day	  	 Master Agreement

	Celgene	  	 Preamble

	Celgene Corp.	  	 Preamble

	Celgene RIVOT	  	 Preamble

	Celgene Indemnified Parties	  	 Section 13.2(a)

	Celgene Clinical-Scale Manufacturing Responsibilities	  	 Section 4.1(c)

	Celgene Commercial-Scale Manufacturing Responsibilities	  	 Section 4.1(c)

	Celgene Manufacturing Responsibilities	  	 Section 4.1(c)

	Challenge	  	 Section 14.3(d)

	Challenging Party	  	 Section 14.3(d)

	Co-Co Buy-In	  	 Section 3.4

	Combination Product	  	 Exhibit D

	Commercialization/Commercialize	  	 Master Agreement

	Commercialization Expenses	  	 Exhibit D

	Commercialization Budget	  	 Section 6.2(a)(i)

	Commercialization Plan	  	 Section 6.2(a)(i)

	Commercially Reasonable Efforts	  	 Master Agreement

	Competitive Infringement	  	 Section 10.3(b)

	Competitive Program	  	 Section 8.6(b)(iv)

	Competitive Program Party	  	 Section 8.6(b)(iv)

	Control/Controlled	  	 Master Agreement

	Cooperating Party	  	 Section 11.3(b)(iii)

	Cover/Covering/Covered	  	 Master Agreement

	CPI	  	 Exhibit D

	Cure Period	  	 Section 14.3(b)(i)

	Damages	  	 Master Agreement

  
 - 9 - 

			
	 DEFINITION
	  	 SECTION

		
	 Deemed Buy-In
	  	 Section 3.3(c)

	 Develop/Development
	  	 Master Agreement

	 Development Budget
	  	 Section 3.1(a)

	 Development Costs
	  	 Exhibit D

	 Disclosing Party
	  	 Section 11.1

	 Dispute
	  	 Section 15.1

	 Distribution Costs
	  	 Exhibit D

	 Earlier Patent
	  	 Section 10.7

	 Electronic Delivery
	  	 Section 15.16

	 Execution Date
	  	 Preamble

	 FDA
	  	 Master Agreement

	 FDCA
	  	 Master Agreement

	 force majeure event
	  	 Section 15.7

	 FTE
	  	 Exhibit D

	 FTE Costs
	  	 Exhibit D

	 FTE Rate
	  	 Exhibit D

	 Global Safety Database
	  	 Section 5.3

	 Health Care Reform Fees
	  	 Exhibit D

	 IND
	  	 Master Agreement

	 [**]
	  	 Section 9.9(b)(i)

	 Indication
	  	 Master Agreement

	 Initial Enforcement Party
	  	 Section 10.3(b)

	 Invalidity Claim
	  	 Section 10.4(b)

	 Joint Inventions
	  	 Section 10.1(c)

	 Joint Patents
	  	 Section 10.1(c)

	 JPC Designee
	  	 Section 2.2(e)

	 Know-How
	  	 Master Agreement

	 Law
	  	 Master Agreement

	 Licensed Branding
	  	 Section 6.4(c)

	 Licensing Party
	  	 Section 8.5(c)

	 Loss
	  	 Exhibit D

	 Lump Sum
	  	 Section 3.3(c)

	 Manufacture/Manufacturing
	  	 Master Agreement

	 Manufacturing Costs
	  	 Exhibit D

	 Manufacturing Scale-Up Costs
	  	 Exhibit D

	 Marketing Activities
	  	 Section 6.3(a)

	 Marketing Expenses
	  	 Exhibit D

	 Marketing Management Expenses
	  	 Exhibit D

	 Master Agreement
	  	 Introduction

	 Material Breach
	  	 Section 14.3(b)(i)

	 Medical Education Expenses
	  	 Exhibit D

	 Metabolic Target
	  	 Master Agreement

	 Net Sales
	  	 Exhibit D

	 Non-Proposing Party
	  	 Section 3.3

	 Ongoing Clinical Trial
	  	 Section 3.1(c)

  
 - 10 - 

			
	 DEFINITION
	  	 SECTION

		
	 Other Commercialization Costs
	  	 Exhibit D

	 Out-of-Pocket Costs
	  	 Exhibit D

	 Party or Parties
	  	 Preamble

	 Patent and Trademark Prosecution and Enforcement Costs
	  	 Exhibit D

	 Patent Prosecution Expenses
	  	 Section 10.2(c)

	 Patents
	  	 Master Agreement

	 Payee Party
	  	 Section 9.9(b)(i)

	 Paying Party
	  	 Section 9.9(b)(i)

	 Person
	  	 Master Agreement

	 Pharmacovigilance Agreement
	  	 Section 5.3

	 Phase I Study
	  	 Master Agreement

	 Phase II Study
	  	 Master Agreement

	 Phase III Study
	  	 Master Agreement

	 Phase IV Study Expenses
	  	 Exhibit D

	 Pivotal Clinical Trial
	  	 Master Agreement

	 PPACA
	  	 Exhibit D

	 Product Liabilities
	  	 Exhibit D

	 Product Trademarks
	  	 Section 6.4(a)

	 Profit
	  	 Exhibit D

	 Profit or Loss
	  	 Exhibit D

	 Proposing Party
	  	 Section 3.3

	 Prosecuting Party
	  	 Section 10.2(d)(i)

	 Prosecution/Prosecute
	  	 Master Agreement

	 Publication
	  	 Master Agreement

	 Pursuing Party
	  	 Section 14.3(d)

	 Recall Expenses
	  	 Exhibit D

	 Receiving Party
	  	 Section 11.1

	 Redacted Version
	  	 Section 11.3(b)(i)

	 Regulatory Approval
	  	 Master Agreement

	 Regulatory Authority
	  	 Master Agreement

	 Regulatory Interactions
	  	 Section 5.1(b)

	 Regulatory Expenses
	  	 Exhibit D

	 Regulatory Maintenance Costs
	  	 Exhibit D

	 Requesting Party
	  	 Section 11.3(b)(iii)

	 Royalty Rate
	  	 Section 9.5(a)

	 Royalty Term
	  	 Section 9.5(b)

	 SEC
	  	 Section 11.3(b)(i)

	 Selling Expenses
	  	 Exhibit D

	 Sole
	  	 Master Agreement

	 Step-In Enforcement Party
	  	 Section 10.3(d)

	 Subsequent Third Party Agreement
	  	 Section 9.6(b)(ii)

	 Supply Agreement
	  	 Section 4.1(g)

	 Supply Plan
	  	 Section 4.1(e)

	 Term
	  	 Section 14.1

	 Therapeutic Modality
	  	 Section 8.6(a)

  
 - 11 - 

			
	 DEFINITION
	  	 SECTION

		
	 Third Party Contractors
	  	 Section 8.2(a)(ii)

	 Third Party Infringement
	  	 Section 10.3(a)

	 Third Party Infringement Action
	  	 Section 10.4(a)

	 Third Party Patent Costs
	  	 Exhibit D

	 Third Party Products Liability Action
	  	 Section 13.4(a)

 Article II 

Governance; Collaboration 

Section 2.1    Certain Interactions with and Effects on the Master Agreement. Upon and after
the Effective Date, notwithstanding anything to the contrary in the Master Agreement: 
 (a)    During
the Term, the Committees shall remain established as set forth in Article IV of the Master Agreement to perform the functions set forth therein with respect to the Parties’ activities under this Agreement. 

(b)    Except as otherwise set forth in this Agreement, all activities regarding Development and
Manufacturing of a Compound or a Licensed Product shall cease under the Master Agreement and all future such activities shall be conducted solely under this Agreement. 

(c)    None of the Parties’ activities performed in accordance with this Agreement (including those
activities specifically permitted upon and after termination) shall be deemed a violation of Section 5.2 of the Master Agreement. 

Section 2.2    Decision Making. 

(a)    Committee Voting. All decisions of a Committee with respect to the Parties’
activities under this Agreement shall be attempted to be made by unanimous vote, with each Party’s representatives collectively having one (1) vote, and each such decision (if made) shall be set forth in minutes approved by both Parties’
representatives on the Committee. Upon [**] prior written notice, either Party may convene a special meeting of a Committee for the purpose of resolving any failure to reach agreement on a matter within the scope of the authority and
responsibility of such Committee. No Committee shall have the authority to resolve any dispute involving the breach or alleged breach of this Agreement or to amend or modify this Agreement or the Parties’ respective rights and obligations
hereunder. 
 (b)    Referrals from JDC or JCC to JSC. If the JDC or JCC is unable to
decide, by unanimous vote, on any matter so referred to it for resolution by one or both Parties within [**] after the matter is so referred to it, the chairperson of the JDC or JCC, as applicable, shall refer such matter to the JSC for attempted
resolution by unanimous vote. 
 (c)    Referrals from the JSC to Executive Officers. If
the JSC is unable to decide, by unanimous vote, on any such matter referred to it by the JDC or the JCC or on any other matter specified in this Agreement to be decided by the JSC, within [**] after the matter is referred to it or first considered
by it, the chairperson of the JSC shall submit such matter for attempted resolution by agreement of the Executive Officers. 

  
 - 12 - 

 (d)    Decision-Making Authority. If the
Executive Officers are unable to resolve any matter referred to them by the chairperson of the JSC within [**] after the matter is referred to them, then, subject to Section 2.2(f): 

(i)    if the unresolved matter relates to the Development of the Compounds and Licensed Products, [**]
during Development and Regulatory Interactions in a geography until Regulatory Approval for such geography: (A) the Lead US Party shall have the right to decide any such unresolved matter that relates solely to the US Territory except for the
matters specified in subsection (ii)(B) below, (B) Celgene shall have the right to decide any such unresolved matter that relates solely to the ROW Territory, and (C) if Agios is the Lead US Party and such unresolved matter relates to both the US
Territory and the ROW Territory, Agios shall have the right to decide such unresolved matter with respect to the US Territory and Celgene shall have the right to decide such unresolved matter with respect to the ROW Territory; provided
that, in each case ((A), (B) and (C)), the resolving Party shall give due consideration to any comments or preferences expressed by the other Party with respect to such matter. 

(ii)    if the unresolved matter relates to Manufacturing of the Licensed Products for Commercialization,
(A) if the unresolved matter relates to Agios Commercial-Scale Manufacturing Responsibilities, then Agios shall have final decision-making rights with respect to such matter, and (B) if the unresolved matter relates to Celgene Manufacturing
Responsibilities, then Celgene shall have final decision-making rights with respect to such matter, provided that such resolving Party shall give due consideration to any comments or preferences expressed by the other Party with
respect to such matter; and 
 (iii)    if the unresolved matter relates to Commercialization of the
Licensed Products: (A) subject to Section 6.3(f), the Lead US Party shall have the right to decide the unresolved matter for the US Territory except for the matters specified in subsection (ii)(B) above and (B) Celgene shall have the right to decide
the unresolved matter for the ROW Territory; provided that the resolving Party shall give due consideration to any comments or preferences expressed by the other Party with respect to such matter. 

(e)    JPC. If the JPC is unable to decide, by unanimous vote, on any matter within [**]
after the matter is first raised with the JPC, then the matter will be referred to the [**] of Celgene and the [**] of Agios (each, a “JPC Designee”) for resolution. If such matter is not resolved by such JPC Designees of the
Parties within [**] after the matter was referred to them, then the applicable Prosecuting Party (as set forth in Article X) may decide the matter. Notwithstanding the foregoing, if at any time the Party who has decision-making rights for
such matter under Article X reasonably believes that the delay in decision resulting from such procedure will create a risk that any rights to Know-How or Patents will be lost or otherwise diminished, then such Party may exercise such
decision-making rights immediately, provided that such resolving Party shall give due consideration to any comments or preferences expressed by the other Party with respect to such matter. 

(f)    Exceptions.

(i)    This Section 2.2 is subject to the applicable terms and conditions of Article IV of the Master
Agreement. 

  
 - 13 - 

 (ii)    Notwithstanding anything to the contrary contained
herein, the Parties understand and agree that, from and after the date that Agios provides the Agios Opt-Out Notice, the Committees shall no longer have any decision-making authority, but shall continue to function for information sharing purposes.

 Section 2.3    Agios Opt-Out. 

(a)    Opt-Out Notice. Without it being a breach of Article VII, Agios shall have the right
to elect to opt-out of its Development, Manufacturing and Commercialization rights and the sharing of Development Costs and Profit or Loss under this Agreement by written notice to Celgene (such notice, the “Agios Opt-Out Notice”);
provided, however, that Agios may not, without consent of Celgene, provide any such notice (x) within [**] after any Regulatory Authority or the other Party has provided to any Committee or Agios any notification [**] with
respect to any Licensed Product or (y) within [**] after any Committee or Agios receives [**]. After Agios provides such Agios Opt-Out Notice, Celgene shall have sole discretion with respect to any matters regarding further Development,
Manufacturing and Commercialization (including any sales force activities and designation of sales representatives) hereunder, provided that, during the period between such Agios Opt-Out Notice and the applicable Agios Opt-Out Date, Celgene shall
use Commercially Reasonable Efforts to continue such activities in accordance with the plans and budgets therefor in effect as of such Agios Opt-Out Notice. 

(b)    Opt-Out Date. Agios’ opt-out shall be effective [**] after the Agios Opt-Out
Notice is given; provided that, if Agios exercises its right to opt-out at any time during the [**] period prior to [**] of any Licensed Product, then such notice period shall commence on the date of the Agios Opt-Out Notice and
continue until [**] after the [**] of such Licensed Product [**] (the “Agios Opt-Out Date”). 

(c)    Effects of Agios Opt-Out Notice or Agios Opt-Out Date. Following the Agios Opt-Out
Notice: 
 (i)    the license and sublicense granted to Agios under Section 8.1(b) shall terminate
effective as of the Agios Opt-Out Date and all licenses granted by Agios to Celgene under Section 8.1(a) with respect to the Licensed Product(s) that are the subject of the applicable breach by Celgene shall convert to worldwide licenses as if
Celgene were the Lead Party worldwide and otherwise remain in effect, and, from and after such termination; 

(ii)    effective as of the Agios Opt-Out Date, Celgene shall become (if it is not then already) the Lead
Party with respect to the entire Territory and, in accordance with Section 2.2(f)(ii), all decisions that a Committee would have made relating to Development, Manufacturing or Commercialization shall be made solely by Celgene; provided
that Celgene shall perform such functions in a manner consistent with a commitment of Commercially Reasonable Efforts to the Development and Commercialization of the Licensed Products; 

(iii)    neither Party shall have any further obligations under the Development Plan or Commercialization
Plan effective as of the Agios Opt-Out Date; 

  
 - 14 - 

 (iv)    effective as of the Agios Opt-Out Date, Celgene (but
not Agios) shall continue to have obligations under Section 7.1(b) and Section 7.2, but neither Party shall have any obligations under Section 7.1(a); 

(v)    Celgene shall be solely responsible for all Development Costs and Commercialization Expenses for
the Licensed Products incurred after the Agios Opt-Out Date, except as provided in clause (vi) immediately below and as provided in Section 5.4, Section 13.3 and Section 13.4; 

(vi)    effective as of the Agios Opt-Out Date, Agios shall cease to conduct any further Development or
Commercialization activities (including Marketing Activities) with respect to any Licensed Products, cease to have any obligations to use Commercially Reasonable Efforts with respect to Article III (Development) and Article VI (Commercialization),
and cease to incur any further Development Costs or Commercialization Expenses except as approved by Celgene or as provided in Section 5.4, Section 13.3 and Section 13.4; 

(vii)    within [**] after the Agios Opt-Out Date, Agios shall provide to Celgene a reasonably detailed
accounting of all Development Costs and Commercialization Expenses incurred by Agios under the Collaboration prior to the Agios Opt-Out Date for the purpose of calculating a final reconciliation of shared costs through the Agios Opt-Out Date in
accordance with Section 9.2 and Section 9.4; 
 (viii)    within [**] after the Agios Opt-Out Notice,
Agios shall provide to Celgene a reasonably detailed summary of Development and Commercialization activities undertaken by Agios under the Collaboration, including any Clinical Trials committed but not yet completed as of such date; 

(ix)    within [**] after the Agios Opt-Out Date, Agios shall provide to Celgene an update to the summary
provided pursuant to subsection (viii) above; 
 (x)    Agios shall undertake, and coordinate with
Celgene with respect to, any wind-down or transitional activities reasonably necessary to transfer to Celgene all Development, Manufacturing (including all Agios Clinical-Scale Manufacturing Responsibilities and Agios Commercial-Scale Manufacturing
Responsibilities) and Commercialization responsibility for the Licensed Products throughout the Territory, at [**] expense, including those activities referenced in Section 14.4(b)(vii), and Agios shall use Commercially Reasonable Efforts to
complete such activities before the Agios Opt-Out Date; provided that the Parties shall reasonably cooperate in seeking to minimize the costs of such wind-down or transitional activities; provided further that, (A)
if [**] requests that any contracts or agreements that extend beyond the Agios Opt-Out Date be terminated, [**] all costs associated with such termination, and, (B) if [**] requests that any such contract or agreement remain in effect, [**] shall be
responsible for all Development Costs and Commercialization Expenses incurred under such contract or agreement following the Agios Opt-Out Date or, if [**] requests assignment of such contract or agreement prior to the Agios Opt-Out Date, incurred
following such assignment (whichever is earlier); 

  
 - 15 - 

 (xi)    Celgene shall have the option to obtain Agios’
inventory of the Licensed Products and their active pharmaceutical ingredients at a price equal to [**]% of Agios’ Manufacturing Costs; 

(xii)    in the event Agios is utilizing a Third Party manufacturer to Manufacture the Licensed Products
or their active pharmaceutical ingredients, to the extent permitted by the terms of such contract, Agios shall, if requested by Celgene, promptly assign to Celgene the manufacturing agreements with such Third Party with respect to such products and
ingredients (it being understood that Agios shall remain fully responsible for its share of obligations thereunder arising with respect to periods prior to such assignment in accordance with the terms and conditions of this Agreement); 

(xiii)    Agios shall transfer, or have transferred, to Celgene or its designee, pursuant to a technology
transfer plan to be mutually agreed by the Parties promptly after the Agios Opt-Out Notice, all Manufacturing Technology Controlled by Agios within Agios Intellectual Property that is necessary to Manufacture the Licensed Products or their active
pharmaceutical ingredients as Manufactured by or on behalf of Agios and its Affiliates, and Agios shall provide reasonable assistance in connection with the transfer of such Manufacturing Technology to Celgene or its designee, all of which shall be
deemed Development Costs and Agios shall use Commercially Reasonable Efforts to complete such activities before the Agios Opt-Out Date; 

(xiv)    effective as of the Agios Opt Out Date, each Licensed Product shall be subject to the royalty
provisions of Section 9.5 from and after the Agios Opt-Out Date, in lieu of the sharing of Development Costs under Section 9.2 and Profit or Loss under Section 9.4; and 

(xv)    as quickly as reasonably possible, [**] shall transition to [**] Prosecution and enforcement
responsibilities (if any) with respect to Agios Patents, Agios Co-Co Collaboration Patents, Joint Inventions and Joint Collaboration Patents, which transition Agios shall use Commercially Reasonable Efforts to complete prior to the Agios Opt-Out
Date, and provide reasonable assistance to [**] and cooperation in connection therewith, including execution of such documents as may be necessary to effect such transition, provided that [**] shall retain step-in rights (in the event
that [**] elects not to Prosecute) on Prosecution matters relating to Joint Collaboration Patents, Agios Patents and Agios Co-Co Collaboration Patents that are not Joint Collaboration Patents comparable to [**]. 

(d)    No Reversion. For purposes of clarity, except as provided in this Agreement, after the
Agios Opt-Out Date, Celgene shall be responsible for all costs and expenses for the Program and Agios shall not have any option or right to buy back into any co-Development or co-Commercialization rights. 

  
 - 16 - 

 Article III 

Development 

Section 3.1    Development of Licensed Products. 

(a)    Development Plan and Changes. Subject to Section 2.2 and Section 2.3, Development of
Licensed Products shall be governed by the Development Plan for each of the US Territory and the ROW Territory that, collectively, describe the Development activities to be undertaken with respect to the Licensed Products in the Territory, which
shall include an annual budget of Development Costs pursuant to Section 3.1(b) (“Development Budget”) and anticipated timelines for performance. Promptly after the Effective Date, but in any event within [**] thereafter, the
Lead US Party (with respect to Development of the Licensed Products in the United States) and Celgene (with respect to Development of the Licensed Product in the ROW Territory) shall each prepare and submit to the JSC for review and approval its
applicable portion (for the territory in which it is the Lead Party) of an initial global Development Plan for Licensed Products. The JDC will establish the required form and contents of the Development Plan, and will review and approve each
Development Plan in accordance with Section 3.1(e). The JDC may propose changes to the Development Plan to the JSC. The Development Plan may be amended from time to time by agreement between the Parties, or by the Lead Party (including
without limitation in the event of any failure by the JSC to approve the initial Development Plan proposal by such Lead Party, or any amendment or update) for the relevant portion of the Territory, provided that (subject to the terms and conditions
of this Agreement), the Parties agree that the Development Plan shall incorporate any reasonable comments made by either Party in relation to the Development of Licensed Products either within or outside such Party’s territory. Subject to
Article IV of the Master Agreement and Section 3.3 of this Agreement, the Lead Party may not make any amendments, without agreement of the other Party, that would impose any obligations on the other Party beyond those for which the other Party is
responsible, or diminish the other Party’s rights, under this Agreement and/or the then-current Development Plan and/or Development Budget (including by increasing the other Party’s financial obligations hereunder). 

(b)    Development Budgets. Promptly after the Effective Date, but in any event within [**]
thereafter, and concurrently with the preparation of the Development Plan pursuant to Section 3.1(a), the Parties shall cooperate to prepare the initial Development Budget, which shall be reviewed and approved by the JDC (provided that, in the event
that the JDC is unable to agree upon and approve the initial Development Budget proposal, the applicable Lead Party shall be entitled to approve such proposed Development Budget for its respective portion of the Territory). The Lead US Party
shall be responsible for the preparation of the budget for the Development activities for, including all Clinical Trials to support Regulatory Approval of Licensed Products in, the United States, and Celgene shall be responsible for the preparation
of the portion of the budget for the Development activities, including all Clinical Trials to support Regulatory Approval of Licensed Products in, the ROW Territory. For Development Costs to be incurred from and after the Effective Date, the
JDC will review and approve the Development Budget reasonably in advance of the applicable Development Costs being incurred (with the intent being to obtain such approval at least [**] in advance of such costs being incurred, where
practicable). Thereafter, the JDC will update and provide the JSC with a copy of the Development Budget, including the budgeted Development Costs, each Calendar Year at a meeting of the JSC sufficiently in advance of the next Calendar Year so
as to provide the Parties with an opportunity to budget accordingly, but in any event no later than [**] of each Calendar Year during the Term. The JSC will review and approve any such update or any other amendment to the Development
Budget. In addition, either Party may request at any time that the JDC consider, and the JSC approve, other updates to the Development Budget. The 

  
 - 17 - 

 
Development Budget may be amended from time to time either by agreement between the Parties through the JSC or by the Lead Party in the event that the JSC is unable to agree upon and approve any
such amendment or updates for its respective portion of the Territory, provided that, subject to the terms and conditions of this Agreement, the Parties agree that each Party shall consider any reasonable comments made by either Party in relation to
the Development of Licensed Products either within or outside the territory for which such Party is the Lead Party. The Parties understand and agree that, if the Non-Proposing Party does not elect to participate in an Additional Study as set
forth in Section 3.3, the Proposing Party shall have the sole right to amend the Development Budget to account for the costs of such Additional Study (but, for clarity, shall not have the right to impose any additional payment obligations on the
Non-Proposing Party for expenses related to such Additional Study, unless and until a Co-Co Buy-In occurs as set forth in Section 3.4, or a Deemed Buy-In occurs pursuant to Section 3.3(c)), after which time any changes to the Development Budget
shall be run through the procedures described in this Section 3.1(b). 
 (c)    Ongoing Clinical
Trials. Notwithstanding the foregoing: 
 (i)    if Agios was conducting a Clinical Trial(s)
as part of Pre-Exercise Phase I Development (as defined in the Master Agreement), excluding any expansion cohorts in such Clinical Trial(s) that are not part of Pre-Exercise Phase I Development, anywhere in the world with respect to any Compound
and/or Licensed Product under the Collaboration which has not been completed as of the Effective Date (“Ongoing Clinical Trial”), then, at Celgene’s sole election, Agios will continue to be responsible for the performance of
such Ongoing Clinical Trial, at Agios’ expense, in accordance with the Development Plan, and in accordance with the terms of the applicable Clinical Trial protocol until completion thereof, and notwithstanding Section 5.3, Agios will be
responsible for adverse drug experiences reporting with respect to such Ongoing Clinical Trial until its completion; and 

(ii)    if Agios was responsible for supply of Compound and/or Licensed Product for any Ongoing Clinical
Trial(s) that have not been completed as of the Effective Date, then Agios will continue to be responsible at its cost for supplying such Compound and/or Licensed Product for such Ongoing Clinical Trial(s) (in the relevant dosage strength,
formulation and presentation). 
 (d)    Development Responsibilities. Each Party shall use
Commercially Reasonable Efforts to perform the activities assigned to it in accordance with the specifications, timelines and budgets indicated in the Development Plan. 

(e)    General Development Principles. It is the intent of the Parties that Development of
the Licensed Products will be conducted in accordance with the following principles, except to the extent (if any) otherwise expressly provided in the then-current Development Plan. The JDC (or the JSC or the Executive Officers as applicable) shall
take into account and attempt to implement the following principles in its decision-making, including preparation, review and approval of any updates to and amendments of the Development Plan: 

(i)    Regardless of the specific division of responsibility between the Parties for particular
activities at any particular time, the JDC (and JSC) shall serve as a conduit for sharing information, knowledge and expertise relating to the Development of the Licensed Products. 

  
 - 18 - 

 (ii)    Clinical Development of the Licensed Products should
be performed according to a single, integrated global program (with, for the avoidance of doubt, allowance of Additional Studies as provided in Section 3.3). 

(iii)    The Development Plan should include an allocation of responsibilities between the Parties
reasonably determined after taking into consideration each Party’s expertise, capabilities, staffing and available resources to take on such activities. 

(iv)    After receipt of Regulatory Approval of a Licensed Product in any Major Market, the Development
Plan should (absent special circumstances or significant changes in circumstances) include pursuit of Regulatory Approval for such Licensed Product in the other Major Markets, Japan, and such other countries as the JSC deems appropriate. 

(f)    Coordination and Reports. Each Party shall coordinate with, and keep the JDC informed
with respect to, activities assigned to such Party under the Development Plan, including the conduct of any applicable Clinical Trials. Each Party shall provide the JDC with regular quarterly written reports on such Party’s Development
activities relating to the Collaboration, including a summary of results, information, and data generated, any activities planned with respect to Development going forward (including, for example, updates regarding regulatory matters and Development
activities for the next Calendar Quarter), challenges anticipated and updates regarding intellectual property issues (including a disclosure of Collaboration Intellectual Property developed or generated since the last written report) relating to the
Collaboration. Such written reports may be discussed by telephone or video-conference, or may be provided at each JDC meeting; provided that, reasonably in advance of the meeting of the JDC, the Party providing the written report
will deliver to the JDC an agenda setting forth what will be discussed during the meeting. The Party receiving such written report shall have the right to reasonably request, and to receive in a timely manner at or after the JDC meeting,
clarifications and answers to questions with respect to such reports. 
 Section 3.2    Development
Costs. The Parties will share all Development Costs incurred from and after the Execution Date in accordance with Section 9.2.

Section 3.3    Additional Development Activities. If, following the Effective Date, a Party
(the “[**]”) wishes (i) to conduct a Clinical Trial or other study (including to repeat any Clinical Trial previously conducted under the Development Plan that failed to meet its primary endpoints) of Licensed Products not contemplated by
the Development Plan, (ii) to Develop Licensed Products for a territory for which it is the Lead Party for any Indication in the Field other than an Indication for which such Licensed Products are being Developed pursuant to the Development Plan,
(iii) to Develop a dosage form or formulation of Licensed Products for a territory for which the [**] is the Lead Party other than that being studied in the Development Plan, or (iv) to conduct any other Clinical Trial of a Licensed Product in the
Field for a territory for which the [**] is the Lead Party that the [**] believes may have utility to support Regulatory Approval in the [**] territory, including any Phase IV Study or any combination of pharmaceutical products (each such study or
activity in (i)-(iv) not already included in a 

  
 - 19 - 

 
Development Plan, an “[**]”), then (A) the [**] shall first provide the proposed trial design and protocol for such Additional Study to the other Party (the “[**]”), through
its members of the JDC, for review and approval as to the clinical and regulatory aspects of such Additional Study, and shall incorporate reasonable comments from the [**] Party’s JDC members into such Additional Study design and protocol, and
(B) following such review by the [**] Party’s JDC members, provide the final proposed design and projected costs of such Additional Study to the [**] Party’s JSC members. In any such case the following shall apply: 

(a)    If the [**], through its members of the JSC, [**] to [**] such Additional Study, the Parties shall
amend the Development Plan and the Development Budget to [**] such Additional Study, and the [**] of such Additional Study shall [**] in the Development Cost share in accordance with Section 9.2.

(b)    If [**] to include costs incurred with respect to such proposed Additional Study within the
Development Cost share, the [**] may proceed with such Additional Study and shall [**] for the conduct and [**] of such study. In such case, the [**] would have [**] to use any resulting data (including any Licensed Product Data), except as set
forth in Section 3.6(b) with respect to safety information required to be filed with the applicable Regulatory Authorities, in any such filings with Regulatory Authorities in the territory for which such [**] is the Lead Party, unless and until a
[**] occurs as set forth in Section 3.4, or a [**] occurs pursuant to Section 3.3(c). 
 (c)    If (i)
the [**] an Additional Study, [**] Additional Study as Development Costs or exercise a [**] with respect to such Additional Study pursuant to Section 3.4 prior to the initiation of the earlier of (A) a [**] or (B) a [**] and (ii) the [**] (each, an
“Additional Study Approval”), such [**] shall be deemed to have elected to buy in to such Additional Study (a “[**]”), and shall pay to the [**] for such Additional Study a lump sum payment (“Lump Sum”)
equal to [**] percent ([**]%) of the costs that otherwise would have been apportioned to the [**] as Development Costs had such [**] originally opted-in, to conduct such Additional Study prior to the [**]. For example, in the case of the
Shared 65/35 Program, where Celgene bears sixty-five percent (65%) of the Development Cost share and Agios bears thirty-five percent (35%) of the Development Cost share, if Agios were the [**] and Celgene incurred $[**] in Development Costs prior to
the [**], then Agios would be required to pay $[**] (which represents [**] percent ([**]%) of the thirty-five percent (35%) share that Agios otherwise would have been required to pay under the Development Cost share pursuant to Section
9.2). The [**] shall pay to the [**] the [**] amounts set forth in this Section 3.3(c) within [**] after the [**] notifies the [**] in writing that the [**] has received Additional Study Approval. 

(d)    If the Non-Proposing Party elects to co-fund an Additional Study, or elects to exercise a Co-Co
Buy-In pursuant to Section 3.4, or is subject to a Deemed Buy-In as set forth in Section 3.3(c), then following such Non-Proposing Party’s decision to co-fund, or following such Co-Co Buy-In, or Deemed Buy-In, as applicable, all data resulting
from such Additional Study (including any Licensed Product Data) shall be available for use by (i) the Non-Proposing Party [**] and (ii) both Parties in the Territory to perform activities allocated to each such Party in the Development Plan or
otherwise as set forth in this Agreement. 

  
 - 20 - 

 (e)    For clarity, the [**] of any such Additional Study
shall [**] in the Development Cost share pursuant to Section 9.2 unless and until (i) the [**] agrees to [**] pursuant to Section 3.3(a); (ii) a [**] occurs pursuant to Section 3.4; or (iii) a [**] occurs pursuant to Section 3.3(c). 

Section 3.4    Buy-In Right. Notwithstanding Section 3.3(b) above, and subject to Section
3.3(c), at any time prior to the initiation of the earlier of (a) a [**] or (b) a [**], the [**] would have the right to elect by written notice to the [**] to include within the Development Cost share the costs of such Additional Study (the
“[**]”). In such case, (x) the Parties shall share any Development Costs from the day of such notice onward incurred by the [**] to conduct such Additional Study after the [**] in accordance with their respective Profit or Loss
Allocations, and (y) the [**] shall reimburse the [**] an amount equal to [**] percent ([**]%) of the costs that otherwise would have been apportioned to the [**] as Development Costs had such [**] originally opted-in, to conduct such Additional
Study prior to the [**]. For example, in the case of the Shared 65/35 Program, where Celgene bears sixty-five percent (65%) of the Development Cost share and Agios bears thirty-five percent (35%) of the Development Cost share, if [**] were
the [**] and [**] incurred $[**] in Development Costs prior to the [**], then [**]would be required to pay $[**] (which represents [**]% of the thirty-five percent (35%) share that [**]otherwise would have been required to pay under the Development
Cost share). Upon any such [**], the Parties shall have the rights with respect to such Clinical Trial or studies and the data arising therefrom as set forth in Section 3.3(d) and Section 3.6. If the [**] elects a [**], it shall pay to
the [**] the [**] amounts set forth in subsection (y) within [**] after the [**] notifies the [**] in writing that the [**] is exercising its right to effect the [**] pursuant to this Section 3.4 and, for clarity, from and after any [**], the
ongoing costs incurred for such Additional Study shall be included in the Profit or Loss and borne by the Parties in accordance with the Parties’ applicable Profit or Loss Allocations. 

Section 3.5    Retained Rights for Certain Development Activities. Notwithstanding anything to
the contrary contained herein, (a) [**] retains the right to conduct Development of Licensed Products in the ROW Territory (when it is the Lead US Party), (b) [**] retains the right to conduct Development of Licensed Products in the United States
(whether or not [**]is the Lead US Party), in each case of (a) and (b) solely to the extent necessary or useful to support Regulatory Approval for or conduct post-marketing studies of such Licensed Product in connection with the Lead US Party’s
Commercialization of Licensed Product in the US Territory, or [**] Commercialization of Licensed Product in the ROW Territory, as applicable, and (c)(i) [**] retains the right in the ROW Territory (when it is the Lead US Party), and (ii) [**]
retains the right in the United States (whether or not [**] is the Lead US Party), to Manufacture and have Manufactured Compounds and Licensed Products to the extent reasonably required to support, in the case of the Lead US Party, such Party’s
Development and Commercialization of Compounds and Licensed Products in the United States, and in the case of [**] Development and Commercialization of Compounds and Licensed Products within the ROW Territory, in each case to the extent such Party
has the right to conduct such Manufacturing. If either Party plans to undertake such activities, it shall so notify the other Party. The rights retained by the Parties in this Section 3.5 [**] to use or enroll patients in association with
any Clinical Trial(s) or other Development study(ies) of Licensed Products, or Companion Diagnostics in the ROW Territory (in the case of [**], when it is the Lead US Party) and in the United States (in the case of either [**] or [**]),
notwithstanding anything to the contrary in Article IV of the Master Agreement. 

  
 - 21 - 

 Section 3.6    Rights to Use Licensed Product Data.

 (a)    Each Party, in a given country for Development of Compounds and Licensed Products in such
country, shall keep accurate records of all Licensed Product Data generated as a result of all activity by or on behalf of such Party in performing Development and Commercialization in relation to Compounds, Licensed Products and Companion
Diagnostics, including any data generated pursuant to the Party’s activities under Section 3.3. Except as provided in Section 3.3(b), each Party shall provide the other Party with copies of all such Licensed Product Data Controlled by the
Party during the Term that is necessary for or reasonably related to the Development and Commercialization of Compounds, Licensed Products and Companion Diagnostics promptly following the generation of such Licensed Product Data. Licensed
Product Data Controlled by Celgene (other than that to which Agios does not have rights pursuant to Section 3.3(b)) shall be included in the license grant to Agios pursuant to Section 8.1(b), and Licensed Product Data Controlled by Agios (other than
that to which Celgene does not have rights pursuant to Section 3.3(b)) shall be included in the Agios Know-How and licensed to Celgene pursuant to Section 8.1(a).

(b)    Notwithstanding anything to the contrary in this Agreement, each Party shall promptly provide to
the other Party, free of charge, copies of and rights of reference to and use of all Licensed Product Data that is Controlled by such Party, and that are relevant to or necessary to address issues relating to: (i) the safety of Licensed Products in
the Territory, including data that is related to adverse effects experienced with Compounds or Licensed Products, and/or (ii) all activities relating to CMC regarding Compounds or Licensed Products, and in each of (i) and (ii), that are required to
be reported or made available to Regulatory Authorities in the Territory, when and as such data become available.
 Section
3.7    Companion Diagnostics. 
 (a)    Development of Companion
Diagnostic. The Parties may mutually agree to Develop or Commercialize a Companion Diagnostic for use with the Licensed Products; provided that, in the event the Parties do not agree to jointly Develop or Commercialize a
Companion Diagnostic, the Lead Party shall be entitled to Develop or Commercialize a Companion Diagnostic for use with Licensed Products in its applicable portion of the Territory. The Parties will use a Third Party Contractor reasonably
acceptable to both Parties to perform all Development and Commercialization for the Companion Diagnostic. In such event, (i) the definition of “Licensed Product” shall and hereby does include the Companion Diagnostic for purposes of
defining Agios Patents, Celgene Patents, Celgene Collaboration Patents, Agios Co-Co Collaboration Patents and Joint Collaboration Patents, and each of the licenses granted to a Party under Section 8.1; and (ii) all costs and profits with respect to
such Development or Commercialization of the Companion Diagnostic (as Developed and Commercialized in accordance with this Section 3.7(a)) shall be shared by the Parties in accordance with their respective Profit or Loss Allocation percentages
pursuant to a mechanism agreed to by the Parties at the time the Third Party Contractor is appointed. 

(b)    Separate Obligations. No payments shall be owed by Celgene to Agios pursuant to
Section 9.3 or Section 9.5 or by Agios to Celgene pursuant to Section 14.4(a)(i) with respect to a Companion Diagnostic. Upon termination of this Agreement, or reversion of 

  
 - 22 - 

 
rights to a Party with respect to the Licensed Products, in addition to the effects of such termination or reversion set forth in Section 14.4, separate transitional activities shall be
undertaken with respect to the Companion Diagnostic to ensure that the appropriate Regulatory Approvals, Manufacturing Technology or other Know-How or Patents necessary for the Development, Manufacture or Commercialization of such Companion
Diagnostic shall be transferred to the Party to whom the rights to the Licensed Products are transferred to the same extent as Regulatory Approvals, Manufacturing Technology or other Know-How or Patents otherwise associated with such Licensed
Products are transferred. 
 (c)    No Other Diagnostics. For purposes of clarity, unless
otherwise mutually agreed by the Parties, neither Party shall have any right, under the licenses granted to such Party pursuant to Section 8.1 and notwithstanding the definition of “Field” hereunder, to Develop, Manufacture or
Commercialize any biomarker or diagnostic product for use with the Licensed Products, other than a Companion Diagnostic pursuant to this Section 3.7. 

Section 3.8    Records; Tech Transfer. 

(a)    Maintenance of Records. Each Party shall maintain in all material respects, and shall
require its Third Party Contractors to maintain in all material respects, complete and accurate records in segregated books of all Development work conducted in furtherance of the Collaboration and all results, data and developments made in
conducting such activities. Such records shall be complete and accurate and shall fully and properly reflect all such work done and results achieved in sufficient detail and in good scientific manner appropriate for patent and regulatory
purposes. Each Party shall require the applicable study sites to maintain original source documents from Clinical Trials of the Licensed Products for at least [**] (or such longer period as is commercially reasonable under the circumstances,
taking into account maintenance requirements under applicable Law) following completion of the Development activities undertaken by such Party or its Third Party Contractors; provided that Celgene or Agios shall be entitled to obtain
copies of such source documents at the end of such [**] period. 
 (b)    Inspection. Each
Party shall have the right, during normal business hours and upon reasonable notice, to inspect and copy (or request the other Party to copy) all records of the other Party or its Third Party Contractors, as applicable, maintained in connection with
the work done and results achieved in the performance of Development activities under the Collaboration, but solely to the extent access to such records is necessary for such Party to exercise its rights under this Agreement. 

(c)    Tech Transfer. As soon as reasonably practical after the Effective Date and thereafter
upon Celgene’s reasonable request during the Term, Agios shall transfer to Celgene, at no cost to Celgene, copies of all Agios Know-How, Agios Co-Co Collaboration Know-How and Agios’ interest in the Joint Collaboration Know-How related to
the Licensed Product, to the extent not previously transferred to Celgene. Upon Agios’ reasonable request during the Term, Celgene shall transfer to Agios, at no cost to Agios, copies of all Celgene Know-How, Celgene Collaboration Know-How
and Celgene’s interest in the Joint Collaboration Know-How related to the Licensed Product, to the extent not previously transferred to Agios. In addition, each Party shall provide reasonable assistance, including

  
 - 23 - 

 
making its personnel reasonably available for meetings or teleconferences to answer questions and provide technical support to the other Party with respect to the use of such transferred Know-How
in the Development, Manufacture and Commercialization of Licensed Products. The costs and expense incurred by either Party in connection with such assistance shall constitute Development Costs. 

Article IV 
 Manufacture
and Supply 
 Section 4.1    Pre-Clinical, Clinical and Commercial Supply. 

(a)    Agios Responsibilities. Subject to the Supply Agreement, if any, Agios shall be
responsible for Manufacturing, or having Manufactured by its designee, (i) all pre-clinical supply of Licensed Products, (ii) all active pharmaceutical ingredients for all Clinical Trials (collectively, items (i) and (ii), the “Agios
Clinical-Scale Manufacturing Responsibilities”), and (iii) all active pharmaceutical ingredients for Commercialization of Licensed Products (the “Agios Commercial-Scale Manufacturing Responsibilities”). 

(b)    Agios Commercial-Scale Manufacturing Responsibilities. Subject to the Supply
Agreement, if any, Agios or its Affiliate may have any Third Party conduct on behalf of Agios any of the Agios Commercial-Scale Manufacturing Responsibilities, provided that, from the period commencing on the Effective Date and ending on the first
to occur of (i) the first date [**], and (ii) a [**], Agios shall notify Celgene at least [**] prior to the time at which it anticipates it will engage a Third Party to conduct such activities, and the Parties thereafter shall discuss the selection
of the Third Party, provided that Celgene may, in its discretion, indicate that it is interested in undertaking the applicable Agios Commercial-Scale Manufacturing Responsibilities, in which event the Parties shall discuss that as well. Agios
retains the right to determine whether a Third Party or Celgene shall conduct the applicable Agios Commercial-Scale Manufacturing Responsibilities, and the terms thereof, provided that such manufacturing still conforms to the requirements of this
Section 4.1(b). Agios shall fulfill a substantial portion of the Agios Commercial-Scale Manufacturing Responsibilities from within, and ship all such active pharmaceutical ingredients to Celgene from, [**] for purposes of Section 954(d) of the
Code and Section 1.954-3(a)(2) of the Treasury Regulations (or any other similar provision of the Code or Treasury Regulations in effect as of any time); provided that Agios may obtain raw materials from any country as determined by
Agios for use in connection with the Agios Commercial-Scale Manufacturing Responsibilities, and provided further that if [**]. 

(c)    Celgene Responsibilities. As of the Effective Date, Celgene shall be responsible for
all drug product manufacturing and processing and filling of Licensed Products for all Clinical Trials (“Celgene Clinical-Scale Manufacturing Responsibilities”) and for Commercialization of Licensed Products (the “Celgene
Commercial-Scale Manufacturing Responsibilities”) (Celgene Clinical-Scale Manufacturing Responsibilities and Celgene Commercial-Scale Manufacturing Responsibilities, collectively, the “Celgene Manufacturing
Responsibilities”). Celgene shall fulfill a substantial portion of the Celgene Commercial-Scale Manufacturing Responsibilities from [**] for purposes of Section 954(d) of the Code and Section 1.954-3(a)(2) of the Treasury Regulations
(or any other similar provision of the Code or Treasury Regulations in effect as of any time); provided that Celgene may obtain raw materials from any country as determined by Celgene for use in connection with the Celgene
Manufacturing Responsibilities, and provided further that [**]. 

  
 - 24 - 

 (d)    Lead Party Responsibilities. As to each
of the US Territory and the ROW Territory, the respective Lead Party shall be responsible for Manufacturing, or having Manufactured by its designee, all supply of Licensed Products not included within Agios Clinical-Scale Manufacturing
Responsibilities, Agios Commercial-Scale Manufacturing Responsibilities and Celgene Manufacturing Responsibilities, including drug product packaging, labeling, shipping and storage. 

(e)    The JDC with respect to clinical supply and the JCC with respect to commercial supply may from
time to time each agree on a supply plan consistent with the Supply Agreement, if any, (each, a “Supply Plan”) to set forth the details regarding the Parties’ supply of active pharmaceutical ingredients, drug product and
Licensed Product. Each Supply Plan shall include customary terms such as forecasting procedures and a definition of “supply failure” in terms of failure to provide adequate and/or timely supply.

(f)    Manufacturing Costs. Manufacturing Costs associated with clinical supply of the
Licensed Products shall be shared in accordance with Section 9.2. Manufacturing Costs associated with commercial supply of the Licensed Products shall constitute Commercialization Expenses. 

(g)    The Parties intend to enter into an agreement that will govern the terms of manufacture and supply
of Licensed Products for the Collaboration (a “Supply Agreement”). Notwithstanding the foregoing, the Parties understand and agree (1) that the following principles do not set forth all of the material terms and conditions of
any such Supply Agreement, and (2) the Parties shall not be obligated to enter into any Supply Agreement unless pursuant to definitive terms and conditions that the Parties shall mutually agree upon. If the Parties decide to enter into a Supply
Agreement, such Supply Agreement shall incorporate the following principles, and other material terms such as pricing, as the Parties shall mutually agree upon: 

(i)    The Supply Agreement shall contain reasonable and customary provisions to minimize the risk of
supply interruptions, including, if agreed by the Parties, the establishment of backup Manufacturing capabilities for Agios Clinical-Scale Manufacturing Responsibilities, Agios Commercial-Scale Manufacturing Responsibilities, Celgene Clinical-Scale
Manufacturing Responsibilities and Celgene Commercial-Scale Manufacturing Responsibilities at Third Party facilities; and 

(ii)    If a Supply Failure occurs, the Non-Supplying Party shall have the right to step in and
manufacture or procure its own supply of the applicable Licensed Product and the Responsible Supply Party will transfer to the Non-Supplying Party (A) a copy of all Agios Know-How or Celgene Know-How, as applicable, that is Controlled by and in
the possession of the Responsible Supply Party or its Affiliates and that is necessary or useful to enable the Manufacture of Licensed Product in accordance with the applicable specifications, and by making available its or its Affiliates’
qualified technical personnel during normal business hours on a reasonable basis to consult with the Non-Supplying Party with respect to 

  
 - 25 - 

 
such Know-How and (B) at Non-Supplying Party’s request and cost, any materials then in the Responsible Supply Party’s or its Affiliates’ possession and Control that has been
specifically designated to be used by the Responsible Supply Party or its Affiliates or Third Party Contractors in the Manufacture of such Licensed Product. Such Know-How and material transfer will be conducted pursuant to a technology transfer
plan developed by the Parties for the purpose of ensuring the complete and timely transfer of such Know-How and materials. The Non-Supplying Party and its Third Party manufacturer may only use the Know-How and materials provided to the Non-Supplying
Party pursuant to this Section 4.1(g)(ii) in support of Manufacturing Licensed Product and solely in accordance with this Agreement, and will not use any such Know-How and materials for any other reason or for any other product or product candidate
(or intermediate or component thereof). All Manufacturing for Commercialization under this Section 4.1(g)(ii) will be located in [**] for purposes of Section 954(d) of the Code and Section 1.954-3(a)(2) of the Treasury Regulations (or any other
similar provision of the Code or Treasury Regulations in effect as of any time)). 
 Section
4.2    Third Party Manufacturers. For each Third Party that a Party uses to fulfill its Manufacturing obligations or rights under Section 4.1 with respect to a primary source or under Section 4.4 with respect to a
secondary source for any supply to be used in any Development or Commercialization activities under the Collaboration, the Third Party and the terms of the agreement with such Third Party must be approved by the JDC or JCC, as applicable, in each
case subject to Section 2.2. 
 Section 4.3    Transfer of Manufacturing Responsibility. In
order to assist Celgene to perform the Celgene Manufacturing Responsibilities or, if selected by Agios pursuant to Section 4.1(b), the Agios Commercial-Scale Manufacturing Responsibilities, Agios shall (a) transfer, or have transferred, to Celgene
or its designee, pursuant to a technology transfer plan to be mutually agreed by the Parties, all Manufacturing Technology Controlled by Agios and used in Manufacturing Licensed Products at the time of such transfer to the extent relevant to the
Celgene Manufacturing Responsibilities or, if selected by Agios pursuant to Section 4.1(b), the Agios Commercial-Scale Manufacturing Responsibilities, and (b) provide reasonable assistance in connection with the transfer of such Manufacturing
responsibility to Celgene or its designee. Costs incurred by either Party in such transfer shall be Development Costs. 

Section 4.4    Manufacturing Efforts. The Party that is responsible for Manufacturing
hereunder shall use Commercially Reasonable Efforts to ensure adequate manufacturing capacity to meet forecast demand for the applicable Licensed Product, including the possible establishment of an alternative supply source. The Party that is
responsible for Manufacturing hereunder shall also use Commercially Reasonable Efforts to ensure adequate pre-clinical, clinical and commercial supply of the applicable Licensed Product for both Parties to Develop or Commercialize, as applicable,
such Licensed Products as contemplated under the applicable Development Plan or Commercialization Plan. 

  
 - 26 - 

 Article V 

Regulatory Matters 

Section 5.1    Lead Responsibility for Regulatory Interactions. Except as may otherwise be
mutually agreed by the Parties or the JSC, JDC or JCC, as applicable, and subject to oversight by the JSC, JDC or JCC: 

(a)    Lead Responsibility.

(i)    US Territory. The Lead US Party shall have lead responsibility for all Regulatory
Interactions with Regulatory Authorities in the US Territory for the applicable Licensed Product (including after any transfer set forth in Section 5.1(c)).

(ii)    ROW Territory. Celgene shall have the lead responsibility for all Regulatory
Interactions with Regulatory Authorities in the ROW Territory with respect to each Licensed Product.

(b)    Regulatory Interactions Defined. For purposes of this Agreement, “Regulatory
Interactions” means (i) monitoring and coordinating all regulatory actions, preparing, submitting and coordinating all communications and filings with, and submissions to, all Regulatory Authorities with respect to the Licensed Products and
(ii) interfacing, corresponding and meeting with the Regulatory Authorities with respect to the Licensed Products. 

(c)    Transfer of Regulatory Responsibility. Celgene shall become the Lead Party for
Regulatory Interactions for any Licensed Product upon an Agios Opt-Out Notice being delivered to Celgene. 

(d)    Regulatory Responsibilities. Upon and after such time that Celgene becomes the Lead
Party for Regulatory Interactions for any Licensed Product pursuant to Sections 5.1(a) or 5.1(c): 

(i)    Agios shall (A) at Celgene’s option, either close or inactivate Agios’ IND(s) for such
Licensed Product, or transfer such IND(s) to Celgene, and (B) with Celgene input, complete all relevant activities related to such IND as required for Celgene to assume regulatory ownership, as applicable, all within [**] after Celgene’s
notice; 
 (ii)    Celgene shall be responsible for the preparation and filing of all regulatory
filings with respect to any subsequent Development, Manufacturing or Commercialization for Licensed Products after such activities described in clause (i) above are completed; and 

(iii)    Agios shall provide Celgene with all relevant clinical and non-clinical data reasonably
requested by Celgene or a Regulatory Authority, including CMC, pharmacology and toxicology generated by Agios with respect to the subject Licensed Product. 

Section 5.2    Participation Rights. 

(a)    Review of Regulatory Documentation. Each Party shall keep the JDC reasonably informed
in connection with all Regulatory Interactions, preparation of all Regulatory Documentation, Regulatory Authority review of Regulatory Documentation, 

  
 - 27 - 

 
Regulatory Approvals, annual reports, including annual safety reports to the respective health authorities, annual re-assessments, and any subsequent variations and changes to labeling, in each
case with respect to the Licensed Products. Each Party shall respond within a reasonable time frame to all reasonable inquiries by the other Party with respect to any information provided pursuant to this Section 5.2(a) (and sufficiently
promptly for the other Party to provide meaningful input with respect to responses to Regulatory Authorities). 

(b)    Participation in Meetings. The Party not having the lead responsibility for Regulatory
Interactions in a country with respect to the Licensed Products shall have the right to have two senior, experienced employees reasonably acceptable to the responsible Party participate as an observer in material or scheduled face-to-face meetings,
video conferences and any teleconferences with the applicable Regulatory Authority, and shall be provided with advance access to the responsible Party’s material documentation prepared for such meetings. 

(c)    Review. Prior to submission of material correspondence to any Regulatory Authority
with respect to the Licensed Products, the Party having the lead responsibility for Regulatory Interactions shall, sufficiently in advance for the other Party to review and comment, provide the other Party any material correspondence with the
Regulatory Authority related to such meetings. The responsible Party shall also provide the other Party with copies of any material correspondence with Regulatory Authorities relating to Development of, or the process of obtaining Regulatory
Approval for, the Licensed Products in such Party’s territory, and respond within a reasonable time frame to all reasonable inquiries by the other Party with respect thereto. 

Section 5.3    Global Safety Database; Pharmacovigilance Agreement. At a time to be mutually
agreed by the Parties, the Parties shall establish, hold and maintain a single electronic system for the collection and storage of all safety information for the Licensed Products (the “Global Safety Database”). Such database
shall comply in all material respects with all Laws reasonably applicable to pharmacovigilance anywhere where the Licensed Products are being or have been Developed or Commercialized. Unless the Parties otherwise agree in the Pharmacovigilance
Agreement, the Lead US Party shall initially be responsible for the Global Safety Database for the Licensed Products, and the other Party shall assume control on a Licensed Product-by-Licensed Product basis following the transfer, if any, of lead
responsibility for Regulatory Interactions in the US Territory for such Licensed Product to the other Party. The Party not maintaining the Global Safety Database may hold and maintain a parallel safety database for the Licensed Products as
needed or required according to applicable Laws. The Parties will use Commercially Reasonable Efforts to negotiate a pharmacovigilance agreement (the “Pharmacovigilance Agreement”) to govern cooperation among the Parties that
will enable each of them to comply with its respective obligations under applicable Laws and to satisfy its duty of care with respect to the Licensed Products, including with regard to ownership of the Global Safety Database, adverse event data
collection, analysis and reporting. The Pharmacovigilance Agreement will be entered among the Parties no later than [**] following the Effective Date. 

  
 - 28 - 

 Section 5.4    Recalls, Market Withdrawals or Corrective
Actions. 
 (a)    In the event that any Regulatory Authority issues or requests a recall, market
withdrawal or similar action in connection with a Licensed Product in any portion of the Territory, or in the event either Party determines that an event, incident or circumstance has occurred that may result in the need for a recall, market
withdrawal or similar action in any portion of the Territory, the Party notified of such recall, market withdrawal or similar action, or the Party that desires such recall, market withdrawal or similar action, shall within [**] advise the other
Party thereof by telephone or facsimile. The Lead Party shall, after reasonable consultation with the other Party, decide whether to conduct a recall, market withdrawal or similar action in its applicable portion of the Territory and the manner
in which any such recall, market withdrawal or similar action shall be conducted. Each Party will make available to the other Party, upon request, all of such Party’s (and its Affiliates’) pertinent records that such other Party may
reasonably request to assist such other Party in effecting any recall, market withdrawal or similar action. 

(b)    The costs and expenses incurred before the Agios Opt-Out Date relating to a recall, market
withdrawal or similar action of any Licensed Product(s) in the Territory shall be taken into account in determining Profit or Loss as, and to the extent, provided in Exhibit D. The costs and expenses incurred after the Agios Opt-Out Date for
any recall, market withdrawal or similar action of any Licensed Product(s) in the Territory shall be borne solely by Celgene if and only to the extent (i) such recall, market withdrawal or similar action was caused by the occurrence after the Agios
Opt-Out Date of the event, incident or circumstance that led to the recall, market withdrawal or similar action and (ii) the event, incident or circumstance and the costs and expenses for such recall, market withdrawal or similar action are not the
subject of an indemnity obligation of Agios under Section 13.2. The costs and expenses incurred after the Agios Opt-Out Date relating to any recall, market withdrawal or similar action of any Licensed Product(s) in the Territory shall be borne
by the Parties in accordance with their respective Profit or Loss Allocation percentages to the extent (A) such recall, market withdrawal or similar action was caused by the occurrence before the Agios Opt-Out Date of the event, incident or
circumstance that led to the recall, market withdrawal or similar action and (B) such event, incident or circumstance and such costs and expenses are not the subject of an indemnity obligation of either Party under Section 13.1 or Section
13.2. If Agios is invoiced for its portion of such costs and expenses incurred after the Agios Opt-Out Date, payment is due within [**] of receipt of invoice. 

Article VI 

Commercialization 

Section 6.1    Commercialization Responsibilities for Licensed Products. 

(a)    Responsibility. Subject to oversight by the JCC and to Section 2.2, Section 2.3 and
Section 6.3(f), each Party shall have the responsibilities for the Commercialization of Licensed Products as specified in the Commercialization Plan. Subject to the foregoing and the remainder of this Article VI, the applicable Lead Party in
each of the US Territory and the ROW Territory shall have primary responsibility for Commercialization of Licensed Products in the US Territory and the ROW Territory, respectively. 

  
 - 29 - 

 (b)    Sales. The applicable Lead Party will
book all sales of the Licensed Products in the US Territory and the ROW Territory, respectively, and will have the sole responsibility for the processing of orders, invoicing, terms of sale, and distribution of the Licensed Products throughout the
US Territory and the ROW Territory, respectively, associated therewith. 
 Section
6.2    Commercialization Plan. 
 (a)    Initial Commercialization
Plan. 
 (i)    Subject to Section 2.2 and Section 2.3, Commercialization of Licensed Products
shall be governed by a Commercialization Plan (the “Commercialization Plan”), for each of the US Territory and the ROW Territory that, collectively, describe the Commercialization activities (including pre-launch and launch
activities, if applicable) to be undertaken with respect to the Licensed Products in the Territory, which shall include an annual budget of Commercialization Expenses (“Commercialization Budget”) and anticipated timelines for
performance. 
 (ii)    Commencing no later than [**] prior to the anticipated First Commercial Sale of
each Licensed Product in the US Territory and the ROW Territory, the applicable Lead Party shall prepare the initial Commercialization Plan covering the first [**] after First Commercial Sale of each Licensed Product in the US Territory or the ROW
Territory, with input and guidance from the JDC and the JCC. Such Commercialization Plans shall describe Commercialization activities to be undertaken by the Parties in the US Territory and the ROW Territory, respectively. 

(b)    JCC Approval; Amendments. The JCC shall approve the first Commercialization Plan for
each Licensed Product in each of the US Territory and the ROW Territory no later than [**] prior to the anticipated First Commercial Sale of the first such Licensed Product in the US Territory and the ROW Territory, respectively. Thereafter,
the JCC shall review and approve the Commercialization Plan(s) (for the current Calendar Year and the next succeeding Calendar Year) each Calendar Year (provided that, in the event the JCC is unable to agree on such proposed plan, the Lead Party in
the applicable Territory shall have the final say for its portion of the proposed Commercialization Plan). Either Party may also develop and submit to the JCC for review from time to time other proposed amendments to the applicable
Commercialization Plan(s). The initial Commercialization Plan(s), and any amendments and updates to the Commercialization Plan(s), shall be effective upon the approval of the JCC. 

Section 6.3    Field-Based Marketing Activities. 

(a)    General. The JCC shall determine the type and scope of field-based marketing efforts
to be used for Commercialization of each Licensed Product in the Territory (e.g., [**]) (collectively, “Marketing Activities”), and the Commercialization Plan(s) for each Licensed Product in the Territory shall set forth such
Marketing Activities for each Indication which is marketed in the Territory. 

  
 - 30 - 

 (b)    Allocation of Activities. The
Commercialization Plan(s) will allocate to each Party its portion of the total Marketing Activities for each Licensed Product in the Territory; provided that, unless otherwise agreed to by the Parties, each Party will be allocated a
percentage of the Marketing Activities in the [**] equal to its respective Profit or Loss Allocation, wherein such percentages refer to the total number of FTEs devoted to an activity when applicable. The Commercialization Plan will attempt to
provide that Marketing Activities are distributed geographically within the [**] in a manner reasonably consistent with the distribution of the population in the [**] and that each Party’s detailing effort, if applicable, will be directed to
physicians of similar prescribing potential but shall take into account the competitive situation of the Licensed Product. In overseeing the Marketing Activities, the JCC will take into account the Licensed Product’s [**] for the Licensed
Product. Notwithstanding anything to the contrary contained herein, the non-Lead Party (itself or by or through any others, including any Affiliates or Licensee Partners), will not take any action regarding the Commercialization of Licensed
Products in the countries for which it is not the Lead Party (except as contemplated by this Agreement) unless mutually agreed in writing, described in the Commercialization Plan, or otherwise approved by the JCC. 

(c)    Sales Force. To the extent the Marketing Activities include detailing efforts, the JCC
shall determine the number of sales representatives needed to carry out the required Marketing Activities in the [**] for each Licensed Product. Each Party, in its sole discretion, shall create a field management structure for its sales
effort. Each sales representative shall have a sales territory that allows such sales representative to perform a reasonable number of details within a reasonable geographic area (i.e., without overly-burdensome travel
requirements). The effort of the Agios and Celgene sales forces in promoting the Licensed Products will be organized under the supervision of the JCC as to qualifications of sales representatives and field-based sales managerial personnel and
the timing of hiring in light of the then-current Commercialization Plan(s); provided that the Commercialization Plan(s) shall identify the portion of the detailing effort to be undertaken by each Party in the [**] no later than [**]
before the planned date of the NDA submission in, as applicable, the [**]. The following provisions shall apply to the activities of sales representatives with respect to Commercialization of Licensed Products: 

(i)    Each Party will be solely responsible for recruiting, hiring and maintaining its sales force of
sales representatives for promotion of Licensed Product in accordance with its standard procedures, the requirements of this Agreement and the minimum qualifications set forth on Schedule 6.3. Each Party will be responsible for the
activities of its sales representatives, including compliance by its sales representatives with training and detailing requirements. In particular, each Party will provide its sales representatives assigned to promote the Licensed Product in
the [**] with the level of oversight, management, direction and sales support with respect to the promotion of Licensed Product necessary to effectively and efficiently promote the Licensed Product in accordance with the terms of this Agreement and
applicable Law. Each Party agrees that none of its sales representatives involved in the promotion of the Licensed Product will have any legal or regulatory disqualifications, bars or sanctions. [**]. 

  
 - 31 - 

 (ii)    Notwithstanding the foregoing, neither Party will
have the right to use any Third Party contract sales force to fulfill its obligations under this Agreement in the [**], except during the first [**] following First Commercial Sale in such portion of the Territory.

(iii)    The Commercialization Plan will set forth (A) the precise number of each Party’s sales
representatives for Licensed Product in the [**], consistent with the foregoing, (B) policies and processes for the creation of marketing and promotional materials, (C) planning for conferences, (D) the number, type (e.g., first position,
second position, etc.) and frequency of details to be conducted by sales representatives for Licensed Products in each Calendar Year, (E) the allocation of sales details between the Parties, (F) development of sales forecasts, and (G) coordinating
strategies for compensation packages for sales representatives. 
 (iv)    If either Party does not
provide in the [**] at any particular time, for any reason, the number of sales representatives specified in the Commercialization Plan to be provided for the [**], then the other Party will have the right to make up such shortfall using its sales
representatives until such time as the non-fulfilling Party is able to provide its agreed upon number of sales representatives, and, for clarity, all costs incurred by the other Party related to making up such shortfall shall be included in the
calculation of the Profit or Loss Allocation. 
 (v)    The calculation of costs of engaging sales
representatives for purposes of calculating the Profit or Loss Allocation shall be based on the FTE Rate, and such FTE Rate shall be used by both Parties for promotion of Licensed Product in the [**]. 

(d)    Training Materials and Sessions. The JCC will develop product-specific training
materials and arrange for provision of such materials to each Party’s sales forces, if applicable, for use in the [**]. The JCC will develop a sales training program directed towards the Licensed Products for use in the [**]. Unless
otherwise mutually agreed by the Parties, Celgene and Agios sales representatives will participate in a launch meeting(s) (which may be held together or separately) for each Licensed Product, which shall include training sessions of product-specific
sales skills with respect to the approved Indications for the Licensed Products. Each Party will train and instruct their respective sales representatives to make only those statements and claims regarding the Licensed Product, including as to
efficacy and safety, that are consistent with the Licensed Product labeling and accompanying inserts and the approved promotional materials. Subsequent to launch, Celgene and Agios shall periodically hold meetings with Agios and Celgene field
management (down to and including district managers or their equivalents who are directly supervising territory sales representatives) to coordinate promotion of the Licensed Products in the [**]. As requested by the applicable Lead Party, the
other Party shall make its management, marketing, training and other personnel reasonably available to participate in the Lead Party’s national and regional sales meetings and Licensed Product training events for the [**], as applicable. For
clarity, all marketing and promotional materials used in the [**] must be approved by the applicable Lead Party prior to use. 

(e)    Other Obligations. Subject to Section 2.3, in conducting the Marketing Activities in
the [**], the Parties will comply with all applicable Laws, applicable industry professional standards and compliance policies of the Lead Party that have been previously furnished to the other Party, as the same may be updated from time to time and
provided to the other Party and not in violation of any applicable Law. Each Party will reasonably assist the 

  
 - 32 - 

 
other Party in training sales representatives in such standards. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with
the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan(s) or otherwise approved by the JCC. 

(f)    Termination of Marketing Activities. (i) To the extent Agios is not the Lead US Party,
Agios shall have the right to terminate its Marketing Activities obligations in the US Territory, and (ii) Agios shall have the right to terminate its Marketing Activities obligations in the [**], with respect to any Licensed Product by providing at
least [**] prior written notice to Celgene (or sooner as Celgene may determine, in its sole discretion). Upon exercise of such termination right, effective upon the expiration of such [**] (or, if applicable, shorter) notice period, Agios’
obligations to perform Marketing Activities under this Section 6.3 in the US Territory or [**], as applicable, shall terminate. Further, if Agios exercises this right with respect to the US Territory, then Celgene shall have final
decision-making authority over all matters regarding Commercialization with respect to the US Territory. 
 Section
6.4    Trademarks. 
 (a)    Selection of Trademarks. The JCC
shall select the trademark(s) to be used in connection with the marketing and sale of the Licensed Products in the Territory (such marks, together will registrations, applications for registration and common law rights therein, collectively,
“Product Trademarks”). Any dispute over the selection of a Product Trademarks shall be presented to the JSC for resolution. The Parties shall adhere to the use of the Product Trademark(s) in their Commercialization of the
Licensed Products in the Territory hereunder, to the extent permitted by Law. 

(b)    Ownership. The [**] shall own all Product Trademarks for any Licensed Product in the
Territory. Effective as of the Agios Opt-Out Date, if Agios is the [**] under this Agreement, it hereby assigns to Celgene all right, title and interest in and to the Product Trademarks in the Territory that are owned by Agios free and clear of
any liens and encumbrances. Agios will execute and deliver any further document reasonably requested by Celgene to further document or record such assignment. 

(c)    Branding. At such time as the JCC deems appropriate, the Parties shall discuss in good
faith any branding and/or co-branding of the Licensed Products (the “Licensed Branding”), and the Parties will enter into appropriate trademark licensing agreements to achieve the foregoing. For the avoidance of doubt, nothing
in this Agreement shall be construed to grant either Party any rights in or to any of the other Party’s trademarks, tradenames, logos, or other marks (other than Product Trademarks), including use thereof, absent a separate trademark licensing
agreement entered into in accordance with this Section 6.4(c). Notwithstanding the foregoing, subject to any restrictions on the form or content of the Licensed Branding imposed by any Regulatory Authority, unless the Parties mutually agree
otherwise in writing, the Licensed Branding used with respect to Licensed Products shall feature the logos of Agios and Celgene with approximately equal sizing and similar prominence, with the Lead Party’s name first, on all packaging and
materials used for Commercialization of such Licensed Products, to the extent permitted by applicable Law. 

  
 - 33 - 

 Article VII 

Diligence 

Section 7.1    Collaboration Activities. 

(a)    General. Each Party shall use Commercially Reasonable Efforts to perform all
Development, Manufacturing and Commercialization activities for which such Party is responsible hereunder in compliance with the applicable Development Plan or Commercialization Plan, including any budget(s) and timeframe(s) set forth therein and
including making available those resources set forth in any applicable Development Plan or Commercialization Plan, and the terms of this Agreement. 

(b)    Compliance with Laws. Each Party shall: 

(i)    perform its obligations under this Agreement in a scientifically sound and workmanlike manner; and

 (ii)    carry out all work done in the course of the Collaboration in compliance with all applicable
Laws governing the conduct of such work. 
 Section 7.2    Diligence Obligations. 

(a)    In addition to the diligence obligations set forth in Section 7.1, the Parties (directly or
through one or more Affiliates or Licensee Partners) shall use Commercially Reasonable Efforts to Develop and achieve Regulatory Approval for the Licensed Products in each of the [**] and, following such Regulatory Approval, to Commercialize such
Licensed Products in each of the [**]. 
 (b)    A breach of the diligence obligations set forth in
this Section 7.2 shall be deemed a material breach and shall be subject to termination under Article XIV. Notwithstanding the foregoing, the Parties acknowledge that it might be commercially reasonable, under certain circumstances, for the Lead
Party for a given [**] to determine not to launch a Licensed Product in such [**], and failure under such circumstances to launch such Licensed Product shall not be a breach of this Agreement. 

Section 7.3    Day-to-Day Responsibility. Each Party shall be responsible for day-to-day
implementation of the Development, Manufacturing and Commercialization activities for which it (or its Affiliate) has or otherwise is assigned responsibility under this Agreement or the applicable Development Plan or Commercialization Plan and shall
keep the other Party reasonably informed as to the progress of such activities, as determined by the JDC and JCC. 
 Article VIII 

Grant of Rights; Exclusivity 

Section 8.1    License Grants. Subject to the terms and conditions of this Agreement: 

(a)    License Granted to Celgene. Agios hereby grants to Celgene: 

  
 - 34 - 

 (i)     a non-transferable (except as set forth in (a)),
exclusive right and license in each country of the Territory for which Celgene is the Lead Party (subject to the rights of Agios and its Affiliates to Develop, Manufacture and Commercialize Compounds, Licensed Products and Companion Diagnostics
as specifically set forth in this Agreement, including to Develop and Manufacture in such country(ies) to support Development, Manufacture and Commercialization in the US Territory if Agios is the Lead US Party), with the right to grant sublicenses
as set forth in Section 8.2(a) and Section 8.2(b), under Agios’ rights in Agios Intellectual Property, Agios Co-Co Collaboration Intellectual Property and Agios’ interest in the Joint Collaboration IP and Manufacturing Technology, to
Develop, Manufacture or Commercialize Compounds, Licensed Products and Companion Diagnostics; provided that, as to Companion Diagnostics, such license grant shall be limited to Developing, Manufacturing and Commercializing Companion
Diagnostics for use as companion diagnostics with Licensed Products under this Agreement; 
 (ii)    a
non-transferable (except as set forth in Section 15.4), non-exclusive right and license in each country of the Territory for which Celgene is not the Lead Party under Agios’ rights in Agios Intellectual Property, Agios Co-Co Collaboration
Intellectual Property and Agios’ interest in the Joint Collaboration IP and Manufacturing Technology, to Develop and Manufacture Compounds, Licensed Products and Companion Diagnostics in such countries to support Development, Manufacture and
Commercialization in the ROW Territory; provided that, as to Companion Diagnostics, such license grant shall be limited to Developing, Manufacturing and Commercializing Companion Diagnostics for use as companion diagnostics with
Licensed Products under this Agreement; and 
 (iii)    a non-transferable (except as set forth in
Section 15.4), non-exclusive right and license in the Territory under Agios’ rights in Agios Intellectual Property, Agios Co-Co Collaboration Intellectual Property and Agios’ interest in the Joint Collaboration IP and Manufacturing
Technology, solely to permit Celgene to perform its obligations under the Development Plans and Commercialization Plans. 

(b)    License Granted to Agios. Celgene hereby grants to Agios: 

(i)    if Agios is the Lead US Party, a non-transferable (except as set forth in (a)), exclusive right
and license in the US Territory (subject to the rights of Celgene and its Affiliates to Develop, Manufacture and Commercialize Compounds, Licensed Products and Companion Diagnostics as specifically set forth in this Agreement, including to Develop
and Manufacture in the US Territory to support Development, Manufacture and Commercialization in the ROW Territory), with the right to grant sublicenses as set forth in Section 8.2(a) and Section 8.2(b), under Celgene’s rights in Celgene
Intellectual Property, Celgene Collaboration Intellectual Property and Celgene’s interest in the Joint Collaboration IP and Manufacturing Technology, to Develop, Manufacture or Commercialize Compounds, Licensed Products and Companion
Diagnostics; provided that, as to Companion Diagnostics, such license grant shall be limited to Developing, Manufacturing and Commercializing Companion Diagnostics for use as companion diagnostics with Licensed Products under this
Agreement; 

  
 - 35 - 

 (ii)    a non-transferable (except as set forth in Section
15.4), non-exclusive right and license in each country of the Territory for which Agios is not the Lead Party under Celgene’s rights in Celgene Intellectual Property, Celgene Collaboration Intellectual Property and Celgene’s interest in
the Joint Collaboration IP, to Develop and Manufacture Compounds, Licensed Products and Companion Diagnostics in such countries to support Development, Manufacture and Commercialization in the United States; provided that, as to
Companion Diagnostics, such license grant shall be limited to Developing, Manufacturing and Commercializing Companion Diagnostics for use as companion diagnostics with Licensed Products under this Agreement; and 

(iii)    a non-transferable (except as set forth in Section 15.4), non-exclusive right and license in the
Territory under Celgene’s rights in Celgene Intellectual Property, Celgene Collaboration Intellectual Property and Celgene’s interest in the Joint Collaboration IP and Manufacturing Technology, solely to permit Agios to perform its
obligations under the Development Plans and Commercialization Plans. 
 Section 8.2    Sublicense
Rights. Subject to Section 8.3, the Parties have the following sublicensing rights. 

(a)    Sublicenses to Affiliates and Subcontractors. Each Party shall have the right to grant
sublicenses within the scope of the licenses and sublicense under Section 8.1: 
 (i)    to such
Party’s Affiliates; and 
 (ii)    to Third Parties for the purpose of (X) [**] any Compound,
Licensed Product or related Companion Diagnostic or (Y) engaging Third Parties as contract research organizations, contract manufacturers, contract sales forces, consultants, academic researchers and the like (“Third Party
Contractors”) in connection with Development, Manufacturing or Commercialization activities throughout the Territory on behalf of such Party or its Affiliates with respect to the Collaboration under this Agreement, subject to the following:

 (A)    unless otherwise mutually agreed by the Parties, each Party shall require any such Third
Party to whom such Party discloses Confidential Information to enter into an appropriate written agreement obligating such Third Party to be bound by obligations of confidentiality and restrictions on use of such Confidential Information that are no
less restrictive than the obligations set forth in Article XI, including requiring such Third Party to agree in writing not to issue any Publications except in compliance with the terms of this Agreement (including approval by the JDC or JCC, as
applicable, pursuant to the approved publication plan, and the obligations set forth in Section 11.4, except that Publications by academic collaborators shall be permitted (without JDC or JCC consent, as applicable) if the academic collaborator (i)
provides an advance copy of the proposed Publication (under the same time periods as described in Section 11.4(a)), which may be shared with the other Party, (ii) agrees to delay such Publication sufficiently long enough to permit the timely
preparation and filing of a patent application, and (iii) upon the request of either Party, removes from such Publication any Confidential Information of such Party); 

(B)    unless otherwise mutually agreed by the Parties, each Party will obligate such Third Party to
agree in writing to assign ownership of, or grant an exclusive, royalty-free, worldwide, perpetual and irrevocable license (with the right to grant sublicenses) to, 

  
 - 36 - 

 
any inventions arising under its agreement with such Third Party to the extent related to Development, Manufacturing or Commercialization with respect to the Compounds or Licensed Products in the
Field; and such Party shall structure such assignment or exclusive license so as to enable such Party to sublicense such Third Party inventions to the other Party pursuant to Section 8.1 (including permitting such other Party to grant further
sublicenses); provided that, in connection with any academic collaborator performing research work with respect to the Target, Compounds or Licensed Products that is not reasonably expected by the applicable Party to result in
inventions related to composition of matter or methods of use, it shall be sufficient for such Party to obtain a non-exclusive, worldwide, royalty-free, perpetual license (with the right to grant sublicenses) to, and a right to negotiate for an
exclusive license, with the right to grant sublicenses, to, any inventions resulting from such research work, which sublicensing rights must permit sublicensing to the other Party pursuant to Section 8.1 (including permitting such other Party to
grant further sublicenses); 
 (C)    each Party shall notify the JDC or JCC, as applicable, at a
regular meeting of the JDC or JCC, as applicable, of the execution any such agreement with such Third Party and, if requested, shall provide the other Party with a copy of such agreement, which copy may be redacted with respect to matters that do
not relate to the Collaboration; and 
 (D)    unless otherwise mutually agreed by the Parties, each
Party will require any such Third Party to grant to the other Party access to all confidential protocols and data generated by such Third Party’s work with respect to the Licensed Products to the same extent as such other Party’s licenses
under Section 8.1, and grant the other Party the right to audit the records of such Third Party. 

(b)    Other Sublicenses. Except as provided in Section 8.2(a), any other sublicense by
either Party under the licenses and sublicense set forth in Section 8.1 shall require the prior written approval of the other Party. 

Section 8.3    Sublicense Requirements. Any sublicense granted by a Party pursuant to this
Agreement shall be subject to the following: 
 (a)    each sublicense granted hereunder by a Party or
its Affiliates shall be consistent with the requirements of this Agreement; 
 (b)    any transfer of
rights between a Party and its Affiliates shall not be deemed a sublicense by such Party but shall be deemed a direct license by the other Party to such Party’s Affiliate; provided that such Party shall remain responsible for the
activities of its Affiliate; 
 (c)    a Party’s or its Affiliates’ Licensee Partners shall
have no right to grant further sublicenses without the other Party’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed; 

(d)    such Party shall be primarily liable for any failure by its Affiliates and Licensee Partners to
comply with all relevant restrictions, limitations and obligations in this Agreement; and 

  
 -37 - 

 (e)    such sublicense must be granted pursuant to a written
sublicense agreement and, with respect to any sublicense other than a sublicense by a Party to an Affiliate of such Party, such Party must provide the other Party with a copy of any sublicense agreement entered into under Section 8.2 above within
[**] after the execution of such sublicense agreement; provided that any such copy may be reasonably redacted to remove any confidential, proprietary or competitive information, but such copy shall not be redacted to the extent that it
impairs the other Party’s ability to ensure compliance with this Agreement. Such sublicense agreement shall be treated as Confidential Information of the sublicensing Party and no copies are required with respect to sublicense agreements
with Third Party Contractors. 
 Section 8.4    Affiliates and Third Party
Contractors. Either Party may exercise its rights and perform its obligations hereunder itself or through its Affiliates and sublicensees. Each Party shall be primarily liable for any failure by its Affiliates and sublicensees
(including Third Party Contractors) to comply with all relevant restrictions, limitations and obligations in this Agreement. If either Party desires to use any Person to conduct any of its Development, Commercialization or other Collaboration
activities hereunder, such Party must comply with the obligations of Section 8.2(a)(ii)(A) through (D), even to the extent no sublicense of rights is granted to such Third Party. 

Section 8.5    Third Party Agreements. 

(a)    Acknowledgement. Except as provided in Section 8.5(b) and Section 9.6, each Party
acknowledges that Agios is responsible for the fulfillment of its obligations under each Existing Third Party Agreement, and each Party is responsible for the fulfillment of its obligations under any Subsequent Third Party Agreement that it enters
into, and each Party agrees to fulfill the same obligations, including any provisions necessary to maintain in effect any rights sublicensed to the other Party hereunder and the exclusive or non-exclusive nature of such rights, as applicable,
subject to the other Party’s compliance with its obligations hereunder.
 (b)    Incorporation
of Certain Provisions. Each Party agrees and acknowledges that Agios is required to provide to licensors under the Existing Third Party Agreements, and either Party may be required to provide to licensors under any Subsequent Third Party
Agreements, periodic reports relating to the gross sales and Net Sales of Licensed Products. Each Party shall keep true and accurate records and books of account, and open such books and records for inspection by such licensors, for a duration
of [**] from the date of origination of such books or records. Furthermore, each Party acknowledges that the other Party may be required to share certain reports and copies of sublicense agreements provided hereunder with any licensor under an
Existing Third Party Agreement or Subsequent Third Party Agreement, and each Party consents to the sharing of such reports and such copies of such sublicense agreements to the extent required under such Existing Third Party Agreement or Subsequent
Third Party Agreement to the same extent as disclosures are permitted under Section 11.3(b) hereunder; provided that any such copies of sublicense agreements must be redacted to the extent permitted under such Existing Third Party
Agreement or Subsequent Third Party Agreement. In addition, each Party acknowledges that the Prosecution, enforcement and other intellectual property management rights under this Agreement with respect to Patents and other intellectual property
licensed under Existing Third Party Agreements or Subsequent Third Party Agreements shall be subject to the terms and conditions of the applicable Existing Third Party 

  
 - 38 - 

 
Agreements or Subsequent Third Party Agreements and, in the case of Existing Third Party Agreements or Subsequent Third Party Agreements in which the licensor is an academic institution, other
provisions of such Existing Third Party Agreements or Subsequent Third Party Agreements that are customarily required to be imposed on sublicensees in academic licenses (in no event to include any exclusivity covenant). 

(c)    Covenants Regarding Third Party Agreements. Each Party that has entered into an
Existing Third Party Agreement or Subsequent Third Party Agreement (the “Licensing Party”) agrees that during the Term: 

(i)    The Licensing Party shall not modify or amend any Existing Third Party Agreement or Subsequent
Third Party Agreement in any way that adversely affects the other Party’s rights hereunder without the other Party’s prior written consent; 

(ii)    The Licensing Party shall not terminate any Existing Third Party Agreement or Subsequent Third
Party Agreement, in whole or in part, without the other Party’s prior written consent; 

(iii)    Subject to Section 9.6, the Licensing Party shall be solely responsible for, and shall make, all
royalty payments, milestone payments, yearly fees, sublicensee fees, Prosecution fees, and all other payments owed to any licensor under and pursuant to any Existing Third Party Agreement or Subsequent Third Party Agreement; 

(iv)    The Licensing Party shall not exercise or fail to exercise any of its rights, or fail to perform
any of its obligations, under any Existing Third Party Agreement or Subsequent Third Party Agreement that relates to the other Party’s rights hereunder without the prior written consent of the other Party, including rights with respect to
including improvements within the licenses granted under such Existing Third Party Agreement or Subsequent Third Party Agreement; and, at the reasonable request of the other Party, the Licensing Party shall exercise such rights and make such
requests that relate to the other Party’s rights hereunder as are permitted under such Existing Third Party Agreement or Subsequent Third Party Agreement; 

(v)    The Licensing Party shall promptly furnish the other Party with copies of all reports and other
communications that the Licensing Party furnishes to any licensor under any Existing Third Party Agreement or Subsequent Third Party Agreement to the extent that such reports relate to this Agreement; 

(vi)    The Licensing Party shall promptly furnish the other Party with copies of all reports and other
communications that the Licensing Party receives from any licensor under any Existing Third Party Agreement or Subsequent Third Party Agreement that relate to the subject of this Agreement (including notices relating to improvements under such
Existing Third Party Agreement or Subsequent Third Party Agreement); 
 (vii)    The Licensing Party
shall furnish the other Party with copies of all notices received by the Licensing Party relating to any alleged breach or default by the Licensing Party under any Existing Third Party Agreement or Subsequent Third Party Agreement within [**] after
the Licensing Party’s receipt thereof; in addition, if the Licensing Party should at any time breach an Existing Third Party Agreement or subsequent Third Party Agreement or become unable to timely perform its obligations thereunder, the
Licensing Party shall immediately notify the other Party; and 

  
 - 39 - 

 (viii)    If the Licensing Party cannot or chooses not to
cure or otherwise resolve any alleged breach or default under any Existing Third Party Agreement or Subsequent Third Party Agreement, (A) the Licensing Party shall so notify the other Party within [**] of such decision, which shall not be less than
[**] prior to the expiration of the cure period under such Existing Third Party Agreement or Subsequent Third Party Agreement; provided that the Licensing Party shall use Commercially Reasonable Efforts to cure any such breach or
default; and (B) the other Party, in its sole discretion, shall be permitted (but shall not be obligated), on behalf of the Licensing Party, to cure any breach or default under such Existing Third Party Agreement or Subsequent Third Party Agreement
in accordance with the terms and conditions of such Existing Third Party Agreement or Subsequent Third Party Agreement or otherwise resolve such breach directly with the applicable licensor(s) under such Existing Third Party Agreement or Subsequent
Third Party Agreement; and (C) if the other Party pays any such licensor any amounts owed by the Licensing Party under such Existing Third Party Agreement or Subsequent Third Party Agreement, then, provided that such amounts have not arisen as a
result of the other Party’s failure to comply with the terms and conditions of such Existing Third Party Agreement or Subsequent Third Party Agreement within the categories described in Section 8.5(b) applicable to the other Party as a
sublicensee, the other Party may deduct the Licensing Party’s share of such amounts from payments the other Party is required to make thereafter to the Licensing Party hereunder or, at the other Party’s election, may otherwise seek
reimbursement of such amounts from the Licensing Party. 
 (d)    Survival of Rights Following
Termination of Third Party Agreement. The Parties agree that in the event of any termination of any Existing Third Party Agreement or Subsequent Third Party Agreement with respect to any intellectual property rights licensed to a Party
hereunder, such Party shall have any rights available under such Existing Third Party Agreement or Subsequent Third Party Agreement to become a direct licensee of the Third Party licensor(s) under such Existing Third Party Agreement or Subsequent
Third Party Agreement and the Licensing Party shall use Commercially Reasonable Efforts to assist the other Party in exercising such rights; provided that the other Party has not breached this Agreement, or breached the applicable
Third Party Rights under such Existing Third Party Agreement or Subsequent Third Party Agreement. In addition, notwithstanding the foregoing, in the event of such termination, the other Party may in any event approach any licensor under any
Existing Third Party Agreement or Subsequent Third Party Agreement for a direct license.

(e)    Termination of Third Party Agreements. The Parties agree that termination, without
both Parties’ prior written consent, of any Existing Third Party Agreement or Subsequent Third Party Agreement with respect to any Patent or Know-How that is necessary to Develop, Manufacture or Commercialize the Licensed Products shall be
deemed a breach of this Agreement by the Licensing Party; provided that (i) if the other Party’s breach of this Agreement results in a breach of any Existing Third Party Agreement or Subsequent Third Party Agreement, Celgene
agrees to use Commercially Reasonable Efforts to assist the Licensing Party in curing such breach of such Existing Third Party Agreement or Subsequent Third Party Agreement, and (ii) if the other Party’s breach of this Agreement results in a
termination of any Existing Third Party Agreement or Subsequent Third Party Agreement, such termination of such Existing Third Party Agreement or Subsequent Third Party Agreement shall not be deemed a breach by the Licensing Party of this Agreement.

  
 - 40 - 

 Section 8.6    Exclusivity. 

(a)    Exclusivity Obligations. From the Effective Date until the end of the Term, the
Parties and, subject to Section 15.4, their Affiliates shall not, directly or indirectly, Develop, Manufacture or Commercialize [**] for application in [**] that [**] the Target through direct binding to the Target with [**], except for (i) Licensed
Products (including those activities specifically permitted following termination of this Agreement) and (ii) Programs (as defined in the Master Agreement) directed to the Target (A) that are being conducted pursuant to the Master Agreement, (B) to
which Celgene has exercised its Option (as defined in the Master Agreement) under the Master Agreement or (C) the rights to which have reverted to Agios in accordance with Section 2.12 of the Master Agreement. 

(b)    Exceptions.

(i)    Incidental Discoveries. A Party shall be deemed not to be, directly or indirectly
(whether such activities are conducted internally or with or through a Third Party), Developing, Manufacturing or Commercializing in violation of the provisions of Section 8.6(a) as a result of conducting a research program or discovery effort (or
manufacturing or commercializing a [**] resulting from such research program or discovery effort) that has as its specified and primary goal, as evidenced by items such as laboratory notebooks or other relevant documents contemporaneously kept,
taken as a whole, to discover or Develop compounds that [**] through direct binding to a target other than the Target. 

(ii)    Celgene Exception. It is agreed and understood by the Parties that any Celgene research,
discovery and commercialization activities existing as of the effective date of the Master Agreement, whether such activities are undertaken by Celgene alone or in conjunction with one or more partners, licensors, licensees, and/or collaborators,
are expressly excluded from the provisions of this Section 8.6. In particular and without limitation, Celgene research, discovery, and commercialization activities related to (i) [**]; (ii) [**]; (iii) [**]; (iv) [**]; (v) [**]; or (vi) [**], are
expressly excluded from the provisions of this Section 8.6. 
 (iii)    Academic
Collaborations. Notwithstanding the provisions of Section 8.6(a), and without limiting Section 8.2(a)(ii), each Party shall be permitted to perform any of the activities that would otherwise be prohibited under Section 8.6(a) in relation to
the Target, if such activities are (A) the subject of an existing agreement between such Party and an academic institution or academic collaborator entered into prior to the effective date of the Master Agreement, provided that such Party shall not
be permitted to amend any such agreement unless such amendment contains provisions consistent with the terms and conditions of such agreement in effect as of the effective date of the Master Agreement with respect to (1) [**], or (B) the subject of
a new agreement entered into between such Party and an academic institution or academic collaborator that contains terms and conditions with respect to the [**] consistent with the terms and conditions of [**]; provided that, if any
[**] of an amendment described in (A) or an agreement described in (B) would not be [**] the agreements between such Party and an academic institution or academic collaborator entered into prior to the effective date of the Master Agreement, such
Party [**]. 

  
 - 41 - 

 (iv)    Competitive Programs. Section 8.6(a)
shall not apply if, during the [**], any Party or its Affiliates (other than in a Change of Control transaction with respect to such Party) merges or consolidates with, or otherwise acquires, a Third Party that is then engaged in activities that
would otherwise constitute a breach of this Section 8.6 by any Party or its Affiliates (a “Competitive Program”); it being understood and agreed that, unless the Parties agree otherwise in writing, such Party that is engaged in a
Competitive Program (the “Competitive Program Party”) shall, within [**] after the date of such merger, consolidation or acquisition, notify the other Party that it intends to either: (A) terminate, or cause its relevant
Affiliate to terminate, the Competitive Program or (B) divest, or cause its relevant Affiliate to divest, whether by license or otherwise, the Competitive Program. If the Competitive Program Party notifies the other Party within such [**]
period that it intends to [**], such Competitive Program, the Competitive Program Party or its relevant Affiliate, shall (X) terminate such Competitive Program as quickly as possible, and in any event within [**] (unless applicable Law requires a
longer termination period) after the Competitive Program Party delivers such notice to the other Party; and (Y) confirm to the other Party when such termination has been completed, and the Competitive Program Party’s continuation of the
Competitive Program during such [**] (or, as required by applicable Law, longer) period shall not constitute a breach of the Competitive Program Party’s exclusivity obligations under Section 8.6(a). If the Competitive Program Party
notifies the other Party within such [**] period that it intends to divest such Competitive Program, the Competitive Program Party or its relevant Affiliate shall use all reasonable efforts to effect such divestiture as quickly as possible, and in
any event within [**] after the Competitive Program Party delivers such notice to the other Party, and shall confirm to the other Party when such divestiture has been completed. If the Competitive Program Party or its relevant Affiliate fails
to complete such divestiture within such [**] period, but has used reasonable efforts to effect such divestiture within such [**] period, then, unless otherwise required by applicable Law, such [**] period shall be extended for such additional
reasonable period thereafter as is necessary to enable such Competitive Program to be in fact divested, not to exceed an additional [**]; provided that such additional [**] period shall be extended for such period as is necessary to
obtain any governmental or regulatory approvals required to complete such divestiture if the Competitive Program Party or its relevant Affiliate is using good faith efforts to obtain such approvals. The Competitive Program Party’s
continuation of the Competitive Program during such divestiture period shall not constitute a breach of the Competitive Program Party’s exclusivity obligations under Section 8.6(a). 

(v)    Certain Permitted Activities.

(A)    The [**] shall not constitute a breach of Section 8.6(a). Each Party shall report to the JSC
on a [**] basis [**] and that would otherwise breach Section 8.6(a). For clarity, [**] without violation of Section 8.6(a) [**] shall not constitute [**] in violation of such Party’s exclusivity obligations under this Section 8.6 as
long as [**]. 
 (B)    The [**] shall not constitute a breach of Section 8.6(a); provided
that [**] shall be subject to Section 8.6(a) and shall not be permitted under this Section 8.6(b)(v). 

  
 - 42 - 

 (C)    The restrictions set forth in Section 8.6(a) shall
not be deemed to prevent either Party or its respective Affiliates from (1) fulfilling its obligations under this Agreement, or (2) engaging any subcontractors in accordance with Section 8.2(a)(ii) of this Agreement. 

(D)    If [**] occurs with respect to either Party with a Third Party and the Third Party already is
conducting or is planning to conduct activities that would cause a Party or an Affiliate to violate Section 8.6(a) (an “Acquirer Program”), then such Third Party [**]; provided that (1) [**] in any Acquirer Program,
(2) [**] in any Acquirer Program, (3) [**] in any such Acquirer Program, and (4) [**] to such Acquirer Program, including by [**] the activities under this Agreement, and the activities covered under such Acquirer Program (except that this
requirement shall not apply to [**] activities under such Acquirer Program). 
 (vi)    Clinical
Combinations. Notwithstanding anything to the contrary in this Agreement, for purposes of this Section 8.6, either Party shall, at all times, have the right to conduct clinical Development of Licensed Products, alone or with Third Parties, in
which the [**]’s regulatory filings for purposes of enabling such Party and such Third Party to include the relevant use of Licensed Products in combination with such other therapeutic product in the approved label for such Licensed Products
and/or such other therapeutic product, respectively, provided that [**] may grant to any such Third Party the right to sell, offer for sale and otherwise commercially exploit such Licensed Products. 

Section 8.7    Retained Rights. 

(a)    No Implied Licenses or Rights. Except as expressly provided in Section 8.1, and
subject to Section 8.6, all rights in and to the Agios Intellectual Property, Agios’ and its Affiliates’ interests in Agios Co-Co Collaboration Intellectual Property, Joint Collaboration IP and any other Patents or Know-How of Agios and
its Affiliates, are hereby retained by Agios and its Affiliates. Except as expressly provided in Section 8.1, and subject to Section 8.6, all rights in and to the Celgene Intellectual Property, Celgene’s and its Affiliates’ interests
in Celgene Collaboration Intellectual Property and any other Patents or Know-How of Celgene and its Affiliates, are hereby retained by Celgene and its Affiliates. 

(b)    Other Retained Rights. The Parties acknowledge that the licenses granted hereunder are
subject to any rights retained by any licensor under any Existing Third Party Agreement pursuant to any provision of such Existing Third Party Agreement, as identified in Exhibit C; provided that, upon Celgene’s reasonable
request, Agios shall cooperate fully in requesting and obtaining any waiver with respect to the requirement, if applicable under such agreements, that the Licensed Products used or sold in the United States be manufactured substantially in the
United States. 
 Section 8.8    Section 365(n) of the Bankruptcy Code. All rights and
licenses granted under or pursuant to any section of this Agreement are and will otherwise be deemed to be for purposes of Section 365(n) of the United States Bankruptcy Code (Title 11, US Code), as amended (the “Bankruptcy Code”),
licenses of rights to “intellectual property” as defined in Section 101(35A) of the Bankruptcy Code. The Parties will retain and may fully exercise all of their respective rights and elections under the Bankruptcy Code. The
Parties agree that each 

  
 - 43 - 

 
Party, as licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the Bankruptcy Code or any other provisions of applicable law
outside the United States that provide similar protection for “intellectual property.” The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party under the Bankruptcy Code or
analogous provisions of applicable Law outside the United States, the Party that is not subject to such proceeding will be entitled to a complete duplicate of (or complete access to, as appropriate) such intellectual property and all embodiments of
such intellectual property, which, if not already in the non-subject Party’s possession, will be promptly delivered to it upon the non-subject Party’s written request thereof. Any agreements supplemental hereto will be deemed to be
“agreements supplementary to” this Agreement for purposes of Section 365(n) of the Bankruptcy Code. 
 Article IX 

Financial Provisions 

Section 9.1    Upfront Option Payment. In consideration of Agios’ discovery and initial
Development under the Master Agreement of the Compound(s) and the rights and licenses granted hereunder, Celgene shall make an initial, non-refundable payment to Agios equal to the applicable Upfront Option Payment set forth in paragraph 4 and Annex
I of Exhibit A, within [**] following the Effective Date. 
 Section 9.2    Sharing of
Development Costs. Subject to Section 2.3 and Section 3.3: 
 (a)    The Development Costs to
be shared by the Parties under this Agreement are those (i) Development Costs that are incurred after the Execution Date and (ii) Manufacturing Costs associated with clinical supply of Licensed Products incurred after the Execution Date, and, in
either case, that are within [**] percent ([**]%) of the approved Development Budget under the Development Plan, if any, applicable to such Development Costs, as measured on a Party-by-Party basis (such that the [**]% limit is applicable to each
Party’s allocated activities and budgeted amounts under the Development Plan and Development Budget). Any Development Costs in excess of [**] percent ([**]%) of the approved portion of the Development Budget allocated to such Party under
the Development Plan shall be borne solely by the Party incurring such costs unless such Party has received the other Party’s written approval to share such excess costs. Celgene shall be responsible for a percentage of the Development
Costs allocated to this Agreement equal to the Celgene Profit or Loss Allocation and Agios shall be responsible for a percentage of such Development Costs equal to the Agios Profit or Loss Allocation. 

(b)    Within [**] following the beginning of the last month of each Calendar Quarter, each Party shall
prepare and deliver to the JCC a quarterly report detailing its and its Affiliates’ Development Costs incurred during the first two (2) months of such Calendar Quarter, estimated to be incurred during the last month of such Calendar Quarter,
and actually incurred in the last month of the immediately preceding Calendar Quarter which are required to be shared pursuant to this Section 9.2. Each Party shall submit any supporting information or clarifications reasonably requested by the
other Party related to such Development Costs included in such Party’s report within [**] after the other Party’s receipt of such request. The Parties, with the assistance of the JCC, shall conduct a reconciliation of Development
Costs for 

  
 - 44 - 

 
the subject Calendar Quarter within [**] after receipt of all such supporting information, and an invoice shall be issued to the Party (if any) that has not paid for its full share of the
Development Costs for such Calendar Quarter. Such reconciliation shall balance the actual amount of Development Costs incurred during the last month of the immediately preceding Calendar Quarter (to correct for any differences between the
estimates and actual amount of such costs) together with the amounts incurred during the first two (2) months of such Calendar Quarter and those estimated to be incurred during the last month of such Calendar Quarter. The paying Party shall pay
all amounts payable under any such invoice within [**] after its receipt of such invoice. 
 Section
9.3    Milestone Payments. 
 (a)    Development and Regulatory
Milestones. Celgene shall pay Agios the following amounts after the first achievement by or on behalf of the Parties or their respective Affiliates or Licensee Partners of the corresponding development and regulatory milestone events set
forth below with respect to the first Licensed Product to achieve such milestone events. 
  

					
	Milestones	  	 Amount for Shared
65/35
 Program (as indicated on

Exhibit A)
  
	  	
Amount for Shared 50/50

Program (as indicated on

Exhibit A)
  

	 [**]

 
	  	 US $25,000,000

(Twenty-Five Million US Dollars)
  
	  	 US
$20,000,000
 (Twenty Million US Dollars)
  

	 [**]

 
	  	 [**]

 
	  	
[**]
  

	 [**]

 
	  	 [**]

 
	  	
[**]
  

	 [**]

 
	  	 [**]

 
	  	
[**]
  

 (i)    For purposes of determining the occurrence of milestones under
items (2) and (3) in the table above, (A) the [**] shall be deemed a single [**] for purposes of determining whether the [**] and (B) achievement of such milestones with respect to the [**] shall be deemed to have occurred only if [**] have been
obtained. For purposes of clarity, no milestone amount shall be payable to Agios under item (3) if [**], but Celgene shall pay Agios the milestone amount set forth in item (3) upon receipt of [**]as applicable, than the [**] for purposes of
item (3). 
 (ii)    The milestone payments under items (2), (3) and (4) shall be paid at [**] percent
([**]%) of the specified amounts upon the [**] of the applicable milestone event by a Licensed Product for a different Indication than the Indication for which such Licensed Product first achieved such milestone event. For the avoidance of
doubt, each distinct histology shall qualify as a distinct Indication for purposes of this Section 9.3. For the further avoidance of doubt, if a Licensed Product achieves a milestone for an Indication and subsequently achieves the same
milestone for an earlier line setting in the same Indication, no milestone payments shall be due for such earlier line setting (e.g., if a Licensed Product [**], no milestone payments 

  
 - 45 - 

 
would be due if such Licensed Product later [**]). For the further avoidance of doubt, for purposes of this Section 9.3, if a Licensed Product achieves a milestone for an Indication as part
of a monotherapy or combination therapy and subsequently achieves the same milestone in the same Indication as part of a combination therapy or monotherapy, respectively, no milestone payments shall be due for such subsequent milestone. 

(iii)    Each milestone payment under this Section 9.3 shall be made within [**] after the achievement of
the applicable milestone by Celgene or any of its Affiliates or sublicensees (or, if achievement of such milestone is within the control of Agios, within [**] following Celgene’s receipt of written notice of the achievement of such milestone).

 (iv)    For clarity, except as set forth in subsection (ii), the milestone payments set forth in the
table above in this Section 9.3 (to the extent payable) shall be paid only once, regardless of the number of Licensed Products to achieve the applicable milestone event and regardless of the number of Indications for which the milestone event
may be achieved.
 Section 9.4    Profit or Loss. Subject to Section 2.3: 

(a)    Profit or Loss. The Parties shall share in Profit or Loss as follows: Agios shall
bear (and be entitled to) a percentage of Profit or Loss equal to the Agios Profit or Loss Allocation, and Celgene shall bear (and be entitled to) a percentage of Profit or Loss equal to the Celgene Profit or Loss Allocation. Each Party may
include Commercialization Expenses in the Profit or Loss incurred by such Party that are within [**] percent ([**]%) of the approved portion of the Commercialization Budget allocated to such Party under the Commercialization Plan (and, for clarity,
Commercialization activities are measured on a Party-by-Party basis, such that the [**]% limit is applicable to each Party’s allocated activities and budgeted amounts under the Commercialization Plan and Commercialization Budget). Any
Commercialization Expenses in excess of [**] percent ([**]%) of the budgeted amount in the approved Commercialization Budget under the Commercialization Plan shall be borne solely by the Party incurring such costs and not included in Profit or Loss
unless such Party has received the other Party’s written approval to share such excess costs. 

(b)    Quarterly Reconciliation and Payments. Unless the Parties otherwise agree within [**]
following the end of each Calendar Quarter, each Party shall prepare and deliver to the JCC a quarterly report detailing its Net Sales made and Commercialization Expenses incurred, and other amounts necessary to calculate Profit or Loss, during such
Calendar Quarter, with respect to which the Parties share Profit or Loss pursuant to this Section 9.4. Each Party shall submit any supporting information reasonably requested by the other Party related to such Net Sales, Commercialization
Expenses and such other amounts included in such Party’s reconciliation report within [**] after the other Party’s receipt of such request. The Parties, with the assistance of the JCC, shall conduct a reconciliation of Profit or Loss
for the full Calendar Quarter within [**] after receipt of all such supporting information, and an invoice shall be issued to the Party (if any) that owes the other Party a payment to accomplish the sharing, in accordance with the Profit or Loss
Allocations, of the Profit or Loss identified in such reconciliation for such Calendar Quarter by the other Party. The paying Party shall pay all amounts payable under any such invoice within [**] after its receipt of such invoice. 

  
 - 46 - 

 Section 9.5    Royalty Payments Following Agios
Opt-Out. Following any Agios Opt-Out Date: 
 (a)    Royalty Rate. Subject to
Section 9.5(b), Celgene shall pay to Agios royalties on worldwide Annual Net Sales of Licensed Products following any Agios Opt-Out Date at the applicable royalty rate set forth below (each, a “Royalty Rate”) on a Licensed
Product-by-Licensed Product basis (in no event to include Companion Diagnostics): 
  

			
	 Worldwide Annual Net Sales of Licensed Products from a

Shared 50/50 Program
  
	  	          Royalty Rate  
        
	 On the tranche of worldwide Annual Net Sales occurring until aggregate worldwide Annual
Net Sales reaches [**] US Dollars (US$[**])
  
	  	[**]%
	 On the tranche of worldwide Annual Net Sales occurring so long as aggregate worldwide
Annual Net Sales is equal to or greater than [**] US Dollars (US$[**]) and less than [**] US Dollars (US$[**])
  
	  	[**]%
	 On the tranche of worldwide Annual Net Sales occurring upon and after aggregate worldwide
Annual Net Sales equals [**] US Dollars (US$[**])
  
	  	[**]%
		  	
		  	
	 Worldwide Annual Net Sales of Licensed Products from a

Shared 65/35 Program
  
	  	Royalty Rate
	 On the tranche of worldwide Annual Net Sales occurring until aggregate worldwide Annual
Net Sales reaches [**] US Dollars (US$[**])
  
	  	[**]%
	 On the tranche of worldwide Annual Net Sales occurring so long as aggregate worldwide
Annual Net Sales is equal to or greater than [**] US Dollars (US$[**]) and less than [**] US Dollars (US$[**])
  
	  	[**]%
	 On the tranche of worldwide Annual Net Sales occurring upon and after aggregate worldwide
Annual Net Sales equals [**] US Dollars (US$[**])
  
	  	[**]%

 Each Royalty Rate set forth in the tables above will apply only to that portion of the worldwide Annual Net
Sales of a given Licensed Product in the Territory during a given Calendar Year that falls within the indicated tranche. 

  
 - 47 - 

 For example, if worldwide Annual Net Sales of a given Licensed Product in the Territory by
Celgene and its Affiliates and Licensee Partners was $[**] and such Licensed Product was under a Shared 50/50 Program, then the royalties payable with respect to such worldwide Annual Net Sales, subject to adjustment as set forth in this Section
9.5(a), would be: 
 [**]. 

(b)    Royalty Term. Royalties payable under this Section 9.5 shall be paid by Celgene on a
Licensed Product-by-Licensed Product and country-by-country basis from the later of (i) the Agios Opt-Out Date and (ii) the date of First Commercial Sale of each Licensed Product in a country with respect to which royalty payments are due, until the
latest of: 
 (i)    the last to expire of any Valid Claim of Agios Patents, Celgene Collaboration
Patents or Agios Co-Co Collaboration Patents (including Joint Collaboration Patents), in each case Covering such Licensed Product in such country; 

(ii)    [**] following the date of First Commercial Sale in such country; and 

(iii)    the expiration of Regulatory Exclusivity for such Licensed Product in such country; 

(each such term with respect to a Licensed Product and a country, a “Royalty Term”). 

(iv)    Notwithstanding the foregoing, (A) in the event that the Royalty Term for a Licensed Product in a
country continues solely due to Section 9.5(b)(ii) above (i.e., the Licensed Product is not Covered by a Valid Claim of Agios Patents, Celgene Collaboration Patents or Agios Co-Co Collaboration Patents (including Joint Collaboration Patents)
in the applicable country, and such Licensed Product is not subject to Regulatory Exclusivity in such country) or (B) in the event that, and for so long as, Generic Competition for a Licensed Product occurs in a country, then, in either such event,
the royalty rate in such country will be reduced to [**] percent ([**]%) of the applicable rate in Section 9.5(a) in such country. 

(v)    Upon the expiration of the Royalty Term with respect to a Licensed Product in a country, the
license granted by Agios to Celgene pursuant to Section 8.1(a) shall be deemed to be fully paid-up, irrevocable and perpetual with respect to such Licensed Product in such country; provided that, notwithstanding Section 9.6(a), Celgene
shall assume and be solely responsible (without deduction under Section 9.5(c)) for any amounts payable to Third Party licensors and Celgene shall be responsible for complying with the terms of any license agreements with such Third Party licensors,
in each case, with respect to Celgene’s exercise of such rights as to such Licensed Product in such country following the expiration of the Royalty Term. 

(c)    Deduction for Third Party Payments after Agios Opt-Out. In the event that, following
an Agios Opt-Out Date, royalties are payable by Celgene to Agios with respect to any Licensed Product under this Section 9.5, the Parties shall continue to be responsible for amounts payable to Third Party licensors under Existing Third Party
Agreements as set forth in Section 9.6 (which amounts shall not be deductible from royalties as set forth in this Section 9.5(c)) 

  
 - 48 - 

 
and Celgene shall have the right to deduct from royalty payments otherwise due and payable by Celgene to Agios under this Section 9.5, on a Licensed Product-by-Licensed Product and
country-by-country basis, a maximum of [**] percent ([**]%) of any royalties or other amounts actually paid by Celgene to a Third Party from and after the Agios Opt-Out Date with respect to any Subsequent Third Party Agreement, but only to the
extent that the Patents or Know-How licensed under such Subsequent Third Party Agreement are necessary (i) to [**] the Target to which the applicable Licensed Product is directed or (ii) for the Development, Manufacture or Commercialization
of such Licensed Product in a country(ies); provided that, on a Licensed Product-by-Licensed Product basis, any royalty deductions that are not credited against royalties for the Calendar Quarter in which they were accrued due to the
limitation in the preceding proviso shall be carried forward and credited against royalties payable in subsequent Calendar Quarter(s) hereunder until such royalty credits are completely expended. 

(d)    Royalty Reports; Payments. Within [**] after the end of each Calendar Quarter
following the Agios Opt-Out Date, Celgene with respect to each Licensed Product shall provide Agios with a report stating the sales in units and in value of such Licensed Product made by Celgene, its Affiliates, and Licensee Partners, as applicable,
on a country-by-country basis, together with the calculation of the royalties due to Agios, including the method used to calculate the royalties, the exchange rates used, and itemized deductions. Payments of all amounts payable under this
Section 9.5 shall be made by Celgene to the bank account indicated by Agios concurrently with the delivery of such report. 

(e)    Cumulative Effect of Royalty Reductions. In no event shall the royalty reductions
described in this Section 9.5, alone or together, reduce the royalties payable by Celgene for a Licensed Product in a country in any given Calendar Quarter to less than [**] percent ([**]%) of the amounts otherwise payable by Celgene for such
Calendar Quarter. Celgene may carry over and apply any such royalty reductions, which are incurred or accrued in a Calendar Quarter and are not deducted in such Calendar Quarter due to the limitation set forth above in this Section 9.5(e), to
any subsequent Calendar Quarter(s) and shall begin applying such reduction to such royalties as soon as practicable and continue applying such reduction on a Calendar Quarterly basis thereafter until fully deducted, in all cases subject to the
limitation set forth above in this Section 9.5(e). 
 Section 9.6    Third Party Payments. 

(a)    Existing Third Party Agreements. All royalties payable under the Existing Third
Party Agreements, in the aggregate, on or after the Effective Date that (i) directly relate to a Licensed Product and (ii) in no event exceed [**] percent ([**]%) of worldwide Net Sales in the aggregate shall be shared as Development Costs if paid
prior to the First Commercial Sale of such Licensed Product or Commercialization Expenses if paid thereafter and, for clarity, all royalties payable under the Existing Third Party Agreements in excess of [**] percent ([**]%) of worldwide Net Sales
in the aggregate, and all non-royalty amounts payable under such Existing Third Party Agreements shall be paid by Agios (and in no event shall be included in the Profit or Loss Allocation). 

  
 - 49 - 

 (b)    Additional Agreements. After the
Effective Date, if Celgene at any time or Agios before an Agios Opt-Out Notice believes that a license under Third Party Patents or Third Party Know-How, other than an Existing Third Party Agreement, could be necessary or useful to Develop,
Manufacture or Commercialize the Licensed Products, then such Party shall notify (A) the JDC if such notice is provided during Development or Manufacturing of Licensed Products for Development or (B) the JCC if such notice is provided during
Commercialization. 
 (i)    If the JDC or JCC, as applicable, agrees by unanimous vote to obtain such
license, and if so, which of the Parties will do so, then the Parties will proceed as determined by the JDC or JCC, as applicable. If the JDC or JCC, as applicable, cannot agree on whether to obtain such license or which Party will do so, then
the matter will be escalated to the JSC for resolution in accordance with Section 2.2; provided that, if the JSC cannot agree on which Party should obtain such license, then the Lead Party in the applicable Territory shall have the
first right to obtain such license and if the applicable Lead Party does not promptly exercise such right then the other Party shall have the right to do so; provided, further, that, after an Agios Opt-Out Notice, Celgene shall
have the sole right to obtain such license throughout the Territory. 
 (ii)    The costs of each such
license (each, a “Subsequent Third Party Agreement”) to the extent the costs directly relate to the Licensed Products shall be shared as Development Costs if paid prior to the First Commercial Sale of a Licensed Product or
Commercialization Expenses if paid thereafter and, in the event of an Agios Opt-Out Date, shall be borne solely by Celgene to the extent incurred after the Agios Opt-Out Date, subject to deduction from royalties in accordance with Section 9.5(c).

 (iii)    For purposes of this Agreement, the Third Party Patents and Third Party Know-How licensed
pursuant to this Section 9.6(b) shall be deemed “Co-Co Collaboration Intellectual Property” of the Party obtaining such license. 

(iv)    (1) The Party designated to pursue the Subsequent Third Party Agreement shall keep the other
Party fully informed of the status of the negotiations with the Third Party and provide the other Party with copies of all draft agreements; (2) the other Party may provide comments and suggestions with respect to the negotiation of the agreement
with the Third Party, and the Party seeking the Subsequent Third Party Agreement shall reasonably consider all comments and suggestions reasonably recommended by the other Party; and (3) the Party seeking the Subsequent Third Party Agreement shall
obtain a license that is sublicensable to the other Party in accordance with the terms of this Agreement, treating (unless otherwise agreed by the Parties) the Third Party intellectual property as Co-Co Collaboration Intellectual Property hereunder
and treating the agreement licensing such Third Party intellectual property in the same way as the Existing Third Party Agreement (including as provided in Section 8.5), except for payment obligations, which will be treated as provided in this
Section 9.6. 
 Section 9.7    Financial Records. The Parties shall keep, and shall require
their respective Affiliates and sublicensees to keep, complete and accurate books and records in accordance with the applicable Accounting Standards. The Parties shall keep, and shall require their respective Affiliates and sublicensees to
keep, such books and records for at least [**] following the end of the Calendar Year to which they pertain. Such books of accounts shall be kept at the principal place of business of the financial personnel with responsibility for preparing
and maintaining such records. With respect to royalties, such records shall be in sufficient detail to support calculations of royalties due to Agios. Celgene and Agios shall also keep, and require

  
 - 50 - 

 
their respective Affiliates and sublicensees to keep, complete and accurate records and books of accounts containing all data reasonably required for the calculation and verification of
Development Costs, including internal FTEs utilized by either Party, Profit or Loss and, if applicable, Annual Net Sales. 

Section 9.8    Audits. 

(a)    Audit Team. Each Party may, upon request and at its expense (except as provided for
herein), cause an internationally recognized independent accounting firm selected by it (except one to whom the Auditee has a reasonable objection) (the “Audit Team”) to audit during ordinary business hours the books and records of
the other Party and the correctness of any payment made or required to be made to or by such Party, and any report underlying such payment (or lack thereof), pursuant to the terms of this Agreement. Prior to commencing its work pursuant to this
Agreement, the Audit Team shall enter into an appropriate confidentiality agreement with the Auditee obligating the Audit Team to be bound by obligations of confidentiality and restrictions on use of such Confidential Information that are no less
restrictive than the obligations set forth in Article XI. 
 (b)    Limitations. In respect
of each audit of the Auditee’s books and records: (i) the Auditee may be audited [**], (ii) no records for any given year for an Auditee may be audited more than [**]; provided that the Auditee’s records shall still be
made available if such records impact another financial year which is being audited, and (iii) the Audit Rights Holder shall only be entitled to audit books and records of an Auditee from the [**] prior to the Calendar Year in which the audit
request is made. 
 (c)    Audit Notice. In order to initiate an audit for a particular
Calendar Year, the Audit Rights Holder must provide written notice to the Auditee. The Audit Rights Holder exercising its audit rights shall provide the Auditee with notice of one or more proposed dates of the audit not less than [**]prior to
the first proposed date. The Auditee will reasonably accommodate the scheduling of such audit. The Auditee shall provide such Audit Team(s) with full and complete access to the applicable books and records and otherwise reasonably
cooperate with such audit. 
 (d)    Payments. If the audit shows any under-reporting or
underpayment, or overcharging by any Party, that under-reporting, underpayment or overcharging shall be reported to the Audit Rights Holder and the underpaying or overcharging Party shall remit such underpayment or reimburse such overcompensation
(together with interest at the rate set forth in Section 9.11) to the underpaid or overcharged Party within [**] after receiving the audit report. Further, if the audit for an annual period shows an under-reporting or underpayment or an
overcharge by any Party for that period in excess of [**] percent ([**]%) of the amounts properly determined, the underpaying or overcharging Party, as the case may be, shall reimburse the applicable underpaid or overcharged Audit Rights Holder
conducting the audit, for its respective audit fees and reasonable Out-of-Pocket Costs in connection with said audit, which reimbursement shall be made within [**] after receiving appropriate invoices and other support for such audit-related costs.

  
 - 51 - 

 (e)    Definitions. For the purposes of the
audit rights described herein, an individual Party subject to an audit in any given year will be referred to as the “Auditee” and the other Party who has certain and respective rights to audit the books and records of the Auditee
will be referred to as the “Audit Rights Holder.” 
 Section 9.9 Tax Matters. 

(a)    General. The Parties acknowledge that the rights and obligations imposed on each of
them pursuant to this Agreement that relate to the sharing of profits from the development and commercialization of the Licensed Products in the [US/ROW] Territory to the Compounds, Licensed Products and Companion Diagnostics and the collaborative
relationship formed between them in connection therewith, gives rise to a partnership (whether deemed, constructive, imputed or similar) for US federal (and, to the extent applicable, state) income tax purposes (but not for any non-tax or non-US
purpose), and the Parties shall act in accordance with Exhibit G.
 (b)    Withholding
Taxes.
 (i)    Each Party shall be entitled to deduct and withhold from any amounts payable under
this Agreement (or allocable to another Party pursuant to Article IV of Exhibit G) such taxes as are required to be deducted or withheld therefrom under any provision of applicable Law. The Party that is required to make such withholding (the
“Paying Party”) will: (A) deduct those taxes from such payment, (B) timely remit the taxes to the proper taxing authority, and (C) send evidence of the obligation together with proof of tax payment to the recipient Party (the
“Payee Party”) on a timely basis following that tax payment; provided, however, that before making any such deduction or withholding, the Paying Party shall give the Payee Party notice of the intention to make such deduction or
withholding (and such notice, which shall set forth in reasonable detail the authority, basis and method of calculation for the proposed deduction or withholding, shall be given at least a reasonable period of time before such deduction or
withholding is required, in order for such Payee Party to obtain reduction of or relief from such deduction or withholding). Each Party agrees to cooperate with the other Parties in claiming refunds or exemptions from such deductions or
withholdings under any relevant agreement or treaty or other applicable Law which is in effect to ensure that any amounts required to be withheld pursuant to this 9.9(b) are reduced in amount to the fullest extent permitted by applicable
Law. In addition, the Parties shall cooperate in accordance with applicable Laws to minimize [**] in connection with this Agreement, as applicable. 

(ii)    Tax Documentation. Each Party has provided a properly completed and duly executed IRS
Form W-9 or applicable Form W-8 to the other Parties. Each Party and any other recipient of payments under this Agreement shall provide to the other Party, at the time or times reasonably requested by such other Parties or as required by applicable
Law, such other properly completed and duly executed documentation as will permit payments made under this Agreement to be made without, or at a reduced rate of, withholding for taxes, and the applicable payment shall be made without (or at a
reduced rate of) withholding to the extent permitted by such documentation, as reasonably determined by the Paying Party. 

  
 - 52 - 

 Section 9.10    Currency Exchange; Blocked Payments;
Prohibitions on Payments. 
 (a)    Currency Exchange. Unless otherwise expressly
stated in this Agreement, all amounts specified in, and all payments made under, this Agreement shall be in United States Dollars. If any currency conversion shall be required in connection with the calculation of amounts payable under this
Agreement, such conversion shall be performed in a manner consistent with the paying Party’s normal practices used to prepare its audited financial statements for internal and external reporting purposes. For clarity, Celgene sets currency
transaction rates for the month on the last business day of the month prior. Agios has the right to verify that the exchange rates used by Celgene for a given month are within the trading range of the last business day of the month prior. 

(b)    Blocked Payments. In the event that, by reason of applicable Law in any country, it
becomes impossible or illegal for the paying Party (or any of its Affiliates or Licensee Partners) to transfer, or have transferred on its behalf, payments owed the other Party hereunder, the paying Party will promptly notify the other Party of the
conditions preventing such transfer and such payments will be deposited in local currency in the relevant country to the credit of the other Party in a recognized banking institution designated by the other Party or, if none is designated by the
other Party within a period of [**], in a recognized banking institution selected by the paying Party or any of its Affiliates or its Licensee Partners, as the case may be, and identified in a written notice given to the other Party. 

(c)    Prohibitions on Payments. When in any country in the Territory applicable Law
prohibits both the transmittal and the deposit of royalties on sales in such country, royalty payments due on Net Sales shall be suspended for as long as such prohibition is in effect and as soon as such prohibition ceases to be in effect, all
royalties that Celgene would have been under an obligation to transmit or deposit but for the prohibition shall forthwith be deposited or transmitted, to the extent allowable. 

Section 9.11    Late Payments. The paying Party shall pay interest to the receiving Party on
the aggregate amount of any payments that are not paid on or before the date such payments are due under this Agreement at a rate per annum equal to the lesser of the [**], or the highest rate permitted by applicable Law, calculated on the number of
days such payments are paid after the date such payments are due; provided that, with respect to any disputed payments, no interest payment shall be due until such dispute is resolved and the interest which shall be payable thereon
shall be based on the finally-resolved amount of such payment, calculated from the original date on which the disputed payment was due through the date on which payment is actually made. 

Article X 
 Intellectual
Property Ownership, Protection and Related Matters 
 Section 10.1    Ownership of
Inventions. 
 (a)    Non-Co-Co Collaboration Know-How. Any Know-How developed or
generated by Celgene or Agios prior to or outside the Collaboration shall remain the sole property of such Party. 

  
 - 53 - 

 (b)    Sole Inventions. All Co-Co Collaboration
Know-How developed or generated solely by employees, agents and consultants of a Party shall be owned exclusively by such Party. 

(c)    Joint Inventions. All Co-Co Collaboration Know-How developed or generated jointly by
employees, agents and consultants of Celgene, on the one hand, and employees, agents and consultants of Agios, on the other hand, in the conduct of activities under this Agreement (“Joint Inventions” and, any Patents Covering such
Joint Inventions, “Joint Patents”) shall be owned jointly on the basis of each Party having an undivided interest without a duty to account to the other Party and shall be deemed to be Controlled by each Party. Each Party shall
have the right to use such Joint Inventions, or license such Joint Inventions to its Affiliates or any Third Party, or sell or otherwise transfer its interest in such Joint Inventions to its Affiliates or a Third Party, in each case without the
consent of the other Party (and, to the extent that applicable Law requires the consent of the other Party, this Section 10.1(c) shall constitute such consent), so long as such use, sale, license or transfer is subject to Section 8.6 and the
licenses granted pursuant to this Agreement and is otherwise consistent with this Agreement. 

(d)    Notice. Each Party agrees to provide regular quarterly written reports disclosing to
the other Party all Co-Co Collaboration Intellectual Property developed or generated by employees, agents and consultants of such Party and all Agios Intellectual Property and Celgene Intellectual Property that becomes subject to this Agreement,
which disclosures may be made in connection with the updates made in accordance with Section 3.1(f). 

(e)    Inventorship. The determination of inventorship shall be made in accordance with
United States patent laws. In the event of a dispute regarding inventorship, if the Parties are unable to resolve the dispute, the Parties shall jointly engage mutually acceptable independent patent counsel not regularly employed by either
Party to resolve such dispute. The decision of such independent patent counsel shall be binding on the Parties with respect to the issue of inventorship. 

(f)    Further Actions and Assignments. Each Party shall take all further actions and execute
all assignments requested by the other Party and reasonably necessary or desirable to vest in the other Party the ownership rights set forth in this Article X. 

Section 10.2    Prosecution of Patents. Subject to the terms and conditions of any Existing
Third Party Agreement or Subsequent Third Party Agreement to the extent such agreement applies to the Agios Patents, Agios Co-Co Collaboration Patents, Celgene Patents or Celgene Collaboration Patents, the following provisions shall apply with
respect to the Agios Patents, Celgene Patents, Celgene Collaboration Patents, Agios Co-Co Collaboration Patents and Joint Collaboration Patents in the Territory: 

(a)    Lead US Party. Subject to the provisions of Section 10.2(f) and coordination with the
JPC, the Lead US Party (or, in the event of any Agios Opt-Out, Celgene) shall have the initial right and option to Prosecute the [**]. In the event that the Lead US Party declines to Prosecute such Patents, it shall give the other Party
reasonable notice to this effect, 

  
 - 54 - 

 
sufficiently in advance to permit the other Party to undertake such Prosecution in any applicable country without a loss of rights, and thereafter the other Party may, upon written notice to the
Lead US Party, Prosecute such Patents in the owning Party(ies)’s name(s) subject to coordination with the JPC. 

(b)    Celgene. Celgene shall have the sole right and option to Prosecute the [**]. 

(c)    Costs and Expenses. The Parties shall jointly bear all costs and expenses in
Prosecuting Agios Patents, Agios Co-Co Collaboration Patents, Celgene Collaboration Patents and Joint Collaboration Patents (collectively, “Patent Prosecution Expenses”) as either Development Costs (to the extent incurred for any
country or jurisdiction prior to the First Commercial Sale of the Licensed Product in the country or jurisdiction to which the Patents relate) or Commercialization Expenses (if incurred after First Commercial Sale of the Licensed Product in such
country or jurisdiction); provided, however, that, in the event of an Agios Opt-Out Date, all such Patent Prosecution Expenses incurred by Celgene following the Agios Opt-Out Date shall be borne solely by Celgene. 

(d)    Strategy; Failure of JPC to Agree; Diligence and Cooperation. 

(i)    The JPC shall attempt to agree upon a strategy (which may be updated from time to time) for
Prosecution of Agios Patents, Celgene Collaboration Patents, Agios Co-Co Collaboration Patents and Joint Collaboration Patents, including the scope and priority of the claims to be pursued within such Patents and to maximize the value of such
Patents, on a global basis. Any failure by the JPC to agree by unanimous vote with respect to such strategy or any other Prosecution matter will be attempted to be resolved as specified in Section 2.2(e), and if such attempt fails, then the
Party conducting Prosecution (the “Prosecuting Party”) may resolve such matter. The Prosecuting Party with respect to each such Patent shall follow such strategy in connection with all Prosecution of such Patents unless the JPC
approves of a divergence from such strategy (with any failure by the JPC to agree by unanimous vote to be resolved in accordance with Section 2.2(e) and the foregoing sentence). 

(ii)    The Prosecuting Party shall be entitled to use patent counsel selected by it and reasonably
acceptable to the non-Prosecuting Party (including in-house patent counsel as well as outside patent counsel) for the Prosecution of the Patents Rights subject to Section 10.2(a) and Section 10.2(b). Each Party agrees to cooperate with the
other with respect to the Prosecution of such Patents pursuant to this Section 10.2, including (X) executing all such documents and instruments and performing such acts as may be reasonably necessary in order to permit the other Party to undertake
any Prosecution of Patents that such other Party is entitled, and has elected, to Prosecute, as provided for in Section 10.2(a) and Section 10.2(b) and (Y) giving consideration to the proper scope of Patents. The Prosecuting Party shall: 

(A)    use Commercially Reasonable Efforts to regularly provide the JPC in advance with reasonable
information relating to the Prosecuting Party’s Prosecution of Patents hereunder, including by providing copies of substantive communications, notices and actions submitted to or received from the relevant patent authorities and copies of
drafts of filings and correspondence that the Prosecuting Party proposes to submit to such patent authorities, each of which shall be provided as far in advance as is practicable but with sufficient time for the non-Prosecuting party to provide
meaningful input; 

  
 - 55 - 

 (B)    use Commercially Reasonable Efforts to consider in
good faith and consult with the non-Prosecuting Party regarding its timely comments with respect to the same; 

(C)    use Commercially Reasonable Efforts to Prosecute additional claims substantially similar to those
suggested by the non-Prosecuting Party, if any, in such jurisdictions of the Territory reasonably requested by the non-Prosecuting Party; and 

(D)    consult with the JPC and non-Prosecuting Party before taking any action that would have a material
adverse impact on the scope of claims within the Agios Patents, Celgene Collaboration Patents or Agios Co-Co Collaboration Patents (including the Joint Collaboration Patents), as applicable. 

(iii)    The JPC shall determine the countries in which Agios Patents, Celgene Collaboration Patents and
Agios Co-Co Collaboration Patents (including Joint Collaboration Patents) shall be Prosecuted, with the understanding that the countries set forth on Exhibit E of this Agreement shall generally form the basis for the overall Prosecution
strategy for such Patents and that any failure of the JPC to determine such countries by unanimous vote will be resolved as provided in clause (i) of this Section 10.2(d). Further, the Prosecuting Party shall consult with the JPC well in
advance of PCT national phase and Paris Convention deadlines as to additional countries (if any) in which the JPC or non-Prosecuting Party desires that the Agios Patents, Celgene Collaboration Patents and Agios Co-Co Collaboration Patents (including
Joint Collaboration Patents) be Prosecuted. 
 (iv)    The Prosecuting Party agrees not to abandon the
subject matter of a claim in an Agios Patent, Celgene Collaboration Patent, Agios Co-Co Collaboration Patent or Joint Collaboration Patent or narrow such claim except in response to an office action from the applicable patent office that, in the
Prosecuting Party’s reasonable judgment after consultation with the non-Prosecuting Party, requires such abandonment or narrowing; provided that, prior to such abandonment or narrowing, if feasible, the Parties will co-operate to
file divisional or continuation applications to separate such claim. 
 (e)    Third Party
Rights. Agios covenants and agrees that it shall not grant any Third Party any right to control the Prosecution of the Agios Patents or Agios Co-Co Collaboration Patents or to approve or consult with respect to any Patents licensed to
Celgene hereunder, in any case, that is more favorable to the Third Party than the rights granted to Celgene hereunder or that otherwise conflicts with Celgene’s rights hereunder. Celgene covenants and agrees that it shall not grant any
Third Party any right to control the Prosecution of the Celgene Collaboration Patents or to approve or consult with respect to the Celgene Collaboration Patents licensed to Agios hereunder, in any case, that is more favorable to the Third Party than
the rights granted to Agios hereunder or that otherwise conflicts with Agios’ rights hereunder. 

  
 - 56 - 

 (f)    Third Party Agreements. Each Party
acknowledges that, pursuant to an Existing Third Party Agreement or Subsequent Third Party Agreement, the applicable licensor(s) thereunder may retain the right to Prosecute the Agios Patents, Agios Co-Co Collaboration Patents or Celgene
Collaboration Patents covered by such agreement; provided that Agios or Celgene, as applicable, may have certain rights to assume Prosecution under such agreement. Agios and Celgene, as applicable, each agrees to keep the other
Party fully informed of these rights, as well as provide to the other Party all information and copies of documents received from the licensor(s) under any such Existing Third Party Agreement or Subsequent Third Party Agreement, or their patent
counsel, relating to the Agios Patents, Agios Co-Co Collaboration Patents or Celgene Collaboration Patents covered by such agreement. To the extent that Agios or Celgene, as applicable, is permitted to proceed with Prosecution or provide
comments or suggestions to patent documents under an Existing Third Party Agreement or Subsequent Third Party Agreement, then the Agios Patents, Agios Co-Co Collaboration Patents or Celgene Collaboration Patents under such Existing Third Party
Agreement or Subsequent Third Party Agreement shall be treated in the same manner as other Agios Patents, Agios Co-Co Collaboration Patents or Celgene Collaboration Patents under this Section 10.2, and Agios or Celgene, as applicable, shall exercise
all such rights with respect to such Agios Patents, Agios Co-Co Collaboration Patents or Celgene Collaboration Patents pursuant to the instructions of the other Party, if the other Party is given the right to act under this Section 10.2. 

Section 10.3    Third Party Infringement of Agios Patents, Celgene Collaboration Patents and Agios
Co-Co Collaboration Patents. Subject to the terms and conditions of any Existing Third Party Agreement or Subsequent Third Party Agreement to the extent such agreement applies to the Agios Patents, Agios Co-Co Collaboration Patents or
Celgene Collaboration Patents, the following provisions shall apply with respect to the Agios Patents, Agios Co-Co Collaboration Patents, Celgene Collaboration Patents, Joint Collaboration Patents, Agios Know-How, Agios Co-Co Collaboration Know-How,
Celgene Collaboration Know-How and Joint Collaboration Know-How: 
 (a)    Notice. Each
Party shall immediately provide the other Party with written notice reasonably detailing any (i) known or alleged infringement of any Agios Patents, Celgene Patents, Celgene Collaboration Patents, Agios Co-Co Collaboration Patents or Joint
Collaboration Patents, or known or alleged misappropriation of any Agios Know-How, Celgene Know-How, Celgene Collaboration Know-How, Agios Co-Co Collaboration Know-How or Joint Collaboration Know-How, by a Third Party, (ii) “patent
certification” filed in the United States under 21 U.S.C. §355(b)(2) or 21 U.S.C. §355(j)(2) or similar provisions in other jurisdictions, and (iii) any declaratory judgment, opposition, or similar action alleging the invalidity,
unenforceability or non-infringement of any such intellectual property rights (collectively “Third Party Infringement”). 

(b)    First Right to Initiate Infringement Actions. Each Party shall have the initial right
[**], but not the obligation, to initiate a suit or take other appropriate action that such Party believes is reasonably required to protect the Agios Intellectual Property, Celgene Intellectual Property, Celgene Collaboration Intellectual Property,
Agios Co-Co Collaboration Intellectual Property or Joint Collaboration IP against the infringement in such part of the Territory, including Third Party Infringement, unauthorized use or misappropriation by a Third Party that relates to a Licensed
Product, which, in the case of a Companion Diagnostic, shall 

  
 - 57 - 

 
mean Third Party Infringement, unauthorized use or misappropriation in connection with a Companion Diagnostic in the [IO Field/I&I Field] [identify applicable field prior to
execution] (as defined in the Master Agreement) (“Competitive Infringement”); provided, however, that if [**], Celgene rather than Agios shall have such initial right as to Celgene Intellectual Property
[**]. The Party having such initial right under the preceding sentence (“Initial Enforcement Party”) shall give the other Party advance notice of the Initial Enforcement Party’s intent to file any such suit or take any
such action and the reasons therefor, and shall provide the other Party with an opportunity to make suggestions and comments regarding such suit or action. Thereafter, the Initial Enforcement Party shall keep the other Party promptly informed,
and shall from time to time consult with the other Party regarding the status of any such suit or action and shall provide the other Party with copies of all material documents (e.g., complaints, answers, counterclaims, material motions,
orders of the court, memoranda of law and legal briefs, interrogatory responses, depositions, material pre-trial filings, expert reports, affidavits filed in court, transcripts of hearings and trial testimony, trial exhibits and notices of appeal)
filed in, or otherwise relating to, such suit or action. Without limiting the generality of the foregoing, the Parties shall discuss in good faith the Initial Enforcement Party’s intended response to a Competitive Infringement. 

(c)    Preparation to Enforce. After the First Commercial Sale of a Licensed Product in the
US Territory or the ROW Territory, as applicable, subject to coordination with the JPC, the Initial Enforcement Party for such part of the Territory shall use reasonable efforts to prepare for the possibility of suit for Competitive Infringement
starting [**] after such First Commercial Sale. Such preparation includes identifying and retaining experts, selecting and retaining outside counsel, having outside counsel conduct a pre-litigation diligence investigation into potential
validity and unenforceability arguments, data and document collection and review, and other actions reasonably capable of being conducted before initiation of any such litigation. 

(d)    Step-in Rights. If the Initial Enforcement Party fails to initiate a suit or take such
other appropriate action under Section 10.3(b) above within [**] after becoming aware of the Competitive Infringement, then the other Party may, in its discretion, provide the Initial Enforcement Party with written notice of such Party’s intent
to initiate a suit or take other appropriate action to combat such Competitive Infringement. If the Party with such step-in rights under the preceding sentence (“Step-In Enforcement Party”) provides such notice and the
Initial Enforcement Party fails to initiate a suit or take such other appropriate action within [**] after receipt of such notice from the Step-In Enforcement Party, then the Step-In Enforcement Party shall have the right, but not the obligation, to
initiate a suit or take other appropriate action that it believes is reasonably required to protect the applicable Agios Intellectual Property, Celgene Intellectual Property, Celgene Collaboration Intellectual Property, Agios Co-Co Collaboration
Intellectual Property or Joint Collaboration IP from Competitive Infringement. The Step-In Enforcement Party shall give the Initial Enforcement Party advance notice of the Step-In Enforcement Party’s intent to file any such suit or take
any such action and the reasons therefor and shall provide the Initial Enforcement Party with an opportunity to make suggestions and comments regarding such suit or action. Thereafter, the Step-In Enforcement Party shall keep the Initial
Enforcement Party promptly informed and shall from time to time consult with the Initial Enforcement Party regarding the status of any such suit or action and shall provide the Initial Enforcement Party with copies of all material documents
(e.g., 

  
 - 58 - 

 
complaints, answers, counterclaims, material motions, orders of the court, memoranda of law and legal briefs, interrogatory responses, depositions, material pre-trial filings, expert reports,
affidavits filed in court, transcripts of hearings and trial testimony, trial exhibits and notices of appeal) filed in, or otherwise relating to, such suit or action. 

(e)    Conduct of Action; Costs. The Party initiating suit shall have the sole and exclusive
right to select counsel for any suit initiated by it under this Section 10.3, which counsel must be reasonably acceptable to the other Party. If required under applicable Law in order for such Party to initiate or maintain such suit, the other
Party shall join as a party to the suit. If requested by the Party initiating suit, the other Party shall provide reasonable assistance to the Party initiating suit in connection therewith at no charge to such Party except that the initiating
Party shall reimburse the other Party for Out-of-Pocket Costs, other than outside counsel expenses, incurred in rendering such assistance. The Party initiating suit shall assume and pay all of its own Out-of-Pocket Costs incurred in connection
with any litigation or proceedings described in this Section 10.3, including the fees and expenses of the counsel selected by it, provided that, prior to the Agios Opt-Out Date, if any, such fees and expenses shall be included in the
calculation of Development Costs (if incurred in any country or jurisdiction of the Territory prior to the First Commercial Sale of a Licensed Product in such country or jurisdiction) or Commercialization Expenses (if incurred after the First
Commercial Sale of a Licensed Product in such country or jurisdiction). The other Party shall have the right to participate and be represented in any such suit by its own counsel at its own expense (and which shall not be a Patent and Trademark
Enforcement Cost or other cost that is a factor in the calculation of Profit or Loss). 

(f)    Recoveries. Any recovery obtained as a result of any proceeding described in this
Section 10.3 or from any counterclaim or similar claim asserted in a proceeding described in Section 10.4, by settlement or otherwise, shall be applied in the following order of priority: 

(i)    first, the Party initiating the suit or action shall be reimbursed for all previously unreimbursed
(or not otherwise included in the calculation of Development Costs or Commercialization Expenses) Out-of-Pocket Costs in connection with such proceeding; and 

(ii)    second, any remainder shall be (A) treated as Additional Revenue, if obtained before the Agios
Opt-Out Date, if any; or (B) paid [**] percent ([**]%) to the Party initiating the suit or action, and [**] percent ([**]%) to the other Party, if obtained on or after the Agios Opt-Out Date, if any. 

(g)    Third Party Agreements. In the event that (i) a Patent covered by an Existing Third
Party Agreement or Subsequent Third Party Agreement is at issue in an action under this Section 10.3 or Section 10.4, (ii) Agios or Celgene, as applicable, has a right to enforce the Agios Patents, Agios Co-Co Collaboration Patents or Celgene
Collaboration Patents under such Existing Third Party Agreement or Subsequent Third Party Agreement, and (iii) Celgene or Agios, respectively, desires to enforce such Patent in accordance with the procedures under this Section 10.3 or Section 10.4,
as applicable, then Agios or Celgene, respectively, shall either (A) obtain the licensor(s)’ consent under such Existing Third Party Agreement or Subsequent Third Party Agreement so that Celgene or Agios, respectively, may file such an action
in its own name or (B) shall undertake such an action on Celgene’s behalf and at Celgene’s expense or on Agios’ behalf and at Agios’ expense, respectively. 

  
 - 59 - 

 Section 10.4    Claimed Infringement; Claimed
Invalidity. 
 (a)    Infringement of Third Party Rights. Each Party shall promptly
notify the other Party in writing of any allegation by a Third Party that the activity of either Party or their Affiliates or Licensee Partners under this Agreement infringes or may infringe the intellectual property rights of such Third
Party. If a Third Party asserts or files against a Party or its Affiliates any claim of infringement of the intellectual property rights of such Third Party or other action relating to alleged infringement of such intellectual property rights
(“Third Party Infringement Action”), then, unless otherwise agreed by the Parties: 

(i)    In the event of a Third Party Infringement Action against a single Party, the unnamed Party shall
have the right, in the unnamed Party’s sole discretion, to participate in the defense of such legal action with legal counsel selected by the unnamed Party and reasonably acceptable to the named Party (the costs of which shall not be a Patent
and Trademark Enforcement Cost or other cost that is a factor in the calculation of Profit or Loss). The Party named in such Third Party Infringement Action shall have the right to control the defense of the action, but shall notify and keep
the unnamed Party apprised in writing of such action and shall consider and take into account the unnamed Party’s reasonable interests and requests and suggestions regarding the defense of such action. In the event of a Third Party
Infringement Action against both Parties, the Parties shall attempt to mutually agree as to which Party shall control the defense of such Third Party Infringement Action; provided that, in the event of the failure of the Parties to so
mutually agree, [**] in which the suit arises shall have the right to control the defense of such Third Party Infringement Action. 

(ii)    The non-controlling Party of a Third Party Infringement Action shall reasonably cooperate with
the controlling Party in the preparation and formulation of a defense to such Third Party Infringement Action, and in taking other steps reasonably necessary to respond to such Third Party Infringement Action. The controlling Party shall have
the right to select its counsel for the defense to such Third Party Infringement Action, which counsel must be reasonably acceptable to the non-controlling Party if both Parties have been named as defendants in the action. The non-controlling
Party shall also have the right to participate and be represented in any such suit by its own counsel at its own expense (and which shall not be a Patent and Trademark Enforcement Cost or other cost that is a factor in the calculation of Profit or
Loss). The controlling Party shall not (and shall cause its Affiliates and Licensee Partners not to) either (A) admit infringement, validity or enforceability of the asserted intellectual property rights, (B) pay any amount of money in
settlement thereof, unless the controlling Party does not claim the payment as a Patent and Trademark Enforcement Cost or other cost that is a factor in the calculation of Profit or Loss, or (C) enter into a license for the asserted intellectual
property rights upon terms that would restrict either Party from fully exploiting such rights consistently with the scope of the rights and obligations of both Parties under this Agreement, in each case (A) through (C), without the written consent
of the non-controlling Party, which will not be unreasonably withheld, conditioned or delayed. For the avoidance of doubt, except as provided in the foregoing clause (B), the costs of such defense and settlement (if approved by the
non-controlling Party) shall be deemed Patent and Trademark Enforcement Costs that are factored into the calculation of Profit or Loss. 

  
 - 60 - 

 (iii)    If the Party entitled to control the defense under
Section 10.4(a)(i) or (ii) fails to proceed in a timely manner with respect to such defense, the other Party shall have the right to control the defense of such claim upon the same conditions set forth therein. 

(iv)    If requested by the Party controlling the defense, the Parties shall enter into a joint defense
agreement that further outlines their rights and responsibilities consistent with the terms of this Section or as otherwise mutually agreed. 

(b)    Patent Invalidity Claim. If a Third Party at any time asserts a claim that any issued
Agios Patent, Celgene Collaboration Patent or Agios Co-Co Collaboration Patent (including Joint Collaboration Patents) is invalid or otherwise unenforceable (an “Invalidity Claim”), whether as a defense in an infringement
action brought by Agios or Celgene pursuant to Section 10.3(b) or (d), in a declaratory judgment action or in a Third Party Infringement claim brought against Agios or Celgene, the Parties shall cooperate with each other in preparing and formulating
a response to such Invalidity Claim; provided that, subject to the terms and conditions of any Existing Third Party Agreement or Subsequent Third Party Agreement to the extent such agreement applies to such Agios Patent, Agios Co-Co
Collaboration Patent or Celgene Collaboration Patent, the Party who has (or would have) control over litigation pursuant to Section 10.3(b) or (d) shall have the sole right to control the defense and settlement of any such Invalidity Claim as if it
were litigation initiated therein. For the avoidance of doubt, any claim asserted against any Agios Patent, Celgene Collaboration Patent or Agios Co-Co Collaboration Patent before any such Patent is issued is deemed a Prosecution matter that is
the subject of Section 10.2.
 Section 10.5    Patent Term Extensions. The JPC shall, as
necessary and appropriate, use reasonable efforts to agree upon a joint strategy for obtaining, and cooperate with each other in obtaining, patent term extensions for Agios Patents, Agios Co-Co Collaboration Patents, Celgene Collaboration Patents
and Joint Collaboration Patents that Cover Licensed Products. If the JPC is unable to agree upon which of such Patents should be extended, and the matter remains unresolved after the procedure described in Section 2.2(e), then [**] shall have
the right to resolve the dispute, subject in each case to the terms and conditions of any Existing Third Party Agreement or Subsequent Third Party Agreement to the extent such agreement applies to such Agios Patent, Agios Co-Co Collaboration Patent
or Celgene Collaboration Patent.
 Section 10.6    Patent Marking. Each Party shall comply
with the patent marking statutes in each country in which the Licensed Product is Manufactured or Commercialized by or on behalf of a Party or their respective Affiliates or sublicensees, as applicable, hereunder. 

Section 10.7    Application of 35 U.S.C. § 102(c). It is agreed and
acknowledged that this Agreement establishes a qualifying collaboration within the scope of 35 U.S.C. § 102(c) and, accordingly, shall be deemed to constitute a “Joint Research Agreement” for all purposes under 35 U.S.C. §
102(c). Neither Party shall invoke the provisions of 35 U.S.C. § 102(c), or file this Agreement, in connection with the prosecution of any patent application claiming, in whole or in part, any 35 U.S.C. § 102(c) invention without the
prior written consent of the other Party. In the 

  
 - 61 - 

 
event that a Party, during the course of prosecuting a patent application claiming a 35 U.S.C. § 102(c) invention (a “35 U.S.C. § 102(c) Patent”), deems it necessary to
file a terminal disclaimer to overcome an obviousness type double patenting rejection in view of an earlier filed patent held by the other Party (the “Earlier Patent”), then, if the Parties agree, the Parties shall coordinate the
filing of such terminal disclaimer in good faith, and, to the extent required under 35 U.S.C. § 102(c), both Parties shall agree, in such terminal disclaimer, that they shall not separately enforce 35 U.S.C. § 102(c) Patent independently
from the Earlier Patent. To this end, to the extent required under 35 U.S.C. § 102(c), following the filing of such terminal disclaimer, the Parties shall, in good faith, coordinate all enforcement actions with respect to 35 U.S.C. §
102(c) Patent. 
 Article XI 

Confidentiality 

Section 11.1    Confidential Information. Each Party agrees that a Party (the
“Receiving Party”) receiving Confidential Information of any other Party (the “Disclosing Party”) shall (a) maintain in confidence such Confidential Information using not less than the efforts such Receiving Party
uses to maintain in confidence its own proprietary information of similar kind and value, but in no event less than a reasonable degree of effort, (b) not disclose such Confidential Information to any Third Party without the prior written consent of
the Disclosing Party, except for disclosures expressly permitted below, and (c) not use such Confidential Information for any purpose except those permitted by this Agreement (it being understood that this clause (c) shall not create or imply any
rights or licenses not expressly granted under this Agreement). All Confidential Information of the Disclosing Party shall not be used by the Receiving Party except in performing its obligations or exercising rights explicitly granted
under this Agreement, except to the extent that the Confidential Information: 
 (a)    was known by
the Receiving Party or its Affiliates prior to its date of disclosure to the Receiving Party, as established by written evidence; or 

(b)    is lawfully disclosed to the Receiving Party or its Affiliates by sources other than the
Disclosing Party rightfully in possession of the Confidential Information; or 
 (c)    becomes
published or generally known to the public through no fault or omission on the part of the Receiving Party, its Affiliates or its sublicensees; or 

(d)    is independently developed by or for the Receiving Party or its Affiliates without reference to or
reliance upon such Confidential Information, as established by written records. 
 Section
11.2    Permitted Disclosure. The Receiving Party may provide the Disclosing Party’s Confidential Information: 

(a)    to the Receiving Party’s respective employees, consultants and advisors, and to the
employees, consultants and advisors of such Party’s Affiliates, who have a need to know such information and materials for performing obligations or exercising rights expressly granted under this Agreement and have an obligation to treat such
information and materials as confidential; 

  
 - 62 - 

 (b)    to patent offices in order to seek or obtain Patents
or to Regulatory Authorities in order to seek or obtain approval to conduct Clinical Trials or to gain Regulatory Approval with respect to the Licensed Products as contemplated by this Agreement; provided that such disclosure may be
made only following reasonable notice to the Disclosing Party and to the extent reasonably necessary to seek or obtain such Patents or Regulatory Approvals; or 

(c)    if such disclosure is required by judicial order or applicable Law or to defend or prosecute
litigation or arbitration; provided that, prior to such disclosure, to the extent permitted by Law, the Receiving Party promptly notifies the Disclosing Party of such requirement, cooperates with the Disclosing Party to take whatever
action it may deem appropriate to protect the confidentiality of the information and furnishes only that portion of the Disclosing Party’s Confidential Information that the Receiving Party is legally required to furnish. 

Section 11.3    Publicity; Terms of this Agreement; Non-Use of Names. 

(a)    Public Announcements. Except as required by judicial order or applicable Law (in which
case, Section 11.3(b) must be complied with) or as explicitly permitted by this Article XI, neither Party shall make any public announcement concerning this Agreement without the prior written consent of the other Party, which consent shall not be
unreasonably withheld or delayed. The Party preparing any such public announcement shall provide the other Party with a draft thereof at least [**] prior to the date on which such Party would like to make the public announcement (or, in
extraordinary circumstances, such shorter period as required to comply with applicable Law). Notwithstanding the foregoing, the Parties shall issue a press release, in the form attached as Exhibit F to this Agreement within [**] after
the Effective Date. Neither Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity or news release relating to this Agreement or its subject matter, without the prior express written
permission of the other Party. For purposes of clarity, either Party may issue a press release or public announcement or make such other disclosure relating to this Agreement if the contents of such press release, public announcement or
disclosure (i) (A) does not consist of financial information and has previously been made public other than through a breach of this Agreement by the issuing Party or its Affiliates, (B) is contained in such Party’s financial statements
prepared in accordance with Accounting Standards, or (C) is contained in the a redacted version of this Agreement, and (ii) is material to the event or purpose for which the new press release or public announcement is made. 

(b)    Notwithstanding the terms of this Article XI: 

(i)    Either Party shall be permitted to disclose the existence and terms of this Agreement to the
extent required, in the reasonable opinion of such Party’s legal counsel, to comply with applicable Laws, including the rules and regulations promulgated by the Securities and Exchange Commission or any other governmental
authority. Notwithstanding the foregoing, before disclosing this Agreement or any of the terms hereof pursuant to this Section 11.3(b)(i), the Parties will coordinate in advance with each other in connection with the redaction of certain
provisions of this Agreement with respect to any filings with the US Securities and Exchange Commission (“SEC”), London Stock Exchange, the UK Listing Authority, NYSE, the NASDAQ Stock Market or any other stock exchange on which
securities issued by a Party or a 

  
 - 63 - 

 
Party’s Affiliate are traded (the “Redacted Version”), and each Party will use commercially reasonable efforts to seek confidential treatment for such terms as may be
reasonably requested by the other Party; provided that the Parties will use commercially reasonable efforts to file redacted versions with any governing bodies which are consistent with the Redacted Version. 

(ii)    Notwithstanding Section 11.1, the Receiving Party may disclose Confidential Information belonging
to the Disclosing Party, and Confidential Information deemed to belong to both the Disclosing Party and the Receiving Party, to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances: 

(A)    subject to Section 11.3(a), complying with applicable Laws (including the rules and regulations of
the SEC or any national securities exchange) and with judicial process, if in the reasonable opinion of the Receiving Party’s counsel, such disclosure is necessary for such compliance; 

(B)    disclosure, solely on a “need to know basis,” to (1) Affiliates, subcontractors,
advisors (including attorneys and accountants), (2) subject to Section 11.3(b)(ii)(C), investment bankers, and (3) in each case of (1) and (2), their and each of the Parties’ respective directors, employees, contractors and agents;
provided that, in all cases of (1), (2) and (3), prior to any such disclosure, each disclosee must be bound by written obligations of confidentiality, non-disclosure and non-use no less restrictive than the obligations set forth in
this Article XI (provided, however, that in the case of prospective investment bankers, the term of confidentiality may be [**] from the date of disclosure and in the case of legal advisors, no written agreement shall be required), which for the
avoidance of doubt, will not permit use of such Confidential Information for any purpose except those permitted by this Agreement; provided, however, that, in each of the above situations, the Receiving Party shall remain responsible for any failure
by any Person who receives Confidential Information pursuant to this Section 11.3(b)(ii)(B) to treat such Confidential Information as required under this Article XI; and 

(C)    in the case of any disclosure of this Agreement to any actual or potential acquirer, assignee,
licensee, licensor, investment banker, institutional investor, lender or other financial partners, such disclosure shall solely be [**]; it being understood and agreed that, in connection with a proposed [**] with respect to such Party, only [**]
this Agreement as applicable, to such Third Party; provided that a Party may also disclose an unredacted version of this Agreement to Third Party attorneys, professional accountants and auditors who are engaged by licensors and lenders
and who are under obligations of confidentiality not to disclose the unredacted terms of this agreement to such licensors or lenders for the purpose of confirming such Party’s compliance with the terms of its applicable license and loan
agreements with such licensors and lenders.
 (iii)    [**]. Such disclosures may include
achievement of milestones, significant events in the development and regulatory process, commercialization activities and the like. In addition to the initial press release described in Section 11.3(a), a Party (the “Requesting
Party”) may elect to make any such public disclosure of such achievement of milestones, significant events in the development and regulatory process and commercialization activities, and in such event it shall first notify the other Party
(the “Cooperating Party”) of such 

  
 - 64 - 

 
planned press release or public announcement and provide a draft for review at least [**] in advance of issuing such press release or making such public announcement (or, with respect to press
releases and public announcements that are required by applicable Law, or by regulation or rule of any public stock exchange (including NASDAQ), with as much advance notice as possible under the circumstances if it is not possible to provide notice
at least [**] in advance); provided, however, that a Party may issue such press release or public announcement without such prior review by the other Party if (A) the contents of such press release or public announcement have
previously been made public other than through a breach of this Agreement by the issuing Party and (B) such press release or public announcement does not materially differ from the previously issued press release or other publicly available
information. The Cooperating Party may notify the Requesting Party of any reasonable objections or suggestions that the Cooperating Party may have regarding the proposed press release or public announcement, and the Requesting Party shall
reasonably consider any such objections or suggestions that are provided in at timely manner. The principles to be observed in such disclosures shall include accuracy, compliance with applicable Law and regulatory guidance documents, reasonable
sensitivity to potential negative reactions of the FDA (and its foreign counterparts) and the need to keep investors informed regarding the Requesting Party’s business. 

Section 11.4    Publications. The Parties agree that decisions regarding the timing and
content of Publications shall be subject to the oversight and approval of the JSC and JPC and neither Party nor its Affiliates shall have the right to make Publications pertaining to the Collaboration except as provided herein. If a Party or
its Affiliates desire to make a Publication, such Party must comply with the following procedure: 

(a)    JSC Review. The publishing Party shall provide the JSC and the non-publishing Party
with an advance copy of the proposed Publication, and the JSC shall then have [**] prior to submission for any Publication ([**] in the case of an abstract or oral presentation) in which to determine whether the Publication may be published and
under what conditions, including (i) delaying sufficiently long to permit the timely preparation and filing of a patent application or (ii) specifying changes the JSC reasonably believes are necessary to preserve any Patents or Know-How belonging
(whether through ownership or license, including under this Agreement) in whole or in part to the non-publishing Party. 

(b)    Removal of Confidential Information. In addition, if the non-publishing Party informs
the publishing Party that such Publication, in the non-publishing Party’s reasonable judgment, discloses any Confidential Information of the non-publishing Party or could be expected to have a material adverse effect on any Know-How which is
Confidential Information of the non-publishing Party, such Confidential Information or Know-How shall be deleted from the Publication. 

(c)    Scientific Conferences. Each Party shall have the right to present its Publications
approved pursuant to this Section 11.4 at scientific conferences, including at any conferences in any country in the world, subject to any conditions imposed by the JSC in its approval. 

  
 - 65 - 

 (d)    Academic Publications. Notwithstanding
the foregoing, the Parties acknowledge that, to the extent that any Publication relates to Agios Intellectual Property that is subject to an Existing Third Party Agreement, the parties to such Existing Third Party Agreement may have retained the
right to publish certain information, and nothing in this Section 11.4 is intended to restrict the exercise of such rights; provided that, to the extent that Agios has the right to review and comment on any such publications, Agios
shall, to the extent permissible under such Existing Third Party Agreement, exercise such rights after consultation with Celgene. 

(e)    Delegation. For purposes of convenience, the JSC may delegate its responsibilities
under this Section 11.4 to one or more representatives of Agios and Celgene. 
 Section
11.5    Term. All obligations under Sections 11.1, 11.2, 11.3 and 11.6 shall survive termination or expiration of this Agreement and shall expire [**] following termination or expiration of this Agreement. 

Section 11.6    Return of Confidential Information. 

(a)    Obligations to Return or Destroy. Upon the expiration or termination of this
Agreement, the Receiving Party shall return to the Disclosing Party all Confidential Information received by the Receiving Party from the Disclosing Party (and all copies and reproductions thereof). In addition, the Receiving Party shall
destroy: 
 (i)    any notes, reports or other documents prepared by the Receiving Party which contain
Confidential Information of the Disclosing Party; and 
 (ii)    any Confidential Information of the
Disclosing Party (and all copies and reproductions thereof) which is in electronic form or cannot otherwise be returned to the Disclosing Party. 

(b)    Destruction. Alternatively, upon written request of the Disclosing Party, the
Receiving Party shall destroy all Confidential Information received by the Receiving Party from the Disclosing Party (and all copies and reproductions thereof) and any notes, reports or other documents prepared by the Receiving Party which contain
Confidential Information of the Disclosing Party. Any requested destruction of Confidential Information shall be certified in writing to the Disclosing Party by an authorized officer of the Receiving Party supervising such destruction. 

(c)    Limitation. Nothing in this Section 11.6 shall require the alteration, modification,
deletion or destruction of archival tapes or other electronic back-up media made in the ordinary course of business; provided that the Receiving Party shall continue to be bound by its obligations of confidentiality and other
obligations under this Article XI with respect to any Confidential Information contained in such archival tapes or other electronic back-up media. 

(d)    Exceptions. Notwithstanding the foregoing, 

(i)    the Receiving Party’s legal counsel may retain one copy of the Disclosing Party’s
Confidential Information solely for the purpose of determining the Receiving Party’s continuing obligations under this Article XI; and 

  
 - 66 - 

 (ii)    the Receiving Party may retain the Disclosing
Party’s Confidential Information and its own notes, reports and other documents 
 (A)    to the
extent reasonably required (1) to exercise the rights and licenses of the Receiving Party expressly surviving expiration or termination of this Agreement; or (2) to perform the obligations of the Receiving Party expressly surviving expiration or
termination of this Agreement; or 
 (B)    to the extent it is impracticable to do so without
incurring disproportionate cost. 
 Notwithstanding the return or destruction of the Disclosing Party’s Confidential Information, the
Receiving Party shall continue to be bound by its obligations of confidentiality and other obligations under this Article XI. 
 Article
XII 
 Representations and Warranties 

Section 12.1    Mutual Representations. Agios and Celgene each represents, warrants and
covenants to the other Party, as of the Execution Date, that: 
 (a)    Authority. Each
Party is duly organized, validly existing and in good standing under the Laws of the jurisdiction of its formation and has full corporate power and authority to enter into this Agreement, and to carry out the provisions hereof or thereof, as
applicable. 
 (b)    Consents. All necessary consents, approvals and authorizations of all
government authorities and other Persons required to be obtained by it as of the Execution Date in connection with the execution, delivery and performance of this Agreement, and the performance of its obligations hereunder or thereunder, as
applicable, have been obtained, except for authorizations and consents that may be necessary under Antitrust Law. 

(c)    No Conflict. Notwithstanding anything to the contrary in this Agreement, the execution and
delivery of this Agreement, the performance of such Party’s obligations in the conduct of the Collaboration and the licenses and sublicenses to be granted pursuant to this Agreement (i) do not and will not conflict with or violate any
requirement of applicable Laws existing as of the Execution Date and (ii) do not and will not conflict with, violate, breach or constitute a default under any agreement or any provision thereof, or any contract, oral or written, to which it is a
party or by which it or any of its Affiliates is bound, existing as of the Execution Date. 

(d)    Enforceability. This Agreement has been duly executed and delivered on behalf of each Party
and is a legal and valid obligation binding upon it and is enforceable in accordance with its terms. 

(e)    Employee Obligations. To its knowledge, none of its or its Affiliates’ employees who
have been, are or will be involved in the Collaboration are, as a result of the nature of such Collaboration to be conducted by the Parties, in violation of any covenant in any contract with a Third Party relating to non-disclosure of proprietary
information, noncompetition or non-solicitation. 

  
 - 67 - 

 Section 12.2    Additional Agios Representations.
Agios represents, warrants and covenants to Celgene, as of the Execution Date, as follows: [**] 

(a)    Agios has all rights, authorizations and consents necessary to grant all rights and licenses it
purports to grant to Celgene under this Agreement, except for authorizations and consents that may be necessary under Antitrust Law. 

(b)    Agios has not used, and during the Term will not knowingly use, any Know-How in a Program
conducted by Agios that is encumbered by any contractual right of or obligation to a Third Party that conflicts or interferes with any of the rights or licenses granted or to be granted to Celgene hereunder. 

(c)    Agios has not granted, and during the Term Agios will not grant, any right or license, to any
Third Party relating to any of the intellectual property rights it Controls, that conflicts with or limits the scope of the rights or licenses granted or to be granted to Celgene hereunder. 

(d)    There are no claims, litigations, suits, actions, disputes, arbitrations, or legal, administrative
or other proceedings or governmental investigations pending or, to Agios’ knowledge, threatened against Agios, nor is Agios a party to any judgment or settlement, which would be reasonably expected to adversely affect or restrict the ability of
Agios to consummate the transactions contemplated under this Agreement and to perform its obligations under this Agreement, or which would affect the Agios Intellectual Property, or Agios’ Control thereof, or any Target or Compound.* 

(e)    To Agios’ knowledge, the practice of the Agios Intellectual Property as contemplated under
this Agreement does not (i) infringe any claims of any Patents of any Third Party, or (ii) misappropriate any Know-How of any Third Party.* 

(f)    None of (i) the Agios Patents owned by Agios or both Controlled by and Prosecuted by Agios and
(ii) to Agios’ knowledge, the Agios Patents Controlled but not Prosecuted by Agios are subject to any pending re-examination, opposition, interference or litigation proceedings.* 

(g)    To the knowledge of Agios, the Agios Patents Controlled by Agios or any Affiliate pursuant to any
Existing Third Party Agreement were not and are not subject to any restrictions or limitations except as set forth in the Existing Third Party Agreements. 

(h)    Agios has and, to Agios’ knowledge, the applicable licensor under each Existing Third Party
Agreement has, complied with any and all obligations under the Bayh-Dole Act to perfect rights to the applicable Patent Rights or Know-How licensed thereunder.* Neither Agios nor any of its Affiliates has granted any liens or security interests on
the Agios Intellectual Property and the Agios Intellectual Property is free and clear of any mortgage, pledge, claim, security interest, covenant, easement, encumbrance, lien or charge of any kind, except in each case with respect to licenses,
covenants not to sue, immunities from suit, standstills, releases and options which would not, in the aggregate, fundamentally frustrate the purposes of the Collaboration. 

  
 - 68 - 

 (i)    Schedule 12.2(i) contains a complete and
accurate list of all Patents owned by Agios and/or its Affiliates as of the Execution Date that are included in the Patents licensed hereunder, indicating any co-owner(s), if applicable. Except as set forth on Schedule 12.2(i), Agios and
its Affiliates do not own any Patent that is necessary or, to Agios’ reasonable belief as of the Execution Date, reasonably useful to research, Develop, Manufacture or Commercialize any Compounds or Licensed Products. 

(j)    Schedule 12.2(j) sets forth a complete and accurate list of all Existing Third Party
Agreements, true and correct copies of which have been provided to Celgene, and such agreements are in full force and effect and have not been modified or amended. Neither Agios nor, to the knowledge of Agios, any licensor under the Existing Third
Party Agreements is in default with respect to a material obligation under, and none of such parties has claimed or has grounds upon which to claim that the other party is in default with respect to a material obligation under, the Existing Third
Party Agreements.* 
 (k)    Except under the Existing Third Party Agreements in effect as of the
Execution Date, and except as set forth on Schedule 12.2(j), Agios and its Affiliates are not subject to any payment obligations to Third Parties as a result of the execution or performance of this Agreement. 

Section 12.3    Covenants. 

(a)    Mutual Covenants. Each Party hereby covenants to the other Party that: 

(i)    all employees of such Party or its Affiliates or Third Party subcontractors working under this
Agreement will be under appropriate confidentiality provisions at least as protective as those contained in this Agreement and, to the extent permitted under applicable Law, the obligation to assign all right, title and interest in and to their
inventions and discoveries, whether or not patentable, to such Party as the sole owner thereof; 

(ii)    to its knowledge, such Party will not (A) employ or use, nor hire or use any contractor or
consultant that employs or uses, any individual or entity, including a clinical investigator, institution or institutional review board, debarred or disqualified by the FDA (or subject to a similar sanction by any Regulatory Authority outside the
United States) or (B) employ any individual who or entity that is the subject of an FDA debarment investigation or proceeding (or similar proceeding by any Regulatory Authority outside the United States), in each of subclauses (A) and (B) in the
conduct of its activities under this Agreement 
 (iii)    neither such Party nor any of its Affiliates
shall, during the Term, grant any right or license to any Third Party relating to any of the intellectual property rights it owns or Controls which would conflict with any of the rights or licenses granted to the other Party hereunder; and 

  
 - 69 - 

 (iv)    such Party and its Affiliates shall perform its
activities pursuant to this Agreement, in compliance (and shall ensure compliance by any of its subcontractors) in all material respects with all applicable Laws, including GCP, GLP and GMP as applicable and with respect to the Development,
Manufacturing and Commercialization activities hereunder. 
 (b)    Third Party Agreement
Covenants. Agios hereby covenants to Celgene that Agios shall maintain the Existing Third Party Agreements and each Party hereby covenants to the other Party that it shall maintain any Subsequent Third Party Agreements, and shall not amend
or terminate such agreements entered into by such Party, and will not breach such agreements, if such amendment, modification, termination or breach would adversely affect the other Party’s rights under this Agreement.

Section 12.4    Agios Covenants During the Term. Except to the extent expressly permitted
under Section 8.6, during the Term, neither Agios nor its Affiliates will, other than to an Affiliate of Agios who agrees in writing to be bound by the terms and conditions of this Agreement (a) assign, transfer, convey, encumber (including any
liens or charges, but excluding any licenses, which are the subject of subsection (b), below) or dispose of, or enter into any agreement with any Third Party to assign, transfer, convey, encumber (including any liens or charges, but excluding any
licenses, which are the subject of subsection (b), below) or dispose of, any assets specifically related to this Agreement, including with respect to the Compound(s), any Licensed Product(s) and any then-identified Companion Diagnostic(s) developed
therefor, or pre-clinical study or Clinical Trial results or other data specifically related to such Program, or any intellectual property specifically related to any of the foregoing (with respect to each Program, the “Agios Program
Assets”), except to the extent such assignment, transfer, conveyance, encumbrance or disposition would not fundamentally frustrate the purpose of this Agreement with respect to such Program, (b) license or grant to any Third Party, or agree
to license or grant to any Third Party, any rights to any Agios Program Assets if such license or grant would fundamentally frustrate the purpose of this Agreement with respect to such Program, or (c) disclose any Confidential Information relating
to the Agios Program Assets to any Third Party if such disclosure would fundamentally frustrate the purpose of this Agreement with respect to such Program. Agios and/or its Affiliates shall have the right to assign, transfer, convey or dispose
of any assets specifically related to such Program to any Affiliate of Agios to the extent permitted under Section 15.4. 

Section 12.5    Disclaimer. Except as otherwise expressly set forth in this Agreement, NEITHER
PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY THAT ANY PATENTS ARE VALID OR ENFORCEABLE, AND EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING IMPLIED WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. Without limiting the generality of the foregoing, each Party disclaims any warranties with regards to: (a) the success of any study or test commenced under this Agreement; (b)
the safety or usefulness for any purpose of the technology or materials, including any Compound, Licensed Product or Companion Diagnostic; and/or (c) the validity, enforceability, or non-infringement of any intellectual property rights or technology
it provides or licenses to the other Party under this Agreement. 

  
 - 70 - 

 Section 12.6    Additional Celgene
Representations. Celgene represents and warrants to Agios, as of the Execution Date that Celgene possesses sufficient rights to enable Celgene to grant all rights and licenses it purports to grant to Agios under this Agreement as of the
Execution Date. 
 Article XIII 

Indemnification; Product Liabilities 

Section 13.1    By Celgene. 

(a)    Celgene Indemnification Obligation. Celgene agrees, at Celgene’s cost and
expense, to defend, indemnify and hold harmless Agios and its Affiliates and their respective directors, officers, employees and agents (the “Agios Indemnified Parties”) from and against any Damages arising out of any Third Party
claim relating to: 
 (i)    any breach by Celgene of any of its representations, warranties or
obligations pursuant to this Agreement; or 
 (ii)    the gross negligence, or willful misconduct or
violation of Law of Celgene or its Affiliates. 
 (b)    Indemnification Procedures. In the
event of any such claim against the Agios Indemnified Parties by any Third Party, Agios shall promptly, and in any event within [**], notify Celgene in writing of the claim. Celgene shall have the right, exercisable by notice to Agios within
[**] after receipt of notice from Agios of the claim, to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the claim (provided that such claim is solely for monetary damages and Celgene agrees to pay
all Damages relating to such matter, as evidenced in a written confirmation delivered by Celgene to Agios) with counsel selected by Celgene and reasonably acceptable to Agios; provided that the failure to provide timely notice of a
claim by a Third Party shall not limit an Agios Indemnified Party’s right for indemnification hereunder except to the extent such failure results in actual prejudice to Celgene. The Agios Indemnified Parties shall cooperate with Celgene
and may, at their option and expense, be separately represented in any such action or proceeding. Celgene shall not be liable for any litigation costs or expenses incurred by the Agios Indemnified Parties without Celgene’s prior written
authorization. In addition, Celgene shall not be responsible for the indemnification or defense of any Agios Indemnified Party to the extent arising from any negligent or intentional acts by any Agios Indemnified Party or the breach by Agios of
any representation, obligation or warranty under this Agreement, or any claims compromised or settled without its prior written consent. Each Party shall use reasonable efforts to mitigate Damages indemnified under this Section 13.1. 

Section 13.2    By Agios. 

(a)    Agios Indemnification Obligation. Agios agrees, at Agios’ cost and expense, to
defend, indemnify and hold harmless Celgene and its Affiliates and their respective directors, officers, employees and agents (the “Celgene Indemnified Parties”) from and against any Damages arising out of any Third Party claim
relating to: 
 (i)    any breach by Agios of any of its representations, warranties or obligations
pursuant to this Agreement; 

  
 - 71 - 

 (ii)    the gross negligence, willful misconduct or
violation of Law of Agios or its Affiliates; 
 (iii)    any of the matters disclosed by Agios in a
disclosure schedule pursuant to Section 12.2, where the cause of action underlying such Damages accrued prior to the Execution Date. For the avoidance of doubt, amounts payable under Subsequent Third Party Agreements shall be borne by the
Parties as set forth in Section 9.6(b), and shall not be subject to indemnification under this Section 13.2; or 

(iv)    any of the matters disclosed by Agios in a disclosure schedule pursuant to Section 12.2, where
the cause of action underlying such Damages accrued prior to the Execution Date. For the avoidance of doubt, amounts payable under Third Party licenses entered into under Section 9.6(b) shall be borne by Celgene as set forth in Section 9.6(b),
and shall not be subject to indemnification under this Section 13.2. 
 (b)    Indemnification
Procedures. In the event of any such claim against the Celgene Indemnified Parties by any Third Party, Celgene shall promptly, and in any event within [**], notify Agios in writing of the claim. Agios shall have the right, exercisable
by notice to Celgene within [**] after receipt of notice from Celgene of the claim, to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the claim (provided that such claim is solely for monetary
damages and Agios agrees to pay all Damages relating to such matter, as evidenced in a written confirmation delivered by Celgene to Agios) with counsel selected by Agios and reasonably acceptable to Celgene; provided that the failure
to provide timely notice of a claim by a Third Party shall not limit a Celgene Indemnified Party’s right for indemnification hereunder except to the extent such failure results in actual prejudice to Agios. The Celgene Indemnified Parties
shall cooperate with Agios and may, at their option and expense, be separately represented in any such action or proceeding. Agios shall not be liable for any litigation costs or expenses incurred by the Celgene Indemnified Parties without
Agios’ prior written authorization. In addition, Agios shall not be responsible for the indemnification or defense of any Celgene Indemnified Party to the extent arising from any negligent or intentional acts by any Celgene Indemnified
Party or the breach by Celgene of any representation, obligation or warranty under this Agreement, or any claims compromised or settled without its prior written consent. Each Party shall use reasonable efforts to mitigate Damages indemnified
under this Section 13.2. 
 Section 13.3    Product Liability Costs. Except with respect to
such portion (if any) of Product Liabilities that are claims entitled to indemnification under Section 13.1 or Section 13.2, the Parties shall be responsible for all Product Liabilities, all Out-of-Pocket Costs and FTE Costs incurred by the
controlling Party under Section 13.4 in connection with any litigation or proceeding related to such Third Party Products Liability Action, and all Out-of-Pocket Costs and FTE Costs incurred by the non-controlling Party under Section 13.4 at the
request of the controlling Party under Section 13.4 as follows: 
 (a)    All such costs and expenses
incurred before the Agios Opt-Out Date relating to Licensed Products distributed prior to the Agios Opt-Out Date shall be taken into account in determining Profit or Loss as, and to the extent, provided in Exhibit D. 

  
 - 72 - 

 (b)    All such costs and expenses incurred after the Agios
Opt-Out Date relating to Licensed Products shall be borne solely by Celgene if and only to the extent such Product Liabilities arose from Licensed Products distributed after the Agios Opt-Out Date. 

Section 13.4    Conduct of Product Liability Claims. 

(a)    Each Party shall promptly notify the other in the event that any Third Party asserts or files any
products liability claim or other action relating to alleged defects in the Licensed Product (whether design defects, manufacturing defects or defects in sales or marketing) (“Third Party Products Liability Action”) against such
Party. In the event of a Third Party Products Liability Action against such a single Party, the unnamed Party shall have the right, in the unnamed Party’s sole discretion, to join or otherwise participate in such legal action with legal
counsel selected by the unnamed Party and reasonably acceptable to the named Party. The Party named in such Third Party Products Liability Action shall have the right to control the defense of the action, but shall notify and keep the unnamed
Party apprised in writing of such action and shall consider and take into account the unnamed Party’s reasonable interests and requests and suggestions regarding the defense of such action; provided that, in the event of an Agios
Opt-Out Notice, Celgene shall have the right to control the defense of all Third Party Product Liability Actions after the Agios Opt-Out Date. In the event of a Third Party Products Liability Action against both Parties, unless otherwise agreed
by the Parties in writing, the Lead Party of the relevant portion of the Territory shall control the response to such Third Party Products Liability Action; provided that, in the event of an Agios Opt-Out Notice, Celgene shall have the
right to control the defense of all Third Party Product Liability Actions. 
 (b)    The
non-controlling Party of a Third Party Products Liability Action shall reasonably cooperate with the controlling Party in the preparation and formulation of a defense to such Third Party Products Liability Action, and in taking other steps
reasonably necessary to respond to such Third Party Products Liability Action. The controlling Party shall have the right to select its counsel for the defense to such Third Party Products Liability Action, which counsel must be reasonably
acceptable to the non-controlling Party. If required under applicable Law in order for the controlling Party to maintain a suit in response to such Third Party Products Liability Action, the non-controlling Party shall join as a party to the
suit. The non-controlling Party shall also have the right to participate and be represented in any such suit on a voluntary basis by its own counsel at its own expense. The controlling Party shall not settle or compromise any Third Party
Products Liability Action without the consent of the other Party, which consent shall not be unreasonably withheld. 

Section 13.5    Limitation of Liability. EXCEPT WITH RESPECT TO A BREACH OF SECTION 8.6 OR
ARTICLE XI, OR A PARTY’S LIABILITY PURSUANT TO SECTION 13.1 OR SECTION 13.2, NEITHER PARTY SHALL BE LIABLE FOR SPECIAL, CONSEQUENTIAL, EXEMPLARY, PUNITIVE, MULTIPLE OR OTHER INDIRECT OR REMOTE DAMAGES, OR FOR LOSS OF PROFITS, LOSS OF DATA OR
LOSS OF USE DAMAGES ARISING IN ANY WAY OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, WHETHER BASED UPON WARRANTY, CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES
OR LOSS. 

  
 - 73 - 

 Section 13.6    Insurance. Beginning on [**] and
thereafter during the Term, each Party shall maintain commercial general liability insurance (including product liability insurance) from a recognized, creditworthy insurance company, with coverage limits of at least [**] US Dollars ($[**]) per
claim and annual aggregate. Celgene may elect to self-insure all or parts of the limits described above. Within [**] following written request from the other Party, each Party shall furnish to the other Party a certificate of insurance
evidencing such coverage. If such coverage is modified or cancelled, the insured Party shall notify the other Party and promptly provide such other Party with a new certificate of insurance evidencing that such insured Party’s coverage
meets the requirements of this Section 13.6. 
 Article XIV 

Term and Termination 

Section 14.1    Term. The term of this Agreement (the “Term”) shall commence
on the Effective Date and shall continue, unless earlier terminated pursuant to Section 14.3 on a Licensed Product-by-Licensed Product and country-by-country basis, in full force and effect: 

(a)    as long as the Parties continue to Develop or Commercialize Licensed Products in accordance with
the terms and conditions of this Agreement; or, 
 (b)    in the event of an Agios Opt-Out Date, this
Agreement shall expire: 
 (i)    on a Licensed Product-by-Licensed Product and country-by-country
basis, upon the expiration of the applicable Royalty Term with respect to such Licensed Product in such country; and 

(ii)    in its entirety upon the expiration of all applicable Royalty Terms under this Agreement with
respect to all Licensed Products in all countries worldwide. 
 For the avoidance of doubt, this Agreement shall not be effective until the
Effective Date, and this Agreement may be subject to termination prior to the Effective Date as set forth in Section 3.2 of the Master Agreement, in which case all rights to the Program (as defined in the Master Agreement) that is the subject of
this Agreement shall revert to Agios in accordance with Section 2.12 of the Master Agreement. 
 Section
14.2    Effect of Expiration. Following any Agios Opt-Out, after the expiration of the Term pursuant to Section 14.1(b) above, the following terms shall apply: 

(a)    Licenses after Licensed Product Expiration. After expiration of the Term (but not
after early termination) with respect to any Licensed Product in a country in the world pursuant to Section 14(b)(i), Celgene’s rights and licenses hereunder under the Agios Intellectual Property, Agios Co-Co Collaboration Intellectual Property
and Agios’ rights in the Joint Collaboration IP to develop, manufacture, have manufactured, use, offer for sale, sell, import and otherwise commercialize such Licensed Product and related Companion Diagnostics in the Field in such country, for
so long as it continues to do so, shall convert to irrevocable, non-terminable rights and licenses, with the right to grant sublicenses; provided that, following such expiration and notwithstanding Section 9.6(a), (i) Celgene shall be
solely responsible for all payments owed to any Third Party licensors and (ii) Celgene shall be responsible for complying with the terms of any license agreements with such Third Party licensors, in each case ((i) and (ii)), solely with respect to
Celgene’s exercise of such rights. 

  
 - 74 - 

 (b)    Licenses after Expiration of
Agreement. After expiration of the Term (but not after early termination) with respect to this Agreement in its entirety pursuant to Section 14.1(b)(ii), Celgene’s rights and licenses hereunder under the Agios Intellectual Property,
Agios Co-Co Collaboration Intellectual Property and Agios’ rights in the Joint Collaboration IP to develop, manufacture, have manufactured, use, offer for sale, sell, import and otherwise commercialize Licensed Products and Companion
Diagnostics in the Field worldwide, for so long as it continues to do so, shall convert to irrevocable, non-terminable rights and licenses, with the right to grant sublicenses; provided that, following such expiration and
notwithstanding Section 9.6(a), (i) Celgene shall be solely responsible for all payments owed to any Third Party licensors and (ii) Celgene shall be responsible for complying with the terms of any license agreements with such Third Party licensors,
in each case, ((i) and (ii)), solely with respect to Celgene’s exercise of such rights. 
 Section
14.3    Termination. 
 (a)    Termination for
Convenience. Celgene shall have the right to terminate this Agreement in its entirety for convenience upon [**] prior written notice to Agios; provided that Celgene shall not have the right to terminate this Agreement until
[**] following the Effective Date (it being understood and agreed that Celgene shall be entitled to terminate upon [**] written notice at any time it reasonably determines that such termination is necessary to comply with any Antitrust Law). 

(b)    Termination for Material Breach. 

(i)    Termination by Either Party for Breach. Subject to Section 14.3(b)(ii) (with respect
to a Material Breach by either Party of its obligations to use Commercially Reasonable Efforts), this Agreement and the rights granted herein may be terminated by either Party for the material breach of this Agreement in a manner that fundamentally
frustrates the transactions contemplated by this Agreement taken as a whole by the other Party to this Agreement (each, a “Material Breach”), provided that, if the breaching Party has not cured such Material Breach
within [**] after the date of written notice to the breaching Party of such breach (or [**], in the case of Celgene’s payment obligations under this Agreement or the specified time period provided in Section 14.3(b)(ii) with respect to a
Material Breach by either Party of its obligation to use Commercially Reasonable Efforts, each as applicable) (the “Cure Period”), which notice shall describe such breach in reasonable detail and shall state the non-breaching
Party’s intention to terminate this Agreement pursuant to this Section 14.3(b)(i). Notwithstanding the preceding sentence, the Cure Period for any allegation made in good faith as to a Material Breach under this Agreement will run from the date
that written notice was first provided to the breaching Party by the non-breaching Party. Any such termination of this Agreement under this Section 14.3(b)(i) shall become effective at the end of the Cure Period, unless the breaching Party has
cured any such Material Breach prior to the expiration of such Cure Period, or, if such Material Breach is not susceptible to cure within the Cure Period, then, the non-breaching Party’s right of termination shall be suspended only if and for
so long as the breaching Party has provided to the non-breaching Party a written plan that is 

  
 - 75 - 

 
reasonably calculated to effect a cure and such plan is acceptable to the non-breaching Party, and the breaching Party commits to and carries out such plan as provided to the non-breaching Party
within [**] after the date that written notice was first provided to the breaching Party by the non-breaching Party. The Parties understand and agree that the totality of this Agreement and the [**]. 

(ii)    Additional Procedures for Termination by either Party for Failure of the Other Party to Use
Commercially Reasonable Efforts. If either Party wishes to exercise its right to terminate this Agreement pursuant to Section 14.3(b)(i) for the other Party’s Material Breach of its obligations to use Commercially Reasonable Efforts,
it shall provide to such other Party a written notice of its intent to exercise such right, which notice shall be labeled as a “notice of Material Breach for failure to use Commercially Reasonable Efforts,” and shall state the reasons and
justification for such termination [**]. For any such notice of breach by a Party, the Cure Period shall, subject to Section 14.3(b)(iii), be [**], and shall become effective in accordance with Section 14.3(b)(i). 

(iii)    Disagreement as to Material Breach. If the Parties reasonably and in good faith
disagree as to whether there has been a Material Breach pursuant to Section 14.3(b) then subject to Section 15.1: (A) the Party that disputes that there has been a Material Breach may contest the allegation by referring such matter, within [**] for
resolution to the Executive Officers, who shall meet promptly to discuss the matter, and determine, within [**] following referral of such matter, whether or not a Material Breach has occurred pursuant to Section 14.3(b); (B) the relevant Cure
Period with respect thereto will be tolled from the date the breaching Party notifies the non-breaching Party of such dispute and through the resolution of such dispute in accordance with the applicable provisions of this Agreement (provided,
that if such dispute relates to payment, the Cure Period will only be tolled with respect to payment of disputed amounts, and not with respect to undisputed amounts), (C) it is understood and agreed that during the pendency of such dispute, all of
the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder) and (D) if it is finally and conclusively determined in accordance with Section 15.2 that the
breaching Party committed such Material Breach, then the breaching Party shall have the right to cure such Material Breach after such determination within the Cure Period [**]. 

(iv)    If the Executive Officers are unable to resolve a dispute within such [**] period after it is
referred to them, the matter will be resolved as provided in Section 15.1. 

(v)    Payments. No milestone payments by Celgene will be due on milestones achieved during
the period between the notice of termination under Section 14.3(b) and the effective date of termination; provided, however, if either Party provides notice of a dispute pursuant to Section 14.3(b) or otherwise and such dispute is resolved in a
manner in which no termination of this Agreement occurs with respect to such breach or the breaching Party cures the applicable breach during the Cure Period, then upon such resolution or cure Celgene will within [**] pay to Agios the applicable
milestone payment for each milestone achieved during the period between the notice of termination under Section 14.3(b) and the resolution of such dispute or cure of such breach, and if it was determined that Celgene wrongly asserted breach by Agios
under Section 14.3(b), then Celgene shall also pay interest on such amount as provided in Section 9.11. 

  
 - 76 - 

 (c)    Termination for Insolvency. To the extent
permitted by Law, this Agreement may be terminated by either Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of
creditors by the other Party; provided, however, that, in the event of any involuntary bankruptcy or receivership proceeding such right to terminate shall only become effective if the Party consents to the involuntary bankruptcy
or receivership or such proceeding is not dismissed within ninety (90) days after the filing thereof. 

(d)    Termination for Patent Challenge. Either Party shall have the right to terminate this
Agreement solely on a Licensed Product-by-Licensed Product basis upon written notice if the other Party or any of its Affiliates challenges the validity, scope or enforceability of or otherwise opposes any Patent (i) included in the Agios
Intellectual Property or Agios Co-Co Collaboration Intellectual Property and that is licensed to Celgene under this Agreement in any action or proceeding, or (ii) included in the Celgene Intellectual Property or Celgene Collaboration Intellectual
Property that is licensed to Agios under this Agreement in any action or proceeding (subject to the exceptions described in this Section 14.3(d), a “Challenge”) (other than as may be necessary or reasonably required to assert a
defense, cross-claim or a counter-claim in an action or proceeding asserted by either Party or any of its Affiliates or Licensee Partners against the other Party or any of its Affiliates or to respond to a court request or order or administrative
law, request or order) it being understood and agreed that either Party’s right to terminate this Agreement under this Section 14.3(d) shall not apply to any actions undertaken by an Affiliate of the other Party (the “Challenging
Party”) that first becomes such an Affiliate as a result of a Change of Control involving the Challenging Party, where such new Affiliate was undertaking any of the activities described in the foregoing clause prior to such Change of
Control; provided that a Party’s right to terminate this Agreement under this Section 14.3(d) shall apply to actions undertaken by such new Affiliate if the Challenging Party is the acquiror in such Change of Control and such
new Affiliate does not terminate or otherwise cease participating in such action, proceeding, challenge or opposition within [**] after the effective date of such Change of Control. If a Licensee Partner of either Party challenges the validity,
scope or enforceability of or otherwise opposes any Patent included in any of the intellectual property described in this Section 14.3(d) under which such Sublicensee is sublicensed in any action or proceeding, then the Party that granted such
sublicense shall, upon written notice from the other Party, terminate such sublicense. For the avoidance of doubt, an action by a Party or any of its Affiliates (collectively the “Pursuing Party”) in accordance with this Agreement
and the Master Agreement to amend claims within a pending patent application of the other Party during the course of the Pursuing Party’s Prosecution of such pending patent application or in defense of a Third Party proceeding, or to make a
negative determination of patentability of claims of a patent application of the other Party or to abandon a patent application of the other Party during the course of the Pursuing Party’s Prosecution of such pending patent application, shall
not constitute a challenge under this Section 14.3(d). Neither Party shall, and each Party shall ensure that its Affiliates and Licensee Partners do not, use or disclose any Confidential Information of the other Party or any nonpublic
information regarding the Prosecution or enforcement of any Agios Patent, Celgene Collaboration Patent or Agios Co-Co Collaboration Patent (including Joint Collaboration Patents) to which a Party or any of its Affiliates or

  
 - 77 - 

 
sublicensees are or become privy as a consequence of the rights granted to such Party pursuant to Article X, in initiating, requesting, making, filing or maintaining, or in funding or otherwise
assisting any other Person with respect to, any Challenge. 
 Section 14.4    Effects Of
Termination. 
 (a)    Effects of Celgene Termination for Convenience or Agios Termination for
Celgene Breach, Insolvency or Patent Challenge. Upon termination of this Agreement by Celgene under Section 14.3(a) or by Agios under Section 14.3(b), 14.3(c) or 14.3(d), the following shall apply: 

(i)    all licenses granted by Agios to Celgene under Section 8.1(a) shall terminate in their entirety if
pursuant to Section 14.3(a), Section 14.3(b) or Section 14.3(c), and (ii) with respect to the corresponding Compound and Licensed Product if pursuant to Section 14.3(d), and all licenses granted by Celgene to Agios under Section 8.1(b)(i) shall
convert to worldwide licenses as if Agios were the Lead Party worldwide and otherwise remain in effect, and, from and after such termination, Agios shall pay Celgene royalties on Annual Net Sales of Licensed Products pursuant to Section 9.5,
reducing such royalties by [**] percent ([**]%) and substituting “Agios” for “Celgene” and vice versa with respect to all obligations and definitions, and otherwise mutatis mutandis, with the Agios Opt-Out Date, as used
therein, deemed to be the effective date of termination; provided that (i) Agios shall be solely responsible for all payments owed to any Third Party licensors (without any right to offset any such amounts against royalties payable to
Celgene hereunder) and (ii) Agios shall be responsible for complying with the terms of any license agreements with such Third Party licensors, in each case ((i) and (ii)), solely with respect to Agios’ exercise of such rights 

(ii)    each Party shall be released from its Development, Manufacture and Commercialization obligations
(except as set forth in Section 14.4(a)(vii) and (viii) below with respect to Celgene’s transfer of Manufacturing to Agios hereunder); 

(iii)    within [**] after such termination, unless there has been an Agios Opt-Out Date, each Party
shall provide the other with a report of Development Costs, Net Sales and Commercialization Expenses and other amounts incurred by such Party that are subject to the Parties’ cost-sharing obligations through the effective date of termination
for the purpose of calculating a final reconciliation of shared costs and payments in accordance with Section 9.2 and Section 9.4, as applicable. Each Party shall submit any supporting information reasonably requested by the other Party related
to such Development Costs, Net Sales, Commercialization Expenses and such other amounts included in such Party’s reconciliation report within [**] after the other Party’s receipt of such request. The Parties, with the assistance of
the JCC, shall conduct a final reconciliation of such costs and payments within [**] after receipt of all such supporting information, and an invoice shall be issued to the Party (if any) that owes the other Party a payment to accomplish the cost
sharing or payment envisioned under this Agreement pursuant to Section 9.2 and Section 9.4, as applicable. The paying Party shall pay all amounts payable under any such invoice within [**] after its receipt of such invoice; provided,
however, that, Celgene shall remain responsible for its applicable share of all Developments Costs and Commercialization Expenses committed prior to the effective date of termination and not cancelable by Agios, which Agios shall
reasonably seek to minimize, with respect to the 

  
 - 78 - 

 
Licensed Products to the extent such Development Costs and Commercialization Expenses (A) are within an approved Development Budget under an approved Development Plan or Commercialization Budget
under an approved Commercialization Budget, respectively, in place prior to termination and (B) are solely incurred by Agios during the period ending [**] after the effective date of termination of this Agreement. 

(iv)    within [**] after such termination, Celgene shall provide to Agios a fair and accurate summary
report of the status of Development and Commercialization activities conducted by Celgene with respect to the Licensed Products; 

(v)    Celgene shall promptly transfer and assign to Agios all of Celgene’s and its Affiliates’
rights, title and interests in and to the product trademark(s) (but not any Celgene house marks or composite marks including a house mark) owned by Celgene (if Celgene was the Lead US Party, in accordance with Section 6.4(b)) and solely used for
Licensed Products; 
 (vi)    Celgene shall as soon as reasonably practicable transfer and assign to
Agios all Regulatory Approvals of the Licensed Products, their corresponding Regulatory Documentation, and a copy of all of the data comprising the Global Safety Database; provided that Celgene may retain such data and a single copy of
such Regulatory Approvals and Regulatory Documentation for its records. Notwithstanding the foregoing, if such Regulatory Approvals or Regulatory Documentation are necessary or useful for the Development, Manufacture or Commercialization of any
product other than the Licensed Products, in place of transferring or assigning the foregoing, Celgene shall instead grant Agios a Right of Reference or Use with respect to such approvals or documentation with respect to the Licensed Products; 

(vii)    Agios shall have the option, exercisable within [**] following the effective date of such
termination of this Agreement, to obtain Celgene’s inventory of the Licensed Products at a price equal to [**] percent ([**]%) of Celgene’s Manufacturing Costs for such inventory of the Licensed Products; provided that, if
Celgene, its Affiliates or sublicensees have outstanding orders, at Agios’ election, either Agios shall fulfill such orders or, notwithstanding Agios’ option to purchase inventory, Celgene may retain sufficient inventory to fulfill such
orders. Agios may exercise such option by written notice to Celgene during such [**] period; provided that, in the event Agios exercises such right to purchase such inventory, Celgene shall grant, and hereby does grant, a
royalty-free right and license to any trademarks, names and logos of Celgene contained therein for a period of [**] solely to permit the orderly sale of such inventory, subject to Agios meeting reasonable quality control standards imposed by Celgene
on the use of such trademarks, names and logos, which shall be consistent with the standards used by Celgene prior to such termination; 

(viii)    to the extent that Celgene is responsible for Manufacturing the Licensed Products immediately
prior to such termination, at Agios’ written request: 
 (A)    in exchange for a payment equal to
[**] percent ([**]%) of Celgene’s Manufacturing Costs and upon other commercially reasonable terms as may be mutually agreed between the Parties or their respective Affiliates in a supply agreement, Celgene shall use Commercially Reasonable
Efforts to supply Agios and its Affiliates with comparable 

  
 - 79 - 

 
quantities of the Licensed Products in the form, formulation and presentation as were being Developed or Commercialized immediately prior to termination until the earlier of [**] after the
effective date of the termination and establishment by Agios of an alternative supply for such product(s); 

(B)    in the event Celgene was utilizing a Third Party manufacturer to Manufacture the Licensed
Products, to the extent permitted by the terms of such contract, Celgene shall promptly assign to Agios the manufacturing agreements with such Third Party with respect to such product(s); and 

(C)    Celgene shall transfer, or have transferred, to Agios or its designee, pursuant to a technology
transfer plan to be mutually agreed by the Parties, all Manufacturing Technology Controlled by Celgene within Celgene Collaboration Intellectual Property that is both necessary to Manufacture the Licensed Products as Manufactured by or on behalf of
Celgene and its Affiliates prior to termination and has been incorporated in regulatory documentation submitted to a Regulatory Authority in support of Development or Commercialization of the Licensed Products (or is in the process of being
incorporated), and Celgene shall provide reasonable assistance in connection with the transfer of such Manufacturing Technology to Agios or its designee, all of which shall be transferred or provided at Celgene’s Out-of-Pocket Costs; 

(ix)    separate transitional activities shall be undertaken with respect to any Companion Diagnostic(s)
to ensure that the appropriate Regulatory Approvals, Manufacturing Technology or other Know-How or Patents necessary for the Development, Manufacture or Commercialization of such Companion Diagnostic(s) shall be transferred to Agios to the same
extent as Regulatory Approvals, Manufacturing Technology or other Know-How or Patents otherwise associated with such Licensed Products are transferred; 

(x)    notwithstanding anything to the contrary in Section 8.6, Agios shall have the right to pursue the
Development, Manufacture and Commercialization of the Licensed Products; and 
 (xi)    the provisions
of Article X (other than Section 10.1) shall terminate, and Celgene shall, if applicable, provide reasonable assistance to Agios and cooperation in connection with the transition of Prosecution and enforcement responsibilities to Agios with respect
to Celgene Collaboration Patents, Agios Co-Co Collaboration Patents and Joint Collaboration Patents then being Prosecuted or enforced by Celgene, including execution of such documents as may be necessary to effect such transition. 

(b)    Effects of Celgene Termination for Agios Breach, Insolvency or Patent Challenge. Upon
any termination of this Agreement by Celgene under Section 14.3(b), 14.3(c) or 14.3(d): 
 (i)    if
Celgene has the right to terminate this Agreement pursuant to Section 14.3(b), (c) or (d), Celgene may elect, upon written notice to Agios, to either: 

(A)    terminate this Agreement in its entirety, if pursuant to Section 14.3(b) or (c), or with respect
to the corresponding Compound and Licensed Product, if 

  
 - 80 - 

 
pursuant to Section 14.3(d), in which case (1) all rights and obligations of the Parties under this Agreement or the corresponding Compound and Licensed Product, respectively, shall terminate,
except (I) Celgene’s payment obligations (accrued as of the effective date of such termination) and the audit rights set forth in Article IX, and (II) Section 14.4(d) shall, in each case (I) and (II), survive such termination, (2) Agios shall
return any Confidential Information of Celgene pursuant to Article VIII of the Master Agreement that is not necessary to practice any licenses retained by Agios following such termination under this Agreement, another Development &
Commercialization Agreement (as defined in the Master Agreement) or the Master Agreement, (3) all licenses granted by Celgene to Agios under Section 8.1(b)(i) with respect to the Licensed Product(s) that are the subject of the applicable breach by
Agios shall convert to worldwide licenses as if Agios were the Lead Party worldwide and otherwise remain in effect, and, from and after such termination, Agios shall pay Celgene royalties on Annual Net Sales of such Licensed Product(s) pursuant to
Section 9.5, reducing such royalties by [**] percent ([**]%) and substituting “Agios” for “Celgene” and vice versa with respect to all obligations and definitions, and otherwise mutatis mutandis, with the Agios Opt-Out
Date, as used therein, deemed to be the effective date of termination, under Celgene’s rights in Celgene Intellectual Property, Celgene Collaboration Intellectual Property, Joint Inventions, Joint Patents and Manufacturing Technology to
Develop, Manufacture and Commercialize Compounds and Licensed Products; provided that (I) Agios shall be solely responsible for all payments owed to any Third Party licensors (without any right to offset any such amounts against
royalties payable to Celgene hereunder) and (II) Agios shall be responsible for complying with the terms of any license agreements with such Third Party licensors, in each case ((I) and (II)), solely with respect to Agios’ exercise of such
rights, and (4) Celgene may seek any damages that Celgene can establish that are not compensated by the royalties set forth in Section 14.4(b)(i)(A)(3); or 

(B)    maintain this Agreement in full force and effect (foregoing, for the avoidance of doubt, the right
to terminate this Agreement for such occurrence of such breach) and, with respect to the Licensed Product(s) that are the subject of the applicable breach by Agios: (1) all future milestones and royalty obligations in respect of such Licensed
Products payable by Celgene under this Agreement following such election shall be subject to a reduction of [**] percent ([**]%) and (2) Agios’ Profit or Loss Allocation shall be terminated (and the Parties shall treat this Agreement as though
an Agios Opt-Out had occurred pursuant to Section 2.3). 
 (ii)    if Celgene has made the election set
forth in Section 14.4(b)(i)(B), from and after such election: 
 (A)    if the Agios Opt-Out Date has
not occurred before the effective date of termination, then Celgene shall pay Agios milestones and royalties on Annual Net Sales of Licensed Products following such termination (subject to the [**] percent ([**]%) reduction described in Section
14.4(b)(i) above), with the Agios Opt-Out Date, as used therein, deemed to be the effective date of termination, or 

(B)    if the Agios Opt-Out Date has occurred before the effective date of termination, then Celgene
shall continue to pay to Agios milestones and royalties on Net Sales of Licensed Products following such termination (subject to the [**] percent ([**]%) reduction described in Section 14.4(b)(i) above). 

  
 - 81 - 

 (iii)    all licenses granted by Celgene to Agios under
Section 8.1(b) with respect to the Licensed Products shall terminate if Celgene has made the election set forth in Section 14.4(b)(i)(B) and all licenses granted by Agios to Celgene under Section 8.1(a) with respect to the Licensed Product(s) that
are the subject of the applicable breach by Celgene shall convert to worldwide licenses as if Celgene were the Lead Party worldwide and otherwise remain in effect, and, from and after such termination; 

(iv)    Agios shall be released from its Development, Manufacture and Commercialization obligations
(except as set forth in clause (vii) below with respect to Agios’ transfer of Manufacturing to Celgene hereunder); 

(v)    each Party shall provide the other with a report of the Development Costs and Commercialization
Expenses incurred by such Party that are subject to the Parties’ cost-sharing obligations through the effective date of termination for the purpose of calculating a final reconciliation of shared costs in accordance with Section 9.2 and Section
9.4; 
 (vi)    if Celgene has made the election set forth in Section 14.4(b)(i)(B) within [**] after
such termination, Agios shall provide to Celgene a fair and accurate summary report of the status of Development and Commercialization activities conducted by Agios with respect to the Licensed Products; 

(vii)    if Agios is the Lead US Party and Celgene has made the election set forth in Section
14.4(b)(i)(B) above:
 (A)    Agios shall promptly transfer and assign to Celgene all of Agios’
and its Affiliates’ rights, title and interests in and to the Product Trademark(s) (but not any Agios house marks or composite marks including a house mark) owned by Agios and solely used for Licensed Products in the US Territory; 

(B)    Agios shall as soon as reasonably practicable transfer and assign to Celgene all Regulatory
Approvals of the Licensed Products for the US Territory, their corresponding Regulatory Documentation, and a copy of all of the data comprising the Global Safety Database for the US Territory; provided that Agios may retain such data
and a single copy of such Regulatory Approvals and Regulatory Documentation for its records; and provided further that, if such Regulatory Approvals or Regulatory Documentation are necessary or useful for the Development,
Manufacture or Commercialization of any product other than the Licensed Products, in place of transferring or assigning the foregoing, Agios shall grant Celgene a Right of Reference or Use with respect to such approvals or documentation with respect
to the Licensed Products; and 
 (C)    Celgene shall have the option, exercisable within [**]
following the effective date of such termination of this Agreement, to obtain Agios’ inventory of the Licensed Products at a price equal to [**] percent ([**]%) of Agios’ Manufacturing Costs for such inventory of the Licensed Products;
provided that, if Agios, its Affiliates or sublicensees have outstanding orders, at Celgene’s election, either Celgene shall fulfill such orders or, notwithstanding Celgene’s option to purchase inventory, Agios may retain
sufficient inventory to fulfill such orders. Celgene may exercise such option by written notice to Agios during such 

  
 - 82 - 

 
[**] period; provided that, in the event Celgene exercises such right to purchase such inventory, Agios shall grant, and hereby does grant, a royalty-free right and license to any
trademarks, names and logos of Agios contained therein for a period of [**] solely to permit the orderly sale of such inventory, subject to Celgene meeting reasonable quality control standards imposed by Agios on the use of such trademarks, names
and logos, which shall be consistent with the standards used by Agios prior to such termination. Unless Celgene exercises its option under the first sentence of this Section 14.4(b)(vii)(C) and Agios, its Affiliates or sublicensees at
termination of this Agreement possess Licensed Product, have started the manufacture thereof or have accepted orders therefor, Agios, its Affiliates or sublicensees shall have the right, for up to [**] following the date of termination, to sell
their inventories thereof, complete the manufacture thereof and Commercialize such fully-manufactured Licensed Product, in order to fulfill such accepted orders or distribute such fully-manufactured Licensed Product in the US Territory, subject to
the obligation of Agios to pay Celgene any and all payments as provided in this Agreement. 

(viii)    if Celgene has made the election set forth in Section 14.4(b)(i)(B), Celgene shall be solely
responsible for any payments owed to any Third Party licensors of Agios Intellectual Property, Agios Co-Co Collaboration Intellectual Property or Celgene Collaboration Intellectual Property (without deduction under Section 9.5(c)) and shall be
responsible for complying with the terms of any license agreements with such Third Party licensors, in either case, directly related to Celgene’s exercise of such license; and 

(ix)    if Celgene has made the election set forth in Section 14.4(b)(i)(B), the rights of Agios in
Article X (other than Section 10.1) shall be terminated and Agios shall, if applicable, provide reasonable assistance to Celgene and cooperation in connection with the transition of Prosecution and enforcement responsibilities to Celgene with
respect to Celgene Collaboration Patents, Agios Co-Co Collaboration Patents and Joint Collaboration Patents then being Prosecuted or enforced by Agios, including execution of such documents as may be necessary to effect such transition; and 

(x)    if Celgene has made the election set forth in Section 14.4(b)(i)(A), separate transitional
activities shall be undertaken with respect to any Companion Diagnostic(s) to ensure that the appropriate Regulatory Approvals, Manufacturing Technology or other Know-How or Patents necessary for the Development, Manufacture or Commercialization of
such Companion Diagnostic(s) shall be transferred to Agios to the same extent as Regulatory Approvals, Manufacturing Technology or other Know-How or Patents otherwise associated with such Licensed Products are transferred. 

(c)    In the case of any termination of this Agreement, if any Clinical Trials (including any Additional
Studies) are then being conducted at the time of such termination with respect to any Licensed Product, the Parties hereby agree (i) to reasonably cooperate in the completion of any such Clinical Trials (including any Additional Studies), and (ii)
notwithstanding anything to the contrary contained herein, to grant to the Party that retains global Commercialization rights to such Licensed Product following such termination (A) free of charge, copies of and rights of reference to and use of all
Licensed Product Data that is Controlled by such Party and generated pursuant to such Clinical Trials (including any Additional Studies) that are relevant to or necessary to address issues relating to: (1) the safety

  
 - 83 - 

 
of such Licensed Product in the Territory, including data that is related to adverse effects experienced with such Licensed Product and/or (2) all activities relating to CMC regarding such
Licensed Product and in each of (1) and (2), that are required to be reported or made available to Regulatory Authorities in the Territory, when and as such data become available, and (B) copies of and rights of reference to and use of all Licensed
Product Data (other than the Licensed Product Data referred to in subclause (A) above) that is Controlled by such Party and generated pursuant to such Clinical Trials (including any Additional Studies) that are relevant to or necessary to address
the Development and Commercialization of such Licensed Product promptly following the generation of such Licensed Product Data if, but only if, as to such Licensed Product Data described in this subclause (B), such Party that retains global
Commercialization rights to such Licensed Product following such termination promptly pays for all Development Costs incurred following any such termination of this Agreement with respect to such Clinical Trials (including any Additional Studies).

 (d)    Survival. Upon any termination or expiration of this Agreement, unless otherwise
specified in this Agreement and except for any rights or obligations that have accrued prior to the effective date of termination or expiration, all rights and obligations of each Party under this Agreement shall terminate in whole or with respect
to the Licensed Products, as the case may be; provided, however, that Section 2.1, Section 3.7(b), Section 8.8, Section 9.2(b), Section 9.5(b)(v), Section 9.7, Section 9.8, Section 9.9, Section 9.10, Section 9.11, Section 10.1,
Section 12.5, Section 11.5, Section 11.6, Section 13.1, Section 13.2, Section 13.3, Section 13.4, Section 13.5, Section 14.4 and Section 15.2, as well as any other provision which by its terms or by the context thereof is intended to survive, shall
survive any such termination or expiration of this Agreement. 
 (e)    Equitable
Relief. Termination of this Agreement shall be in addition to, and shall not prejudice, the Parties’ remedies at law or in equity, including the Parties’ ability to receive legal damages or equitable relief with respect to any
breach of this Agreement, regardless of whether or not such breach was the reason for the termination. 

(f)    Accrued Liabilities. Except as otherwise specifically provided herein, termination of
this Agreement shall not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination, nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or
in equity with respect to any breach of this Agreement nor prejudice either Party’s right to obtain performance of any obligation. In addition, termination of this Agreement shall not terminate provisions which provide by their respective
terms for obligations or undertakings following the expiration of the term of this Agreement. 
 Article XV 

Miscellaneous 

Section 15.1    Dispute Resolution. Except for any disagreements that are within the authority
of any Committee as provided in Article II (which disagreements shall be resolved in accordance with Section 2.2), the Parties agree that any disputes arising with respect to the interpretation, enforcement, termination or invalidity of this
Agreement (each, a “Dispute”) shall first be presented to the Parties’ respective Executive Officers for resolution. If the Parties are 

  
 - 84 - 

 
unable to resolve a given dispute pursuant to this Section 15.1 after in-person discussions between the Executive Officers within [**] after referring such dispute to the Executive Officers,
either Party may, at its sole discretion, seek resolution of such matter in accordance with Section 15.2. 
 Section
15.2    Submission to Court for Resolution. Subject to Section 15.1, the Parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction of the courts located in the Southern District of New York
for any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement, and agree not to commence any action, suit or proceeding (other than appeals therefrom) related thereto except in such courts. The
Parties further hereby irrevocably and unconditionally waive any objection to the laying of venue of any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement in the courts of New York, and hereby
further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum. Each Party further agrees that service
of any process, summons, notice or document by registered mail to its address set forth in Section 15.8 shall be effective service of process for any action, suit or proceeding brought against it under this Agreement in any such court. 

Section 15.3    Governing Law. This Agreement and all questions regarding its validity or
interpretation, or the performance or breach of this Agreement, shall be governed by and construed and enforced in accordance with the laws of the State of New York, without reference to conflicts of laws principles. 

Section 15.4    Assignment. 

(a)    Generally. This Agreement may not be assigned by any Party, nor may any Party delegate
its obligations or otherwise transfer licenses or other rights created by this Agreement, except as expressly permitted hereunder without the prior written consent of the other Party, which consent will not be unreasonably withheld, delayed or
conditioned. 
 (b)    Celgene. Notwithstanding the limitations in Section 15.4(a), Celgene
Corp. and Celgene RIVOT may assign this Agreement, or any rights or obligations hereunder in whole or in part, to (i) one or more Affiliates solely as provided in this Section 15.4(b) or (ii) its successor in interest in connection with the merger,
consolidation, or sale of all or substantially all of its assets or that portion of its business pertaining to the subject matter of this Agreement; provided, however, that, except in the case where Celgene Corp., or Celgene
RIVOT, as applicable, is involved in a merger or consolidation where it is the surviving entity and no assets of Celgene Corp. or Celgene RIVOT, as applicable have been transferred as a result of such merger or consolidation (for example, a reverse
triangular merger), (A) Celgene Corp. or Celgene RIVOT, as applicable, provides Agios with at least [**] advance written notice of any such assignment(s), (B) prior to such assignment(s), Celgene Corp. or Celgene RIVOT, as applicable, agrees in a
written agreement delivered to Agios (and upon which Agios may rely) to remain fully liable for the performance of its obligations under this Agreement by its assignee(s), and (C) prior to such assignment(s), the assignee(s) agree in a written
agreement delivered to Agios (and upon which Agios may rely) to assume performance of all such assigned obligations. If Celgene Corp. or Celgene RIVOT, as applicable, wishes to assign any Celgene Collaboration

  
 - 85 - 

 
Intellectual Property or Joint Collaboration IP which Celgene Corp. or Celgene RIVOT, as applicable, Controls, or Agios Program Assets for each Program, to one or more permitted Affiliate(s), it
will be permitted to do so conditioned on such Affiliate(s) becoming a party to this Agreement, in the form of an amendment to this Agreement executed by Celgene, Agios and such Affiliate(s), pursuant to which such Affiliate(s) would agree to assume
all obligations hereunder, and grant to Agios all rights hereunder, with respect to the assets so assigned. 

(c)    Agios. Notwithstanding the limitations in Section 15.4(a), Agios Pharmaceuticals and
[Agios Ex-US] may assign this Agreement, or any rights or obligations hereunder in whole or in part, to (i) one or more Affiliates solely as provided in this Section 15.4(c) or (ii) its successor in connection with the merger, consolidation, or sale
of all or substantially all of its assets or that portion of its business pertaining to the subject matter of this Agreement; provided, however, that, except in the case where [**], (A) Agios Pharmaceuticals or [Agios Ex-US], as
applicable, provides Celgene with at least [**] advance written notice of any such assignment(s), (B) prior to such assignment(s), Agios Pharmaceuticals or [Agios Ex-US], as applicable, agrees in a written agreement delivered to Celgene (and upon
which Celgene may rely) to remain fully liable for the performance of its obligations under this Agreement by its assignee(s), and (C) prior to such assignment(s), the assignee(s) agree in a written agreement delivered to Celgene (and upon which
Celgene may rely) to assume performance of all such assigned obligations, (D) in the case of any assignment(s) by Agios Pharmaceuticals or [Agios Ex-US], as applicable, all Co-Co Collaboration Intellectual Property and Joint Collaboration IP which
Agios Pharmaceuticals or [Agios Ex-US], as applicable, Controls, and all Program Assets for each Program will be transferred to such assignee(s) effective as of such assignment(s), and (E) all of the matters referred to in clauses (A), (B), (C) and
(D), as applicable, will be set forth in documentation [**] prior to any such assignment(s) ([**]) and in all cases will provide [**]. Subject to the terms of this Section 15.4(c), if Agios Pharmaceuticals or [Agios Ex-US], as applicable,
wishes to assign any [**], it will be permitted to do so conditioned on [**], pursuant to which such [**]. Nothing in this Agreement (including this Section 15.4(c)) shall be construed to contradict the requirement in Section 9.3.1(e)(iii)(B)
of the Master Agreement. 
 (d)    In the event the Implementation Date for this Agreement has not
occurred within [**] following the Effective Date, Celgene shall be entitled to [**], if required by any Antitrust Law; provided that the right to [**] set forth in this Section 15.4(d) shall not apply if a breach by Celgene of its
obligations under Section 8.6(a) is a material cause of the failure to obtain clearance under Antitrust Laws. 

(e)    Nothing in this Section 15.4 shall be construed to relieve any Party (or its assignee, as
applicable) of its obligation under Sections 4.1(a), 4.1(c), or 4.1(g)(i) of this Agreement to locate a manufacturing facility or Backup Facility in a particular jurisdiction. 

Section 15.5    All Other Assignments Null and Void. The terms of this Agreement will be
binding upon and will inure to the benefit of the successors, heirs, administrators and permitted assigns of the Parties. Any purported assignment in violation of Section 15.4 will be null and void ab initio. 

  
 - 86 - 

 Section 15.6    Change of
Control. Notwithstanding anything to the contrary in this Agreement, with respect to any intellectual property rights controlled by the acquiring party or its Affiliates (if other than one of the Parties to this Agreement) involved in any
Change of Control of either Party, such intellectual property rights shall not be included in the technology and intellectual property rights licensed to the other Party hereunder to the extent held by such acquirer or its Affiliate (other than the
relevant Party to this Agreement) prior to such transaction, or to the extent such technology is developed outside the scope of activities conducted with respect to the Collaboration, Compounds or Licensed Products, or related Companion
Diagnostics. The Agios Intellectual Property and the Celgene Intellectual Property shall exclude any intellectual property owned or controlled by a permitted assignee or successor and not developed in connection with the
Collaboration, Compounds or Licensed Products, or related Companion Diagnostics, Developed, Manufactured or Commercialized pursuant to this Agreement or the Master Agreement.

Section 15.7    Force Majeure. If the performance of any part of this Agreement by a Party is
prevented, restricted, interfered with or delayed by an occurrence beyond the control of such Party (and which did not occur as a result of such Party’s financial condition, negligence or fault), including fire, earthquake, flood, embargo,
power shortage or failure, acts of war or terrorism, insurrection, riot, lockout or other labor disturbance, governmental acts or orders or restrictions, acts of God (for the purposes of this Agreement, a “force majeure
event”), such Party shall, upon giving written notice to the other Party, be excused from such performance to the extent of such prevention, restriction, interference or delay; provided that the affected Party shall use
its Commercially Reasonable Efforts to avoid or remove such causes of non-performance and shall continue performance with the utmost dispatch whenever such causes are removed. 

Section 15.8    Notices. Unless otherwise agreed by the Parties or specified in this
Agreement, all notices required or permitted to be given under this Agreement shall be in writing and shall be sufficient if: (a) personally delivered; (b) sent by registered or certified mail (return receipt requested and postage prepaid); (c)
sent by express courier service providing evidence of receipt and postage prepaid where applicable; or (d) sent by facsimile transmission (receipt verified and a copy promptly sent by another permissible method of providing notice described in
clauses (a), (b) or (c) above), to address for a Party set forth below, or such other address for a Party as may be specified in writing by like notice: 
  

			
	 To Agios Pharmaceuticals:
  

Agios Pharmaceuticals, Inc.
 88 Sidney Street

Cambridge, MA 02139
 Attention:   Chief Executive
Officer
 Telephone:   617-649-8600

Facsimile:   [**]
	  	 To Celgene Corp. or Celgene RIVOT:
  

Celgene Corporation
 86 Morris Avenue

Summit, NJ 07901
 Attention:   Senior Vice
President Business Development
 Telephone:   (908) 673-9000

Facsimile:   [**]

		
	 With a copy to:
 Agios Pharmaceuticals, Inc.

88 Sidney Street
 Cambridge, MA 02139
	  	 With a copy to:
 Celgene Corporation

86 Morris Avenue
 Summit, NJ
07901

  
 - 87 - 

			
	 Attention:   Legal Department

Telephone:   (617) 649-8600

Facsimile:   [**]
  

and
  

WilmerHale
 60 State Street

Boston, MA 02109
 Attention: Steven D. Singer

Telephone: (617) 526-6410
 Facsimile: (617) 526-5000
	  	 Attention:   Legal Department

Telephone:   (908) 673-9000

Facsimile:   [**]
  

and
  

Celgene RIVOT Ltd.
 Aon House

30 Woodbourne Avenue
 Pembroke HM 08

Bermuda
 Phone: 441-296-4803

 
 and
  

Dechert LLP
 1900 K St. NW

Washington, DC 20006
 Attention: David E. Schulman

Telephone: (202) 261-3440
 Facsimile: [**]

	 To [Agios Ex-US]:
  

[____________________]
  
	  	
	 With a copy to:
 [____________________]

 
 and
  

WilmerHale
 60 State Street

Boston, MA 02109
 Attention: Steven D. Singer

Telephone: (617) 526-6410
 Facsimile: (617) 526-5000
	  	

 Any such notices shall be effective upon receipt by the Party to whom it is addressed. 

Section 15.9    Waiver. Except as otherwise expressly provided in this Agreement, any term of
this Agreement may be waived only by a written instrument executed by a duly authorized representative of the Party waiving compliance. The delay or failure of either Party at any time to require performance of any provision of this Agreement
shall in no manner affect such Party’s rights at a later time to thereafter enforce such provision. No waiver by either Party of any condition or term in any one or more instances shall be construed as a further or continuing waiver of
such condition or term or of another condition or term. 

  
 - 88 - 

 Section 15.10    Severability. If any provision
of this Agreement should be held invalid, illegal or unenforceable in any jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and
all other provisions of this Agreement shall remain in full force and effect in such jurisdiction and shall be liberally construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. If the Parties cannot
agree upon a substitute provision, the invalid, illegal or unenforceable provision of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid, illegal or unenforceable provision is of such essential importance
to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid, illegal or unenforceable provision. 

Section 15.11    Entire Agreement. This Agreement (including the Exhibits attached hereto),
together with the Master Agreement, constitutes the entire agreement between the Parties relating to its subject matter, and supersedes all prior and contemporaneous agreements, representations or understandings, either written or oral, between the
Parties with respect to such subject matter. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as set forth herein and therein. 

Section 15.12    Modification. No modification, amendment or addition to this Agreement, or
any provision hereof, shall be effective unless reduced to writing and signed by a duly authorized representative of each Party. No provision of this Agreement shall be varied, contradicted or explained by any oral agreement, course of dealing
or performance or any other matter not set forth in an agreement in writing and signed by a duly authorized representative of each Party. 

Section 15.13    Independent Contractors; No Intended Third Party Beneficiaries. This
Agreement is not intended nor shall be deemed or construed to create any relationship of employer and employee, agent and principal, partnership, or joint venture between the Parties. Each Party is an independent contractor. Neither Party
shall assume, either directly or indirectly, any liability of or for the other Party. Neither Party shall have any express or implied right or authority to assume or create any obligations on behalf of, or in the name of, the other Party, nor
to bind the other Party to any contract, agreement or undertaking with any Third Party. There are no express or implied third party beneficiaries hereunder, (a) except for the indemnitees identified in Section 13.1 and Section 13.2 and (b)
except for any licensor under any Existing Third Party Agreement, to the extent described in Exhibit C. Notwithstanding the provisions of this Section 15.13, the provisions of Section 15.17 shall control for US federal income tax
purposes, as applicable. 
 Section 15.14    Interpretation; Construction. The captions to
the several Articles and Sections of this Agreement are included only for convenience of reference and shall not in any way affect the construction of, or be taken into consideration in interpreting, this Agreement. In this Agreement, unless
the context requires otherwise, (a) the word “including” shall be deemed to be followed by the phrase “without limitation” or like expression, whether or not followed by 

  
 - 89 - 

 
the same; (b) references to the singular shall include the plural and vice versa; (c) references to masculine, feminine and neuter pronouns and expressions shall be interchangeable; (d) the words
“herein” or “hereunder” relate to this Agreement; (e) “or” is disjunctive but not necessarily exclusive; (f) the word “will” shall be construed to have the same meaning and effect as the word
“shall”; and (g) all references to “dollars” or “$” herein shall mean US Dollars. Each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has
participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which drafted such terms and provisions. 

Section 15.15    Performance by Affiliates.

(a)    To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party agrees
to cause its Affiliates to perform such obligations. 
 (b)    The Parties hereby acknowledge and agree
that (a) Celgene Corp. and Agios Pharmaceuticals are the parties to this Agreement with respect to all rights and obligations (including payment obligations) under this Agreement in the United States; and (b) Celgene RIVOT and [Agios Ex-US] are the
parties to this Agreement with respect to all rights and obligations under this Agreement outside of the United States. 

Section 15.16    Counterparts. This Agreement may be executed in two (2) counterparts, each of
which shall be deemed an original, and both of which together shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of a fax machine or by .pdf, .tif, .gif, .jpeg or similar attachment to electronic
mail (any such delivery, an “Electronic Delivery”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed
version thereof delivered in person. No Party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic
Delivery as a claim or defense with respect to the formation of a contract, and each Party forever waives any such claim or defense, except to the extent that such claim or defense relates to lack of authenticity. 

Section 15.17    Certain US Federal Income Tax Treatment. Pursuant to Section 15.13, this
Agreement is not intended nor shall be deemed or construed to create any relationship of employer and employee, agent and principal, legal partnership, or joint venture between the Parties; provided, however, that the Parties hereby acknowledge and
agree that the Collaboration shall be treated as a partnership with respect to the [US / ROW] Territory for US federal and state income tax purposes only pursuant to Section 7701(a)(2) of the Code and the Treasury Regulations thereunder, and each of
[Agios / Agios Ex-US] and [Celgene Corp. / Celgene RIVOT] shall be treated as partners in such partnership for all taxable periods that the Collaboration is effective and before the Agios Opt-Out Date. Agios and Celgene agree that each will
take no position inconsistent with partnership tax treatment for US federal and state income tax purposes for such time. Exhibit G of this Agreement sets forth the Parties’ intentions regarding allocations and other tax matters related to
the tax partnership. Exhibit G shall be interpreted in a manner consistent with this Section 15.17. 

  
 - 90 - 

 Section 15.18    HSR Clearance; Cooperation. For
the avoidance of doubt, the Parties shall continue to comply with Section 3.2 of the Master Agreement.     

Section 15.19    Equitable Relief. Notwithstanding anything to the contrary herein, the
Parties shall be entitled to seek equitable relief, including injunction and specific performance, as a remedy for any breach of this Agreement. Such remedies shall not be deemed to be the exclusive remedies for a breach of this Agreement but
shall be in addition to all other remedies available at law or equity.
 Section 15.20    Further
Assurances. Each Party shall execute, acknowledge and deliver such further instruments, and do all such other acts, as may be necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this
Agreement.
 [Remainder of page intentionally left blank] 

  
 - 91 - 

 IN WITNESS WHEREOF, the Parties have executed this Co-Development and
Co-Commercialization Agreement as of the Effective Date. 
  

	
	AGIOS PHARMACEUTICALS, INC.
	
	By:                                     
                                  
	Name:                                     
                             
	Title:                                     
                               
	
	Solely with respect to the rights and obligations under this Co-Development and Co-Commercialization Agreement outside of the United States (subject to Section 15.15):
	
	[AGIOS EX-US]
	
	By:                                     
                                  
	Name:                                     
                             
	Title:                                     
                               
	
	CELGENE CORPORATION
	
	By:                                     
                                  
	Name:                                     
                             
	Title:                                     
                               
	
	Solely with respect to the rights and obligations under this Co-Development and Co-Commercialization Agreement outside of the United States (subject to Section 15.15):
	
	CELGENE RIVOT LTD.
	
	By:                                     
                                  
	Name:                                     
                             
	Title:                                     
                               

  

 Exhibit A 

Target, Compound(s), Shared Program Type and Upfront Option Payment 

1.         Target: [check applicable box and identify applicable Program
Target] The definitions under the selected Target shall apply to this Agreement: 
  ̈ [**] 
  ̈ [**] 

 ̈ Other __________________ 

 

	2.	 Compounds [check applicable box and include Agios identifiers and structure(s)]:

  ̈ inhibitors of Target 

or 

 ̈ activators of Target 

Description of Compound: 
  

	3.	 Shared Program Type: [check applicable boxes] 

 ̈ Shared 65/35 Program (and, for clarity, Celgene is the Lead Party) 

or 

 ̈ Shared 50/50 Program     

Lead US Party:
             ̈ Agios              ̈
Celgene 
  

	4.	 Upfront Option Payment calculated as either: [check applicable boxes]

  ̈ If the Program
under this Agreement is a Designated Development Program or the Deemed DC Program, the sum of Thirty Million US Dollars ($30,000,000) plus the Reimbursable Back-up Expenses and the Reimbursable Manufacturing Expenses (such Reimbursable Back-up
Expenses and Reimbursable Manufacturing Expenses, in the aggregate, not to exceed [**] US Dollars ($[**])); 

  
 A - 1 

 OR 

 ̈ If the Program under this Agreement is
a Continuation Program (other than the Deemed DC Program), the sum of Thirty-Five Million US Dollars ($35,000,000) plus the Reimbursable Back-up Expenses and the Reimbursable Manufacturing Expenses (such Reimbursable Back-up Expenses and
Reimbursable Manufacturing Expenses, in the aggregate, not to exceed [**] US Dollars ($[**])). 
 [Note: delete bracketed references to the [**] and
[**] Programs throughout, to the extent not applicable] 
 [Note: exceptions to Agios representations and warranties in Section 12.2 to be
identified, if applicable] 
  
  

 

  
 A - 2 

 ANNEX I 

REIMBURSABLE MANUFACTURING EXPENSES AND REIMBURSABLE BACK-UP 

EXPENSES 
 Reference is
made to the Upfront Option Fee described in paragraph 4 of Exhibit A to this Agreement, which will include the following Reimbursable Manufacturing Expenses and/or Reimbursable Back-Up Expenses as applicable: [check applicable
boxes] 
  ̈ Reimbursable Back-up Expenses
shall only include amounts incurred for: 
  

	 	•	 	 [describe pre-approved back-up Compounds] which back-up Compounds have been agreed to by the
Parties on [insert relevant dates] and 

  

	 	•	 	 in the aggregate, equals $_______________________ (which amount is subject to review pursuant to
Section 9.8 and, in the event of any good faith dispute between the Parties, such amount shall not be payable until the final resolution pursuant to Section 9.8). 

 ̈ Reimbursable Manufacturing Expenses shall only include
amounts incurred for: 
  

	 	•	 	 [describe pre-approved Manufacturing Expenses, including any relevant quantities of conforming Compounds
that were Manufactured for post-Pre-Exercise Phase I Development activities]; and 

  

	 	•	 	 in the aggregate, equals $_______________________ (which amount is subject to review pursuant to
Section 9.8 and, in the event of any good faith dispute between the Parties, such amount shall not be payable until the final resolution pursuant to Section 9.8). 

  
 A - 3 

 Exhibit B 

Agios Patents, Celgene Patents and Celgene Collaboration Patents 

(as of the Execution Date) 

  
 B-1 

 Exhibit C 

Existing Third Party Agreements 

[Parties to identify each applicable Existing Third Party Agreement referenced in the Option Data Package and each provision
thereof that must be included in this Agreement, including for Third Party Programs and Third Party Licenses] 

  
 C-1 

 Exhibit D 

Certain Financial Definitions 

“Accounting Standards” means (a) GAAP (United States Generally Accepted Accounting Principles) or (b) IFRS
(International Financial Reporting Standards), in either case, consistently applied, and reported in such Person’s financial statements. 

“Additional Revenue” means the sum of (a) recoveries pursuant to Section 10.3(f)(ii)(A) of this
Agreement, (b) insurance proceeds relating to liabilities previously paid by the Parties and reflected in Commercialization Expenses, and (c) any payments or income (other than Net Sales) received by a Party or its Affiliates that are
attributable to the Licensed Products and relate to the Territory. 
 “Advertising and Market Research
Expenses” means those expenses incurred related to: (a) conducting and monitoring professional and consumer appraisals of the Licensed Products in the Territory, such as market share services (e.g., IMS data), pricing analysis,
special research testing and focus groups; and (b) advertising and promotion of the Licensed Products in the Territory through any means, including (i) television and radio advertisements; (ii) advertisements appearing in journals, newspapers,
magazines or other media; (iii) seminars, symposia and conventions; (iv) packaging design; (v) programs for education of health care professionals; (vi) product samples; (vii) visual aids and other selling materials; (viii) hospital formulary
committee presentations; (ix) presentations to state and other governmental formulary committees; and (x) all media costs associated with product advertising. 

“Annual Net Sales” means, with respect to Licensed Products sold after the Agios Opt-Out Date under this
Agreement, the aggregate Net Sales of such Licensed Products by Celgene or its Affiliates or sublicensees in the portion of such Calendar Year following the Agios Opt-Out Date, and in each subsequent Calendar Year during which this Agreement is in
effect. 
 “Commercialization Expenses” mean those expenses incurred by either Party (as detailed below)
for the purpose of, and directly and specifically attributable to, the Commercialization of the Licensed Products in the Territory, and shall consist of the following expenses: (a) Distribution Costs; (b) Health Care Reform Fees; (c) Manufacturing
Costs for commercial supply in the Territory; (d) Marketing Expenses; (e) Other Commercialization Costs; (f) Patent and Trademark Prosecution and Enforcement Costs incurred in any country of the Territory from and after the First Commercial Sale of
a Licensed Product in the country; (g) Product Liabilities; (h) Recall Expenses; (i) Regulatory Maintenance Costs; (j) Selling Expenses; and (k) Third Party Patent Costs incurred in a country from and after the First Commercial Sale of a Licensed
Product in the country. 
 Commercialization Expenses shall not include: (w) expenses related to any Clinical Trial even if
incurred after the First Commercial Sale of a Licensed Product in any country of the Territory; (x) costs that are deductible from Net Sales under the definition thereof; (y) any losses, damages, fees, costs and other liabilities incurred by a Party
as a result of such Party’s negligence, gross negligence, illegal conduct, willful misconduct or breach of such Party’s representations and warranties made hereunder and any such losses, damages, fees, costs and

  
 D-1 

 
other liabilities will be treated as the sole and exclusive responsibility of the Party whose actions or omissions gave rise to such losses, damages, fees, costs and other liabilities; or (z)
fines, penalties, assessments or other financial sanctions levied by any governmental authority on either Party. 
 All of
such costs shall be as determined from the books and records of the applicable Party and its Affiliates maintained in accordance with the Accounting Standards. Notwithstanding anything in this definition to the contrary, only those
Commercialization Expenses that are contemplated by, and materially consistent with, the Commercialization Plan and Commercialization Budget for the Licensed Product shall be chargeable as Commercialization Expenses. For purposes of clarity, no
general corporate overhead or fixed charges, such as depreciation, shall constitute Commercialization Expenses (except as otherwise provided under the definition of Manufacturing Costs). 

“Development Costs” means the costs and expenses that are actually incurred by or on behalf of a Party and
specifically identifiable or specifically allocable to the Development of the Licensed Products or Companion Diagnostics throughout the Territory. “Development Costs” shall include: 

(a)    the FTE Costs of the relevant Party or its Affiliates with respect to such Development; it being
understood and agreed that, in the case of FTE Costs involving Development activities incurred by Celgene and its Affiliates, in lieu of an FTE Cost reimbursement, Celgene shall be reimbursed at an amount equal to [**] percent ([**]%) of the
Out-of-Pocket Costs referred to in clause (b) below; 
 (b)    all Out-of-Pocket Costs incurred by the
Parties or their Affiliates, including payments made to Third Parties, with respect to such Development, including Phase IV Study Expenses (except to the extent that such costs have been included in FTE Costs); 

(c)    Regulatory Expenses other than Regulatory Maintenance Costs; 

(d)    the cost of contract research organizations (CROs); 

(e)    Manufacturing Costs for clinical supply, including: 

(i)    costs of packaging of drug products and distribution of drug products used in Clinical Trials;

 (ii)    expenses incurred to purchase or package comparator drugs; 

(iii)    costs and expenses of disposal of clinical samples; and 

(iv)    costs and expenses incurred in scaling up Manufacturing activities related to pre-clinical or
clinical supply, including formulation development activities; 
 (f)    Manufacturing Scale-Up Costs;
and 

  
 D-2 

 (g)    Third Party Patent Costs and Patent and Trademark
Prosecution and Enforcement Costs incurred in each country of the Territory prior to the First Commercial Sale of a Licensed Product in the country. 

Development Costs shall not include: (x) any losses, damages, fees, costs and other liabilities incurred by a Party as a
result of such Party’s negligence, gross negligence, illegal conduct, willful misconduct or breach of such Party’s representations and warranties made hereunder and any such losses, damages, fees, costs and other liabilities will be
treated as the sole and exclusive responsibility of the Party whose actions or omissions gave rise to such losses, damages, fees, costs and other liabilities; or (y) fines, penalties, assessments or other financial sanctions levied by any
governmental authority on either Party. 
 All of such costs shall be as determined from the books and records of the
applicable Party and its Affiliates maintained in accordance with the Accounting Standards. Notwithstanding anything in this definition to the contrary, only those Development Costs that are contemplated by, and materially consistent with, the
Development Plan and Development Budget for the Licensed Product shall be chargeable as Development Costs. For purposes of clarity, no general corporate overhead or fixed charges, such as depreciation, shall constitute Development Costs (except
as otherwise provided under the definition of Manufacturing Costs). 
 “Distribution Costs” means
Out-of-Pocket Costs and FTE Costs identifiable to the distribution of the Licensed Products in the Territory, including customer and wholesaler services, collection of data on sales, order entry, billing, shipping, logistics, warehousing, product
insurance, freight not paid by customers, credit collection and similar activities. 
 “FTE” means the
equivalent of the work of one (1) full-time employee of a Party or its Affiliates for one (1) year (consisting of [**] hours per year) in directly conducting Development, Manufacturing and/or Commercialization activities hereunder. Any
Party’s employee who devotes fewer than [**] hours per year on the applicable activities shall be treated as an FTE on a pro-rata basis, calculated by dividing the actual number of hours worked by such employee on such activities by
[**]. Any employee who devotes more than [**] hours per year on the applicable activities shall be treated as one (1) FTE. For the avoidance of doubt, FTE shall not include the work of general corporate or administrative personnel, except
for the portion of such personnel’s work time actually spent on conducting scientific, technical or commercial activities directly related to the Development, Manufacture or Commercialization of Licensed Products. 

“FTE Costs” means, for any period, the FTE Rate multiplied by the number of FTEs in such period. 

“FTE Rate” means, during the Term: (a) with respect to Development activities, $[**] per FTE and (b) with
respect to Commercialization activities, $[**] per FTE. On January 1 of the Calendar Year following the Effective Date and on January 1st of each subsequent Calendar Year, the foregoing rate shall be increased for the Calendar Year then
commencing by the percentage increase, if any, [**] as of December 31 of the then most recently completed Calendar Year with respect to the level of the [**] on December 31 of the Calendar Year preceding the Effective Date. As used in this
definition, [**]. 

  
 D-3 

 “Health Care Reform Fees” means Out-of-Pocket Costs representing
the annual fee paid to the US Government as defined in the Patient Protection and Affordable Care Act (“PPACA”) and similar taxes and governmental fees in the United States, in each case to the extent directly attributable to the
Licensed Products. If any similar governmental fee is legislated or rule created in any jurisdiction in the Territory, such fee would be considered Health Care Reform Fees to the extent directly attributable to the Licensed Products. 

“Manufacturing Costs” means, with respect to the Licensed Products, the reasonable FTE Costs and
Out-of-Pocket Costs of a Party or any of its Affiliates or sublicensees incurred in Manufacturing the Licensed Products, excluding Manufacturing Scale-Up Costs, but including: 

(h)    to the extent that the Licensed Products are manufactured by a Party or any of its Affiliates or
sublicensees, direct material and direct labor costs, plus manufacturing overhead attributable to the Compound and any Products (including facility start-up costs, all directly incurred manufacturing variances, and a reasonable allocation of related
manufacturing administrative and facilities costs (including depreciation) and a reasonable allocation of the costs of failed batches to be further described in the applicable supply agreement, to be provided for the Licensed Products, but excluding
costs associated with excess capacity), all determined in accordance with the books and records of the applicable Party or its Affiliates or sublicensees maintained in accordance with the Accounting Standards, consistently applied; and 

(i)    to the extent that the Licensed Products are manufactured by a Third Party manufacturer, the
Out-of-Pocket Costs paid by a Party or any of its Affiliates or sublicensees to the Third Party for the manufacture, supply, packaging and labeling of the Licensed Products, and any reasonable Out-of-Pocket Costs and direct labor costs actually
incurred by such Party or any of its Affiliates or sublicensees in managing or overseeing the Third Party relationship, determined in accordance with the books and records of the applicable Party or its Affiliates or sublicensees maintained in
accordance with the Accounting Standards, consistently applied. 
 “Manufacturing Scale-Up Costs” means the
reasonable FTE Costs and Out-of-Pocket Costs of a Party or any of its Affiliates or sublicensees incurred in scaling up Manufacturing activities related to the Licensed Products for clinical and commercial supply, including (a) costs for
process development work, analytical method optimization, and process validation, (b) costs for complete technology transfer to a commercial site (including costs for Manufacturing of demonstration batches on a suitable scale), and (c)
Regulatory Expenses associated with such Manufacturing activities. 
 “Marketing Expenses” mean the sum of
Marketing Management Expenses, Advertising and Market Research Expenses and Medical Education Expenses. 

“Marketing Management Expenses” mean FTE Costs of the Parties arising from the management of marketing
activities for the Licensed Products in the Field in the Territory, including management and administration of managed care and national accounts and other activities associated with developing overall sales and marketing strategies; product-related
advertising, market research and public relations; relationship maintenance with opinion leaders, professional societies, contract pricing administrators, and market information systems; education programs for health care professionals; governmental
affairs activities for 

  
 D-4 

 
reimbursement, formulary acceptance; and other activities directly related to the marketing or promotion of a Licensed Product in the Territory; provided that, in each case, such
costs may be allocated to the Licensed Product on a percent of sales or other basis consistently applied within and across a Party’s operating units; provided, further, that such allocation is made no less favorable to the
Licensed Product than to the internal allocation to such Party’s other products. 
 “Medical Education
Expenses” means all Out-of-Pocket Costs specifically incurred to educate health care professionals licensed to practice in the Territory with respect to a Licensed Product in the Territory through any means not covered in the definition of
“Advertising and Marketing Research Expenses”, but including articles appearing in journals, newspapers, magazines or other media; seminars, scientific exhibits, and conventions; and symposia, advisory boards and opinion leader development
activities; medical science liaison (MSL) and medical affairs activities, and education grant programs. 
 “Net
Sales” means, with respect to any Licensed Product, the gross amounts invoiced by the Parties, their respective Affiliates or Licensee Partners to Third Parties (that are not Licensee Partners) for the sale or other commercial disposition
of such Licensed Product anywhere within the Territory (each, a “Selling Party”) to Third Party customers for sales of such Licensed Product, less the following deductions actually incurred, allowed, paid, accrued or specifically
allocated in its financial statements in accordance with (as applicable to the Selling Party) the Accounting Standards, for: 

[**]. 
 If
non-monetary consideration is received by a Selling Party for any Licensed Product in the relevant country, Net Sales will be calculated based on the average price charged for such Licensed Product, as applicable, during the preceding royalty
period, or in the absence of such sales, the fair market value of the Licensed Product, as applicable, as determined by the Parties in good faith. Notwithstanding the foregoing, Net Sales shall not be imputed to transfers of Licensed Products, as
applicable, for use in Clinical Trials, non-clinical development activities or other development activities with respect to Licensed Products by or on behalf of the Parties, for bona fide charitable purposes or for compassionate use or for Licensed
Product samples, if no monetary consideration is received for such transfers. 
 If a Licensed Product is sold as part of a Combination
Product (as defined below), Net Sales will be the product of (i) Net Sales of the Combination Product calculated as above (i.e., calculated as for a non-Combination Product) and (ii) the fraction (A/(A+B)), where: 

“A” is the gross invoice price in such country of the Licensed Product comprising a Compound as the sole therapeutically active
ingredient; and 
 “B” is the gross invoice price in such country of the other therapeutically active ingredients contained in the
Combination Product. 
 If “A” or “B” cannot be determined by reference to non-Combination Product sales as described
above, then Net Sales will be calculated as above, but the gross invoice price in the above equation shall be determined by mutual agreement reached in good faith by the Parties prior to the end of the accounting period in question based on an
equitable method of determining the same that takes into account, in the applicable country, variation in dosage units and the relative fair market value of each therapeutically active ingredient in the Combination Product. 

  
 D-5 

 As used in this definition of “Net Sales,” “Combination Product” means
a Licensed Product that contains one or more additional active ingredients (whether co-formulated or co-packaged) that are neither Compounds nor generic or other non-proprietary compositions of matter. Pharmaceutical dosage form vehicles, adjuvants
and excipients shall be deemed not to be “active ingredients.” 
 There shall be no double counting in determining the foregoing
deductions from gross amounts invoiced to calculate Net Sales. Subject to the foregoing, the calculations set forth in this definition of Net Sales shall be determined in accordance with Accounting Standards so as to arrive at Net Sales under
Accounting Standards as reported by the Selling Party in such Person’s financial statements.
 “Other
Commercialization Costs” means any Out-of-Pocket Costs and FTE Costs approved by the JCC and included in the Commercialization Budget and Commercialization Plan that is not otherwise included in any other Commercialization Expense
category. It is understood that Other Commercialization Costs shall not include costs associated with Development activities. 

“Out-of-Pocket Costs” means, with respect to certain activities hereunder, direct expenses paid or payable by
either Party or its Affiliates to Third Parties (other than employees of such Party or its Affiliates) that are specifically identifiable and incurred to conduct such activities for the Collaboration hereunder and have been recorded in accordance
with the Accounting Standards. 
 “Patent and Trademark Prosecution and Enforcement Costs” means (a) costs
incurred pursuant to Section 10.2(c), Section 10.3(e) and Section 10.4, and (b) costs incurred in connection with the selection, protection, utilization and defense of Product Trademarks relating to the Licensed Products. 

“Phase IV Study Expenses” means all Out-of-Pocket Costs incurred for the Territory related to a Phase IV
Study for any Licensed Product in the Territory, including expenses arising from: (a) the activities related to the performance of the Phase IV Study; (b) Manufacturing Costs for Licensed Product used in connection with such Phase IV Study; (c)
preparation, filing, and maintenance of related Regulatory Documentation; and (d) any Product Liabilities relating to a Licensed Product being used in the course of such Phase IV Study; provided, however, that any losses,
damages, fees, costs and other liabilities, including any Product Liabilities, that are the result of a Party’s negligence, gross negligence, illegal conduct, willful misconduct or breach of such Party’s representations or warranties, are
expressly excluded from the definition of Phase IV Study Expenses, and shall be treated as the sole and exclusive responsibility of the Party whose actions or omissions gave rise to such losses, damages, fees, costs and other liabilities. 

“Product Liabilities” means all losses, damages, fees, costs and other liabilities incurred by a Party, its
Affiliate or its sublicensee and resulting from or relating to the use of a Licensed Product in a human (including clinical trials or Commercialization) in the Territory incurred after 

  
 D-6 

 
the Effective Date. For the avoidance of doubt, Product Liabilities include reasonable attorneys’ and experts’ fees and costs relating to any claim or potential claim against a Party,
its Affiliate, or its sublicensee and all losses, damages, fees and costs associated therewith. Product Liabilities shall not include liabilities associated with recalls or the voluntary or involuntary withdrawal of the Licensed Product. 

“Profit or Loss” means the profits or losses resulting from the Commercialization of the Licensed Products in
the Territory and which shall be equal to (a) the sum of (i) Net Sales of Licensed Products in the Territory, plus (ii) Additional Revenue, less (b) Commercialization Expenses for such Licensed Products. As used herein,
“Profit” refers to a Calendar Quarter or Calendar Year in which a profit exists, and “Loss” refers to a Calendar Quarter or Calendar Year in which a loss exists. 

“Recall Expenses” means Out-of-Pocket Costs and FTE Costs directly associated with notification, retrieval
and return of Licensed Products, distribution of such returned Licensed Products, replacement Licensed Products and distribution of the replacement Licensed Products, in each case that are incurred with respect to a recall conducted in accordance
with Section 5.4 of this Agreement. 
 “Regulatory Expenses” means, with respect to the Licensed Products,
all Out-of-Pocket Costs incurred by or on behalf of a Party in connection with the preparation and filing of regulatory submissions for the Licensed Products and obtaining of Regulatory Approvals and any applicable governmental price and
reimbursement approvals. 
 “Regulatory Maintenance Costs” means Out-of-Pocket Costs and FTE Costs for
maintenance fees relating to Regulatory Approvals for the Licensed Products, and personnel engaged in the filing and maintenance of Regulatory Approvals. 

“Selling Expenses” means (a) the FTE Costs incurred by the Parties in performance of details or Out-of-Pocket
Costs incurred by the Parties for the performance of details by a qualified contract sales force in the Territory; where such FTE Costs shall be calculated on the basis of a fixed rate per detail, which shall be approved by the JSC prior to the
First Commercial Sale, and (b) Out-of-Pocket Costs and FTE Costs directly attributable to selling the Licensed Products, including sales managers, exhibits at shows or conventions including samples, charges for space, sales aids and brochures, sales
meetings, specialty sales forces, call reporting and Third Party monitoring/tracking services. 
 “Third Party
Patent Costs” means Out-of-Pocket Costs paid to Third Parties pursuant to Section 9.6 of this Agreement. 
 All costs in this
Exhibit D shall be as determined from the books and records of the applicable Party and its Affiliates maintained in accordance with the Accounting Standards.

  
 D-7 

 Exhibit E 

Countries for Filing Agios Patents, Celgene Collaboration Patents and Agios Co-Co 

Collaboration Patents 

[**] 

  
 E-1 

 Exhibit F 

Press Release 

  
 F-1 

 Exhibit G 

PARTNERSHIP TAX MATTERS 
  

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of 5 pages were omitted. [**] 

  
 G-1 

 SCHEDULE 6.3 

Minimum Agios and Celgene Sales Representative Qualifications 

[**]. 

  

 Disclosure Schedules 

[tailor as applicable] 

Schedule 12.2(d) 
 Schedule
12.2(e) 
 Schedule 12.2(f) 

Schedule 12.2(h) 
 Schedule
12.2(i)          Patents 
 Schedule
12.2(j)          Existing Third Party Agreements 
 [Note: exceptions in Section 12.2 to be
identified, if applicable] 

  

 APPENDIX B 

FORM OF LICENSE AGREEMENT 

  
 B-1 

 FINAL VERSION 

APPENDIX B 
 FORM OF
LICENSE AGREEMENT 
  
  

LICENSE AGREEMENT 
 by and among

 AGIOS PHARMACEUTICALS, INC. 

and 
 CELGENE CORPORATION 

and 
 CELGENE RIVOT LTD. 

 TABLE OF CONTENTS 

 

							
		  		  	 	Page	  
		
	 ARTICLE I. DEFINITIONS
	  	 	1	  
		
	 ARTICLE II. GOVERNANCE
	  	 	10	  
			
	 Section 2.1.
	  	Meetings and Reports	  	 	10	  
			
	 Section 2.2.
	  	Certain Interactions with and Effects on the Master Agreement	  	 	11	  
		
	 ARTICLE III. DEVELOPMENT
	  	 	11	  
			
	 Section 3.1.
	  	Development of Licensed Products	  	 	11	  
			
	 Section 3.2.
	  	Companion Diagnostics	  	 	12	  
			
	 Section 3.3.
	  	Records; Tech Transfer	  	 	12	  
		
	 ARTICLE IV. MANUFACTURE AND SUPPLY
	  	 	13	  
			
	 Section 4.1.
	  	Pre-Clinical, Clinical and Commercial Supply	  	 	13	  
			
	 Section 4.2.
	  	Transfer of Manufacturing Responsibility	  	 	13	  
			
	 Section 4.3.
	  	Manufacturing Efforts	  	 	13	  
		
	 ARTICLE V. REGULATORY MATTERS
	  	 	14	  
			
	 Section 5.1.
	  	Transfer of Regulatory Documentation	  	 	14	  
			
	 Section 5.2.
	  	Responsibility for Regulatory Interactions	  	 	14	  
			
	 Section 5.3.
	  	Review of Regulatory Documentation	  	 	14	  
			
	 Section 5.4.
	  	Agios Ownership for Ongoing Clinical Trials	  	 	14	  
			
	 Section 5.5.
	  	Right of Reference or Use	  	 	14	  
			
	 Section 5.6.
	  	Pharmacovigilance	  	 	15	  
		
	 ARTICLE VI. COMMERCIALIZATION
	  	 	15	  
			
	 Section 6.1.
	  	Commercialization Responsibilities for Licensed Products	  	 	15	  
			
	 Section 6.2.
	  	Trademarks	  	 	15	  
		
	 ARTICLE VII. DILIGENCE
	  	 	16	  
			
	 Section 7.1.
	  	Compliance with Laws	  	 	16	  
			
	 Section 7.2.
	  	Diligence Obligations	  	 	16	  
			
	 Section 7.3.
	  	No Representation	  	 	16	  
		
	 ARTICLE VIII. GRANT OF RIGHTS; EXCLUSIVITY
	  	 	17	  
			
	 Section 8.1.
	  	License Grants	  	 	17	  
			
	 Section 8.2.
	  	Sublicense Rights	  	 	17	  

  
 -i- 

 TABLE OF CONTENTS 

(continued) 
  

							
		  		  	 	Page	  
			
	 Section 8.3.
	  	Sublicense Requirements	  	 	18	  
			
	 Section 8.4.
	  	Affiliates, Licensee Partners and Third Party Contractors	  	 	18	  
			
	 Section 8.5.
	  	Existing Third Party Agreements	  	 	19	  
			
	 Section 8.6.
	  	Exclusivity	  	 	21	  
			
	 Section 8.7.
	  	Retained Rights	  	 	23	  
			
	 Section 8.8.
	  	Section 365(n) of the Bankruptcy Code	  	 	24	  
		
	 ARTICLE IX. FINANCIAL PROVISIONS
	  	 	24	  
			
	 Section 9.1.
	  	Upfront Option Payment	  	 	24	  
			
	 Section 9.2.
	  	Milestone Payments	  	 	24	  
			
	 Section 9.3.
	  	Royalty Payments	  	 	26	  
			
	 Section 9.4.
	  	Third Party Payments	  	 	28	  
			
	 Section 9.5.
	  	Financial Records	  	 	28	  
			
	 Section 9.6.
	  	Audits	  	 	28	  
			
	 Section 9.7.
	  	Tax Matters	  	 	29	  
			
	 Section 9.8.
	  	Currency Exchange	  	 	30	  
			
	 Section 9.9.
	  	Late Payments	  	 	30	  
			
	 Section 9.10.
	  	Blocked Payments	  	 	30	  
		
	 ARTICLE X. INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED

                   
 MATTERS
	  	 	30	  
			
	 Section 10.1.
	  	Ownership of Inventions	  	 	30	  
			
	 Section 10.2.
	  	Prosecution of Patents	  	 	31	  
			
	 Section 10.3.
	  	Third Party Infringement of Agios Patents, Celgene Collaboration Patents and Joint Patents	  	 	33	  
			
	 Section 10.4.
	  	Claimed Infringement; Claimed Invalidity	  	 	35	  
			
	 Section 10.5.
	  	Patent Term Extensions	  	 	36	  
			
	 Section 10.6.
	  	Patent Marking	  	 	36	  
			
	 Section 10.7.
	  	Celgene Intellectual Property	  	 	36	  
			
	 Section 10.8.
	  	Application of 35 U.S.C. § 102(c)	  	 	36	  
		
	 ARTICLE XI. CONFIDENTIALITY
	  	 	37	  
			
	 Section 11.1.
	  	Confidential Information	  	 	37	  

  
 -ii- 

 TABLE OF CONTENTS 

(continued) 
  

							
		  		  	 	Page	  
			
	 Section 11.2.
	  	Permitted Disclosure	  	 	37	  
			
	 Section 11.3.
	  	Publicity; Terms of this Agreement; Non-Use of Names	  	 	38	  
			
	 Section 11.4.
	  	Publications	  	 	40	  
			
	 Section 11.5.
	  	Term	  	 	40	  
			
	 Section 11.6.
	  	Return of Confidential Information	  	 	41	  
		
	 ARTICLE XII. REPRESENTATIONS AND WARRANTIES
	  	 	42	  
			
	 Section 12.1.
	  	Mutual Representations	  	 	42	  
			
	 Section 12.2.
	  	Additional Agios Representations	  	 	42	  
			
	 Section 12.3.
	  	Covenants	  	 	44	  
			
	 Section 12.4.
	  	Agios Covenants During the Term	  	 	44	  
			
	 Section 12.5.
	  	Disclaimer	  	 	45	  
		
	 ARTICLE XIII. INDEMNIFICATION; PRODUCT LIABILITIES
	  	 	45	  
			
	 Section 13.1.
	  	By Celgene	  	 	45	  
			
	 Section 13.2.
	  	By Agios	  	 	46	  
			
	 Section 13.3.
	  	Product Liability Costs	  	 	47	  
			
	 Section 13.4.
	  	Limitation of Liability	  	 	47	  
			
	 Section 13.5.
	  	Insurance	  	 	47	  
		
	 ARTICLE XIV. TERM AND TERMINATION
	  	 	48	  
			
	 Section 14.1.
	  	Term	  	 	48	  
			
	 Section 14.2.
	  	Effect of Expiration	  	 	48	  
			
	 Section 14.3.
	  	Termination	  	 	49	  
			
	 Section 14.4.
	  	Effects of Termination	  	 	51	  
		
	 ARTICLE XV. MISCELLANEOUS
	  	 	56	  
			
	 Section 15.1.
	  	Dispute Resolution	  	 	56	  
			
	 Section 15.2.
	  	Submission to Court for Resolution	  	 	56	  
			
	 Section 15.3.
	  	Governing Law	  	 	57	  
			
	 Section 15.4.
	  	Assignment	  	 	57	  
			
	 Section 15.5.
	  	Force Majeure	  	 	58	  
			
	 Section 15.6.
	  	Notices	  	 	59	  
			
	 Section 15.7.
	  	Waiver	  	 	60	  

  
 -iii- 

 TABLE OF CONTENTS 

(continued) 
  

							
		  		  	 	Page	  
			
	 Section 15.8.
	  	Severability	  	 	60	  
			
	 Section 15.9.
	  	Entire Agreement	  	 	61	  
			
	 Section 15.10.
	  	Modification	  	 	61	  
			
	 Section 15.11.
	  	Independent Contractors; No Intended Third Party Beneficiaries	  	 	61	  
			
	 Section 15.12.
	  	Interpretation; Construction	  	 	61	  
			
	 Section 15.13.
	  	Performance by Affiliates	  	 	61	  
			
	 Section 15.14.
	  	Counterparts	  	 	62	  
			
	 Section 15.15.
	  	HSR Clearance; Cooperation	  	 	62	  
			
	 Section 15.16.
	  	Equitable Relief	  	 	62	  
			
	 Section 15.17.
	  	Further Assurances	  	 	62	  

  
 -iv- 

			
	 Exhibits

		
	 Exhibit A
	  	 Target, Compound(s) and Upfront Option Payment

		
	 Exhibit B
	  	 Agios Patents and Celgene Collaboration Patents

		
	 Exhibit C
	  	 Existing Third Party Agreements

		
	 Exhibit D
	  	 Countries for Filing Agios Patents, Celgene Collaboration Patents and Joint Patents

		
	 Exhibit E
	  	 Press Release

 Disclosure Schedules 

[tailor as applicable] 

Schedule 12.2(d) 
 Schedule
12.2(e) 
 Schedule 12.2(f) 

Schedule 12.2(h) 
 Schedule
12.2(i)        Patents 
 Schedule 12.2(j)        Existing Third Party
Agreements 

  
 - v - 

 LICENSE AGREEMENT 

This License Agreement (this “Agreement”) is entered into as of [•] (the “Execution
Date”), by and among Agios Pharmaceuticals, Inc., a Delaware corporation (“Agios”), on the one hand, and Celgene Corporation, a Delaware corporation (“Celgene Corp.”), with respect to all rights and
obligations under this Agreement in the United States, and Celgene RIVOT Ltd., a Bermuda company (“Celgene RIVOT”), with respect to all rights and obligations under this Agreement outside of the United States (Celgene RIVOT and
Celgene Corp. together, “Celgene”), on the other hand. Celgene and Agios are each referred to herein by name or as a “Party”, or, collectively, as the “Parties”. 

INTRODUCTION 
  

	1.	 Agios and Celgene are parties to the Master Research and Collaboration Agreement, dated as of May 17, 2016
(the “Master Agreement”). 

  

	2.	 Pursuant to the Master Agreement, Agios has discovered and has been developing the compound(s) in the I&I
Field identified on Exhibit A, each of which the Parties believe to be a potent [inhibitor/activator] [select applicable direction of modulation at Execution] of the metabolic target identified on Exhibit A.

  

	3.	 Except as provided herein, the Parties have agreed that the further Development and Commercialization of the
Compound should be conducted pursuant to the terms of this Agreement and that all further such activities related to the Compound should cease under the Master Agreement. 

NOW, THEREFORE, in consideration of the respective representations, warranties, covenants and agreements contained herein, and
for other valuable consideration, the receipt and adequacy of which are hereby acknowledged, Agios and Celgene hereby agree as follows: 

Article I. 
 Definitions

 Terms used but not defined herein shall have the meaning set forth in the Master Agreement. When used in this
Agreement, each of the following terms shall have the meanings set forth in this Article I: 
 Section
1.1    “Accounting Standards” means (a) GAAP (United States Generally Accepted Accounting Principles) or (b) IFRS (International Financial Reporting Standards), in either case, consistently applied, and reported
in such Person’s financial statements. 
 Section 1.2    “Agios Intellectual
Property” means Agios Know-How and Agios Patents, collectively. 
 Section
1.3    “Agios Know-How” means any Know-How that is (a) Controlled by Agios as of the Execution Date or during the Term, and (b) necessary or useful for the Development, Manufacture or Commercialization of the
Compounds or Licensed Products. 

  

 Section 1.4    “Agios Patents” means any
Patents that (a) are Controlled by Agios as of the Execution Date or during the Term, and (b) Cover, or are useful for, the Development, Manufacture or Commercialization of the Compounds or Licensed Products (including the composition of matter,
manufacture or any use thereof). Agios Patents as of the Execution Date are as set forth on Exhibit B to this Agreement. 

Section 1.5    “Annual Net Sales” means, the aggregate Net Sales of a Licensed Product by
Celgene or its Affiliates or Licensee Partners in each Calendar Year during which this Agreement is in effect. 
 Section
1.6    “Calendar Quarter” means a calendar quarter ending on the last day of March, June, September or December; provided, however, that the first Calendar Quarter shall begin on the Effective Date and end on the
last day of the calendar quarter during which the Effective Date occurs. 
 Section
1.7    “Calendar Year” means a period of time commencing on January 1 and ending on the following December 31; provided, however, that the first Calendar Year shall begin on the Effective Date and end on
December 31 of the calendar year during which the Effective Date occurs. 
 Section
1.8    “Celgene Collaboration Intellectual Property” means Celgene Collaboration Know-How and Celgene Collaboration Patents, collectively. 

Section 1.9    “Celgene Collaboration Know-How” means, collectively, (a) Know-How within
Celgene Collaboration Intellectual Property (as defined in the Master Agreement) that is necessary or useful for the Development, Manufacture and/or Commercialization of any Compounds or Licensed Products and (b) if the Program (as defined in the
Master Agreement) that is the subject of this Agreement is a Qualified Early Exercise I&I Program (as defined in the Master Agreement), all Know-How developed or generated on or after the Execution Date by or on behalf of Celgene and/or its
Affiliates in the conduct of the Development, Manufacture and/or Commercialization of any Compounds or Licensed Products pursuant to this Agreement, in each case ((a) and (b)), Controlled by Celgene. 

Section 1.10    “Celgene Collaboration Patents” means, collectively, (a) Patents within
Celgene Collaboration Intellectual Property (as defined in the Master Agreement) that are necessary or useful for the Development, Manufacture and/or Commercialization of any Compounds or Licensed Products and (b) if the Program (as defined in the
Master Agreement) that is the subject of this Agreement is Qualified Early Exercise I&I Program (as defined in the Master Agreement), all Patents that Cover Celgene Collaboration Know-How, in each case ((a) and (b)) Controlled by
Celgene. Celgene Collaboration Patents as of the Execution Date are as set forth on Exhibit B to this Agreement. 

Section 1.11    “Celgene Intellectual Property” means Celgene Know-How and Celgene
Patents, collectively. 
 Section 1.12    “Celgene Know-How” means any Know-How that is
(a) Controlled by Celgene as of the Effective Date or during the Term; (b) necessary or useful for the Development, Manufacture or Commercialization of the Compounds or Licensed Products; and (c) contributed by Celgene, in Celgene’s sole
discretion, for use in the Collaboration, as evidenced by written notice from Celgene to Agios; but excluding Celgene Collaboration Know-How. 

  
 - 2 - 

 Section 1.13    “Celgene Patents” means any
Patents that (a) are Controlled by Celgene as of the Effective Date or during the Term; (b) Cover the Compounds or Licensed Products; and (c) are contributed by Celgene, in Celgene’s sole discretion, for use in the Collaboration, as evidenced
by written notice from Celgene to Agios; but excluding Celgene Collaboration Patents.
 Section
1.14    “Clinical Trial” means a Phase I Study, a Phase II Study, a Phase III Study, a Phase IV Study or a combination of any of the foregoing studies. 

Section 1.15    “Code” means the United States Internal Revenue Code of 1986, as amended.

 Section 1.16    “Collaboration” means the activities performed or to be performed by
a Party or Parties, as the case may be, relating to the Development, Manufacturing and Commercialization of the Licensed Products under this Agreement or the Master Agreement. 

Section 1.17    “Companion Diagnostic” means a biomarker or diagnostic test that is
developed by a Party or jointly by the Parties in the course of the Collaboration as a companion diagnostic for use with a Licensed Product in accordance with the Regulatory Approval(s) therefor to generate a result for the purposes of diagnosing a
disease or condition, or to facilitate the application of the Licensed Product that is used in the cure, mitigation, treatment, or prevention of disease, including a biomarker or diagnostic test used to diagnose the likelihood that a specific
patient will contract a certain disease or condition or to predict which patients are suitable candidates for a specific form of therapy. 

Section 1.18    “Compound” means (a) any compound that is listed on Exhibit A,
[or, if the applicable program is a Qualified Early Exercise I&I Program, any Program Compounds (as defined in the Master Agreement, including any chemotypes described on Schedule 1.1.83 thereto) that are listed on Exhibit A]
[insert if applicable] and (b) to the extent Active (as defined in the Master Agreement) against the Target, any salt, fluorinated derivative, free acid, free base, clathrate, solvate, hydrate, hemihydrates, anhydride, ester, chelate,
conformer, congener, crystal form, crystal habit, polymorph, amorphous solid, isomer, stereoisomer, enantiomer, racemate, prodrug, isotopic or radiolabeled equivalent, metabolite, conjugate, complex or mixture, of such chemical entity of any such
compound identified in the foregoing clause (a) or in this clause (b). 
 Section
1.19    “Confidential Information” means (a) all confidential or proprietary information relating to the Development, Manufacture or Commercialization of the Compounds or Licensed Products, and (b) all other
confidential or proprietary documents, technology, Know-How or other information (whether or not patentable) actually disclosed by one Party to the other pursuant to this Agreement or the Master Agreement relating to the Licensed Products and all
proprietary biological materials of a Party.

  
 - 3 - 

 Section 1.20    “Data” means any and all
research data, results, pharmacology data, medicinal chemistry data, preclinical data, market research, clinical data (including investigator reports (both preliminary and final), statistical analysis, expert opinions and reports, safety and other
electronic databases), in any and all forms, including files, reports, raw data, source data (including patient medical records and original patient report forms, but excluding patient-specific data to the extent required by applicable Laws) and the
like, in each case directed to, or used in, the Development, Manufacture or Commercialization of the Licensed Products. 

Section 1.21    “Effective Date” means the date on or after the Execution Date that is
the Implementation Date (as defined in the Master Agreement) with respect to this Agreement. 
 Section
1.22    “Executive Officers” means Celgene’s Chief Executive Officer (or the officer or employee of Celgene then serving in a substantially equivalent capacity) or his designee and Agios’ Chief
Executive Officer (or the officer or employee of Agios then serving in a substantially equivalent capacity) or his designee; provided that any such designee must have decision-making authority on behalf of the applicable Party. 

Section 1.23    “Existing Third Party Agreement” means any agreement listed on
Exhibit C to this Agreement. 
 Section 1.24    “Field” means the treatment,
control, mitigation, prevention or cure or diagnosis of any Indications. 
 Section
1.25    “First Commercial Sale” means the first commercial sale of a Licensed Product by Celgene, its Affiliates, Licensee Partners, distributors or agents in a country in an arms’ length transaction to a
Third Party following receipt of applicable Regulatory Approval of such product in such country. Sales for test marketing or clinical trial purposes shall not constitute a First Commercial Sale. 

Section 1.26    “[**]” means [**]. 

Section 1.27    “Generic Competition” means, with respect to a Licensed Product in a
given country in a given Calendar Year, that, during such Calendar Year one or more Generic Products shall be commercially available in such country. 

Section 1.28    “Generic Product” means, as to a Licensed Product, any product (including
a “generic product” approved by way of an Abbreviated New Drug Application by the FDA (or equivalent regulatory mechanism for another Regulatory Authority), “biogeneric,” “follow-on biologic,” “follow-on biological
product,” “follow-on protein product,” “similar biological medicinal product,” or “biosimilar product”) that, in each case, (a) is sold by a Third Party that is not a Licensee Partner of Celgene or any of its
Affiliates and that has not otherwise been authorized by Celgene or any of its Affiliates under a Regulatory Approval granted by a Regulatory Authority to such Third Party that is based upon or relies upon the Regulatory Approval granted by such
Regulatory Authority for such Licensed Product; and (b) in the United States, is “therapeutically equivalent,” “comparable,” “biosimilar,” or “interchangeable,” as evaluated by the FDA, applying the definition
of “therapeutically equivalent” set forth in the preface to the then-current edition of the FDA publication “Approved Drug Products With Therapeutic Equivalence Evaluations” or any other definitions set forth in the U.S. Code,
FDA regulations, or other source of U.S. Law and, outside the United States, meets such equivalent determination by the applicable Regulatory Authorities (including a determination that the 

  
 - 4 - 

 
product is “comparable,” “interchangeable,” “bioequivalent,” or “biosimilar” with respect to the Licensed Product), in each case, as is necessary to permit
a pharmacist or other individual authorized to dispense pharmaceuticals under Law to substitute one product for another product in the absence of specific instruction from a physician or other authorized prescriber under Law 

Section 1.29    “[**]” means [**]. 

Section 1.30    “Licensed Products” means (a) a Compound, and (b) any product that
contains a Compound as an active ingredient. 
 Section 1.31    “Licensee Partner”
means any Third Party to whom Celgene or any of its Affiliates or any other Licensee Partner grants a sublicense or license with respect to the Development, Manufacture or Commercialization of Licensed Products in the Field under the rights to Agios
Intellectual Property, granted to Celgene or its Affiliate hereunder, in each case excluding (a) Third Party Contractors and (b) wholesale distributors or any other Third Party that purchases Licensed Product in an arm’s-length transaction,
where such Third Party does not have a sublicense to Develop, Manufacture or Commercialize the Licensed Product except for a limited sublicense to the extent required to enable such Third Party to perform final packaging for such Licensed Product
for local distribution. 
 Section 1.32    “Major [**]” means [**]. 

Section 1.33    “Major Market” means [**]. 

Section 1.34    “Manufacture” or “Manufacturing” means, as applicable,
all activities associated with the production, manufacture, processing, filling, packaging, labeling, shipping, and storage of a drug substance or drug product, or any components thereof, including process and formulation development, process
validation, stability testing, manufacturing scale up, preclinical, clinical and commercial manufacture and analytical methods development and validation, product characterization, quality assurance and quality control development, testing and
release. 
 Section 1.35    “Manufacturing Technology” means copies of all Agios
Know-How or Celgene Know-How, as applicable, which are necessary or useful for Manufacturing preclinical, clinical or commercial supply, as applicable, of the Licensed Products, including specifications, assays, batch records, quality control data,
and transportation and storage requirements. 
 Section 1.36    “NDA” means an
application submitted to a Regulatory Authority for the marketing approval of a Licensed Product, including (a) a New Drug Application, Product License Application or Biologics License Application (as such capitalized terms are used in C.F.R Title
21) filed with FDA or any successor applications or procedures, (b) a foreign equivalent of a U.S. New Drug Application, Product License Application or Biologics License Application or any successor applications or procedures, including a Marketing
Authorization Application in the European Union, and (c) all supplements and amendments that may be filed with respect to the foregoing. 

  
 - 5 - 

 Section 1.37    “Net Sales” means, with
respect to any Licensed Product, the gross amounts invoiced by Celgene, its respective Affiliates or Licensee Partners to Third Parties (that are not Licensee Partners) for the sale or other commercial disposition of such Licensed Product anywhere
within the Territory (each, a “Selling Party”) to Third Party customers for sales of such Licensed Product, less the following deductions actually incurred, allowed, paid, accrued or specifically allocated in its financial
statements in accordance with (as applicable to the Selling Party) the Accounting Standards, for: 
 [**]. 

If non-monetary consideration is received by a Selling Party for any Licensed Product in the relevant country, Net Sales will be calculated
based on the average price charged for such Licensed Product, as applicable, during the preceding royalty period, or in the absence of such sales, the fair market value of the Licensed Product, as applicable, as determined by the Parties in good
faith. Notwithstanding the foregoing, Net Sales shall not be imputed to transfers of Licensed Products, as applicable, for use in Clinical Trials, non-clinical development activities or other development activities with respect to Licensed Products
by or on behalf of the Parties, for bona fide charitable purposes or for compassionate use or for Licensed Product samples, if no monetary consideration is received for such transfers. 

If a Licensed Product is sold as part of a Combination Product (as defined below), Net Sales will be the product of (i) Net Sales of the
Combination Product calculated as above (i.e., calculated as for a non-Combination Product) and (ii) the fraction (A/(A+B)), where: 

“A” is the gross invoice price in such country of the Licensed Product comprising a Compound as the sole therapeutically active
ingredient; and 
 “B” is the gross invoice price in such country of the other therapeutically active ingredients contained in the
Combination Product. 
 If “A” or “B” cannot be determined by reference to non-Combination Product sales as described
above, then Net Sales will be calculated as above, but the gross invoice price in the above equation shall be determined by mutual agreement reached in good faith by the Parties prior to the end of the accounting period in question based on an
equitable method of determining the same that takes into account, in the applicable country, variation in dosage units and the relative fair market value of each therapeutically active ingredient in the Combination Product. 

As used in this definition of “Net Sales,” “Combination Product” means a Licensed Product that contains one or more
additional active ingredients (whether co-formulated or co-packaged) that are neither Compounds nor generic or other non-proprietary compositions of matter. Pharmaceutical dosage form vehicles, adjuvants and excipients shall be deemed not to be
“active ingredients.” 
 There shall be no double counting in determining the foregoing deductions from gross amounts invoiced to
calculate Net Sales. Subject to the foregoing, the calculations set forth in this definition of Net Sales shall be determined in accordance with Accounting Standards so as to arrive at Net Sales under Accounting Standards as reported by the
Selling Party in such Person’s financial statements. 

  
 - 6 - 

 Section 1.38    “Out-of-Pocket Costs” means,
with respect to certain activities, direct expenses paid or payable by either Party or its Affiliates to Third Parties (other than employees of such Party or its Affiliates) that are specifically identifiable and incurred to conduct such activities
and have been recorded in accordance with the Accounting Standards. 
 Section 1.39    “Phase IV
Study” means a human clinical trial of a product which is (a) conducted to satisfy a requirement of a Regulatory Authority in order to maintain a Regulatory Approval or (b) conducted voluntarily after Regulatory Approval of the product has
been obtained from an appropriate Regulatory Authority for enhancing marketing or scientific knowledge of an approved Indication. 

Section 1.40    “Product Liabilities” means all product liability losses, damages, fees,
costs and other liabilities incurred by a Party, its Affiliate or its Licensee Partner and resulting from or relating to the use of a Licensed Product in a human (including Clinical Trials or Commercialization) incurred after the Execution Date. For
the avoidance of doubt, Product Liabilities include reasonable attorneys’ and experts’ fees and costs relating to any claim or potential claim against a Party, its Affiliate, or its Licensee Partner and all losses, damages, fees and costs
associated therewith. Product Liabilities shall not include liabilities associated with recalls or the voluntary or involuntary withdrawal of the Licensed Product. 

Section 1.41    “Regulatory Documentation” means, with respect to the Licensed Products,
all INDs, NDAs and other regulatory applications submitted to any Regulatory Authority, Regulatory Approvals, pre-clinical and clinical data and information, regulatory materials, drug dossiers, master files (including Drug Master Files, as defined
in 21 C.F.R. 314.420 and any non-United States equivalents), and any other data, reports, records, regulatory correspondence and other materials relating to Development or Regulatory Approval of the Licensed Products, or required to Manufacture,
distribute or sell the Licensed Products, including any information that relates to pharmacology, toxicology, chemistry, Manufacturing and controls data, batch records, safety and efficacy, and any safety database. 

Section 1.42    “Regulatory Exclusivity” means, with respect to a Licensed Product in a
country, that the Licensed Product has been granted marketing exclusivity afforded approved drug products, or approved biological products if applicable, pursuant to (a) Sections 505(c), 505(j), and 505A of the FDCA, and the regulations promulgated
thereunder, as amended from time to time, or similar laws enacted to apply to biological products, and the regulations promulgated thereunder, as amended from time to time, or their equivalent in a country other than the United States, (b) the
orphan drug exclusivity afforded approved drugs designated for rare diseases or conditions under Sections 526 and 527 of the FDCA, and the regulations promulgated thereunder, as amended from time to time, or its equivalent in a country other than
the United States, or (c) any future Law. 
 Section 1.43    “Reimbursable Back-up
Expenses” means, [**]. The amount of the Reimbursable Back-up Expenses, if any, is set forth on Annex I to Exhibit A. 

Section 1.44    “Reimbursable Manufacturing Expenses” means, [**]. The amount of the
Reimbursable Manufacturing Expenses, if any, is set forth on Annex I to Exhibit A. 

  
 - 7 - 

 Section 1.45    “Right of Reference or Use”
means a “Right of Reference or Use” as that term is defined in 21 C.F.R. §314.3(b), and any non-United States equivalents. 

Section 1.46    “Target” means the metabolic target set forth on Exhibit A. 

Section 1.47    “Territory” means worldwide. 

Section 1.48    “Third Party Agreement” means (a) each [**] and (b) any other Third Party
agreement that Celgene may enter into, during the Term in accordance with the terms of this Agreement, to acquire or license Third Party Patents or Know-How that are necessary or useful for the Development, Manufacture or Commercialization of the
Compounds or Licensed Products. 
 Section 1.49    “Third Party Rights” means, with
respect to a Party, any rights of, and any limitations, restrictions or obligations imposed by, Third Parties pursuant to any Third Party Agreements. 

Section 1.50    “Valid Claim” means (a) a claim of any issued, unexpired patent that has
not been revoked or held unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction from which no appeal can be taken, or with respect to which an appeal is not taken within the time allowed for appeal, and
that has not been disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (b) a patent application or subject matter of a claim thereof filed by a Person in good faith that has not been cancelled, withdrawn
or abandoned, nor been pending for more than [**] from the earliest filing date to which such patent application or claim is entitled. 

Section 1.51    Additional Definitions. Each of the following definitions is set forth in the section
of this Agreement indicated below: 
  

			
	 DEFINITION 
	  	 SECTION

		
	35 U.S.C. § 102(c) Patent	  	Section 10.8
	[**]	  	Section 8.6(b)(iii)
	Acquirer Program	  	Section 8.6(b)(v)(4)
	Affiliate	  	Master Agreement
	Agios	  	Preamble
	Agios Indemnified Parties	  	Section 13.1(a)
	Agios Program Assets	  	Section 12.4
	Agreement	  	Preamble
	Antitrust Law	  	Master Agreement
	Audit Team	  	Section 9.6(a)
	Bankruptcy Code	  	Section 8.8
	Business Day	  	Master Agreement
	Celgene	  	Preamble
	Celgene Corp.	  	Preamble
	Celgene RIVOT	  	Preamble
	Celgene Indemnified Parties	  	Section 13.2(a)

  
 - 8 - 

			
	 DEFINITION 
	  	 SECTION

		
	 Celgene Manufacturing Responsibilities
	  	 Section 4.1(a)

	 Challenge
	  	 Section 14.3)(d)

	 Challenging Party
	  	 Section 14.3(d)

	 Combination Product
	  	 Section 1.37

	 Commercialization/Commercialize
	  	 Master Agreement

	 Commercialization Report
	  	 Section 2.1(c)

	 Commercially Reasonable Efforts
	  	 Master Agreement

	 Competitive Infringement
	  	 Section 10.3(b)

	 Competitive Program
	  	 Section 8.6(b)(iv)

	 Competitive Program Party
	  	 Section 8.6(b)(iv)

	 Control/Controlled
	  	 Master Agreement

	 Cooperating Party
	  	 Section 11.3(b)(iii)

	 Cover/Covering/Covered
	  	 Master Agreement

	 Cure Period
	  	 Section 14.3(b)(i)

	 Develop/Development
	  	 Master Agreement

	 Development Costs
	  	 Master Agreement

	 Disclosing Party
	  	 Section 11.1

	 Dispute
	  	 Section 15.1

	 Earlier Patent
	  	 Section 10.8

	 Electronic Delivery
	  	 Section 15.14

	 Execution Date
	  	 Preamble

	 FDA
	  	 Master Agreement

	 FDA
	  	 Master Agreement

	 force majeure event
	  	 Section 15.5

	 IND
	  	 Master Agreement

	 Indication
	  	 Master Agreement

	 [**]
	  	 Section 9.7(a)

	 Invalidity Claim
	  	 Section 10.4(b)

	 Joint Inventions
	  	 Section 10.1(c)

	 Joint Patents
	  	 Section 10.1(c)

	 Know-How
	  	 Master Agreement

	 Law
	  	 Master Agreement

	 Licensed Branding
	  	 Section 6.2(c)

	 Licensed Product Data
	  	 Section 14.4(c)

	 Manufacturing Costs
	  	 Master Agreement

	 Master Agreement
	  	 Introduction

	 Material Breach
	  	 Section 14.3(b)(i)

	 Metabolic Target
	  	 Master Agreement

	 Ongoing Clinical Trial
	  	 Section 3.1(a)

	 Party/Parties
	  	 Preamble

	 Patents
	  	 Master Agreement

	 Payee Party
	  	 Section 9.7(a)

	 Paying Party
	  	 Section 9.7(a)

	 Person
	  	 Master Agreement

	 Phase I Study
	  	 Master Agreement

  
 - 9 - 

			
	 DEFINITION 
	  	 SECTION

		
	 Phase II Study
	  	 Master Agreement

	 Phase III Study
	  	 Master Agreement

	 Product Trademarks
	  	 Section 6.2(a)

	 Prosecuting Party
	  	 Section 10.2(d)(i)

	 Prosecution/Prosecute
	  	 Master Agreement

	 Publication
	  	 Master Agreement

	 Pursuing Party
	  	 Section 14.3(d)

	 Receiving Party
	  	 Section 11.1

	 Redacted Version
	  	 Section 11.3(b)(i)

	 Regulatory Approval
	  	 Master Agreement

	 Regulatory Authority
	  	 Master Agreement

	 Regulatory Interactions
	  	 Section 5.1

	 Requesting Party
	  	 Section 11.3(b)(iii)

	 Royalty Term
	  	 Section 9.3(b)

	 SEC
	  	 Section 11.3(b)(i)

	 Selling Party
	  	 Section 1.37

	 Term
	  	 Section 14.1

	 Therapeutic Modality
	  	 Section 8.6(a)

	 Third Party
	  	 Master Agreement

	 Third Party Contractors
	  	 Section 8.2(a)(ii)

	 Third Party Infringement
	  	 Section 10.3(a)

	 Third Party Infringement Action
	  	 Section 10.4(a)

 Article II. 

Governance 

Section 2.1.    Meetings and Reports. During the Term: 

(a)    Committees. The Committees shall not oversee or review any of the matters under
this Agreement. 
 (b)    Status Reports. Celgene shall provide to Agios a
written progress report every [**] during the Term on the status of its material Development activities with respect to the Program under this Agreement. Celgene shall use Commercially Reasonable Efforts to respond to Agios’ reasonable
requests for further information regarding any status reports provided to Agios by Celgene in accordance with this Section 2.1(b). 

(c)    Commercialization Reports. Every [**] during the Term, Celgene shall provide to Agios,
a written progress report on the status of its material Commercialization activities with respect to Licensed Products (a “Commercialization Report”) during the preceding [**] period. Celgene shall use Commercially Reasonable
Efforts to respond to Agios’ reasonable requests for further information regarding any status reports provided to Agios by Celgene in accordance with this Section 2.1(c). 

  
 - 10 - 

 (d)    Meetings. The Parties shall meet at least
[**] during the Term to discuss Celgene’s Development, Commercialization and Prosecution activities. 
 Section
2.2.    Certain Interactions with and Effects on the Master Agreement. Upon and after the Effective Date, notwithstanding anything to the contrary in the Master Agreement (with each quoted term below having the
meaning given in the Master Agreement): 
 (a)    Except as provided herein, all activities regarding
Development, Manufacturing and Commercialization of a Compound, Licensed Product or Companion Diagnostic shall cease under the Master Agreement and all future such activities shall be conducted solely under this Agreement. 

(b)    None of the Parties’ activities performed in accordance with this Agreement (including those
activities specifically permitted upon and after termination) shall be deemed a violation of Section 5.2 of the Master Agreement. 

(c)    No decision of any “Committee” or working group under the Master Agreement shall have
any binding effect with respect to Development, Manufacturing and Commercialization of a Compound or a Licensed Product under this Agreement.

(d)    All “Confidential Information” disclosed under the Master Agreement that solely relates
to a Compound or any Licensed Product shall be deemed to be Confidential Information disclosed under this Agreement and not the Master Agreement. All “Confidential Information” disclosed under the Master Agreement that relates to, but
does not solely relate to, any Compound or any Licensed Product shall be deemed “Confidential Information” disclosed under the Master Agreement and also Confidential Information disclosed under this Agreement; provided,
however, that any disclosure of such information that is permitted under the Master Agreement shall not be deemed a breach of this Agreement and any disclosure of such information that is permitted under this Agreement shall not be
deemed a breach of the Master Agreement. 
 Article III. 

Development 

Section 3.1.    Development of Licensed Products. As of and after the Effective Date,
except as set forth in Sections 3.1(a) and (b) below, Celgene will assume sole responsibility for, and control of, Developing, Manufacturing and Commercializing Compounds, Licensed Products and Companion Diagnostics in the Field in the Territory,
and, except as otherwise set forth in this Agreement, will have sole responsibility to pay for all costs and expenses arising from the Development, Manufacture and Commercialization of Compounds, Licensed Products and Companion Diagnostics in the
Field in the Territory. Accordingly, the Parties agree as follows: 
 (a)    Ongoing
Clinical Trials. If Agios was conducting a Clinical Trial(s) as part of Pre-Exercise Phase I Development (as defined in the Master Agreement), excluding any expansion cohorts in such Clinical Trial(s) that are not part of Pre-Exercise Phase I
Development, anywhere in the world with respect to any Compound and/or Licensed Product under the Collaboration which has not been completed as of the Effective Date (“Ongoing  

  
 - 11 - 

 
Clinical Trial”), then, at [**] sole election, [**] will [**] be responsible for the performance of such Ongoing Clinical Trial, at [**] expense, in accordance with the terms of the
applicable Clinical Trial protocol, until completion thereof, and notwithstanding Section 5.6, [**] will be responsible for adverse drug experiences reporting with respect to such Ongoing Clinical Trial until its completion; and 

(b)    Clinical Supply. If Agios was responsible for supply of Compound and/or Licensed
Product for any Ongoing Clinical Trial(s) that have not been completed as of the Effective Date, then Agios will continue to be responsible at its cost for supplying such Compound and/or Licensed Product for such Ongoing Clinical Trial(s) (in the
relevant dosage strength, formulation and presentation). 
 Section 3.2.    Companion
Diagnostics. Celgene may, in its sole discretion, Develop, Manufacture or Commercialize a Companion Diagnostic for use with the Licensed Products and may, in its sole discretion, use a Third Party Contractor to perform all Development,
Manufacturing and Commercialization for the Companion Diagnostic, which activities may include continued Development of a Companion Diagnostic for which Development was commenced under the Master Agreement. In such event, (i) the definition of
“Licensed Product” shall include the Companion Diagnostic for purposes of defining Agios Patents, Celgene Patents, Celgene Collaboration Patents and Joint Patents, and each of the licenses granted to Celgene under Article VIII;
provided, however, that in no event shall any payments be owed by Celgene to Agios (including pursuant to Article IX) with respect to a Companion Diagnostic.

Section 3.3.    Records; Tech Transfer. 

(a)    Maintenance of Records. Celgene shall maintain in all material respects, and shall
require its Third Party Contractors to maintain in all material respects, complete and accurate records in segregated books of all Development work conducted under this Agreement and all results, data and developments made in conducting such
activities. Such records shall be complete and accurate and shall fully and properly reflect all such work done and results achieved in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes. Celgene
shall require the applicable study sites to maintain original source documents from Clinical Trials of the Licensed Products for at least [**] (or such longer period as is commercially reasonable under the circumstances, taking into account
maintenance requirements under applicable Law) following completion of the Development activities undertaken by Celgene or its Third Party Contractors; provided that Celgene or Agios shall be entitled to obtain copies of such source
documents at the end of such [**] period, but solely to the extent access to such records are necessary for Agios to exercise its rights under this Agreement. 

(b)    Inspection. Agios shall have the right (no more than [**]), during normal business
hours and upon reasonable notice, to inspect and copy (or request Celgene to copy) all records of Celgene or its Third Party Contractors, as applicable, maintained in connection with the work done and results achieved in the performance of
Development activities under this Agreement, but solely to the extent access to such records is necessary for Agios to exercise its rights under this Agreement. 

  
 - 12 - 

 (c)    Tech Transfer. As soon as reasonably
practical after the Effective Date and thereafter upon Celgene’s reasonable request during the Term, Agios shall transfer to Celgene, at no cost to Celgene, copies of all Agios Know-How (including for the avoidance of doubt any Manufacturing
Technology Controlled by Agios) and any [**] materials Controlled by Agios that are related to the Program related to the Licensed Product, to the extent not previously transferred to Celgene. In addition, Agios shall provide reasonable
assistance, including making its personnel reasonably available for meetings or teleconferences to answer questions and provide technical support to Celgene with respect to regulatory and Manufacturing transition matters and the use of such
transferred Know-How in the Development, Manufacture and Commercialization of Licensed Products. The Out-of-Pocket Costs, as indicated with reasonable supporting evidence of such incurred Out-of-Pocket Costs, incurred by Agios in connection
with such assistance shall be reimbursed by Celgene within [**] after receipt by Celgene of an invoice for such costs. 
 Article IV.

 Manufacture and Supply 

Section 4.1.    Pre-Clinical, Clinical and Commercial Supply.

(a)    Celgene Responsibilities. Celgene shall be responsible for Manufacturing, or having
Manufactured by its designee, all supply of Licensed Products, including drug product manufacturing and processing, filling, packaging, labeling, shipping and storage of Licensed Products for all Clinical Trials (other than Ongoing Clinical Trials
conducted by Agios pursuant to Section 3.1) and for Commercialization of Licensed Products (collectively, the “Celgene Manufacturing Responsibilities”).

(b)    Manufacturing Costs. Except as otherwise set forth herein, Manufacturing Costs
associated with clinical and commercial supply of the Licensed Products shall be borne by Celgene, other than for any Ongoing Clinical Trials conducted by Agios pursuant to Section 3.1. 

Section 4.2.    Transfer of Manufacturing Responsibility. In order to assist Celgene to
perform the Celgene Manufacturing Responsibilities, Agios shall (a) transfer, or have transferred, to Celgene or its designee all Manufacturing Technology Controlled by Agios and used in Manufacturing Licensed Products at the time of such transfer
to the extent relevant to the Celgene Manufacturing Responsibilities and use Commercially Reasonable Efforts to complete such transfer within [**] after the Effective Date, and (b) provide reasonable assistance in connection with the transfer of
such Manufacturing responsibility to Celgene or its designee. The Out-of-Pocket Costs incurred by Agios in connection with such transfer shall be reimbursed by Celgene within [**] after receipt by Celgene of an invoice for such costs. 

Section 4.3.    Manufacturing Efforts. Celgene shall use Commercially Reasonable Efforts to
ensure adequate manufacturing capacity to meet forecast demand for the applicable Licensed Product, including the establishment of an alternative supply source. Celgene shall also use Commercially Reasonable Efforts to ensure adequate
pre-clinical, clinical and commercial supply of the applicable Licensed Product to Develop or Commercialize, as applicable, such Licensed Products.

  
 - 13 - 

 Article V. 

Regulatory Matters 

Section 5.1.    Transfer of Regulatory Documentation. Agios shall transfer, within [**]
after the Effective Date (but subject to Section 5.4), to Celgene any and all Regulatory Approvals and Regulatory Documentation (including the IND and any foreign counterparts thereof) for all Compounds, Licensed Products and Companion Diagnostics
in the Territory, and thereafter Celgene (or its designee) shall file and hold title to all Regulatory Documentation and Regulatory Approvals and supplements thereto relating to Compounds, Licensed Products and Companion Diagnostics in the
Territory. 
 Section 5.2.    Responsibility for Regulatory Interactions. As of and after
the date upon which the transfer described in Section 5.1 is effected, Celgene shall have sole responsibility for all Regulatory Interactions with Regulatory Authorities with respect to each Licensed Product. As used herein, the term
“Regulatory Interactions” means (i) monitoring and coordinating all regulatory actions, preparing, submitting and coordinating all communications and filings with, and submissions to, all Regulatory Authorities with respect to the
Development, Manufacture and Commercialization of Compounds, Licensed Products and Companion Diagnostics and (ii) interfacing, corresponding and meeting with the Regulatory Authorities with respect to the Compounds, Licensed Products and Companion
Diagnostics. 
 Section 5.3.    Review of Regulatory Documentation. During the Term, Celgene
shall keep Agios reasonably informed of all Regulatory Interactions, preparation of all Regulatory Documentation, Regulatory Authority review of Regulatory Documentation, Regulatory Approvals, annual reports, including annual safety reports to the
respective health authorities, annual re-assessments, and any subsequent variations and changes to labeling, in each case with respect to the Compounds, Licensed Products and Companion Diagnostics. Celgene shall respond within [**] to all
reasonable inquiries by Agios with respect to any information provided pursuant to this Section 5.3 (and sufficiently promptly for Agios to provide meaningful input with respect to responses to Regulatory Authorities). 

Section 5.4.    Agios Ownership for Ongoing Clinical Trials. Notwithstanding the
foregoing Section 5.1 and Section 5.2, in the event Agios continues to be responsible for the performance of an Ongoing Clinical Trial pursuant to and in accordance with Section 3.1(a), Agios will retain ownership of any Regulatory Documentation and
Regulatory Approvals (including the IND and any foreign counterparts thereof) for the corresponding Compound and Licensed Products until completion of such Ongoing Clinical Trial.

Section 5.5.    Right of Reference or Use. In the event of failure to assign such
Regulatory Documentation and Regulatory Approvals to Celgene as required by Section 5.1 and Section 5.2, Agios hereby consents and grants to Celgene a Right of Reference or Use (without any further action required on the part of Agios, whose
authorization to file this consent with any Regulatory Authority is hereby granted) to any such Regulatory Documentation and Regulatory Approvals (including all data contained or referenced therein) that are necessary for the Development,
Manufacture or Commercialization (as set forth in this Agreement) of the Compounds, Licensed Products and Companion Diagnostics. 

  
 - 14 - 

 Section 5.6.    Pharmacovigilance. Celgene will
deploy and administer any safety monitoring activity implemented for the Licensed Product in the Territory, and be responsible for all pharmacovigilance activities for the Licensed Product in the Territory. Further, Agios will follow the
adverse event reporting requirements and processes set forth in the pharmacovigilance agreement described in this Section 5.6. In addition: 

(a)    In accordance with the procedures established by the Parties under Section 5.6, each Party shall
cooperate with the other Party and share information concerning the pharmaceutical safety of each Compound and Licensed Product. Each Party shall promptly advise the other Party of any information that comes to its knowledge that may affect the
safety, effectiveness or labelling of such Compound or Licensed Product and any actions taken in response to such information. Treatment of safety information, standard operating procedures and training, as well as a statement of respective
regulatory obligations shall be agreed in a separate pharmacovigilance agreement between Agios and Celgene (or an Affiliate of Celgene, as designated by Celgene).

(b)    Following the date on which the transfer described in Section 5.1 is effected, Celgene shall be
solely responsible for reporting all adverse drug experiences associated with the Compound, Licensed Products and Companion Diagnostics in the Territory, and for establishing, holding and maintaining the global safety database for the Compound,
Licensed Products and Companion Diagnostics. Each Party shall provide the other Party with all Licensed Product and Companion Diagnostics complaints, adverse event information and safety data from clinical studies that are in its possession and
control and that are necessary or desirable for the other Party to comply with all applicable Laws with respect to Compound, Licensed Products and Companion Diagnostics. Further, the Parties shall commence good faith discussions with respect to
entering into a separate pharmacovigilance agreement, as and when requested by Celgene. 
 Article VI. 

Commercialization 

Section 6.1.    Commercialization Responsibilities for Licensed Products. 

(a)    Responsibility. Celgene shall have the sole responsibility for, and right to carry
out, Commercialization of Licensed Products in the Territory.
 (b)    Sales. Celgene will
book all sales of the Licensed Products in the Territory and will have the sole responsibility for the processing of orders, invoicing, terms of sale, and distribution of the Licensed Products throughout the Territory associated therewith. 

Section 6.2.    Trademarks. 

(a)    Selection of Trademarks. Celgene shall select the trademark(s) to be used in
connection with the marketing and sale of the Licensed Products in the Territory (such marks, together will registrations, applications for registration and common law rights therein, collectively, “Product Trademarks”).

  
 - 15 - 

 (b)    Ownership. Celgene shall own all Product
Trademarks for any Licensed Product in the Territory.
 (c)    Branding. Nothing in
this Agreement shall be construed to grant either Party any rights in or to any of the other Party’s trademarks, tradenames, logos, or other marks, including use thereof, absent a separate trademark licensing agreement entered into in
accordance with this Section 6.2(c). Notwithstanding the foregoing, subject to any restrictions on the form or content of the branding and/or co-branding of the Licensed Products (the “Licensed Branding”) imposed by any
Regulatory Authority, unless the Parties mutually agree otherwise in writing, the Licensed Branding used with respect to Licensed Products shall feature the logos of Agios and Celgene with approximately equal sizing and similar prominence, with
Celgene’s name first, on all packaging and materials used for Commercialization of such Licensed Products, to the extent permitted by applicable Law. 

Article VII. 
 Diligence

 Section 7.1.    Compliance with Laws. Celgene shall: 

(i)    perform its obligations under this Agreement in a scientifically sound and workmanlike manner; and

 (ii)    carry out all work done in the course of the Development, Manufacturing and
Commercialization of Licensed Products in compliance with all applicable Laws governing the conduct of such work. 
 Section
7.2.    Diligence Obligations. 
 (a)    Celgene, directly or through one or
more of its Affiliates or Licensee Partners, shall use Commercially Reasonable Efforts to Develop and achieve Regulatory Approval for the Licensed Products in each of the [**], and, following such Regulatory Approval, to Commercialize such Licensed
Products in each of the [**]. 
 (b)    A breach of the diligence obligations set forth in this Section
7.2 shall be deemed a material breach and shall be subject to termination under Section 14.3(b). Notwithstanding the foregoing, the Parties acknowledge that it might be commercially reasonable, under certain circumstances, for Celgene in a
given [**] to determine not to launch a Licensed Product in such [**], and failure under such circumstances to launch such Licensed Product shall not be a breach of this Agreement. 

Section 7.3.    No Representation. Subject to the foregoing obligation to use
Commercially Reasonable Efforts, neither Party makes any representation, warranty or guarantee that the Program will be successful, or that any other particular results will be achieved with respect to the Program, or any Compound, Licensed Product
or Companion Diagnostic hereunder. 

  
 - 16 - 

 Article VIII. 

Grant of Rights; Exclusivity 

Section 8.1.    License Grants. Subject to the terms and conditions of this Agreement, Agios
hereby grants to Celgene an exclusive (even as to Agios and its Affiliates), non-transferable (except as set forth in Section 15.4), worldwide right and license in the Field, with the right to grant sublicenses as set forth in Section 8.2(a) and
Section 8.2(a)(ii)(2), under Agios’ rights in Agios Intellectual Property, Joint Inventions, Joint Patents and Manufacturing Technology, to Develop, Manufacture and Commercialize Compounds and Licensed Products and Companion Diagnostics;
provided that, as to Companion Diagnostics, such license grant shall be limited to Developing, Manufacturing and Commercializing Companion Diagnostics for use as companion diagnostics with Licensed Products under this Agreement. 

Section 8.2.    Sublicense Rights. Subject to Section 8.3, Celgene shall have the following
sublicensing rights: 
 (a)    Sublicenses to Affiliates and Subcontractors. Celgene shall
have the right to grant sublicenses within the scope of the licenses and sublicense under Section 8.1: 

(i)    to its Affiliates; and 

(ii)    to Third Parties for the purpose of (a) [**] or (b) engaging Third Parties as contract research
organizations, contract manufacturers, contract sales forces, consultants, academic researchers and the like (“Third Party Contractors”) in connection with Development, Manufacturing or Commercialization activities on behalf of
Celgene or its Affiliates under this Agreement, subject to the following: 
 (1)    unless otherwise
agreed by mutual agreement of the Parties, Celgene shall require any such Third Party to whom Celgene discloses Confidential Information to enter into an appropriate written agreement obligating such Third Party to be bound by obligations of
confidentiality and restrictions on use of such Confidential Information that are no less restrictive than the obligations set forth in Article XI, including requiring such Third Party to agree in writing not to issue any Publications except in
compliance with the terms of this Agreement (except that Publications by academic collaborators shall be permitted if (i) the academic collaborator provides an advance copy of the proposed Publication under the time periods as described in Section
11.4(a)), which may be shared with Agios, (ii) agrees to delay such Publication sufficiently long enough to permit the timely preparation and filing of a patent application, and (iii) upon the request of either Party, removes from such Publication
any Confidential Information of such Party); and 
 (2)    unless otherwise agreed by mutual agreement
of the Parties, Celgene will obligate such Third Party to agree in writing to assign ownership of, or grant an exclusive, royalty-free, worldwide, perpetual and irrevocable license (with the right to grant sublicenses) to, any inventions arising
under its agreement with such Third Party to the extent related to Development, Manufacturing or Commercialization with respect to the Licensed Products in the Field; and Celgene shall structure such assignment or exclusive license so as to enable
it to sublicense such Third Party inventions to Agios pursuant to Section 8.1 (including 

  
 - 17 - 

 
permitting Agios to grant further sublicenses); provided that, in connection with any academic collaborator performing research work with respect to the Target, Compounds or
Licensed Products that is not reasonably expected by Celgene to result in inventions related to composition of matter or methods of use, it shall be sufficient for Celgene to obtain a non-exclusive, worldwide, royalty-free, perpetual license
(with the right to grant sublicenses) to, and a right to negotiate for an exclusive license, with the right to grant sublicenses, to, any inventions resulting from such research work, which sublicensing rights must permit sublicensing to Agios
pursuant to Section 14.4(a)(ii) (including permitting Agios to grant further sublicenses). 

(b)    Other Sublicenses. Except as provided in Section 8.2(a), any other sublicense by
Celgene under the licenses and sublicense set forth in Section 8.1 shall require the prior written approval of Agios, which approval shall not be unreasonably withheld, conditioned or delayed. 

Section 8.3.    Sublicense Requirements. Any sublicense granted by Celgene pursuant to this
Agreement shall be subject to the following: 
 (a)    each sublicense granted hereunder by Celgene or
its Affiliates shall be consistent with the requirements of this Agreement; 
 (b)    any transfer of
rights between Celgene and its Affiliates shall not be deemed a sublicense by Celgene but shall be deemed a direct license by Agios to Celgene’s Affiliate; provided that Celgene shall remain responsible for the activities of its
Affiliate; 
 (c)    Celgene’s or its Affiliates’ Third Party Licensee Partners shall have no
right to grant further sublicenses without Agios’ prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed; 

(d)    Celgene shall be primarily liable for any failure by its Affiliates and Licensee Partners to
comply with all relevant restrictions, limitations and obligations in this Agreement; and 

(e)    such sublicense must be granted pursuant to a written sublicense agreement and Celgene shall
provide Agios with a copy of any sublicense agreement entered into under Section 8.2 above within [**] after the execution of such sublicense agreement; provided that, any such copy may be reasonably redacted to remove any
confidential, proprietary or competitive information, but such copy shall not be redacted to the extent that it impairs Agios’ ability to ensure compliance with this Agreement. Such sublicense agreement shall be treated as Confidential
Information of Celgene and no copies are required with respect to sublicense agreements with Third Party Contractors. 

Section 8.4.    Affiliates, Licensee Partners and Third Party Contractors. Celgene may
exercise its rights and perform its obligations hereunder itself or through its Affiliates, Licensee Partners and Third Party Contractors. Celgene shall be primarily liable for any failure by its Affiliates, Licensee Partners and Third Party
Contractors to comply with all relevant restrictions, limitations and obligations in this Agreement. If Celgene desires to use any Person to conduct any of its Development, Manufacturing, Commercialization or other activities hereunder, Celgene
must comply with the obligations of Section 8.2(a)(ii)(1) and Section 8.2(a)(ii)(2) even to the extent no sublicense of rights is granted to such Third Party.

  
 - 18 - 

 Section 8.5.    Existing Third Party Agreements. 

(a)    Acknowledgement. Except as provided in Section 8.5(b) and 9.4, Agios acknowledges that
it is responsible for the fulfillment of its obligations under each Existing Third Party Agreement and agrees to fulfill the same, including any provisions necessary to maintain in effect any rights sublicensed to Celgene hereunder and the exclusive
or non-exclusive nature of such rights, as applicable, subject to Celgene’s compliance with its obligations hereunder.

(b)    Incorporation of Certain Provisions. Celgene agrees and acknowledges that Agios is
required to provide to licensors under the Existing Third Party Agreements periodic reports relating to the gross sales and Net Sales of Licensed Products. Celgene shall keep true and accurate records and books of account, and open such books
and records for inspection by such licensors, for a duration of [**] from the date of origination of such books or records. Furthermore, Celgene acknowledges that Agios may be required to share certain reports and copies of sublicense
agreements provided by Celgene to Agios hereunder with any licensor under an Existing Third Party Agreement, and Celgene consents to the sharing of such reports and such copies of such sublicense agreements to the extent required under such Existing
Third Party Agreement to the same extent as disclosures are permitted under Section 11.3(a) hereunder; provided that any such copies of sublicense agreements must be redacted to the extent permitted under such Existing Third Party
Agreement. In addition, Celgene acknowledges that the Prosecution, enforcement and other intellectual property management rights under this Agreement with respect to Patents and other intellectual property licensed under Existing Third Party
Agreements shall be subject to the terms and conditions of the applicable Existing Third Party Agreements and, in the case of Existing Third Party Agreements in which the licensor is an academic institution, other provisions of such Existing Third
Party Agreements that are customarily required to be imposed on sublicensees in academic licenses (in no event to include any exclusivity covenant). 

(c)    Covenants Regarding Existing Third Party Agreements. Agios agrees that during the
Term: 
 (i)    Agios shall not modify or amend any Existing Third Party Agreement in any way that
adversely affects Celgene’s rights hereunder without Celgene’s prior written consent; 

(ii)    Agios shall not terminate any Existing Third Party Agreement, in whole or in part, without
Celgene’s prior written consent; 
 (iii)    Agios shall not exercise or fail to exercise any of
Agios’ rights, or fail to perform any of Agios’ obligations, under any Existing Third Party Agreement that relate to Celgene’s rights hereunder without the prior written consent of Celgene, including rights with respect to including
improvements within the licenses granted under such Existing Third Party Agreement; and, at the reasonable request of Celgene, Agios shall exercise such rights and make such requests that relate to Celgene’s rights hereunder as are permitted
under such Existing Third Party Agreement; 

  
 - 19 - 

 (iv)    Agios shall promptly furnish Celgene with copies of
all reports and other communications that Agios furnishes to any licensor under any Existing Third Party Agreement to the extent that such reports relate to this Agreement; 

(v)    Agios shall promptly furnish Celgene with copies of all reports and other communications that
Agios receives from any licensor under any Existing Third Party Agreement that relate to the subject of this Agreement (including notices relating to improvements under such Existing Third Party Agreement); 

(vi)    Agios shall furnish Celgene with copies of all notices received by Agios relating to any alleged
breach or default by Agios under any Existing Third Party Agreement within [**] after Agios’ receipt thereof; in addition, if Agios should at any time breach an Existing Third Party Agreement or become unable to timely perform its obligations
thereunder, Agios shall immediately notify Celgene; 
 (vii)    If Agios cannot or chooses not to cure
or otherwise resolve any alleged breach or default under any Existing Third Party Agreement, (A) Agios shall so notify Celgene within [**] of such decision, which shall not be less than [**] prior to the expiration of the cure period under such
Existing Third Party Agreement; provided that Agios shall use Commercially Reasonable Efforts to cure any such breach or default; and (B) Celgene, in its sole discretion, shall be permitted (but shall not be obligated), on behalf of
Agios, to cure any breach or default under such Existing Third Party Agreement in accordance with the terms and conditions of such Existing Third Party Agreement or otherwise resolve such breach directly with the applicable licensor(s) under such
Existing Third Party Agreement; and (C) if Celgene pays any such licensor any amounts owed by Agios under such Existing Third Party Agreement, then, provided that such amounts have not arisen as a result of Celgene’s failure to comply with the
terms and conditions of such Existing Third Party Agreement applicable to Celgene as a sublicensee and, subject to Section 9.4, Celgene may deduct Agios’ share of such amounts from payments Celgene is required to make thereafter to Agios
hereunder or, at Celgene’s election, may otherwise seek reimbursement of such amounts from Agios; and 

(viii)    Agios shall not provide any Licensed Products to any licensor under any Existing Third Party
Agreement without Celgene’s prior written consent. 
 (d)    Survival of Celgene’s Rights
Following Termination of Existing Third Party Agreement. The Parties agree that in the event of any termination of any Existing Third Party Agreement with respect to any intellectual property rights licensed to Celgene hereunder, Celgene
shall have any rights available under such Existing Third Party Agreement to become a direct licensee of the Third Party licensor(s) under such Existing Third Party Agreement and Agios shall use Commercially Reasonable Efforts to assist Celgene in
exercising such rights; provided that Celgene has not breached this Agreement, or breached the applicable Third Party Rights under such Existing Third Party Agreement. In addition, notwithstanding the foregoing, in the event of
such termination, Celgene may in any event approach any licensor under any Existing Third Party Agreement for a direct license. In the event of any such direct license 

  
 - 20 - 

 
following any termination of an Existing Third Party Agreement without Celgene’s consent, Celgene shall be entitled to deduct from any payments owed to Agios hereunder the amounts paid by
Celgene to such licensor under such direct license with respect to licenses within the scope of the licenses previously granted to Agios under such Existing Third Party Agreement to the extent permitted under Section 9.4(a); provided
that such termination was not the result of Celgene breaching the applicable Existing Third Party Agreement. 

(e)    Termination of Existing Third Party Agreements. The Parties agree that termination,
without Celgene’s prior written consent, of any Existing Third Party Agreement with respect to any Patent or Know-How that is necessary to Develop, Manufacture or Commercialize the Licensed Products shall be deemed a material breach of this
Agreement by Agios; provided that (i) if Celgene’s breach of this Agreement results in a breach of any Existing Third Party Agreement, Celgene agrees to use Commercially Reasonable Efforts to assist Agios in curing such breach of
such Existing Third Party Agreement, and (ii) if Celgene’s breach of this Agreement results in a termination of any Existing Third Party Agreement, such termination of such Existing Third Party Agreement shall not be deemed a material breach by
Agios of this Agreement. 
 Section 8.6.    Exclusivity. Subject to the terms and
conditions of this Agreement, each of the Parties hereby agrees as follows: 
 (a)    Exclusivity
Obligations. From the Effective Date until the end of the Term, the Parties and, subject to Section 8.6(a), their Affiliates shall not, directly or indirectly, Develop, Manufacture or Commercialize any [**] for application in [**] that [**]
the Target through direct binding to the Target with [**], except for (i) Licensed Products (including those activities specifically permitted following termination of this Agreement) and (ii) Programs (as defined in the Master Agreement) directed
to the Target (A) that are being conducted pursuant to the Master Agreement, (B) to which Celgene has exercised its Option (as defined in the Master Agreement) under the Master Agreement or (C) the rights to which have reverted to Agios in
accordance with Section 2.12 of the Master Agreement. 
 (b)    Exceptions. 

(i)    Incidental Discoveries. A Party shall be deemed not to be, directly or indirectly
(whether such activities are conducted internally or with or through a Third Party), Developing, Manufacturing or Commercializing in violation of the provisions of Section 8.6(a) as a result of conducting a research program or discovery effort (or
manufacturing or commercializing a [**] resulting from such research program or discovery effort) that has as its specified and primary goal, as evidenced by items such as laboratory notebooks or other relevant documents contemporaneously kept,
taken as a whole, to discover or Develop compounds that [**] through direct binding to a target other than the Target. 

(ii)    Celgene Exception. It is agreed and understood by the Parties that any Celgene research,
discovery and commercialization activities existing as of the effective date of the Master Agreement, whether such activities are undertaken by Celgene alone or in conjunction with one or more partners, licensors, licensees, and/or collaborators,
are expressly excluded from the provisions of this Section 8.6. In particular and without limitation, Celgene research, discovery, and commercialization activities related to (i) [**]; (ii) [**]; (iii) [**]; (iv) [**]; (v) [**]; or (vi) [**], are
expressly excluded from the provisions of this Section 8.6. 

  
 - 21 - 

 (iii)    Academic
Collaborations. Notwithstanding the provisions of Section 8.6(a), and without limiting Section 8.2(a)(ii), each Party shall be permitted to perform any of the activities that would otherwise be prohibited under Section 8.6(a) in relation to
the Target, if such activities are (A) the subject of an existing agreement between such Party and an academic institution or academic collaborator entered into prior to the effective date of the Master Agreement, provided that such Party shall not
be permitted to amend any such agreement unless such amendment contains provisions consistent with the terms and conditions of such agreement in effect as of the effective date of the Master Agreement with respect to (1) [**], or (B) the subject of
a new agreement entered into between such Party and an academic institution or academic collaborator that contains terms and conditions with respect to the [**] consistent with the terms and conditions of [**]; provided that, if any
[**] of an amendment described in (A) or an agreement described in (B) would not be [**] the agreements between such Party and an academic institution or academic collaborator entered into prior to the effective date of the Master Agreement, such
Party [**]. 
 (iv)    Competitive Programs. Section 8.6(a) shall not apply if, during the
[**], any Party or its Affiliates (other than in a [**] with respect to such Party) merges or consolidates with, or otherwise acquires, a Third Party that is then engaged in activities that would otherwise constitute a breach of this Section 8.6 by
any Party or its Affiliates (a “Competitive Program”); it being understood and agreed that, unless the Parties agree otherwise in writing, such Party that is engaged in a Competitive Program (the “Competitive Program
Party”) shall, within [**] after the date of such merger, consolidation or acquisition, notify the other Party that it intends to either: (A) terminate, or cause its relevant Affiliate to terminate, the Competitive Program or (B)
divest, or cause its relevant Affiliate to divest, whether by license or otherwise, the Competitive Program. If the Competitive Program Party notifies the other Party within such [**] period that it intends to [**], such Competitive Program,
the Competitive Program Party or its relevant Affiliate, shall (X) terminate such Competitive Program as quickly as possible, and in any event within [**] (unless applicable Law requires a longer termination period) after the Competitive Program
Party delivers such notice to the other Party; and (Y) confirm to the other Party when such termination has been completed, and the Competitive Program Party’s continuation of the Competitive Program during such [**] (or, as required by
applicable Law, longer) period shall not constitute a breach of the Competitive Program Party’s exclusivity obligations under Section 8.6(a). If the Competitive Program Party notifies the other Party within such [**] period that it intends
to divest such Competitive Program, the Competitive Program Party or its relevant Affiliate shall use all reasonable efforts to effect such divestiture as quickly as possible, and in any event within [**] after the Competitive Program Party delivers
such notice to the other Party, and shall confirm to the other Party when such divestiture has been completed. If the Competitive Program Party or its relevant Affiliate fails to complete such divestiture within such [**] period, but has used
reasonable efforts to effect such divestiture within such [**] period, then, unless otherwise required by applicable Law, such [**] period shall be extended for such additional reasonable period thereafter as is necessary to enable such Competitive
Program to be in fact divested, not to exceed an additional [**]; provided that, such additional [**] period shall be extended for such period as is necessary to obtain any governmental or regulatory approvals required to complete such
divestiture if the Competitive 

  
 - 22 - 

 
Program Party or its relevant Affiliate is using good faith efforts to obtain such approvals. The Competitive Program Party’s continuation of the Competitive Program during such
divestiture period shall not constitute a breach of the Competitive Program Party’s exclusivity obligations under Section 8.6(a). 

(v)    Certain Permitted Activities.

(1)    The [**] shall not constitute a breach of Section 8.6(a). Each Party shall report to the
other Party on a [**] basis [**] and that would otherwise breach Section 8.6(a). For clarity, [**] without violation of Section 8.6(a) [**] shall not constitute [**] in violation of such Party’s exclusivity obligations under this
Section 8.6 as long as [**]. 
 (2)    The [**] shall not constitute a breach of Section 8.6(a);
provided that [**] shall be subject to Section 8.6(a) and shall not be permitted under this Section 8.6(b)(v). 

(3)    The restrictions set forth in Section 8.6(a) shall not be deemed to prevent either Party or its
respective Affiliates from (1) fulfilling its obligations under this Agreement, or (2) engaging any subcontractors in accordance with Section 8.2(a)(ii)Section 8.2(a)(i) of this Agreement. 

(4)    If [**] occurs with respect to either Party with a Third Party and the Third Party already is
conducting or is planning to conduct activities that would cause a Party or an Affiliate to violate Section 8.6(a) (an “Acquirer Program”), then such Third Party [**]; provided that, (1) [**] in any Acquirer Program,
(2) [**] in any Acquirer Program, (3) [**] in any such Acquirer Program, and (4) [**] to such Acquirer Program, including by [**] the activities under this Agreement, and the activities covered under such Acquirer Program (except that this
requirement shall not apply to [**] activities under such Acquirer Program). 
 (vi)    Clinical
Combinations. Notwithstanding anything to the contrary in this Agreement, for purposes of this Section 8.6, either Party shall, at all times, have the right to conduct clinical Development of Licensed Products, alone or with Third Parties, in
which the [**]’s regulatory filings for purposes of enabling such Party and such Third Party to include the relevant use of Licensed Products in combination with such other therapeutic product in the approved label for such Licensed Products
and/or such other therapeutic product, respectively, provided that [**] may grant to any such Third Party the right to sell, offer for sale and otherwise commercially exploit such Licensed Products. 

Section 8.7.    Retained Rights. 

(a)    No Implied Licenses or Rights. Except as expressly provided in Section 8.1, and
subject to Section 8.5, all rights in and to the Agios Intellectual Property and any other Patents or Know-How of Agios and its Affiliates, are hereby retained by Agios and its Affiliates. For the avoidance of doubt, all rights in and to the
Celgene Intellectual Property and any other Patents or Know-How of Celgene and its Affiliates, are hereby retained by Celgene and its Affiliates. 

  
 - 23 - 

 (b)    Other Retained Rights. The Parties
acknowledge that the licenses granted hereunder are subject to any rights retained by any licensor under any Existing Third Party Agreement pursuant to any provision of such Existing Third Party Agreement, provided that, upon
Celgene’s reasonable request, Agios shall cooperate fully in requesting and obtaining any waiver with respect to the requirement, if applicable under such agreements, that the Licensed Products used or sold in the United States be manufactured
substantially in the United States. 
 Section 8.8.    Section 365(n) of the Bankruptcy
Code. All rights and licenses granted under or pursuant to any section of this Agreement are and will otherwise be deemed to be for purposes of Section 365(n) of the United States Bankruptcy Code (Title 11, U.S. Code), as amended (the
“Bankruptcy Code”), licenses of rights to “intellectual property” as defined in Section 101(35A) of the Bankruptcy Code. The Parties will retain and may fully exercise all of their respective rights and elections
under the Bankruptcy Code. The Parties agree that each Party, as licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the Bankruptcy Code or any other provisions of applicable
law outside the United States that provide similar protection for “intellectual property.” The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party under the Bankruptcy Code or
analogous provisions of applicable Law outside the United States, the Party that is not subject to such proceeding will be entitled to a complete duplicate of (or complete access to, as appropriate) such intellectual property and all embodiments of
such intellectual property, which, if not already in the non-subject Party’s possession, will be promptly delivered to it upon the non-subject Party’s written request thereof. Any agreements supplemental hereto will be deemed to be
“agreements supplementary to” this Agreement for purposes of Section 365(n) of the Bankruptcy Code. 
 Article IX. 

Financial Provisions 

Section 9.1.    Upfront Option Payment. Within [**] after the Effective Date, Celgene shall
make a one-time, non-refundable payment to Agios equal to the applicable Upfront Option Payment set forth in paragraph 3 on Exhibit A, with respect to the Program (as defined in the Master Agreement) under which the Compounds and Licensed Products
were Developed. 
 Section 9.2.    Milestone Payments.

(a)    Development and Regulatory Milestones. Celgene shall pay Agios the following amounts
after the first achievement by or on behalf of Celgene or its Affiliates or Licensee Partners of the corresponding development and regulatory milestone events set forth below with respect to the first Licensed Product to achieve such milestone
events. 
  

			
	 Milestones

 
	  	
Amount
  

	 [**]

 
	  	
US $25,000,000
  

	 [**]

 
	  	
[**]
  

  
 - 24 - 

			
	 Milestones

 
	  	
Amount
  

	 [**]

 
	  	
[**]
  

	 [**]

 
	  	
[**]
  

 (i)    For purposes of determining the occurrence of milestones under
items (2) and (3) in the table above, (A) the [**] shall be deemed a single [**] for purposes of determining whether the [**] and (B) achievement of such milestones with respect to the [**] shall be deemed to have occurred only if [**] have been
obtained. For purposes of clarity, no milestone amount shall be payable to Agios under item (3) if [**], but Celgene shall pay Agios the milestone amount set forth in item (3) upon receipt of [**], as applicable, than the [**] for purposes of
item (3).
 (ii)    The milestone payments under items (2), (3) and (4) shall be paid at [**] percent
([**]%) of the specified amounts upon the [**] of the applicable milestone event by a Licensed Product for a different Indication than the Indication for which such Licensed Product first achieved such milestone event. For the avoidance of
doubt, each distinct histology shall qualify as a distinct Indication for purposes of this Section 9.2. For the further avoidance of doubt, if a Licensed Product achieves a milestone for an Indication and subsequently achieves the same
milestone for an earlier line setting in the same Indication, no milestone payments shall be due for such earlier line setting (e.g., if a Licensed Product [**], no milestone payments would be due if such Licensed Product later [**]. For
the further avoidance of doubt, for purposes of this Section 9.2, if a Licensed Product achieves a milestone for an Indication as part of a monotherapy or combination therapy and subsequently achieves the same milestone in the same Indication as
part of a combination therapy or monotherapy, respectively, no milestone payments shall be due for such subsequent milestone. 

(iii)    No further milestone payments under this Section 9.2 shall be payable, regardless of the number
of Licensed Products to achieve the applicable milestone event and regardless of the number of Indications for which the milestone event may be achieved.

(iv)    Each milestone payment under this Section 9.2 shall be made within [**] after the achievement of
the applicable milestone by Celgene or any of its Affiliates or Licensee Partners. 
 (b)    Sales
Milestones. Celgene shall make the following non-refundable, non-creditable, one-time payments to Agios within [**] following the first achievement of worldwide Annual Net Sales, on a Licensed Product-by-Licensed Product basis (in no event
to include Companion Diagnostics), that meets or exceeds the minimum worldwide Annual Net Sales threshold per such Licensed Product in the Territory set forth below. 
  

			
	 Per Licensed Product Worldwide Annual Net Sales Threshold

 
	  	Milestone Payment
	 Equal to US$[**]

 
	  	
US$[**]
  

	 Equal to US$[**]

 
	  	
US$[**]
  

  
 - 25 - 

 Section 9.3.    Royalty Payments. 

(a)    Royalty Rate. Celgene shall pay to Agios royalties on worldwide Annual Net Sales of
Licensed Products, on a Licensed Product-by-Licensed Product basis (in no event to include Companion Diagnostics), as follows: 
  

			
	 Per Licensed Product Worldwide Annual Net Sales

 
	  	
Royalty Rate
  

	 On the tranche of worldwide Annual Net Sales occurring until aggregate worldwide Annual
Net Sales reaches US$[**]
  
	  	
[**]%
  

	 On the tranche of worldwide Annual Net Sales occurring so long as aggregate worldwide
Annual Net Sales is equal to or greater than US$[**] and less than US$[**]
  
	  	
[**]%
  

	 On the tranche of worldwide Annual Net Sales occurring upon and after aggregate
worldwide Annual Net Sales equals US$[**]
  
	  	
[**]%
  

 Each Royalty Rate set forth in the table above will apply only to that portion of the worldwide Annual Net
Sales of a given Licensed Product in the Territory during a given Calendar Year that falls within the indicated tranche. 
 For example, if
worldwide Annual Net Sales of a given Licensed Product in the Territory by Celgene, its Affiliates and Licensee Partners was $[**], then the royalties payable with respect to such worldwide Annual Net Sales, subject to adjustment as set forth in
this Section 9.3(a), would be: 
 [**]. 

(b)    Royalty Term. Royalties payable under this Section 9.3 shall be paid by Celgene on a
Licensed Product-by-Licensed Product and country-by-country basis from the date of First Commercial Sale of each Licensed Product in a country with respect to which royalty payments are due, until the latest of: 

(i)    the last to expire of any Valid Claim of Agios Patents, Celgene Collaboration Patents or Joint
Patents Covering such Licensed Product in such country; 
 (ii)    [**] following the date of First
Commercial Sale in such country; and 
 (iii)    the expiration of Regulatory Exclusivity for such
Licensed Product in such country; 
 (each such term with respect to a Licensed Product and a country, a “Royalty Term”).

  
 - 26 - 

 Notwithstanding the foregoing, (A) in the event that the Royalty Term for a
Licensed Product in a country continues solely due to Section 9.3(b)(ii) above (i.e., the Licensed Product is not Covered by a Valid Claim of Agios Patents, Celgene Collaboration Patents or Joint Patents in the applicable country, and such
Licensed Product is not subject to Regulatory Exclusivity in such country) or (B) in the event that, and for so long as, Generic Competition for a Licensed Product occurs in a country, then, in either such event, the royalty rate in such country
will be reduced to [**] percent ([**]%) of the applicable rate in Section 9.3(a) in such country. 

(c)    Expiration of Royalty Term. Upon the expiration of the Royalty Term with respect to a
Licensed Product in a country, the license granted by Agios to Celgene pursuant to Section 8.1 shall be deemed to be fully paid-up, irrevocable and perpetual with respect to such Licensed Product in such country; provided that,
notwithstanding Section 9.4(a), Celgene shall assume and be solely responsible for all amounts payable to Third Party licensors and Celgene shall be responsible for complying with the terms of any license agreements with such Third Party licensors,
in each case, with respect to Celgene’s exercise of such rights as to such Licensed Product in such country following the expiration of the Royalty Term. 

(d)    Deduction for Third Party Payments. In the event that royalties are payable by Celgene
to Agios with respect to any Licensed Product under this Section 9.3, Celgene shall have the right to deduct a maximum of [**] percent ([**]%) of any royalties or other amounts actually paid by Celgene to a Third Party with respect to any license
obtained pursuant to Section 9.4(b) with respect to a Licensed Product in a country, but only to the extent that the Patents or Know-How licensed under such other license are necessary for the Development, Manufacture or Commercialization of such
Licensed Product in such country, from royalty payments otherwise due and payable by Celgene to Agios under this Section 9.3 with respect to such Licensed Product in such country, on a Licensed Product-by-Licensed Product and country-by-country
basis. 
 (e)    Royalty Reports; Payments. Within [**] after the end of each Calendar
Quarter, Celgene with respect to each Licensed Product shall provide Agios with a report stating the sales in units and in value of such Licensed Product made by Celgene, its Affiliates, and Licensee Partners, as applicable, on a country-by-country
basis, together with the calculation of the royalties due to Agios, including the method used to calculate the royalties, the exchange rates used, and itemized deductions. Payments of all amounts payable under this Section 9.3 shall be made by
Celgene to the bank account indicated by Agios concurrently with the delivery of such report. 

(f)    Cumulative Effect of Royalty Reductions. In no event shall the royalty
reductions described in this Section 9.3, alone or together, reduce the royalties payable by Celgene for a Licensed Product in a country in any given Calendar Quarter to less than [**]percent ([**]%) of the amounts otherwise payable by Celgene for
such Calendar Quarter. Celgene may carry over and apply any such royalty reductions, which are incurred or accrued in a Calendar Quarter and are not deducted in such Calendar Quarter due to the limitation set forth above in this Section 9.3(f),
to any subsequent Calendar Quarter(s) and shall begin applying such reduction to such royalties as soon as practicable and continue applying such reduction on a Calendar Quarterly basis thereafter until fully deducted, in all cases subject to the
limitation set forth above in this Section 9.3(f). 

  
 - 27 - 

 Section 9.4.    Third Party Payments.

(a)    Existing Third Party Agreements. All royalties payable under the Existing Third Party
Agreements, in the aggregate, that (i) directly relate to a Licensed Product and (ii) in no event exceed [**] percent ([**]%) of Net Sales in the aggregate, shall be shared by the Parties, with each Party paying [**] percent ([**]%) of such
royalties. For clarity, all royalties payable under the Existing Third Party Agreements in excess of [**] percent ([**]%) of worldwide Net Sales in the aggregate, and all non-royalty amounts payable under such Existing Third Party Agreements,
shall be paid by Agios. 
 (b)    Additional Agreements. After the Effective Date, if Celgene at
any time believes that a license under Third Party Patents or Third Party Know-How, other than an Existing Third Party Agreement, is necessary or useful to Develop, Manufacture or Commercialize the Licensed Products, then Celgene shall have the sole
right make such determination, without escalation to the Executive Officers. The costs of each such license to the extent the costs directly relate to the Licensed Products shall be paid by Celgene, subject to deduction from royalties to the
extent set forth in Section 9.3(d). 
 Section 9.5.    Financial Records. Celgene shall
keep, and shall require its Affiliates and Licensee Partners to keep, complete and accurate books and records in accordance with the applicable Accounting Standards. Celgene shall keep, and shall require its Affiliates and Licensee Partners to
keep, such books and records for at least [**] following the end of the Calendar Year to which they pertain. Such books of accounts shall be kept at the principal place of business of the financial personnel with responsibility for preparing
and maintaining such records. With respect to royalties, such records shall be in sufficient detail to support calculations of royalties due to Agios.

Section 9.6.    Audits. 

(a)    Audit Team. Agios may, upon request and at its expense (except as provided for
herein), cause an internationally recognized independent accounting firm selected by it (except one to whom Celgene has a reasonable objection) (the “Audit Team”) to audit during ordinary business hours the books and records of
Celgene and the correctness of any payment made or required to be made, and any report underlying such payment (or lack thereof), pursuant to the terms of this Agreement. Prior to commencing its work pursuant to this Agreement, the Audit Team
shall enter into an appropriate confidentiality agreement with Celgene obligating the Audit Team to be bound by obligations of confidentiality and restrictions on use of such Confidential Information that are no less restrictive than the obligations
set forth in Article XI. 
 (b)    Limitations. In respect of each audit of Celgene’s
books and records: (i) Celgene may be audited [**], (ii) no records for any given year for Celgene may be audited more than [**]; provided that Celgene’s records shall still be made available if such records impact another
financial year which is being audited, and (iii) Agios shall only be entitled to audit books and records of Celgene from the [**] prior to the Calendar Year in which the audit request is made. 

  
 - 28 - 

 (c)    Audit Notice. In order to initiate an
audit for a particular Calendar Year, Agios must provide written notice to Celgene. Agios shall provide Celgene with notice of one or more proposed dates of the audit not less than [**] prior to the first proposed date. Celgene will
reasonably accommodate the scheduling of such audit. Celgene shall provide such Audit Team(s) with full and complete access to the applicable books and records and otherwise reasonably cooperate with such audit. 

(d)    Payments. If the audit shows any under-reporting or underpayment, or overcharging by
Celgene, that under-reporting, underpayment or overcharging shall be reported to Agios and Celgene shall remit such underpayment or reimburse such overcompensation (together with interest at the rate set forth in Section 9.9) to Agios within [**]
after receiving the audit report. Further, if the audit for an annual period shows an under-reporting or underpayment or an overcharge by Celgene for that period in excess of [**] percent ([**]%) of the amounts properly determined, Celgene,
shall reimburse Agios, for its respective audit fees and reasonable Out-of-Pocket Costs in connection with said audit, which reimbursement shall be made within [**] after receiving appropriate invoices and other support for such audit-related costs.

 Section 9.7.    Tax Matters. 

(a)    Withholding Taxes. Each Party shall be entitled to deduct and withhold from any
amounts payable under this Agreement such taxes as are required to be deducted or withheld therefrom under any provision of applicable Law. The Party that is required to make such withholding (the “Paying Party”) will: (i)
deduct those taxes from such payment, (ii) timely remit the taxes to the proper taxing authority, and (iii) send evidence of the obligation together with proof of tax payment to the recipient Party (the “Payee Party”) on a timely
basis following that tax payment; provided, however, that before making any such deduction or withholding, the Paying Party shall give the Payee Party notice of the intention to make such deduction or withholding (and such notice, which shall set
forth in reasonable detail the authority, basis and method of calculation for the proposed deduction or withholding, shall be given at least a reasonable period of time before such deduction or withholding is required, in order for such Payee Party
to obtain reduction of or relief from such deduction or withholding). Each Party agrees to cooperate with the other Parties in claiming refunds or exemptions from such deductions or withholdings under any relevant agreement or treaty or other
applicable Law which is in effect to ensure that any amounts required to be withheld pursuant to this Section 9.7(a) are reduced in amount to the fullest extent permitted by applicable Laws. In addition, the Parties shall cooperate in
accordance with applicable Laws to minimize [**] in connection with this Agreement, as applicable.

(b)    Tax Documentation. Each Party has provided a properly completed and duly
executed IRS Form W-9 or applicable Form W-8 to the other Parties. Each Party and any other recipient of payments under this Agreement shall provide to the other Party, at the time or times reasonably requested by such other Parties or as required
by applicable Law, such properly completed and duly executed documentation (for example, IRS Forms W-8 or W-9) as will permit payments made under this Agreement to be made without, or at a reduced rate of, withholding for taxes, and the applicable
payment shall be made without (or at a reduced rate of) withholding to the extent permitted by such documentation, as reasonably determined by the Paying Party. 

  
 - 29 - 

 Section 9.8.    Currency Exchange. Unless
otherwise expressly stated in this Agreement, all amounts specified in, and all payments made under, this Agreement shall be in United States Dollars. If any currency conversion shall be required in connection with the calculation of amounts
payable under this Agreement, such conversion shall be performed in a manner consistent with Celgene’s normal practices used to prepare its audited financial statements for internal and external reporting purpose. For clarity, Celgene sets
currency transaction rates for the month on the last business day of the month prior. Agios has the right to verify that the exchange rates used by Celgene for a given month are within the trading range of the last business day of the month
prior. 
 Section 9.9.    Late Payments. Celgene shall pay interest to Agios on the
aggregate amount of any payments that are not paid on or before the date such payments are due under this Agreement at a rate per annum equal to the lesser of the [**], or the highest rate permitted by applicable Law, calculated on the number of
days such payments are paid after the date such payments are due; provided that, with respect to any disputed payments, no interest payment shall be due until such dispute is resolved and the interest which shall be payable thereon
shall be based on the finally-resolved amount of such payment, calculated from the original date on which the disputed payment was due through the date on which payment is actually made. 

Section 9.10.    Blocked Payments. In the event that, by reason of Applicable Law in
any country, it becomes impossible or illegal for Celgene (or any of its Affiliates or Licensee Partners) to transfer, or have transferred on its behalf, payments owed Agios hereunder, Celgene will promptly notify Agios of the conditions preventing
such transfer and such payments will be deposited in local currency in the relevant country to the credit of Agios in a recognized banking institution designated by Agios or, if none is designated by Agios within a period of [**], in a recognized
banking institution selected by Celgene or any of its Affiliates or its Licensee Partners, as the case may be, and identified in a written notice given to Agios. 

Article X. 
 Intellectual
Property Ownership, Protection and Related Matters 
 Section 10.1.    Ownership of
Inventions. 
 (a)    Pre-Existing Know-How. Any Know-How developed or generated by
Celgene or Agios prior to the Effective Date shall remain the sole property of such Party. 

(b)    Sole Inventions. All Know-How developed or generated solely by employees, agents and
consultants of a Party shall be owned exclusively by such Party. 
 (c)    Joint
Inventions. All Know-How developed or generated jointly by employees, agents and consultants of Celgene, on the one hand, and employees, agents and consultants of Agios, on the other hand, in the conduct of activities under this Agreement
(“Joint Inventions” and, any Patents Covering such Joint Inventions, “Joint Patents”) shall be owned jointly on the basis of each Party having an undivided interest without a duty to account to the other Party
(other than as set forth in this Agreement) and shall be deemed to be Controlled by 

  
 - 30 - 

 
each Party. Each Party shall have the right to use such Joint Inventions, or license such Joint Inventions to its Affiliates or any Third Party, or sell or otherwise transfer its interest in
such Joint Inventions to its Affiliates or a Third Party, in each case without the consent of the other Party (and, to the extent that applicable Law requires the consent of the other Party, this Section 10.1(c) shall constitute such consent), so
long as such use, sale, license or transfer is subject to Section 8.6 and the licenses granted pursuant to this Agreement and is otherwise consistent with this Agreement. 

(d)    Inventorship. The determination of inventorship shall be made in accordance with
United States patent laws. In the event of a dispute regarding inventorship, if the Parties are unable to resolve the dispute, the Parties shall jointly engage mutually acceptable independent patent counsel not regularly employed by either
Party to resolve such dispute. The decision of such independent patent counsel shall be binding on the Parties with respect to the issue of inventorship. 

(e)    Further Actions and Assignments. Each Party shall take all further actions and execute
all assignments requested by the other Party and reasonably necessary or desirable to vest in the other Party the ownership rights set forth in this Article X. 

Section 10.2.    Prosecution of Patents. Subject to the terms and conditions of any Existing Third
Party Agreement to the extent such agreement applies to the Agios Patents, the following provisions shall apply with respect to the Agios Patents, Celgene Patents, Celgene Collaboration Patents and Joint Patents: 

(a)    Agios Patents, Celgene Collaboration Patents and Joint Patents. Subject to the
provisions of Section 10.2(f) and coordination with [**] shall have the initial right and option to Prosecute the Agios Patents, Celgene Collaboration Patents and Joint Patents. In the event that [**] declines to Prosecute such Patents, it
shall give [**] reasonable notice to this effect, sufficiently in advance to permit [**] to undertake such Prosecution in such country without a loss of rights, and thereafter [**] may, upon written notice to [**], Prosecute such Patents in the
owning Party(ies)’s name(s) subject to coordination with [**]. 
 (b)    [**]
Patents. Celgene shall have the sole right and option, in its sole discretion and at its sole expense, to Prosecute the [**]. 

(c)    Costs and Expenses. Each Prosecuting Party shall bear all of its own costs and
expenses in Prosecuting Agios Patents, Celgene Collaboration Patents and Joint Patents. 

(d)    Strategy; Diligence and Cooperation. 

(i)    The Party conducting Prosecution (the “Prosecuting Party”) with respect to an
Agios Patent, Celgene Collaboration Patent or Joint Patent shall be entitled to use patent counsel selected by it and reasonably acceptable to the non-Prosecuting Party (including in-house patent counsel as well as outside patent counsel) for the
Prosecution of the Patents Rights subject to Section 10.2(a). Each Party agrees to cooperate with the other with respect to the Prosecution of such Patents pursuant to this Section 10.2, including by (X) executing all such documents and
instruments and performing such acts as may be reasonably necessary in order to permit the other Party to undertake any Prosecution of Patents that such other Party is entitled, and has elected, to Prosecute, as provided for in Section 10.2(a) and
(Y) giving consideration to the proper scope of Patents. The Prosecuting Party shall: 

  
 - 31 - 

 (1)    use Commercially Reasonable Efforts to regularly
provide the non-Prosecuting Party in advance with reasonable information relating to the Prosecuting Party’s Prosecution of Patents hereunder, including by providing copies of substantive communications, notices and actions submitted to or
received from the relevant patent authorities and copies of drafts of filings and correspondence that the Prosecuting Party proposes to submit to such patent authorities, each of which shall be provided as far in advance as is practicable but with
sufficient time for the non-Prosecuting party to provide meaningful input; 
 (2)    use Commercially
Reasonable Efforts to consider in good faith and consult with the non-Prosecuting Party regarding its timely comments with respect to the same; 

(3)    use Commercially Reasonable Efforts to Prosecute additional claims substantially similar to those
suggested by the non-Prosecuting Party, if any, in such jurisdictions of the Territory reasonably requested by the non-Prosecuting Party; and 

(4)    consult with the non-Prosecuting Party before taking any action that would have a material adverse
impact on the scope of claims within the Agios Patents, Celgene Collaboration Patents and Joint Patents, as applicable. 

(ii)    The Prosecuting Party shall determine the countries in which Agios Patents, Celgene Collaboration
Patents and Joint Patents shall be Prosecuted, with the understanding that the countries set forth on Exhibit D of this Agreement shall generally form the basis for the overall Prosecution strategy for such Patents. 

(iii)    The Prosecuting Party agrees not to abandon any Agios Patent, Celgene Collaboration Patent or
Joint Patent without filing a continuation application in respect thereof unless it provides the non-Prosecuting Party with reasonable notice to this effect, sufficiently in advance to permit the non-Prosecuting Party to undertake such Prosecution
of such Agios Patent, Celgene Collaboration Patent or Joint Patent, and thereafter such non-Prosecuting Party may, upon written notice to the Prosecuting Party, Prosecute such Agios Patent, Celgene Collaboration Patent or Joint Patent. 

(e)    Third Party Rights. Agios covenants and agrees that it shall not grant any Third Party
any right to control the Prosecution of the Agios Patents or to approve or consult with respect to any Patents licensed to Celgene hereunder, in any case, that is more favorable to the Third Party than the rights granted to Celgene hereunder or that
otherwise conflicts with Celgene’s rights hereunder.
 (f)    Existing Third Party
Agreements. Each Party acknowledges that, pursuant to an Existing Third Party Agreement, the applicable licensor(s) thereunder may retain the right to Prosecute the Agios Patents covered by such agreements; provided that Agios
may have certain rights to assume Prosecution under such agreement. Agios agrees to keep Celgene fully informed of these rights, as well as provide to Celgene all information and copies of documents received from the licensor(s) under any such
Existing Third Party Agreement or their patent 

  
 - 32 - 

 
counsel relating to the Agios Patents covered by such agreements. To the extent that Agios is permitted to proceed with Prosecution or provide comments or suggestions to patent documents
under an Existing Third Party Agreement, then the Agios Patents under such Existing Third Party Agreement shall be treated in the same manner as other Agios Patents under this Section 10.2, and Agios shall exercise all such rights with respect to
such Agios Patents pursuant to the instructions of Celgene, if Celgene is given the right to act under this Section 10.2. 

Section 10.3.    Third Party Infringement of Agios Patents, Celgene Collaboration Patents and Joint
Patents. Subject to the terms and conditions of the Existing Third Party Agreements to the extent such agreements apply to the Agios Patents, the following provisions shall apply with respect to the Agios Intellectual Property, Celgene
Collaboration Intellectual Property, Joint Patents and Joint Inventions: 

(a)    Notice. Each Party shall immediately provide the other Party with written notice
reasonably detailing any (i) known or alleged infringement of any Agios Patents, Celgene Collaboration Patents or Joint Patents, or known or alleged misappropriation of any Agios Know-How, Celgene Collaboration Know-How or Joint Inventions, by a
Third Party, (ii) “patent certification” filed in the United States under 21 U.S.C. §355(b)(2) or 21 U.S.C. §355(j)(2) or similar provisions in other jurisdictions, and (iii) any declaratory judgment, opposition or similar action
alleging the invalidity, unenforceability or non-infringement of any such intellectual property rights (collectively “Third Party Infringement”). 

(b)    First Right to Initiate Infringement Actions. [**] shall have the initial right, but
not the obligation, to initiate a suit or take other appropriate action that [**] believes is reasonably required to protect the Agios Intellectual Property, Celgene Collaboration Intellectual Property, Joint Inventions and Joint Patents against the
infringement in the Territory, including Third Party Infringement, unauthorized use or misappropriation by a Third Party that relates to a Licensed Product (“Competitive Infringement”). [**] shall give [**] advance notice of
[**] intent to file any such suit or take any such action and the reasons therefor, and shall provide [**] with an opportunity to make suggestions and comments regarding such suit or action. Thereafter, [**] shall keep [**] promptly informed,
and shall from time to time consult with [**] regarding the status of any such suit or action and shall provide [**] with copies of all material documents (e.g., complaints, answers, counterclaims, material motions, orders of the court,
memoranda of law and legal briefs, interrogatory responses, depositions, material pre-trial filings, expert reports, affidavits filed in court, transcripts of hearings and trial testimony, trial exhibits and notices of appeal) filed in, or otherwise
relating to, such suit or action. Without limiting the generality of the foregoing, the Parties shall discuss in good faith [**] intended response to a Competitive Infringement. 

(c)    Step-in Rights. If [**] fails to initiate a suit or take such other appropriate action
under Section 10.3(b) above within [**] after becoming aware of the Competitive Infringement, then [**] may, in its discretion, provide [**] with written notice of its intent to initiate a suit or take other appropriate action to combat such
Competitive Infringement. If [**] provides such notice and [**] fails to initiate a suit or take such other appropriate action within [**] after receipt of such notice from [**], then [**] shall have the right, but not the obligation, to
initiate a suit or take other appropriate action that it believes is reasonably required to protect the applicable Agios Intellectual Property, Celgene Collaboration Intellectual Property, Joint 

  
 - 33 - 

 
Inventions and Joint Patents from Competitive Infringement. [**] shall give [**] advance notice of its intent to file any such suit or take any such action and the reasons therefor and shall
provide [**] with an opportunity to make suggestions and comments regarding such suit or action. Thereafter, [**] shall keep [**] promptly informed and shall from time to time consult with [**] regarding the status of any such suit or action
and shall provide [**] with copies of all material documents (e.g., complaints, answers, counterclaims, material motions, orders of the court, memoranda of law and legal briefs, interrogatory responses, depositions, material pre-trial
filings, expert reports, affidavits filed in court, transcripts of hearings and trial testimony, trial exhibits and notices of appeal) filed in, or otherwise relating to, such suit or action. 

(d)    Conduct of Action; Costs. The Party initiating suit shall have the sole and exclusive
right to select counsel for any suit initiated by it under this Section 10.3, which counsel must be reasonably acceptable to the other Party. If required under applicable Law in order for such Party to initiate or maintain such suit, the other
Party shall join as a party to the suit. If requested by the Party initiating suit, the other Party shall provide reasonable assistance to the Party initiating suit in connection therewith at no charge to such Party except that the initiating
Party shall reimburse the other Party for Out-of-Pocket Costs, other than outside counsel expenses, incurred in rendering such assistance. The Party initiating suit shall assume and pay all of its own Out-of-Pocket Costs incurred in connection
with any litigation or proceedings described in this Section 10.3, including the fees and expenses of the counsel selected by it. The other Party shall have the right to participate and be represented in any such suit by its own counsel at its
own expense. 
 (e)    Recoveries. Any recovery obtained as a result of any proceeding
described in this Section 10.3 or from any counterclaim or similar claim asserted in a proceeding described in Section 10.4, by settlement or otherwise, shall be applied in the following order of priority: 

(i)    first, the Party initiating the suit or action shall be reimbursed for all previously unreimbursed
Out-of-Pocket Costs in connection with such proceeding; and 
 (ii)    second, any remainder shall be
paid [**] percent ([**]%) to the Party initiating the suit or action, and [**] percent ([**]%) to the other Party. 

(f)    Existing Third Party Agreements. In the event that (i) a Patent covered by an Existing
Third Party Agreement is at issue in an action under this Section 10.3 or Section 10.4, (ii) Agios has a right to enforce the Agios Patents under such Existing Third Party Agreement, and (iii) Celgene desires to enforce such Patent in accordance
with the procedures under this Section 10.3 or Section 10.4, as applicable, then Agios shall either obtain the licensor(s)’ consent under such Existing Third Party Agreement so that Celgene may file such an action in its own name or shall
undertake such an action on Celgene’s behalf and at Celgene’s expense. 

  
 - 34 - 

 Section 10.4.    Claimed Infringement; Claimed
Invalidity.
 (a)    Infringement of Third Party Rights. Each Party shall promptly
notify the other Party in writing of any allegation by a Third Party that the activity of either Party or their Affiliates or Licensee Partners under this Agreement infringes or may infringe the intellectual property rights of such Third
Party. If a Third Party asserts or files against a Party or its Affiliates any claim of infringement of the intellectual property rights of such Third Party or other action relating to alleged infringement of such intellectual property rights
(“Third Party Infringement Action”), then, unless otherwise agreed by the Parties: 

(i)    In the event of a Third Party Infringement Action against a single Party, the unnamed Party shall
have the right, in the unnamed Party’s sole discretion, to participate in the defense of such legal action with legal counsel selected by the unnamed Party and reasonably acceptable to the named Party. The Party named in such Third Party
Infringement Action shall have the right to control the defense of the action, but shall notify and keep the unnamed Party apprised in writing of such action and shall consider and take into account the unnamed Party’s reasonable interests and
requests and suggestions regarding the defense of such action. In the event of a Third Party Infringement Action against both Parties, [**] shall have the right to control the defense of such Third Party Infringement Action. 

(ii)    The non-controlling Party of a Third Party Infringement Action shall reasonably cooperate with
the controlling Party in the preparation and formulation of a defense to such Third Party Infringement Action, and in taking other steps reasonably necessary to respond to such Third Party Infringement Action. The controlling Party shall have
the right to select its counsel for the defense to such Third Party Infringement Action, which counsel must be reasonably acceptable to the non-controlling Party if both Parties have been named as defendants in the action. The non-controlling
Party shall also have the right to participate and be represented in any such suit by its own counsel at its own expense. The controlling Party shall not (and shall cause its Affiliates and Licensee Partners not to) either (A) admit
infringement, validity or enforceability of the asserted intellectual property rights, (B) pay any amount of money in settlement thereof, or (C) enter into a license for the asserted intellectual property rights upon terms that would restrict either
Party from fully exploiting such rights consistently with the scope of the rights and obligations of both Parties under this Agreement, in each case (A) through (C), without the written consent of the non-controlling Party, which will not to be
unreasonably withheld, conditioned or delayed. For the avoidance of doubt, except as provided in the foregoing clause (B), the costs of such defense and settlement shall be borne by the controlling Party. 

(iii)    If the Party entitled to control the defense under Section 10.4(a)(i) or Section 10.4(a)(ii)
fails to proceed in a timely manner with respect to such defense, the other Party shall have the right to control the defense of such claim upon the same conditions set forth therein.

(iv)    If requested by the Party controlling the defense, the Parties shall enter into a joint defense
agreement that further outlines their rights and responsibilities consistent with the terms of this Section or as otherwise mutually agreed.

(b)    Patent Invalidity Claim. If a Third Party at any time asserts a claim that any issued
Agios Patent, Celgene Collaboration Patent or Joint Patent is invalid or otherwise unenforceable (an “Invalidity Claim”), whether as a defense in an infringement action brought by Agios or Celgene pursuant to Section 10.3(b) or
Section 10.3(c), in a declaratory judgment 

  
 - 35 - 

 
action or in a Third Party Infringement claim brought against Agios or Celgene, the Parties shall cooperate with each other in preparing and formulating a response to such Invalidity Claim;
provided that, subject to the terms and conditions of any Existing Third Party Agreement to the extent such agreement applies to such Agios Patent, the Party who has (or would have) control over litigation pursuant to Section 10.3(b)
or Section 10.3(c) shall have the sole right to control the defense and settlement of any such Invalidity Claim as if it were litigation initiated therein. For the avoidance of doubt, any claim asserted against any Agios Patent before any such
Patent is issued is deemed a Prosecution matter that is the subject of Section 10.2.
 Section
10.5.    Patent Term Extensions. The Parties shall, as necessary and appropriate, use reasonable efforts to agree upon a joint strategy for obtaining, and cooperate with each other in obtaining, patent term extensions
for Agios Patents, Celgene Collaboration Patents and Joint Patents that Cover Licensed Products. If the Parties are unable to agree upon which of such Patents should be extended, and the matter remains unresolved after the procedure described
in the Master Agreement, then [**] shall have the right to resolve the dispute, subject in each case to the terms and conditions of any Existing Third Party Agreement to the extent such agreement applies to an applicable [**] Patent. 

Section 10.6.    Patent Marking. Celgene shall comply with the patent marking statutes in each
country in which the Licensed Product is Manufactured or Commercialized by or on behalf of Celgene or its Affiliates or Licensee Partners, as applicable, hereunder. 

Section 10.7.    Celgene Intellectual Property. Celgene shall have the sole right, but not the
obligation, to initiate a suit or take other appropriate action that it believes is reasonably required to protect the Celgene Intellectual Property without any obligation to consult with Agios. Notwithstanding anything to the contrary in
Section 10.3 or Section 10.4, all recoveries with respect to any such action, by settlement or otherwise, shall be [**] percent ([**]%) by Celgene.

Section 10.8.    Application of 35 U.S.C. § 102(c). It is agreed and
acknowledged that this Agreement establishes a qualifying collaboration within the scope of 35 U.S.C. § 102(c) and, accordingly, shall be deemed to constitute a “Joint Research Agreement” for all purposes under 35 U.S.C. §
102(c). Neither Party shall invoke the provisions of 35 U.S.C. § 102(c), or file this Agreement, in connection with the prosecution of any patent application claiming, in whole or in part, any 35 U.S.C. § 102(c) invention without the
prior written consent of the other Party. In the event that a Party, during the course of prosecuting a patent application claiming a 35 U.S.C. § 102(c) invention (a “35 U.S.C. § 102(c) Patent”), deems it necessary to
file a terminal disclaimer to overcome an obviousness type double patenting rejection in view of an earlier filed patent held by the other Party (the “Earlier Patent”), then, if the Parties agree, the Parties shall coordinate the
filing of such terminal disclaimer in good faith, and, to the extent required under 35 U.S.C. § 102(c), both Parties shall agree, in such terminal disclaimer, that they shall not separately enforce 35 U.S.C. § 102(c) Patent independently
from the Earlier Patent. To this end, to the extent required under 35 U.S.C. § 102(c), following the filing of such terminal disclaimer, the Parties shall, in good faith, coordinate all enforcement actions with respect to 35 U.S.C. §
102(c) Patent. 

  
 - 36 - 

 Article XI. 

Confidentiality 

Section 11.1.    Confidential Information. Each Party agrees that a Party (the
“Receiving Party”) receiving Confidential Information of any other Party (the “Disclosing Party”) shall (a) maintain in confidence such Confidential Information using not less than the efforts such Receiving Party
uses to maintain in confidence its own proprietary information of similar kind and value, but in no event less than a reasonable degree of effort, (b) not disclose such Confidential Information to any Third Party without the prior written consent of
the Disclosing Party, except for disclosures expressly permitted below, and (c) not use such Confidential Information for any purpose except those permitted by this Agreement (it being understood that this clause (c) shall not create or imply any
rights or licenses not expressly granted under this Agreement). All Confidential Information of the Disclosing Party shall not be used by the Receiving Party except in performing its obligations or exercising rights explicitly granted
under this Agreement, except to the extent that the Confidential Information: 
 (a)    was known by
the Receiving Party or its Affiliates prior to its date of disclosure to the Receiving Party, as established by written evidence; or 

(b)    is lawfully disclosed to the Receiving Party or its Affiliates by sources other than the
Disclosing Party rightfully in possession of the Confidential Information; or 
 (c)    becomes
published or generally known to the public through no fault or omission on the part of the Receiving Party, its Affiliates or its sublicensees; or 

(d)    is independently developed by or for the Receiving Party or its Affiliates without reference to or
reliance upon such Confidential Information, as established by written records. 
 Section
11.2.    Permitted Disclosure. The Receiving Party may provide the Disclosing Party’s Confidential Information: 

(a)    to the Receiving Party’s respective employees, consultants and advisors, and to the
employees, consultants and advisors of such Party’s Affiliates, who have a need to know such information and materials for performing obligations or exercising rights expressly granted under this Agreement and have an obligation to treat such
information and materials as confidential; 
 (b)    to patent offices in order to seek or obtain
Patents or to Regulatory Authorities in order to seek or obtain approval to conduct Clinical Trials or to gain Regulatory Approval with respect to the Licensed Products as contemplated by this Agreement; provided that such disclosure
may be made only following reasonable notice to the Disclosing Party and to the extent reasonably necessary to seek or obtain such Patents or Regulatory Approvals; or 

(c)    if such disclosure is required by judicial order or applicable Law or to defend or prosecute
litigation or arbitration; provided that, prior to such disclosure, to the extent permitted by Law, the Receiving Party promptly notifies the Disclosing Party of such requirement, cooperates with the Disclosing Party to take whatever
action it may deem appropriate to protect the confidentiality of the information and furnishes only that portion of the Disclosing Party’s Confidential Information that the Receiving Party is legally required to furnish. 

  
 - 37 - 

 Section 11.3.    Publicity; Terms of this Agreement;
Non-Use of Names. 
 (a)    Public Announcements. Except as required by judicial order
or applicable Law (in which case, Section 11.3(a) must be complied with) or as explicitly permitted by this Article XI, neither Party shall make any public announcement concerning this Agreement without the prior written consent of the other Party,
which consent shall not be unreasonably withheld or delayed. The Party preparing any such public announcement shall provide the other Party with a draft thereof at least [**] prior to the date on which such Party would like to make the public
announcement (or, in extraordinary circumstances, such shorter period as required to comply with applicable Law). Notwithstanding the foregoing, the Parties shall issue a press release, in the form attached as Exhibit E to this Agreement
within [**] after the Effective Date. Neither Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity or news release relating to this Agreement or its subject matter, without the prior
express written permission of the other Party. For purposes of clarity, either Party may issue a press release or public announcement or make such other disclosure relating to this Agreement if the contents of such press release, public
announcement or disclosure (x) (i) does not consist of financial information and has previously been made public other than through a breach of this Agreement by the issuing Party or its Affiliates, (ii) is contained in such Party’s financial
statements prepared in accordance with Accounting Standards, or (iii) is contained in the a redacted version of this Agreement, and (y) is material to the event or purpose for which the new press release or public announcement is made. 

(b)    Notwithstanding the terms of this Section 11.3: 

(i)    Either Party shall be permitted to disclose the existence and terms of this Agreement to the
extent required, in the reasonable opinion of such Party’s legal counsel, to comply with applicable Laws, including the rules and regulations promulgated by the Securities and Exchange Commission or any other governmental
authority. Notwithstanding the foregoing, before disclosing this Agreement or any of the terms hereof pursuant to this Section 11.3(a), the Parties will coordinate in advance with each other in connection with the redaction of certain
provisions of this Agreement with respect to any filings with the US Securities and Exchange Commission (“SEC”), London Stock Exchange, the UK Listing Authority, NYSE, the NASDAQ Stock Market or any other stock exchange on which
securities issued by a Party or a Party’s Affiliate are traded (the “Redacted Version”), and each Party will use commercially reasonable efforts to seek confidential treatment for such terms as may be reasonably requested by
the other Party; provided that the Parties will use commercially reasonable efforts to file redacted versions with any governing bodies which are consistent with the Redacted Version. 

(ii)    Notwithstanding Section 11.1, the Receiving Party may disclose Confidential Information belonging
to the Disclosing Party, and Confidential Information deemed to belong to both the Disclosing Party and the Receiving Party, to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances: 

  
 - 38 - 

 (1)    subject to Section 11.3, complying with applicable
Laws (including the rules and regulations of the SEC or any national securities exchange) and with judicial process, if in the reasonable opinion of the Receiving Party’s counsel, such disclosure is necessary for such compliance; 

(2)    disclosure, solely on a “need to know basis,” to (1) Affiliates, subcontractors,
advisors (including attorneys and accountants), (2) subject to Section 11.3(b)(ii)(3), investment bankers, and (3) in each case of (1) and (2), their and each of the Parties’ respective directors, employees, contractors and agents; provided,
that in all cases of (1), (2) and (3), prior to any such disclosure, each disclosee must be bound by written obligations of confidentiality, non-disclosure and non-use no less restrictive than the obligations set forth in this Article XI (provided,
however, that in the case of prospective investment bankers, the term of confidentiality may be [**] from the date of disclosure and in the case of legal advisors, no written agreement shall be required), which for the avoidance of doubt, will not
permit use of such Confidential Information for any purpose except those permitted by this Agreement; provided, however, that, in each of the above situations, the Receiving Party shall remain responsible for any failure by any Person who receives
Confidential Information pursuant to this Section 11.3(b)(ii)(2) to treat such Confidential Information as required under this Article XI; and 

(3)    in the case of any disclosure of this Agreement to any actual or potential acquirer, assignee,
licensee, licensor, investment banker, institutional investor, lender or other financial partners, such disclosure shall solely be [**]; it being understood and agreed that, in connection with a proposed [**] with respect to such Party, only [**]
this Agreement as applicable, to such Third Party; provided that, a Party may also disclose an unredacted version of this Agreement to Third Party attorneys, professional accountants and auditors who are engaged by licensors and lenders and who are
under obligations of confidentiality not to disclose the unredacted terms of this agreement to such licensors or lenders for the purpose of confirming such Party’s compliance with the terms of its applicable license and loan agreements with
such licensors and lenders.
 (iii)    [**]. Such disclosures may include achievement of
milestones, significant events in the development and regulatory process, commercialization activities and the like. In addition to the initial press release described in Section 11.3, a Party (the “Requesting Party”) may elect
to make any such public disclosure of such achievement of milestones, significant events in the development and regulatory process and commercialization activities, and in such event it shall first notify the other Party (the “Cooperating
Party”) of such planned press release or public announcement and provide a draft for review at least [**] in advance of issuing such press release or making such public announcement (or, with respect to press releases and public
announcements that are required by applicable Law, or by regulation or rule of any public stock exchange (including NASDAQ), with as much advance notice as possible under the circumstances if it is not possible to provide notice at least [**] in
advance); provided, however, that a Party may issue such press release or public announcement without such prior review by the other Party if (A) the contents of such press release or public announcement have previously been
made public other than through a breach of this Agreement by the issuing Party and (B) such press release or public announcement does not materially differ from the previously issued press release or other publicly available information. The

  
 - 39 - 

 
Cooperating Party may notify the Requesting Party of any reasonable objections or suggestions that the Cooperating Party may have regarding the proposed press release or public announcement, and
the Requesting Party shall reasonably consider any such objections or suggestions that are provided in a timely manner. The principles to be observed in such disclosures shall include accuracy, compliance with applicable Law and regulatory
guidance documents, reasonable sensitivity to potential negative reactions of the FDA (and its foreign counterparts) and the need to keep investors informed regarding the Requesting Party’s business. 

Section 11.4.    Publications. The Parties agree that neither Party nor its Affiliates shall
have the right to make Publications pertaining to the Compounds or Licensed Products except as provided herein. If a Party or its Affiliates desire to make a Publication, such Party must comply with the following procedure: 

(a)    Review by the Non-Publishing Party. The publishing Party shall provide the
non-publishing Party with an advance copy of the proposed Publication, and the non-publishing Party shall then have [**] prior to submission for any Publication ([**] in the case of an abstract or oral presentation) in which to determine whether the
Publication may be published and under what conditions, including (i) delaying sufficiently long to permit the timely preparation and filing of a patent application or (ii) specifying changes the non-Publishing reasonably believes are necessary to
preserve any Patents or Know-How belonging (whether through ownership or license, including under this Agreement) in whole or in part to the non-publishing Party. 

(b)    Removal of Confidential Information. In addition, if the non-publishing Party informs
the publishing Party that such Publication, in the non-publishing Party’s reasonable judgment, discloses any Confidential Information of the non-publishing Party or could be expected to have a material adverse effect on any Know-How which is
Confidential Information of the non-publishing Party, such Confidential Information or Know-How shall be deleted from the Publication. 

(c)    Scientific Conferences. Each Party shall have the right to present its Publications
approved pursuant to this Section 11.4 at scientific conferences, including at any conferences in any country in the world, subject to any conditions imposed by the non-publishing Party in its approval. 

(d)    Academic Publications. Notwithstanding the foregoing, the Parties acknowledge that, to
the extent that any Publication relates to Agios Intellectual Property that is subject to an Existing Third Party Agreement, the parties to such Existing Third Party Agreement may have retained the right to publish certain information, and nothing
in this Section 11.4 is intended to restrict the exercise of such rights; provided that, to the extent that Agios has the right to review and comment on any such publications, Agios shall, to the extent permissible under such Existing
Third Party Agreement, exercise such rights after consultation with Celgene. 
 Section
11.5.    Term. All obligations under Sections 11.1, 11.2, 11.3 and 11.6 shall survive termination or expiration of this Agreement and shall expire [**] following termination or expiration of this Agreement. 

  
 - 40 - 

 Section 11.6.    Return of Confidential Information.

 (a)    Obligations to Return or Destroy. Upon the expiration or termination of this
Agreement, the Receiving Party shall return to the Disclosing Party all Confidential Information received by the Receiving Party from the Disclosing Party (and all copies and reproductions thereof). In addition, the Receiving Party shall
destroy: 
 (i)    any notes, reports or other documents prepared by the Receiving Party which contain
Confidential Information of the Disclosing Party; and 
 (ii)    any Confidential Information of the
Disclosing Party (and all copies and reproductions thereof) which is in electronic form or cannot otherwise be returned to the Disclosing Party. 

(b)    Destruction. Alternatively, upon written request of the Disclosing Party, the
Receiving Party shall destroy all Confidential Information received by the Receiving Party from the Disclosing Party (and all copies and reproductions thereof) and any notes, reports or other documents prepared by the Receiving Party which contain
Confidential Information of the Disclosing Party. Any requested destruction of Confidential Information shall be certified in writing to the Disclosing Party by an authorized officer of the Receiving Party supervising such destruction. 

(c)    Limitation. Nothing in this Section 11.6 shall require the alteration, modification,
deletion or destruction of archival tapes or other electronic back-up media made in the ordinary course of business; provided that the Receiving Party shall continue to be bound by its obligations of confidentiality and other
obligations under this Article XI with respect to any Confidential Information contained in such archival tapes or other electronic back-up media. 

(d)    Exceptions. Notwithstanding the foregoing, 

(i)    the Receiving Party’s legal counsel may retain one copy of the Disclosing Party’s
Confidential Information solely for the purpose of determining the Receiving Party’s continuing obligations under this Article XI; and 

(ii)    the Receiving Party may retain the Disclosing Party’s Confidential Information and its own
notes, reports and other documents 
 (A)    to the extent reasonably required (1) to exercise the
rights and licenses of the Receiving Party expressly surviving expiration or termination of this Agreement; or (2) to perform the obligations of the Receiving Party expressly surviving expiration or termination of this Agreement; or 

(B)    to the extent it is impracticable to do so without incurring disproportionate cost. 

Notwithstanding the return or destruction of the Disclosing Party’s Confidential Information, the Receiving Party shall continue to be
bound by its obligations of confidentiality and other obligations under this Article XI. 

  
 - 41 - 

 Article XII. 

Representations and Warranties 

Section 12.1.    Mutual Representations. Agios and Celgene each represents, warrants and
covenants to the other Party, as of the Execution Date, that: 
 (a)    Authority. Each
Party is duly organized, validly existing and in good standing under the Laws of the jurisdiction of its formation and has full corporate power and authority to enter into this Agreement, and to carry out the provisions hereof or thereof, as
applicable. 
 (b)    Consents. All necessary consents, approvals and authorizations of all
government authorities and other Persons required to be obtained by it as of the Execution Date in connection with the execution, delivery and performance of this Agreement, and the performance of its obligations hereunder or thereunder, as
applicable, have been obtained, except for authorizations and consents that may be necessary under Antitrust Law. 

(c)    No Conflict. Notwithstanding anything to the contrary in this Agreement, the
execution and delivery of this Agreement, the performance of such Party’s obligations in the conduct of the Collaboration and the licenses and sublicenses to be granted pursuant to this Agreement (i) do not and will not conflict with or violate
any requirement of applicable Laws existing as of the Execution Date and (ii) do not and will not conflict with, violate, breach or constitute a default under any agreement or any provision thereof, or any contract, oral or written, to which it is a
party or by which it or any of its Affiliates is bound, existing as of the Execution Date. 

(d)    Enforceability. This Agreement has been duly executed and delivered on behalf of each Party
and is a legal and valid obligation binding upon it and is enforceable in accordance with its terms. 

(e)    Employee Obligations. To its knowledge, none of its or its Affiliates’ employees who
have been, are or will be involved in the Collaboration are, as a result of the nature of such Collaboration to be conducted by the Parties, in violation of any covenant in any contract with a Third Party relating to non-disclosure of proprietary
information, noncompetition or non-solicitation. 
 Section 12.2.    Additional Agios
Representations. Agios represents, warrants and covenants to Celgene, as of the Execution Date, as follows: [**] 

(a)    Agios has all rights, authorizations and consents necessary to grant all rights and licenses it
purports to grant to Celgene under this Agreement, except for authorizations and consents that may be necessary under Antitrust Law. 

(b)    Agios has not used, and during the Term will not knowingly use, any Know-How in a Program
conducted by Agios that is encumbered by any contractual right of or obligation to a Third Party that conflicts or interferes with any of the rights or licenses granted or to be granted to Celgene hereunder. 

  
 - 42 - 

 (c)    Agios has not granted, and during the Term Agios will
not grant, any right or license, to any Third Party relating to any of the intellectual property rights it Controls, that conflicts with or limits the scope of the rights or licenses granted or to be granted to Celgene hereunder. 

(d)    There are no claims, litigations, suits, actions, disputes, arbitrations, or legal, administrative
or other proceedings or governmental investigations pending or, to Agios’ knowledge, threatened against Agios, nor is Agios a party to any judgment or settlement, which would be reasonably expected to adversely affect or restrict the ability of
Agios to consummate the transactions contemplated under this Agreement and to perform its obligations under this Agreement, or which would affect the Agios Intellectual Property, or Agios’ Control thereof, or any Target or Compound.* 

(e)    To Agios’ knowledge, the practice of the Agios Intellectual Property as contemplated under
this Agreement does not (i) infringe any claims of any Patents of any Third Party, or (ii) misappropriate any Know-How of any Third Party.* 

(f)    None of (i) the Agios Patents owned by Agios or both Controlled by and Prosecuted by Agios and
(ii) to Agios’ knowledge, the Agios Patents Controlled but not Prosecuted by Agios are subject to any pending re-examination, opposition, interference or litigation proceedings.* 

(g)    To the knowledge of Agios, the Agios Patents Controlled by Agios or any Affiliate pursuant to any
Existing Third Party Agreement were not and are not subject to any restrictions or limitations except as set forth in the Existing Third Party Agreements. 

(h)    Agios has and, to Agios’ knowledge, the applicable licensor under each Existing Third Party
Agreement has, if applicable, complied with any and all obligations under the Bayh-Dole Act to perfect rights to the applicable Patent Rights or Know-How licensed thereunder.* Neither Agios nor any of its Affiliates has granted any liens or security
interests on the Agios Intellectual Property and the Agios Intellectual Property is free and clear of any mortgage, pledge, claim, security interest, covenant, easement, encumbrance, lien or charge of any kind, except in each case with respect to
licenses, covenants not to sue, immunities from suit, standstills, releases and options which would not, in the aggregate, fundamentally frustrate the purposes of the Collaboration. 

(i)    Schedule 12.2(i) contains a complete and accurate list of all Patents owned by Agios and/or
its Affiliates as of the Execution Date that are included in the Patents licensed hereunder, indicating any co-owner(s), if applicable. Except as set forth on Schedule 12.2(i), Agios and its Affiliates do not own any Patent that is
necessary or, to Agios’ reasonable belief as of the Execution Date, reasonably useful to research, Develop, Manufacture or Commercialize any Compounds or Licensed Products. 

(j)    Schedule 12.2(j) sets forth a complete and accurate list of all Existing Third Party
Agreements, true and correct copies of which have been provided to Celgene, and such agreements are in full force and effect and have not been modified or amended. Neither Agios nor, to the knowledge of Agios, any licensor under the Existing Third
Party Agreements is 

  
 - 43 - 

 
in default with respect to a material obligation under, and none of such parties has claimed or has grounds upon which to claim that the other party is in default with respect to a material
obligation under, the Existing Third Party Agreements.* 
 (k)    Except under the Existing Third Party
Agreements in effect as of the Execution Date, and except as set forth on Schedule 12.2(j), Agios and its Affiliates are not subject to any payment obligations to Third Parties as a result of the execution or performance of this Agreement.

 Section 12.3.    Covenants. 

(a)    Mutual Covenants. Each Party hereby covenants to the other Party that: 

(i)    all employees of such Party or its Affiliates or Third Party subcontractors working under this
Agreement will be under appropriate confidentiality provisions at least as protective as those contained in this Agreement and, to the extent permitted under applicable Law, the obligation to assign all right, title and interest in and to their
inventions and discoveries, whether or not patentable, to such Party as the sole owner thereof; 

(ii)    to its knowledge, such Party will not (i) employ or use, nor hire or use any contractor or
consultant that employs or uses, any individual or entity, including a clinical investigator, institution or institutional review board, debarred or disqualified by the FDA (or subject to a similar sanction by any Regulatory Authority outside the
United States) or (ii) employ any individual who or entity that is the subject of an FDA debarment investigation or proceeding (or similar proceeding by any Regulatory Authority outside the United States), in each of subclauses (i) and (ii) in the
conduct of its activities under this Agreement 
 (iii)    neither such Party nor any of its Affiliates
shall, during the Term, grant any right or license to any Third Party relating to any of the intellectual property rights it owns or Controls which would conflict with any of the rights or licenses granted to the other Party hereunder; and 

(iv)    such Party and its Affiliates shall perform its activities pursuant to this Agreement, in
compliance (and shall ensure compliance by any of its subcontractors) in all material respects with all applicable Laws, including GCP, GLP and GMP as applicable and with respect to the Development, Manufacturing and Commercialization activities
hereunder. 
 (b)    Existing Third Party Agreement Covenants. Agios hereby
covenants to Celgene that Agios shall maintain the Existing Third Party Agreements, and shall not amend or terminate such agreements, and will not breach such agreements, if such amendment, modification, termination or breach would adversely affect
Celgene’s rights under this Agreement.
 Section 12.4.    Agios Covenants During the
Term. Except to the extent expressly permitted under Section 15.4, during the Term, neither Agios nor its Affiliates will, other than to an Affiliate of Agios who agrees in writing to be bound by the terms and conditions of this Agreement
(a) assign, transfer, convey, encumber (including any liens or charges, but excluding any licenses, which are the subject of subsection (b), below) or dispose of, or enter into any 

  
 - 44 - 

 
agreement with any Third Party to assign, transfer, convey, encumber (including any liens or charges, but excluding any licenses, which are the subject of subsection (b), below) or dispose of,
any assets specifically related to this Agreement, including with respect to the Compound(s), Licensed Product(s) and any then-identified Companion Diagnostic(s) developed therefor, or pre-clinical study or Clinical Trial results or other data
specifically related to such Program, or any intellectual property specifically related to any of the foregoing (with respect to each Program, the “Agios Program Assets”), except to the extent such assignment, transfer, conveyance,
encumbrance or disposition would not fundamentally frustrate the purpose of this Agreement with respect to such Program, (b) license or grant to any Third Party, or agree to license or grant to any Third Party, any rights to any Agios Program Assets
if such license or grant would fundamentally frustrate the purpose of this Agreement with respect to such Program, or (c) disclose any Confidential Information relating to the Agios Program Assets to any Third Party if such disclosure would
fundamentally frustrate the purpose of this Agreement with respect to such Program. Agios and/or its Affiliates shall have the right to assign, transfer, convey or dispose of any assets specifically related to such Program to any Affiliate of
Agios to the extent permitted under Section 15.4. 
 Section
12.5.    Disclaimer. Except as otherwise expressly set forth in this Agreement, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY THAT
ANY PATENTS ARE VALID OR ENFORCEABLE, AND EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT. Without limiting the generality of the foregoing,
each Party disclaims any warranties with regards to: (a) the success of any study or test commenced under this Agreement; (b) the safety or usefulness for any purpose of the technology or materials, including the Compound, Licensed Product or
Companion Diagnostic; and/or (c) the validity, enforceability, or non-infringement of any intellectual property rights or technology it provides or licenses to the other Party under this Agreement. 

Article XIII. 

Indemnification; Product Liabilities 

Section 13.1.    By Celgene. 

(a)    Celgene Indemnification Obligation. Celgene agrees, at Celgene’s cost and
expense, to defend, indemnify and hold harmless Agios and its Affiliates and their respective directors, officers, employees and agents (the “Agios Indemnified Parties”) from and against any losses, costs, damages, fees or expenses
arising out of any Third Party claim relating to: 
 (i)    any breach by Celgene of any of its
representations, warranties or obligations pursuant to this Agreement; 
 (ii)    the gross negligence,
or willful misconduct or violation of Law of Celgene or its Affiliates or Licensee Partners; or 

  
 - 45 - 

 (iii)    the Development, Manufacture and Commercialization
of the Licensed Products by Celgene, its Affiliates or its Licensee Partners, including all Product Liabilities claims arising from Licensed Products distributed by Celgene or its Affiliates or Licensee Partners. 

(b)    Indemnification Procedures. In the event of any such claim against the Agios
Indemnified Parties by any Third Party, Agios shall promptly, and in any event within [**], notify Celgene in writing of the claim. Celgene shall have the right, exercisable by notice to Agios within [**] after receipt of notice from Agios of
the claim, to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the claim (provided that such claim is solely for monetary damages and Celgene agrees to pay all Damages relating to such matter, as
evidenced in a written confirmation delivered by Celgene to Agios) with counsel selected by Celgene and reasonably acceptable to Agios; provided that the failure to provide timely notice of a claim by a Third Party shall not limit an Agios
Indemnified Party’s right for indemnification hereunder except to the extent such failure results in actual prejudice to Celgene. The Agios Indemnified Parties shall cooperate with Celgene and may, at their option and expense, be
separately represented in any such action or proceeding. Celgene shall not be liable for any litigation costs or expenses incurred by the Agios Indemnified Parties without Celgene’s prior written authorization. In addition, Celgene
shall not be responsible for the indemnification or defense of any Agios Indemnified Party to the extent arising from any negligent or intentional acts by any Agios Indemnified Party or the breach by Agios of any representation, obligation or
warranty under this Agreement, or any claims compromised or settled without its prior written consent. Each Party shall use reasonable efforts to mitigate Damages indemnified under this Section 13.1. 

Section 13.2.    By Agios.

(a)    Agios Indemnification Obligation. Agios agrees, at Agios’ cost and expense, to
defend, indemnify and hold harmless Celgene and its Affiliates and their respective directors, officers, employees and agents (the “Celgene Indemnified Parties”) from and against any losses, costs, damages, fees or expenses arising
out of any Third Party claim relating to: 
 (i)    any breach by Agios of any of its representations,
warranties or obligations pursuant to this Agreement; 
 (ii)    the gross negligence, willful
misconduct or violation of Law of Agios or its Affiliates, or following termination of this Agreement where Section 14.4 is applicable, its Licensee Partners; 

(iii)    Licensed Products distributed by Agios or its Affiliates, including all Product Liabilities
claims arising from Licensed Products distributed by Agios or its Affiliates; or 
 (iv)    any of the
matters disclosed by Agios in a disclosure schedule pursuant to Section 12.2, where the cause of action underlying such Damages accrued prior to the Execution Date. For the avoidance of doubt, amounts payable under Third Party licenses entered
into under Section 9.4(b) shall be borne by Celgene as set forth in Section 9.4(b), and shall not be subject to indemnification under this Section 13.2. 

  
 - 46 - 

 (b)    Indemnification Procedures. In the event
of any such claim against the Celgene Indemnified Parties by any Third Party, Celgene shall promptly, and in any event within [**], notify Agios in writing of the claim. Agios shall have the right, exercisable by notice to Celgene within [**]
after receipt of notice from Celgene of the claim, to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the claim (provided that such claim is solely for monetary damages and Agios agrees to pay all
Damages relating to such matter, as evidenced in a written confirmation delivered by Agios to Celgene) with counsel selected by Agios and reasonably acceptable to Celgene; provided that the failure to provide timely notice of a claim by a Third
Party shall not limit a Celgene Indemnified Party’s right for indemnification hereunder except to the extent such failure results in actual prejudice to Agios. The Celgene Indemnified Parties shall cooperate with Agios and may, at their
option and expense, be separately represented in any such action or proceeding. Agios shall not be liable for any litigation costs or expenses incurred by the Celgene Indemnified Parties without Agios’ prior written authorization. In
addition, Agios shall not be responsible for the indemnification or defense of any Celgene Indemnified Party to the extent arising from any negligent or intentional acts by any Celgene Indemnified Party or the breach by Celgene of any
representation, obligation or warranty under this Agreement, or any claims compromised or settled without its prior written consent. Each Party shall use reasonable efforts to mitigate Damages indemnified under this Section 13.2. 

Section 13.3.    Product Liability Costs. Except with respect to such portion (if any) of
Product Liabilities that are claims entitled to indemnification under Section 13.1 or Section 13.2, all costs incurred in connection with any litigation or proceeding relating to such Third Party Products Liability Action shall be borne solely by
Celgene. 
 Section 13.4.    Limitation of Liability. EXCEPT WITH RESPECT TO A BREACH OF
SECTION 8.6 OR ARTICLE XI, OR A PARTY’S LIABILITY PURSUANT TO SECTION 13.1 OR SECTION 13.2, NEITHER PARTY SHALL BE LIABLE FOR SPECIAL, CONSEQUENTIAL, EXEMPLARY, PUNITIVE, MULTIPLE OR OTHER INDIRECT OR REMOTE DAMAGES, OR FOR LOSS OF PROFITS,
LOSS OF DATA OR LOSS OF USE DAMAGES ARISING IN ANY WAY OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, WHETHER BASED UPON WARRANTY, CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY
OF SUCH DAMAGES OR LOSS. 
 Section 13.5.    Insurance. Beginning on [**] and thereafter
during the Term, Celgene shall maintain commercial general liability insurance (including product liability insurance) from a recognized, creditworthy insurance company, with coverage limits of at least [**] US Dollars ($[**]) per claim and annual
aggregate. Celgene may elect to self-insure all or parts of the limits described above. Within [**] following written request from Agios, Celgene, shall furnish to Agios a certificate of insurance evidencing such coverage. If such
coverage is modified or cancelled, Celgene shall notify the Agios and promptly provide Agios with a new certificate of insurance evidencing that Celgene’s coverage meets the requirements of this Section 13.5. 

  
 - 47 - 

 Article XIV. 

Term and Termination 

Section 14.1.    Term. This Agreement shall commence on the Effective Date and, unless earlier
terminated pursuant to Section 14.3, shall remain in effect until it expires (the “Term”) as follows: 

(a)    on a Licensed Product-by-Licensed Product and country-by-country basis, this Agreement shall
expire on the date of the expiration of the Royalty Term with respect to such Licensed Product in such country; and 

(b)    in its entirety upon the expiration of all applicable Royalty Terms under this Agreement with
respect to all Licensed Products in all countries in the Territory. 
 For the avoidance of doubt, this Agreement shall not be effective
until the Effective Date, and this Agreement may be subject to termination prior to the Effective Date as set forth in Section 3.2 of the Master Agreement, in which case all rights to the Program (as defined in the Master Agreement) that is the
subject of this Agreement shall revert to Agios in accordance with Section 2.12 of the Master Agreement. 
 Section
14.2.    Effect of Expiration. After the expiration of the Term pursuant to Section 14.1 above, the following terms shall apply: 

(a)    Licenses after Licensed Product Expiration. After expiration of the Term (but
not after early termination) with respect to any Licensed Product in a country in the Territory pursuant to Section 14.1(a), Celgene’s rights and licenses hereunder under Agios’ rights in Agios Intellectual Property, Joint Inventions,
Joint Patents and Manufacturing Technology to develop, manufacture, have manufactured, use, offer for sale, sell, import and otherwise commercialize such Licensed Product and related Companion Diagnostics in the Field in such country, for so long as
it continues to do so, shall convert to irrevocable, non-terminable rights and licenses, with the right to grant sublicenses; provided that, following such expiration and notwithstanding Section 9.4(a), (i) Celgene shall be solely
responsible for all payments owed to any Third Party licensors and (ii) Celgene shall be responsible for complying with the terms of any license agreements with such Third Party licensors, in each case ((i) and (ii)), solely with respect to
Celgene’s exercise of such rights. 
 (b)    Licenses after Expiration of
Agreement. After expiration of the Term (but not after early termination) with respect to this Agreement in its entirety pursuant to Section 14.1(b), Celgene’s rights and licenses hereunder under Agios’ rights in Agios
Intellectual Property, Joint Inventions, Joint Patents and Manufacturing Technology to develop, manufacture, have manufactured, use, offer for sale, sell, import and otherwise commercialize Licensed Products and Companion Diagnostics in the Field
worldwide, for so long as it continues to do so, shall convert to irrevocable, non-terminable rights and licenses, with the right to grant sublicenses; provided that, following such expiration and notwithstanding Section 9.4(a), (i)
Celgene shall be solely responsible for all payments owed to any Third Party licensors and (ii) Celgene shall be responsible for complying with the terms of any license agreements with such Third Party licensors, in each case ((i) and (ii)), solely
with respect to Celgene’s exercise of such rights. 

  
 - 48 - 

 Section 14.3.    Termination. 

(a)    Termination for Convenience. Celgene shall have the right to terminate this Agreement
in its entirety for convenience upon [**] prior written notice to Agios; provided that Celgene shall not have the right to terminate this Agreement until [**] following the Effective Date (it being understood and agreed that Celgene
shall be entitled to terminate upon [**] written notice at any time it reasonably determines that such termination is necessary to comply with any Antitrust Law). 

(b)    Termination for Material Breach. 

(i)    Termination by Either Party for Breach. Subject to Section 14.3(b)(ii) (with
respect to a Material Breach by either Party of its obligations to use Commercially Reasonable Efforts), this Agreement and the rights granted herein may be terminated by either Party for the material breach of this Agreement in a manner that
fundamentally frustrates the transactions contemplated by this Agreement taken as a whole by the other Party to this Agreement (each, a “Material Breach”), provided that, if the breaching Party has not cured such
Material Breach within [**] after the date of written notice to the breaching Party of such breach (or [**], in the case of Celgene’s payment obligations under this Agreement or the specified time period provided in Section 14.3(b)(ii) with
respect to a Material Breach by either Party of its obligation to use Commercially Reasonable Efforts, each as applicable) (the “Cure Period”), which notice shall describe such breach in reasonable detail and shall state the
non-breaching Party’s intention to terminate this Agreement pursuant to this Section 14.3(b)(i). Notwithstanding the preceding sentence, the Cure Period for any allegation made in good faith as to a Material Breach under this Agreement
will run from the date that written notice was first provided to the breaching Party by the non-breaching Party. Any such termination of this Agreement under this Section 14.3(b)(i) shall become effective at the end of the Cure Period, unless
the breaching Party has cured any such Material Breach prior to the expiration of such Cure Period, or, if such Material Breach is not susceptible to cure within the Cure Period, then, the non-breaching Party’s right of termination shall be
suspended only if and for so long as the breaching Party has provided to the non-breaching Party a written plan that is reasonably calculated to effect a cure and such plan is acceptable to the non-breaching Party, and the breaching Party commits to
and carries out such plan as provided to the non-breaching Party within [**] days after the date that written notice was first provided to the breaching Party by the non-breaching Party. The Parties understand and agree that the totality of
this Agreement and the [**]. 
 (ii)    Additional Procedures for Termination by either Party
for Failure of the Other Party to Use Commercially Reasonable Efforts. If either Party wishes to exercise its right to terminate this Agreement pursuant to Section 14.3(b)(i) for the other Party’s Material Breach of its
obligations to use Commercially Reasonable Efforts, it shall provide to such other Party a written notice of its intent to exercise such right, which notice shall be labeled as a “notice of Material Breach for failure to use Commercially
Reasonable Efforts,” and shall state the reasons and justification for such termination [**]. For any such notice of breach by a Party, the Cure Period shall, subject to Section 14.3(b)(iii), be [**], and shall become effective in
accordance with Section 14.3(b)(i). 

  
 - 49 - 

 (iii)    Disagreement as to Material
Breach. If the Parties reasonably and in good faith disagree as to whether there has been a Material Breach pursuant to Section 14.3(b) then: (A) the Party that disputes that there has been a Material Breach may contest the allegation
by referring such matter, within [**] for resolution to the Executive Officers, who shall meet promptly to discuss the matter, and determine, within [**] following referral of such matter, whether or not a Material Breach has occurred pursuant to
Section 14.3(b); (B) the relevant Cure Period with respect thereto will be tolled from the date the breaching Party notifies the non-breaching Party of such dispute and through the resolution of such dispute in accordance with the applicable
provisions of this Agreement (provided, that if such dispute relates to payment, the Cure Period will only apply with respect to payment of disputed amounts, and not with respect to undisputed amounts), (C) it is understood and agreed that during
the pendency of such dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder) and (D) if it is finally and conclusively determined in
accordance with Section 15.2 that the breaching Party committed such Material Breach, then the breaching Party shall have the right to cure such Material Breach after such determination within the Cure Period (provided, that if such dispute relates
to a failure to use Commercially Reasonable Efforts, such post-determination Cure Period shall be strictly limited to [**] and any cure within such [**] period must fully cure such breach prior to the end of such [**] period). 

(iv)    If the Executive Officers are unable to resolve a dispute within such [**] period after it is
referred to them, the matter will be resolved as provided in Section 15.2. 

(v)    Payments. No milestone payments by Celgene will be due on milestones achieved
during the period between the notice of termination under Section 14.3(b) and the effective date of termination; provided, however, that (A) if either Party provides notice of a dispute pursuant to Section 14.3(b)(iii) or
otherwise and such dispute is resolved in a manner in which no termination of this Agreement occurs with respect to such breach or (B) the breaching Party cures the applicable breach during the Cure Period, then upon such resolution or cure Celgene
will within [**] pay to Agios the applicable milestone payment for each milestone achieved during the period between the notice of termination under Section 14.3(b) and the resolution of such dispute or cure of such breach, and if it was determined
that Celgene wrongly asserted breach by Agios under Section 14.3(b)(iii), then Celgene shall also pay interest on such amount as provided in Section 9.9. 

(c)    Termination for Insolvency. To the extent permitted by Law, this Agreement may be
terminated by either Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party;
provided, however, that, in the event of any involuntary bankruptcy or receivership proceeding such right to terminate shall only become effective if either Party consents to the involuntary bankruptcy or receivership or such
proceeding is not dismissed within ninety (90) days after the filing thereof. 

  
 - 50 - 

 (d)    Termination for Patent
Challenge. Either Party shall have the right to terminate this Agreement solely on a Licensed Product-by-Licensed Product basis upon written notice if the other Party or any of its Affiliates challenges the validity, scope or enforceability
of or otherwise opposes any Patent (i) included in the Agios Intellectual Property and that is licensed to Celgene under this Agreement in any action or proceeding, or (ii) included in the Celgene Patents or Celgene Collaboration Patents that is
licensed to Agios under this Agreement in any action or proceeding (subject to the exceptions described in this Section 14.3(d), a “Challenge”) (other than as may be necessary or reasonably required to assert a defense, cross-claim
or a counter-claim in an action or proceeding asserted by such Party or any of its Affiliates or Licensee Partners against the other Party or any of its Affiliates or Licensee Partners or to respond to a court request or order or administrative law,
request or order), it being understood and agreed that either Party’s right to terminate this Agreement under this Section 14.3(d) shall not apply to any actions undertaken by an Affiliate of the other Party (the “Challenging
Party”) that first becomes such an Affiliate as a result of a Change of Control involving the Challenging Party, where such new Affiliate was undertaking any of the activities described in the foregoing clause prior to such Change of
Control; provided that, a Party’s right to terminate this Agreement under this Section 14.3(d) shall apply to actions undertaken by such new Affiliate if the Challenging Party is the acquiror in such Change of Control and such new
Affiliate does not terminate or otherwise cease participating in such action, proceeding, challenge or opposition within [**] after the effective date of such Change of Control. If a Licensee Partner of Celgene challenges the validity, scope or
enforceability of or otherwise opposes any Patent included in any of the intellectual property described in this Section 14.3(d) under which such Licensee Partner is sublicensed in any action or proceeding, then Celgene shall, upon written notice
from Licensor, terminate such sublicense. For the avoidance of doubt, an action by a Party or any Affiliate (collectively the “Pursuing Party”) in accordance with this Agreement and the Master Agreement to amend claims within a
pending patent application of the other Party during the course of the Pursuing Party’s Prosecution of such pending patent application or in defense of a Third Party proceeding, or to make a negative determination of patentability of claims of
a patent application of the other Party or to abandon a patent application of the other Party during the course of the Pursuing Party’s Prosecution of such pending patent application, shall not constitute a challenge under this Section
14.3(d). Neither Party shall, and each Party shall ensure that its Affiliates and Licensee Partners do not, use or disclose any Confidential Information of the other Party or any nonpublic information regarding the Prosecution or enforcement of
any Agios Patents, Celgene Collaboration Patents or Joint Patents to which a Party or any of its Affiliates or Licensee Partners are or become privy as a consequence of the rights granted to Celgene pursuant to Article X, in initiating, requesting,
making, filing or maintaining, or in funding or otherwise assisting any other Person with respect to, any Challenge. 

Section 14.4.    Effects of Termination. 

(a)    Effects of Celgene Termination for Convenience or Agios Termination for Celgene
Breach, Insolvency or Patent Challenge. Upon termination of this Agreement by Celgene under Section 14.3(a) or by Agios under Section 14.3(b), 14.3(c) or 14.3(d), the following shall apply: 

  
 - 51 - 

 (i)    all licenses granted by Agios to Celgene under
Section 8.1 shall terminate (A) in their entirety if pursuant to Section 14.3(a), (b) or (c), and (B) with respect to the corresponding Compound and Licensed Product if pursuant to Section 14.3(d); 

(ii)    Celgene shall grant to Agios an exclusive, non-transferable (except as set forth in Section
15.4), worldwide right and license in the Field, with the right to grant sublicenses in a manner consistent with Section 8.2(a) and Section 8.2(a)(ii)(2), and, from and after such termination, Agios shall pay Celgene royalties on Annual Net Sales of
Licensed Products pursuant to Section 9.3, reducing such royalties by [**] percent ([**]%) and substituting “Agios” for “Celgene” and vice versa with respect to all obligations and definitions, and otherwise mutatis
mutandis, under Celgene’s rights in Celgene Intellectual Property, Celgene Collaboration Intellectual Property, Joint Inventions, Joint Patents and Manufacturing Technology to Develop, Manufacture and Commercialize Compounds and
Licensed Products; provided that, (i) Agios shall be solely responsible for all payments owed to any Third Party licensors (without any right to offset any such amounts against royalties payable to Celgene hereunder) and (ii) Agios
shall be responsible for complying with the terms of any license agreements with such Third Party licensors, in each case ((i) and (ii)), solely with respect to Agios’ exercise of such rights; 

(iii)    Celgene shall be released from its Development, Manufacture and Commercialization obligations
(except as set forth in Section 14.4(a)(vii) and Section 14.4(a)(viii) below with respect to Celgene’s transfer of Manufacturing to Agios hereunder); 

(iv)    within [**] after such termination, Celgene shall provide to Agios a fair and accurate summary
report of the status of Development and Commercialization activities conducted by Celgene with respect to the Licensed Products; 

(v)    Celgene shall promptly transfer and assign to Agios all of Celgene’s and its Affiliates’
rights, title and interests in and to the Product Trademark(s) (but not any Celgene house marks or composite marks including a house mark) owned by Celgene and solely used for Licensed Products in the Territory; 

(vi)    Celgene shall as soon as reasonably practicable transfer and assign to Agios all Regulatory
Approvals of the Licensed Products in the Territory, their corresponding Regulatory Documentation, and a copy of all of the data comprising the global safety database for the Licensed Products and any related Companion Diagnostics; provided
that Celgene may retain such data and a single copy of such Regulatory Approvals and Regulatory Documentation for its records; and provided further that, if such Regulatory Approvals or Regulatory Documentation are
necessary or useful for the Development, Manufacture or Commercialization of any product other than the Licensed Products, in place of transferring or assigning the foregoing, Celgene shall grant Agios a Right of Reference or Use with respect to
such approvals or documentation with respect to the Licensed Products in the Territory; 

(vii)    Agios shall have the option, exercisable within [**]following the effective date of such
termination of this Agreement, to obtain Celgene’s inventory of the Licensed Products at a price equal to [**] percent ([**]%) of Celgene’s Manufacturing Costs for such inventory of the Licensed Products; provided that, if
Celgene, its Affiliates or Licensee 

  
 - 52 - 

 
Partners have outstanding orders, at Agios’ election, either Agios shall fulfill such orders or, notwithstanding Agios’ option to purchase inventory, Celgene may retain sufficient
inventory to fulfill such orders. Agios may exercise such option by written notice to Celgene during such [**] period; provided that, in the event Agios exercises such right to purchase such inventory, Celgene shall grant, and
hereby does grant, a royalty-free right and license to any trademarks, names and logos of Celgene contained therein for a period of [**] solely to permit the orderly sale of such inventory, subject to Agios meeting reasonable quality control
standards imposed by Celgene on the use of such trademarks, names and logos, which shall be consistent with the standards used by Celgene prior to such termination; 

(viii)    at Agios’ written request: 

(1)    in exchange for a payment equal to [**] percent ([**]%) of Celgene’s Manufacturing Costs and
upon other commercially reasonable terms as may be mutually agreed between the Parties or their respective Affiliates in a supply agreement, Celgene shall use Commercially Reasonable Efforts to supply Agios and its Affiliates with comparable
quantities of the Licensed Products in the form, formulation and presentation as were being Developed or Commercialized immediately prior to termination until the earlier of [**] after the effective date of the termination and establishment by Agios
of an alternative supply for such product(s); 
 (2)    in the event Celgene was utilizing a Third
Party manufacturer to Manufacture the Licensed Products, to the extent permitted by the terms of such contract, Celgene shall promptly assign to Agios the manufacturing agreements with such Third Party with respect to such product(s); and 

(3)    Celgene shall transfer, or have transferred, to Agios or its designee, pursuant to a technology
transfer plan to be mutually agreed by the Parties, all Manufacturing Technology Controlled by Celgene that is both necessary to Manufacture the Licensed Products as Manufactured by or on behalf of Celgene and its Affiliates prior to termination and
has been incorporated in regulatory documentation submitted to a Regulatory Authority in support of Development or Commercialization of the Licensed Products (or is in the process of being incorporated), and Celgene shall provide reasonable
assistance in connection with the transfer of such Manufacturing Technology to Agios or its designee, all of which shall be transferred or provided at Celgene’s Out-of-Pocket Costs; 

(ix)    separate transitional activities shall be undertaken with respect to any Companion Diagnostic(s)
to ensure that the appropriate Regulatory Approvals, Manufacturing Technology or other Know-How or Patents necessary for the Development, Manufacture or Commercialization of such Companion Diagnostic(s) shall be transferred to Agios to the same
extent as Regulatory Approvals, Manufacturing Technology or other Know-How or Patents otherwise associated with such Licensed Products are transferred; 

(x)    notwithstanding anything to the contrary in Section 8.6, Agios shall have the right to pursue the
Development, Manufacture and Commercialization of the Licensed Products; and 

  
 - 53 - 

 (xi)    the provisions of Article X (other than Section
10.1) terminate, and Celgene shall, if applicable, provide reasonable assistance to Agios and cooperation in connection with the transition of Prosecution and enforcement responsibilities to Agios with respect to Agios Patents, Celgene Collaboration
Patents and Joint Patents then being Prosecuted or enforced by Celgene, including execution of such documents as may be necessary to effect such transition. 

(xii)    Sell-Down. Unless Agios exercises its option under Section 14.4(a)(vii), if
Celgene, its Affiliates or Licensee Partners at termination of this Agreement possess Licensed Product, have started the manufacture thereof or have accepted orders therefor, Celgene, its Affiliates or Licensee Partners shall have the right, for up
to [**] following the date of termination, to sell their inventories thereof, complete the manufacture thereof and Commercialize such fully-manufactured Licensed Product, in order to fulfill such accepted orders or distribute such fully-manufactured
Licensed Product, subject to the obligation of Celgene to pay Agios any and all payments as provided in this Agreement. 

(b)    Effects of Celgene Termination for Agios Breach, Insolvency or Patent Challenge. Upon
any termination of this Agreement by Celgene under Section 14.3(b), 14.3(c) or 14.3(d): 
 (i)    If
Celgene has the right to terminate this Agreement pursuant to Section 14.3(b), Section 14.3(c) or Section 14.3(d), Celgene may elect upon written notice to Agios, to either: 

(1)     terminate this Agreement in its entirety, if pursuant to Section 14.3(b) or Section 14.3(c), or
with respect to the corresponding Compound and Licensed Product, if pursuant to Section 14.3(d), in which case (1) all rights and obligations of the Parties under this Agreement or the corresponding Compound and Licensed Product, respectively, shall
terminate, except (I) Celgene’s payment obligations (accrued as of the effective date of such termination) and the audit rights set forth in Article IX, and (II) Section 14.4(d), shall, in each of cases (I) and (II), survive such termination,
(2) Agios shall return any Confidential Information of Celgene pursuant to Article VIII of the Master Agreement that is not necessary to practice any licenses retained by Agios following such termination under this Agreement, another Development
& Commercialization Agreement (as defined in the Master Agreement) or the Master Agreement, (3) Celgene shall grant to Agios an exclusive, non-transferable (except as set forth in Section 15.4), worldwide right and license in the Field, with the
right to grant sublicenses in a manner consistent with Section 8.2(a) and Section 8.2(a)(ii)(2), and, from and after such termination, Agios shall pay Celgene royalties on Annual Net Sales of Licensed Products pursuant to Section 9.3, reducing such
royalties by [**] percent ([**]%) and substituting “Agios” for “Celgene” and vice versa with respect to all obligations and definitions, and otherwise mutatis mutandis, under Celgene’s rights in Celgene Intellectual
Property, Celgene Collaboration Intellectual Property, Joint Inventions, Joint Patents and Manufacturing Technology to Develop, Manufacture and Commercialize Compounds and Licensed Products; provided that, (I) Agios shall be
solely responsible for all payments owed to any Third Party licensors (without any right to offset any such amounts against royalties payable to Celgene hereunder) and (II) Agios shall be responsible for complying with the terms of any license
agreements with such Third Party licensors, in each case ((I) and (II)), solely with respect to Agios’ exercise of such rights, and (4) Celgene may seek any damages that Celgene can establish that are not compensated by the royalties set forth
in Section 14.4(b)(i)(A)(3); or 

  
 - 54 - 

 (2)     maintain this Agreement in full force and effect
(foregoing, for the avoidance of doubt, the right to terminate this Agreement for such occurrence of such breach) and, with respect to the Licensed Product(s) that are the subject of the applicable breach by Agios, all future milestones and royalty
obligations in respect of such Licensed Products payable by Celgene under this Agreement following such election shall be subject to a reduction of [**] percent ([**]%). 

(ii)    each Party shall be released from its Development, Manufacture and Commercialization obligations;

 (iii)    if Celgene has made the election set forth in Section 14.4(b)(i)(2), the license granted by
Agios to Celgene in Section 8.1 shall convert to an irrevocable, non-terminable license, with the right to grant sublicenses; provided that, notwithstanding Section 9.4(a), (i) Celgene shall be solely responsible for all payments owed
to any Third Party licensors (without any right to offset any such amounts against royalties payable to Agios hereunder) and (ii) Celgene shall be responsible for complying with the terms of any license agreements with such Third Party licensors, in
each case ((i) and (ii)), solely with respect to Celgene’s exercise of such rights.; and 

(iv)    if Celgene has made the election set forth in Section 14.4(b)(i)(i)(2), the rights of Agios in
Article X (other than Section 10.1) shall be terminated and Agios shall, if applicable, provide reasonable assistance to Celgene and cooperation in connection with the transition of Prosecution and enforcement responsibilities to Celgene with
respect to Agios Patents, including execution of such documents as may be necessary to effect such transition. 

(c)    In the case of any termination of this Agreement, if any Clinical Trials are then being conducted
at the time of such termination with respect to any Licensed Product, the Parties hereby agree (i) to reasonably cooperate in the completion of any such Clinical Trials, and (ii) notwithstanding anything to the contrary contained herein, to grant to
the Party that retains global Commercialization rights to such Licensed Product following such termination (A) free of charge, copies of and rights of reference to and use of all Licensed Product Data that is Controlled by such Party and generated
pursuant to such Clinical Trials that are relevant to or necessary to address issues relating to: (1) the safety of such Licensed Product in the Territory, including data that is related to adverse effects experienced with such Licensed Product
and/or (2) all activities relating to CMC regarding such Licensed Product and in each of (1) and (2), that are required to be reported or made available to Regulatory Authorities in the Territory, when and as such data become available, and (B)
copies of and rights of reference to and use of all Licensed Product Data (other than the Licensed Product Data referred to in subclause (A) above) that is Controlled by such Party and generated pursuant to such Clinical Trials that are relevant to
or necessary to address the Development and Commercialization of such Licensed Product promptly following the generation of such Licensed Product Data if, but only if, as to such Licensed Product Data described in this subclause (B), such Party that
retains global Commercialization rights to such Licensed Product following such termination promptly pays 

  
 - 55 - 

 
for all Development Costs incurred following any such termination of this Agreement with respect to such Clinical Trials. For purposes of this Section 14.4(c), “Licensed Product
Data” means all relevant data included in the Know-How Controlled by either Party or its Affiliates in relation to Licensed Products for use in the Field either: (x) as of the Effective Date; or (y) generated from the applicable Clinical
Trials. 
 (d)    Survival. Upon any termination or expiration of this Agreement, unless
otherwise specified in this Agreement and except for any rights or obligations that have accrued prior to the effective date of termination or expiration, all rights and obligations of each Party under this Agreement shall terminate in whole or with
respect to the Licensed Products, as the case may be; provided, however, that Section 9.3(c), Section 9.5, Section 9.6, Section 9.7, Section 9.8, Section 9.9, Section 9.10, Section 10.1, Section 11.5, Section 11.6, Section 13.1,
Section 13.2, Section 13.3, Section 13.4, Section 14.4, and Section 15.2, as well as any other provision which by its terms or by the context thereof is intended to survive, shall survive any such termination or expiration of this Agreement. 

(e)    Accrued Liabilities. Except as otherwise specifically provided herein, termination of
this Agreement shall not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination, nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or
in equity with respect to any breach of this Agreement nor prejudice either Party’s right to obtain performance of any obligation. In addition, termination of this Agreement shall not terminate provisions which provide by their respective
terms for obligations or undertakings following the expiration of the term of this Agreement. 

(f)    Relationship to Other Agreements. Termination or expiration of this Agreement shall
not affect in any way the terms or provisions of the Master Agreement or any other then-existing executed Development & Commercialization Agreement. 

Article XV. 

Miscellaneous 

Section 15.1.    Dispute Resolution. The Parties agree that any disputes arising with respect
to the interpretation, enforcement, termination or invalidity of this Agreement (each, a “Dispute”) shall first be presented to the Parties’ respective Executive Officers for resolution. If the Parties are unable to
resolve a given dispute pursuant to this Section 15.1 after discussions between the Executive Officers within [**] after referring such dispute to the Executive Officers, either Party may, at its sole discretion, seek resolution of such matter in
accordance with Section 15.2. 
 Section 15.2.    Submission to Court for
Resolution. Subject to Section 15.1, the Parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction of the courts located in the Southern District of New York for any action, suit or proceeding (other than appeals
therefrom) arising out of or relating to this Agreement, and agree not to commence any action, suit or proceeding (other than appeals therefrom) related thereto except in such courts. The Parties further hereby irrevocably and unconditionally
waive any objection to the laying of venue of any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this 

  
 - 56 - 

 
Agreement in the courts of New York, and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit or proceeding brought in
any such court has been brought in an inconvenient forum. Each Party further agrees that service of any process, summons, notice or document by registered mail to its address set forth in Section 15.6 shall be effective service of process for
any action, suit or proceeding brought against it under this Agreement in any such court. 
 Section
15.3.    Governing Law. This Agreement and all questions regarding its validity or interpretation, or the performance or breach of this Agreement, shall be governed by and construed and enforced in accordance with the
laws of the State of New York, without reference to conflicts of laws principles. 
 Section
15.4.    Assignment. 
 (a)    Generally. This Agreement
may not be assigned by any Party, nor may any Party delegate its obligations or otherwise transfer licenses or other rights created by this Agreement, except as expressly permitted hereunder without the prior written consent of the other Party,
which consent will not be unreasonably withheld, delayed or conditioned. 

(b)    Celgene. Notwithstanding the limitations in Section 15.4(a), Celgene Corp. and
Celgene RIVOT may assign this Agreement, or any rights or obligations hereunder in whole or in part, to (i) one or more Affiliates solely as provided in this Section 15.4(b) or (ii) its successor in interest in connection with the merger,
consolidation, or sale of all or substantially all of its assets or that portion of its business pertaining to the subject matter of this Agreement; provided, however, that, except in the case where Celgene Corp., or Celgene RIVOT, as applicable, is
involved in a merger or consolidation where it is the surviving entity and no assets of Celgene Corp. or Celgene RIVOT, as applicable have been transferred as a result of such merger or consolidation (for example, a reverse triangular merger), (A)
Celgene Corp. or Celgene RIVOT, as applicable, provides Agios with at least [**] advance written notice of any such assignment(s), (B) prior to such assignment(s), Celgene Corp. or Celgene RIVOT, as applicable, agrees in a written agreement
delivered to Agios (and upon which Agios may rely) to remain fully liable for the performance of its obligations under this Agreement by its assignee(s), and (C) prior to such assignment(s), the assignee(s) agree in a written agreement delivered to
Agios (and upon which Agios may rely) to assume performance of all such assigned obligations. If Celgene Corp. or Celgene RIVOT, as applicable, wishes to assign any Celgene Intellectual Property, Celgene Collaboration Intellectual Property, Joint
Inventions, Joint Patents or Manufacturing Technology which Celgene Corp. or Celgene RIVOT, as applicable, Controls, or Agios Program Assets for each Program, to one or more permitted Affiliate(s), it will be permitted to do so conditioned on such
Affiliate(s) becoming a party to this Agreement, in the form of an amendment to this Agreement executed by Celgene, Agios and such Affiliate(s), pursuant to which such Affiliate(s) would agree to assume all obligations hereunder, and grant to Agios
all rights hereunder, with respect to the assets so assigned. 

(c)    Agios. Notwithstanding the limitations in Section 15.4(a), Agios may assign
this Agreement, or any rights or obligations hereunder in whole or in part, to (i) one or more Affiliates solely as provided in this Section 15.4(c) or (ii) its successor in connection with the merger, consolidation, or sale of all or substantially
all of its assets or that portion of its 

  
 - 57 - 

 
business pertaining to the subject matter of this Agreement; provided, however, that, except in the case where [**], (A) Agios provides Celgene with at least [**] advance
written notice of any such assignment(s) no later than [**] after such assignment(s), (B) prior to such assignment(s), Agios agrees in a written agreement delivered to Celgene (and upon which Celgene may rely) to remain fully liable for the
performance of its obligations under this Agreement by its assignee(s), and (C) prior to such assignment(s), the assignee(s) agree in a written agreement delivered to Celgene (and upon which Celgene may rely) to assume performance of all such
assigned obligations, (D) in the case of any assignment(s) by Agios of any Agios Intellectual Property, Joint Inventions, Joint Patents or Manufacturing Technology which Agios Controls, and all Program Assets for each Program will be transferred to
such assignee(s) effective as of such assignment(s), and (E) all of the matters referred to in clauses (A), (B), (C) and (D), as applicable, will be set forth in documentation [**] prior to any such assignment(s) ([**]) and in all cases will provide
[**]. Subject to the terms of this Section 15.4(c), if Agios wishes to assign any [**], it will be permitted to do so conditioned on [**], pursuant to which such [**]. 

(d)    In the event the Implementation Date for this Agreement has not occurred within [**] following the
Effective Date, Celgene shall be entitled to [**], if required by any Antitrust Law; provided that, the right to [**] set forth in this Section 15.4(d) shall not apply if a breach by Celgene of its obligations under Section 8.6(a) is a
material cause of the failure to obtain clearance under Antitrust Laws. 
 (e)    All Other
Assignments Null and Void. The terms of this Agreement will be binding upon and will inure to the benefit of the successors, heirs, administrators and permitted assigns of the Parties. Any purported assignment in violation of this
Section 15.4 will be null and void ab initio. 
 (f)    Change of
Control. Notwithstanding anything to the contrary in this Agreement, with respect to any intellectual property rights controlled by the acquiring party or its Affiliates (if other than one of the Parties to this Agreement) involved in any
Change of Control of either Party, such intellectual property rights shall not be included in the technology and intellectual property rights licensed to the other Party hereunder to the extent held by such acquirer or its Affiliate (other than the
relevant Party to this Agreement) prior to such transaction, or to the extent such technology is developed outside the scope of activities conducted with respect to the Collaboration, Compounds, Licensed Products, or related Companion
Diagnostics. The Agios Intellectual Property and the Celgene Intellectual Property shall exclude any intellectual property owned or controlled by a permitted assignee or successor and not developed in connection with the Collaboration,
Compounds , Licensed Products, or related Companion Diagnostics, Developed, Manufactured or Commercialized pursuant to this Agreement or the Master Agreement.

Section 15.5.    Force Majeure. If the performance of any part of this Agreement by a Party is
prevented, restricted, interfered with or delayed by an occurrence beyond the control of such Party (and which did not occur as a result of such Party’s financial condition, negligence or fault), including fire, earthquake, flood, embargo,
power shortage or failure, acts of war or terrorism, insurrection, riot, lockout or other labor disturbance, governmental acts or orders or restrictions, acts of God (for the purposes of this Agreement, a “force majeure
event”), such Party shall, upon giving written notice to the other Party, be excused from such performance to 

  
 - 58 - 

 
the extent of such prevention, restriction, interference or delay; provided that the affected Party shall use its Commercially Reasonable Efforts to avoid or remove such causes of
non-performance and shall continue performance with the utmost dispatch whenever such causes are removed. 
 Section
15.6.    Notices. Unless otherwise agreed by the Parties or specified in this Agreement, all notices required or permitted to be given under this Agreement shall be in writing and shall be sufficient if: (a)
personally delivered; (b) sent by registered or certified mail (return receipt requested and postage prepaid); (c) sent by express courier service providing evidence of receipt and postage prepaid where applicable; or (d) sent by facsimile
transmission (receipt verified and a copy promptly sent by another permissible method of providing notice described in clauses (a), (b) or (c) above), to address for a Party set forth below, or such other address for a Party as may be specified in
writing by like notice: 
  

			
	 To Agios:
  

Agios Pharmaceuticals, Inc.
 88 Sidney Street

Cambridge, MA 02139
 Attention: Chief Executive Officer

Telephone: 617-649-8600
 Facsimile: [**]
	  	 To Celgene Corp. or Celgene RIVOT:
  

Celgene Corporation
 86 Morris Avenue

Summit, NJ 07901
 Attention: Senior Vice President Business
Development
 Telephone: (908) 673-9000

Facsimile: [**]

  
 - 59 - 

 
			
	 With a copy to:
  

Agios Pharmaceuticals, Inc.
 88 Sidney Street

Cambridge, MA 02139
 Attention: Legal Department

Telephone: (617) 649-8600
 Facsimile: [**]

 
 and
  

WilmerHale
 60 State Street

Boston, MA 02109
 Attention: Steven D. Singer

Telephone: (617) 526-6410
 Facsimile: (617) 526-5000
	  	 With a copy to:
  

Celgene Corporation
 86 Morris Avenue

Summit, NJ 07901
 Attention: Legal Department

Telephone: (908) 673-9000
 Facsimile: [**]

 
 and
  

Celgene RIVOT Ltd.
 Aon House

30 Woodbourne Avenue
 Pembroke HM 08

Bermuda
 Phone: 441-296-4803

 
 and
  

Dechert LLP
 1900 K St. NW

Washington, DC 20006
 Attention: David E. Schulman

Telephone: (202) 261-3440
 Facsimile: [**]

 Any such notices shall be effective upon receipt by the Party to whom it is addressed. 

Section 15.7.    Waiver. Except as otherwise expressly provided in this Agreement, any term of
this Agreement may be waived only by a written instrument executed by a duly authorized representative of the Party waiving compliance. The delay or failure of either Party at any time to require performance of any provision of this Agreement
shall in no manner affect such Party’s rights at a later time to thereafter enforce such provision. No waiver by either Party of any condition or term in any one or more instances shall be construed as a further or continuing waiver of
such condition or term or of another condition or term. 
 Section 15.8.    Severability. If
any provision of this Agreement should be held invalid, illegal or unenforceable in any jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the
Parties and all other provisions of this Agreement shall remain in full force and effect in such jurisdiction and shall be liberally construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. If the
Parties cannot agree upon a substitute provision, the invalid, illegal or unenforceable provision of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid, illegal or unenforceable provision is of such
essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid, illegal or unenforceable provision. 

  
 - 60 - 

 Section 15.9.    Entire Agreement. This Agreement
(including the Exhibits attached hereto), together with the Master Agreement, constitutes the entire agreement between the Parties relating to its subject matter, and supersedes all prior and contemporaneous agreements, representations or
understandings, either written or oral, between the Parties with respect to such subject matter. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the
Parties other than as set forth herein and therein. 
 Section 15.10.    Modification. No
modification, amendment or addition to this Agreement, or any provision hereof, shall be effective unless reduced to writing and signed by a duly authorized representative of each Party. No provision of this Agreement shall be varied,
contradicted or explained by any oral agreement, course of dealing or performance or any other matter not set forth in an agreement in writing and signed by a duly authorized representative of each Party. 

Section 15.11.    Independent Contractors; No Intended Third Party Beneficiaries. This
Agreement is not intended nor shall be deemed or construed to create any relationship of employer and employee, agent and principal, partnership, or joint venture between the Parties. Each Party is an independent contractor. Neither Party
shall assume, either directly or indirectly, any liability of or for the other Party. Neither Party shall have any express or implied right or authority to assume or create any obligations on behalf of, or in the name of, the other Party, nor
to bind the other Party to any contract, agreement or undertaking with any Third Party. There are no express or implied third party beneficiaries hereunder, (a) except for the indemnitees identified in Section 13.1 and Section 13.2, and (b)
except for any licensor under any Existing Third Party Agreement. 
 Section
15.12.    Interpretation; Construction. The captions to the several Articles and Sections of this Agreement are included only for convenience of reference and shall not in any way affect the construction of, or be
taken into consideration in interpreting, this Agreement. In this Agreement, unless the context requires otherwise, (a) the word “including” shall be deemed to be followed by the phrase “without limitation” or like
expression, whether or not followed by the same; (b) references to the singular shall include the plural and vice versa; (c) references to masculine, feminine and neuter pronouns and expressions shall be interchangeable; (d) the words
“herein” or “hereunder” relate to this Agreement; (e) “or” is disjunctive but not necessarily exclusive; (f) the word “will” shall be construed to have the same meaning and effect as the word
“shall”; and (g) all references to “dollars” or “$” herein shall mean U.S. Dollars. Each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has
participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which drafted such terms and provisions. 

Section 15.13.    Performance by Affiliates.

  
 - 61 - 

 (a)    To the extent that this Agreement imposes obligations
on Affiliates of a Party, such Party agrees to cause its Affiliates to perform such obligations. 

(b)    The Parties hereby acknowledge and agree that (a) Celgene Corp. is the party to this Agreement
with respect to all rights and obligations (including payment obligations) under this Agreement in the United States; and (b) Celgene RIVOT is the party to this Agreement with respect to all rights and obligations under this Agreement outside of the
United States. 
 Section 15.14.    Counterparts. This Agreement may be executed in two (2)
counterparts, each of which shall be deemed an original, and both of which together shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of a fax machine or by .pdf, .tif, .gif, .jpeg or similar
attachment to electronic mail (any such delivery, an “Electronic Delivery”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were
the original signed version thereof delivered in person. No Party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use
of Electronic Delivery as a claim or defense with respect to the formation of a contract, and each Party forever waives any such claim or defense, except to the extent that such claim or defense relates to lack of authenticity.

Section 15.15.    HSR Clearance; Cooperation. For the avoidance of doubt, the Parties shall
continue to comply with Section 3.2 of the Master Agreement. 
 Section 15.16.    Equitable
Relief. Notwithstanding anything to the contrary herein, the Parties shall be entitled to seek equitable relief, including injunction and specific performance, as a remedy for any breach of this Agreement. Such remedies shall not be
deemed to be the exclusive remedies for a breach of this Agreement but shall be in addition to all other remedies available at law or equity.

Section 15.17.    Further Assurances. Each Party shall execute, acknowledge and deliver such
further instruments, and do all such other acts, as may be necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this Agreement.

[Remainder of page intentionally left blank] 

  
 - 62 - 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Execution
Date. 
  

	
	AGIOS PHARMACEUTICALS, INC.
	
	By:                                     
                                         
     
	Name:                                     
                                        

	Title:                                     
                                         
 
	
	CELGENE CORPORATION
	
	By:                                     
                                         
     
	Name:                                     
                                        

	Title:                                     
                                         
 
	
	 Solely with respect to the rights and obligations

under this License Agreement outside of the United

States (subject to Section 15.13):

	
	CELGENE RIVOT LTD.
	
	By:                                     
                                         
     
	Name:                                     
                                        

	Title:                                     
                                         
 

  

 Exhibit A 

Target, Compound(s) and Upfront Option Payment 
  

	1.	 Target: 

  

	2.	 Compounds [check applicable box and include Agios identifiers and structure(s)]:

 ̈ inhibitors of Target 
 or 

 ̈ activators of Target 
 Description of Compound: 

 

	3.	 Upfront Option Payment calculated as: [check applicable boxes]

  ̈ If the Program under this Agreement is a Designated Development Program or the Deemed DC Program, the sum of Thirty Million US Dollars
($30,000,000) plus the Reimbursable Back-up Expenses and the Reimbursable Manufacturing Expenses (such Reimbursable Back-up Expenses and Reimbursable Manufacturing Expenses, in the aggregate, not to exceed [**] US Dollars ($[**])); 

OR 

 ̈
 If the Program under this Agreement is a Continuation Program (other than the Deemed DC Program), the sum of Thirty-Five Million US Dollars ($35,000,000) plus the Reimbursable Back-up
Expenses and the Reimbursable Manufacturing Expenses (such Reimbursable Back-up Expenses and Reimbursable Manufacturing Expenses, in the aggregate, not to exceed [**] US Dollars ($[**])); 

OR 

 ̈
 If the Program under this Agreement is a Qualified Early Exercise I&I Program, Ten Million US Dollars ($10,000,000). 

  
 A - 1 

 ANNEX I 

REIMBURSABLE MANUFACTURING EXPENSES AND REIMBURSABLE BACK-UP 

EXPENSES 
 Reference is
made to the Upfront Option Payment described in paragraph 3 of Exhibit A to this Agreement, which will include the following Reimbursable Manufacturing Expenses and/or Reimbursable Back-Up Expenses as applicable: [check applicable
boxes] 
  ̈ Reimbursable Back-up Expenses shall only include amounts incurred for: 

 

	 	•	 	 [describe pre-approved back-up Compounds] which back-up Compounds have been agreed to by the
Parties on [insert relevant dates] and 

  

	 	•	 	 in the aggregate, equals $_______________________ (which amount is subject to review pursuant to
Section 9.6 and, in the event of any good faith dispute between the Parties, such amount shall not be payable until the final resolution pursuant to Section 9.6). 

 ̈
 Reimbursable Manufacturing Expenses shall only include amounts incurred for: 
  

	 	•	 	 [describe pre-approved Manufacturing Expenses, including any relevant quantities of conforming Compounds
that were Manufactured for post-Pre-Exercise Phase I Development activities]; and 

  

	 	•	 	 in the aggregate, equals $_______________________ (which amount is subject to review pursuant to
Section 9.6 and, in the event of any good faith dispute between the Parties, such amount shall not be payable until the final resolution pursuant to Section 9.6). 

  
 A- 2 

 Exhibit B 

Agios Patents 
 (as of the
Execution Date) 
 Celgene Collaboration Patents 

(as of the Execution Date) 

  
 B-1 

 Exhibit C 

Existing Third Party Agreements 

[Parties to identify each applicable Existing Third Party Agreement referenced in the Option Data Package and each provision
thereof that must be included in this Agreement, including for Third Party Programs and Third Party Licenses] 

  
 C-1 

 Exhibit D 

Countries for Filing Agios Patents, Celgene Collaboration Patents and Joint Patents 

[**] 

  
 D-1 

 Exhibit E 

Press Release 

  
 E-1 

 Disclosure Schedules 

[tailor as applicable] 

Schedule 12.2(d) 
 Schedule
12.2(e) 
 Schedule 12.2(f) 

Schedule 12.2(h) 
 Schedule
12.2(i)        Patents 
 Schedule 12.2(j)        Existing Third Party
Agreements 
 [Note: exceptions in Section 12.2 to be identified, if applicable] 

  

 APPENDIX C 

CERTAIN FINANCIAL DEFINITIONS 

“Accounting Standards” means (a) GAAP (United States Generally Accepted Accounting Principles); or (b) IFRS
(International Financial Reporting Standards), in either case, consistently applied. 
 “Development Costs”
means the costs and expenses that are actually incurred by or on behalf of a Party and specifically identifiable or specifically allocable to Development activities for a given Program. “Development Costs” shall include: 

(a)    the FTE costs (determined by multiplying the number of FTE hours of service spent by the FTE Rate)
of Agios or its Affiliates with respect to such Development, and in the case of Celgene or its Affiliates, instead of reimbursing Celgene on an FTE basis, Celgene shall be reimbursed for [**]% of Out-of-Pocket costs incurred by Celgene in connection
with any Development Activity); 
 (b)    all Out-of-Pocket Costs incurred by the Parties or their
Affiliates, including payments made to Third Parties with respect to such Development (except to the extent that such costs have been included in FTE costs); 

(c)    Regulatory Expenses; 

(d)    the cost of contract research organizations (CROs); and 

(e)    Manufacturing Costs for clinical supply, including: 

(i)    costs of packaging of drug products and distribution of drug products used in clinical trials;

 (ii)    expenses incurred to purchase or package comparator drugs; 

(iii)    costs and expenses of disposal of clinical samples; and 

(iv)    costs and expenses incurred in scaling up Manufacturing activities related to pre-clinical or
clinical supply, including formulation development activities; 
 all of such costs, as determined from the books and records of the
applicable Party and its Affiliates maintained in accordance with the Accounting Standards. Notwithstanding anything in this definition to the contrary, only those Development Costs that are contemplated by, and materially consistent with, the
Development Plan and Development Budget for the applicable Program shall be chargeable as Development Costs. 

“Manufacturing Costs” means, with respect to Program Compounds included in a given Program, the reasonable
FTE costs and Out-of-Pocket Costs of a Party or any of its Affiliates or sublicensees incurred in Manufacturing such Program Compounds, and including: 

  
 C-1 

 (a)    to the extent that any such Program Compound is
Manufactured by a Party or any of its Affiliates or sublicensees, direct material and direct labor costs, plus manufacturing overhead attributable to such Program Compound (including facility start-up costs, all directly incurred manufacturing
variances, and a reasonable allocation of related manufacturing administrative and facilities costs (including depreciation) and a reasonable allocation of the costs of failed batches to be further described in the applicable supply agreement, to be
provided for such Program Compound, but excluding costs associated with excess capacity), all determined in accordance with the books and records of the applicable Party or its Affiliates or sublicensees maintained in accordance with the Accounting
Standards, consistently applied; and 
 (b)    to the extent that any such Program Compound is
Manufactured by a Third Party manufacturer, the Out-of-Pocket Costs paid by a Party or any of its Affiliates or sublicensees to the Third Party for the manufacture, supply, packaging and labeling of such Program Compound, and any reasonable
Out-of-Pocket Costs and direct labor costs actually incurred by such Party or any of its Affiliates or sublicensees in managing or overseeing the Third Party relationship, determined in accordance with the books and records of the applicable Party
or its Affiliates or sublicensees maintained in accordance with the Accounting Standards, consistently applied.

“Out-of-Pocket Costs” means, with respect to certain activities hereunder, direct expenses paid or payable by
either Party or its Affiliates to Third Parties (other than employees of such Party or its Affiliates) that are specifically identifiable and incurred to conduct such activities for a Program hereunder and have been recorded in accordance with the
Accounting Standards. 
 “Regulatory Expenses” means, with respect to a Program Compound, all Out-of-Pocket
Costs incurred by or on behalf of a Party in connection with the preparation and filing of regulatory submissions for such Program Compound and obtaining of Regulatory Approvals and any applicable governmental price and reimbursement approvals. 

  
 C-2 

 SCHEDULE 1.1.29 

DATA PACKAGE INFORMATION 

Development Candidate Nomination Data Package: All available, relevant data (including [**]) with respect to the applicable Program as
laid out in the Development Candidate Criteria, including [**]. 
 End-of-Research Term Program Data Package: All available, relevant
data (including [**]) with respect to the applicable Program as laid out in the Development Candidate Criteria, including [**]. 
 Option
Data Package: All relevant data (including [**]) with respect to the applicable Program (including any applicable [**]), including (1) [**], (2) [**], and (3) [**]. 

  
 1.1.29-1 

 SCHEDULE 1.1.35 

DEVELOPMENT CANDIDATE CRITERIA 

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of 2 pages were omitted. [**] 

  
 1.1.35-1 

 SCHEDULE 1.1.82 

PUBLICATION GUIDELINES 

Unless the JSC by mutual agreement agrees otherwise, the Parties agree as follows:

[**]

  
 1.1.82 - 1 

 SCHEDULE 1.1.83 

QUALIFIED EARLY EXERCISE I&I PROGRAM CRITERIA 

[**] 

  
 1.1.83 - 1 

 SCHEDULE 9.2.9 

AGIOS PATENTS 
 [**] 

											
	 AGIOS

DOCKET        
  
	  	CC  	  	 APPLICATION

NO.
	  	
FILING    
 DATE
	  	 PUBLICATION

NO.
	  	PATENT   

NO.

	 [**]

 
	  	 [**]
	  	 [**]
	  	 [**]
	  	 	  	 
	 [**]

 
	  	 [**]
	  	 [**]
	  	 [**]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}]]